

# **FPwatch Study Reference Document**

## **Nigeria Outlet Survey**

### **2015-16**



## Suggested citation

FPwatch Group. (2016). *FPwatch Study Reference Document: Nigeria, 2015*. Washington DC: PSI.

## Contact

Dr. Bryan Shaw  
FPwatch Principal Investigator  
PSI | 1120 19<sup>th</sup> St NW Suite 600  
Washington DC 20036  
[bshaw@psi.org](mailto:bshaw@psi.org)

## Country Contact

Dr. Jennifer Anyanti  
Society for Family Health  
Abuja, Nigeria  
[Janyanti@sfnigeria.org](mailto:Janyanti@sfnigeria.org)

## Acknowledgements

ACTwatch is funded by the Bill and Melinda Gates Foundation, UNITAID, and the UK Department for International Development. This study was implemented by Population Services International (PSI) and the Society for Family Health (SFH).

### PSI Country (SFH)

Dr. Jennifer Anyanti  
Dr. Wole Fajemisin  
Chinazo Ujuju

### ACTwatch Consultant

Musa Abubakar

### FPwatch Consultant

Omotola Omotosho

### ACTwatch / FPwatch Team

Andrew Andrada  
Erick Auko  
Dr. Katie Bates  
Dr. Desmond Chavasse  
Kevin Duff  
Keith Esch  
Anna Fulton  
Danielle Garfinkel  
Tarryn Haslam  
Catharine Hurley  
Tabeth Jiri  
Dr. Beth Kangwana  
Gloria Kigo  
Dr. Megan Littrell  
Dr. Kathryn O'Connell  
Julius Ngigi  
Ricki Orford  
Stephen Poyer  
Dr. Justin Rahariniaina  
Christina Riley  
Dr. Andria Rusk  
Mac Schoen

Dr. Bryan Shaw  
Julianna Smith  
Kate Thanel  
Rachel Thompson  
Cynthia Whitman

### Federal Ministry of Health Nigeria

Dr. Wapada I. Balami  
Dr. Kayode Afolabi  
Dr. Gabriel Otunga

### Data Managers

Edadoghwaye Jennifer U  
Ifenyinwa Oguine  
Clement Ameh

### Field Supervisors

Tijani Garba  
Bala Joseph  
Valentine Nwobu  
Agnes Gata Joseph  
Danlami Nakoto  
Shehu-Isah Usman  
ThankGod Nwabueze  
Samson Kadoye Aliyu  
Faith Adesina  
Oyedotun Titilayo  
Adeike Adetoye  
Ngozi Okafocha  
Orji Nnene  
Ability Emmanuel  
Akpan Imoh Emmanuel

### Field Quality Controllers

Charles Okoro  
Mathew Katung  
Faruk Momoh  
Omotayo Salami  
Samul Igbenedion  
Lukman Salihu  
Awa Jane  
Akuchie Elvis Ifeanyi  
Akinola Oluwasegun Michael  
Ifeanyi Sixtus Odili  
Nike Alade  
Samuel Nwoke  
Ugwu Ifeoma  
Ene Adaga  
Oyanmenda Isibhakhomen

### Coders

Gaadi Iveren  
Afoekilim Anthonia Chidi  
Deshi Sarah Sale  
Balogun Iluwaseun Temitope

## **Acknowledgements**

FPwatch is funded by the Bill and Melinda Gates Foundation. This study was implemented by Population Services International and the Society for Family Health (SFH).



## TABLE OF CONTENTS

LIST OF TABLES.....	4
LIST OF FIGURES.....	6
ACRONYMS .....	7
DEFINITIONS.....	8
INTRODUCTION .....	10
SUMMARY OF METHODS AND DATA COLLECTION .....	11
SUMMARY OF KEY FINDINGS.....	13
RESULTS SECTION A: CORE NATIONAL INDICATORS .....	13
RESULTS SECTION B: CORE INDICATORS BY GEOPOLITICAL ZONE .....	40
RESULTS SECTION C: CORE INDICATORS BY URBAN VS. RURAL STRATIFICATION .....	113
ANNEXES .....	156

## List of Tables

### Core Indicator Tables

Table A1: Modern contraceptive method market composition: Relative proportion of outlets with 1 or more methods, by outlet type – National, 2015 .....	13
Table A2: Availability of modern contraceptive method types, among outlets screened, by outlet type – National, 2015.....	14
Table A3: Availability of selected contraceptive commodities, among outlets screened, by outlet type – National, 2015.....	15
Table A4: Availability of modern contraceptive method diversity, among outlets screened, by outlet type – National, 2015.....	17
Table A5: Current stock out* of selected modern contraceptive commodities on day of survey, among outlets reportedly stocking method in previous 3 months, by outlet type – National, 2015.....	18
Table A6: Median price of selected modern contraceptive methods in Nigerian Naira, USD*, and USD per CYP <sup>†‡</sup> , by private outlet type – National, 2015 .....	19
Table A7: Median markup percentage for selected modern contraceptive commodities with interquartile range, by private outlet type – National, 2015 .....	23
Table A8: Contraceptive method market share: Relative proportion of total CYP sold/distributed, by method and outlet type – National, 2015 .....	24
Table A9: Contraceptive method market share within outlet type: Relative proportion of total CYP sold / distributed within outlet type, by method – National, 2015.....	25
Table A10: Availability of selected contraceptive services, among outlets screened, by outlet type – National, 2015 26	
Table A11: Service readiness* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – National, 2015.....	27

### Zonal Indicator Tables

Table B1: Modern contraceptive method market composition: Relative proportion of outlets with 1 or more methods, by outlet type – by Geopolitical Zone, 2015 .....	40
Table B2: Availability of modern contraceptive method types, among outlets screened, by outlet type – by Geopolitical Zone, 2015.....	42
Table B3: Availability of selected contraceptive methods, among outlets screened, by outlet type – by Geopolitical Zone, 2015.....	45
Table B4: Availability of modern contraceptive method diversity, among outlets screened, by outlet type – by Geopolitical Zone, 2015.....	54
Table B5: Current stock out* of selected modern contraceptive commodities on day of survey, among outlets reportedly stocking method in previous 3 months, by outlet type – by Geopolitical Zone, 2015 .....	57
Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD*, and USD per CYP <sup>†‡</sup> , by private outlet type – by Geopolitical Zone, 2015.....	60
Table B7: Median markup percentage for selected modern contraceptive commodities with interquartile range, by private outlet type – by Geopolitical Zone, 2015.....	77
Table B8: Contraceptive method market share: Relative proportion of total CYP sold/distributed, by method and outlet type – by Geopolitical Zone, 2015 .....	80
Table B9: Contraceptive method market share within outlet type: Relative proportion of total CYP sold / distributed within outlet type, by method – by Geopolitical Zone, 2015 .....	85
Table B10: Availability of selected contraceptive services, among outlets screened, by outlet type – by Geopolitical Zone, 2015.....	90
Table B11: Service readiness* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – by Geopolitical Zone, 2015.....	93

## Urban/Rural Indicator Tables

Table C1: Modern contraceptive method market composition: Relative proportion of outlets with 1 or more methods, by outlet type – Urban/Rural, 2015 .....	113
Table C2: Availability of modern contraceptive method types, among outlets screened, by outlet type – Urban/Rural, 2015.....	114
Table C3: Availability of selected contraceptive methods, among outlets screened, by outlet type – Urban/Rural, 2015.....	116
Table C4: Availability of modern contraceptive method diversity, among outlets screened, by outlet type – Urban/Rural, 2015.....	119
Table C5: Current stock out* of selected modern contraceptive commodities on day of survey, among outlets reportedly stocking method in previous 3 months, by outlet type – Urban/Rural, 2015 .....	120
Table C6: Median price of selected modern contraceptive methods in Nigerian Naira, USD*, and USD per CYP <sup>†‡</sup> , by private outlet type – Urban/Rural, 2015.....	122
Table C7: Median markup percentage for selected modern contraceptive commodities with interquartile range, by private outlet type – Urban/Rural, 2015.....	129
Table C8: Contraceptive method market share: Relative proportion of total CYP sold/distributed, by method and outlet type – Urban/Rural, 2015 .....	131
Table C9: Contraceptive method market share within outlet type: Relative proportion of total CYP sold / distributed within outlet type, by method – Urban/Rural, 2015.....	133
Table C10: Availability of selected contraceptive services, among outlets screened, by outlet type – Urban vs. Rural, 2015.....	135
Table C11: Service readiness* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – Urban/Rural.....	136

## Annex Tables

Table X1: National Sample Description .....	172
Table X2: Regional Sample Description .....	172
Table X3: Urban vs Rural Sample Description .....	174
Table X4: CYP Conversion Factors.....	227
Table X5: Reported Contraceptive Method Volumes — National, 2016.....	229
Table X6: Reported Contraceptive Method Volumes — Geopolitical Zones, 2016 .....	230
Table X7: Reported Contraceptive Method Volumes — Urban/Rural, 2016.....	238

*Grey text for data appearing in report tables indicates that the estimate provided was derived from a small sample size. Specifically, grey text is used to indicate point estimates for availability indicators derived from an n of less than 50 and estimates for median price and service readiness indicators derived from an n of less than 5.*

## List of Figures

### Core Indicators

Figure 1: Survey flow diagram, Nigeria, 2015 .....	12
Figure A1. Modern contraceptive method market composition – National, 2015 .....	29
Figure A2. Percentage of modern contraceptive commodity-stocking outlets with selected non-hormonal short-acting contraceptives available – National, 2015 .....	30
Figure A3. Percentage of modern contraceptive commodity-stocking outlets with selected hormonal short-acting contraceptives available – National, 2015 .....	31
Figure A4. Percentage of modern contraceptive commodity-stocking outlets with selected long-acting contraceptives available – National, 2015 .....	32
Figure A5. Percentage of outlets with selected method mixes available – National, 2015 .....	33
Figure A6. Percentage of outlets with stock outs of selected contraceptive methods – National, 2015 .....	34
Figure A7. Price of contraceptive methods in the private sector – National, 2015.....	35
Figure A8. Percentage market share for contraceptives methods – National, 2015 .....	36
Figure A9. Within outlet market share for contraceptive methods – National, 2015.....	37
Figure A10. Percentage of outlets with selected contraceptive services available – National, 2015 .....	38
Figure A11. Service readiness to offer provider-dependent contraceptive services – National, 2015 .....	39

### Zonal Indicators

Figure B1. Modern contraceptive method market composition – Geopolitical Zones, 2015 .....	100
Figure B2. Percentage of modern contraceptive commodity-stocking outlets with selected non-hormonal short-acting contraceptives available – Geopolitical Zones, 2015 .....	101
Figure B3. Percentage of modern contraceptive commodity-stocking outlets with selected hormonal short-acting contraceptives available – Geopolitical Zones, 2015 .....	102
Figure B4. Percentage of modern contraceptive commodity-stocking outlets with selected long-acting contraceptives available – Geopolitical Zones, 2015 .....	103
Figure B5. Percentage of outlets with selected method mixes available – Geopolitical Zones, 2015 .....	104
Figure B6. Percentage of outlets with stock outs of selected contraceptive methods – Geopolitical Zones, 2015 ....	105
Figure B7. Price of contraceptive methods in the private sector – Geopolitical Zones, 2015 .....	106
Figure B8. Percentage market share for contraceptives methods – Geopolitical Zones, 2015 .....	108
Figure B9. Within outlet market share for contraceptive methods – Geopolitical Zones, 2015.....	109
Figure B10. Percentage of outlets with selected contraceptive services available – Geopolitical Zones, 2015 .....	110
Figure B11. Service readiness to offer provider-dependent contraceptive services among outlets reportedly offering services, by sector – Geopolitical Zones, 2015.....	111

## Acronyms

BMGF	Bill and Melinda Gates Foundation
CHW	Community Health Workers
CI	95% Confidence Interval
COC	Combined Oral Contraceptive
CPR	Contraceptive Prevalence Rate
CYP	Couple-Years of Protection
DFID	Department for International Development
DHS	Demographic and Health Survey
FP	Family Planning
FP2020	Family Planning 2020 Initiative
IQR	Interquartile Range
IQA	International Quality-Assured
IUD	Intrauterine Device
KII	Key Informant Interviews
LARC	Long-Acting Reversible Contraceptive
LARC/PM	Long-Acting Reversible Contraceptive or Permanent Method
LGA	Local Government Areas
MOH	Ministry of Health
NHERC	National Health Ethics Research Committee
NGO	Non-Governmental Organization
OS	Outlet survey
QC	Quality Controller
PM	Permanent Method
PMA2020	Performance, Monitoring and Accountability 2020 Study
POP	Progestrone-only pill
PPMV	Proprietary Patent Medicine Vendors
PPS	Probability Proportional to Size
PSI	Population Services International
REB	PSI Research Ethics Board
SFH	Society for Family Health-Nigeria
SRA	Stringent Regulatory Authority
TFR	Total Fertility Rate
3MDG	The Three Millennium Development Goal Fund
UNFPA	United Nations Population Fund
USAID	United States Agency for International Development
WHO	World Health Organization
WRA	Women of Reproductive Age
USD	US Dollar

## Nigeria Geo-political Zones

NC	North Central
NE	North East
NW	North West
SE	South East
SS	South South
SW	South West

## Definitions

### Survey Methods Definitions

<b>Outlet</b>	Any service delivery point or point of sale for commodities. Outlets are not restricted to stationary points of sale and may include mobile units or individuals.
<b>Outlets eligible for inclusion in the study</b>	Outlets were administered a full questionnaire if they met at least one of three inclusion criteria: (1) had one or more modern contraceptive commodities (oral contraceptives, emergency contraceptives, injectable contraceptives, contraceptive implants, intrauterine devices (IUDs), cycle beads) in stock at the time of the survey visit; (2) reportedly had one or more modern contraceptive commodities in stock in the previous three months; or (3) provide modern contraceptive services (contraceptive injections, implant insertions, IUD insertions, male/female sterilization) but do not sell/distribute contraceptive commodities. Outlets not providing services to the general public (e.g. military clinics, brothels, etc.) were excluded from the study.
<b>Cluster (Health area)</b>	The primary sampling unit, or cluster, for the outlet survey. It is an administrative unit determined by the Ministry of Health (MOH) that hosts a population size of approximately 10,000 to 15,000 inhabitants. These units are defined by political boundaries of the locality.
<b>Censused Health Area</b>	A cluster where field teams conducted a full census of all outlets with the potential to sell, distribute or provide contraceptive commodities and/or contraceptive services.

### Family Planning Terminology

<b>Family planning</b>	The ability of individuals and couples to anticipate and attain their desired number of children and the spacing and timing of their births.
<b>(Modern) Contraceptive commodity</b>	Used in reference to the actual product. This is any commodity recognized by the World Health Organization (WHO) as a modern form for the prevention of pregnancy and assigned a Couple-Years of Protection (CYP) conversion factor by the United States Agency for International Development (USAID) ( <a href="https://www.usaid.gov/what-we-do/global-health/family-planning/couple-years-protection-cyp">https://www.usaid.gov/what-we-do/global-health/family-planning/couple-years-protection-cyp</a> ). Traditional methods (e.g., herbs) not recognized by the WHO/USAID were not included in analysis. Behavioral methods without a tangible commodity but with a CYP conversion factor (e.g., fertility awareness methods) were not included in analysis.
<b>Contraceptive service</b>	Used in reference to the provider-assisted procedure associated for use of some contraceptive commodities. This is a medical procedure to deliver a contraceptive commodity or a surgical procedure to prevent pregnancy. For analysis, these include the delivery of an injection for an injectable contraceptive, an insertion of a contraceptive implant, an insertion of an IUD and/or a male/female sterilization procedure. Procedures typically require specialized training and equipment. These are also referred to as provider-dependent procedures.
<b>Contraceptive method</b>	Contraceptive method is used in a general sense to distinguish among categories of 'choice' for a consumer regardless of whether a commodity or service.

<b>Couple years of protection (CYP)</b>	CYP is the estimated protection provided by contraceptive methods during a one-year period, based upon the volume of all contraceptives sold or distributed free of charge to clients during that period. The CYP is calculated by multiplying the quantity of each method distributed to clients by a conversion factor, to yield an estimate of the duration of contraceptive protection provided per unit of that method. See Annex 11 for more description of how CYP was used in the study.
<b>Diversity/range of methods</b>	Indicators that measure contraceptive method choice for an individual consumer. Commonly accepted indicators include three or more and five or more methods available to a consumer from: male condoms, female condoms, oral contraceptives, emergency contraceptives, injectable contraceptives, contraceptive implants, IUDs, male sterilizations, female sterilizations, vaginal rings/patches, vaginal foaming tablets and/or standard days method (e.g. Cycle Beads).
<b>Short-acting methods</b>	Short-acting methods are those that are designed to offer a one-time or up to three months of protection against pregnancy. They include male and female condoms, oral contraceptives, emergency contraceptives and injectables.
<b>Long-acting, reversible contraceptive (LARC) methods</b>	Long-acting contraceptives are those that offer more than one year of protection against pregnancy. They include all types of implants and IUDs.
<b>Permanent methods</b>	Permanent methods include male and female sterilizations and typically provide life-time protection against pregnancy and are not easily reversible. They are often grouped together with LARCs for analytic purposes as long-acting and permanent methods (LARC/PMs).

### Outlet Categories for Nigeria

<b>Public health facilities</b>	Government (federal or state) public facilities including teaching hospitals and federal medical centers at the tertiary level; general hospitals at the secondary level; and primary health centers and clinics at the primary level.
<b>Community health workers</b>	Community-based health volunteers including Community Health Extension Workers and Role Model Mothers.
<b>Private not-for-profit health facilities</b>	Non-governmental (NGO) or mission/faith-based health facilities including hospitals and clinics.
<b>Private for-profit health facilities</b>	Private hospitals and clinics.
<b>Pharmacies</b>	Pharmacies are licensed by the Pharmacy Council of Nigeria and are authorized to sell all classes of medicines including prescription-only medicines. Pharmacies are regulated by the National Agency for Food and Drug Administration and Control. Pharmacies are owned by registered pharmacists or owners employing the services of a registered pharmacist.
<b>Drug stores/PPMVs</b>	Proprietary Patent Medicine Vendors (PPMVs) are small-to-medium sized outlets selling primarily medicines. PPMVs may be registered by the Directorate of Pharmaceutical Services. However, many are not registered. PPMVs are legally permitted to sell over-the-counter medicines including oral contraceptives.
<b>General retailers</b>	Supermarkets, mini-markets and kiosks primarily sell fast-moving consumer goods, food and provisions. Kiosks/tables are points of sale located in non-permanent structures that sell fast-moving goods such as food, beverages and household goods. Although retailers may have over-the-counter medicines including oral contraceptives available, national authorities do not regulate the sale of medicines by retailers.

## Introduction

This country reference document is a detailed presentation of the 2015 FPwatch outlet survey conducted in Nigeria. The study was conducted in all six regions of Nigeria, namely, North Central, North East, North West, South East, South South, South West.

FPwatch is a multi-country research project implemented by Population Services International (PSI) ([www.psi.org](http://www.psi.org)). Standardized tools and approaches are employed to provide comparable data across countries and over time. FPwatch is designed to provide timely, relevant and high-quality, modern contraceptive commodity and associated services market evidence. The goal of providing this market evidence is to inform and monitor national and global policy, strategy and funding decisions for improving availability of a range of quality FP information and contraceptive methods. The project was launched in 2014 with funding from the Bill and Melinda Gates Foundation (BMGF) for Ethiopia, Nigeria, the Democratic Republic of the Congo (DRC) and India, and is currently funded through 2016 by the BMGF. Additional funding was secured through the Three Millennium Development Goal (3MDG) Fund for FPwatch in Myanmar. See Annex 1 for more information about the FPwatch project.

FPwatch contraceptive method market monitoring in Nigeria has been implemented in the context of strategies designed and implemented to improve availability and choice in contraceptive methods. See Annex 2 for more information about the FP context in Nigeria. These strategies include national efforts to:

- Raise the contraceptive prevalence rate of (CPR) from 15% to 36% by 2018 as part of the FP2020 goals and thus avert 400,000 infant and 700,000 child deaths.
- Reduce maternal mortality by 75% and infant mortality by 66% by 2018.
- Train at least 3,700 community health extension workers (CHEWs) in order to increase uptake of long-acting reversible contraceptive (LARC) methods, such as through task-shifting delivery of implants.
- Increase annual funding of family planning and reproductive health by \$8.35 million.

## Report notes

- *This document is a complete reference for the 2015 outlet survey. Please see annexes for information about the study context, design, implementation and data analysis.*
- *Grey text for data appearing in report tables indicates that the estimate provided was derived from a small sample size. Specifically, grey text is used to indicate point estimates for availability indicators derived from an n of less than 50 and estimates for median price and service readiness indicators derived from an n of less than 5.*
- *Contraceptive commodity and service prices are reported in US dollars. Price information is captured in local currency and converted to US dollars based on exchange rates available from [www.oanda.com](http://www.oanda.com) using the historical exchange rates tool. The average exchange rate over the entire data collection period is used for converting local currency captured during data collection to US dollars.*



## Summary of Methods and Data Collection


A nationally representative FP-focused outlet survey was conducted in Nigeria from August to October, 2015. A full description of research design and methods is provided in Annex 3. Briefly, a representative sample of localities was selected with probability proportional to size (PPS) within each Nigerian geo-political zone. Localities in areas of insecurity were excluded from the sampling frame and did not have chance of selection into the study. Within selected clusters, a census of all outlets with the potential to sell or distribute modern contraceptives and/or provide associated FP services was completed.

Outlets were screened to determine eligibility. Outlets eligible for the survey met at least one of three criteria: 1) one or more modern contraceptive commodities (including oral contraceptives, emergency contraceptives, injectables, implants and/or IUDs) were in stock on the day of the survey; 2) one or more modern contraceptive commodities were in stock in the three months preceding the survey; and/or 3) contraceptive services associated with commodities (contraceptive injections, implant insertions, IUD insertions) and/or permanent methods with no commodity (male/female sterilizations) were available. Some questions relating to condoms were asked of all outlets, regardless of eligibility for the full audit or provider interview, to collect information on the condom market. Outlets that do not serve the general public (e.g., military facilities) were excluded from the study. The results of the census are summarized in Figure 1. A detailed sample summary is provided in Annex 6.

A structured questionnaire was used to complete an audit of all modern contraceptive commodities as well as a provider interview for questions relating to contraceptive services (see Annex 7 for the FPwatch 2015 Nigeria questionnaire). See Annex 8 for detailed summaries of modern contraceptive commodities audited. Key informant interviews (KIIs) were conducted with specific stakeholders to supplement information for the country background.

Double data entry was completed using Microsoft Access. All data cleaning and analysis was performed using Stata 13.1 (©StataCorp, College Station, TX). Data were weighted to account for variation in probability of outlet selection (see Annex 9), and standard error calculation reflected clustering of outlets at *LGA* and *locality* levels. Standard indicators were constructed according to definitions applied across FPwatch project countries (see Annex 10).

**Figure 1: Survey flow diagram, Nigeria, 2015**



## Summary of Key Findings

### Results Section A: Core National Indicators

<b>Table A1: Modern contraceptive method market composition: Relative proportion of outlets with 1 or more methods, by outlet type – National, 2015</b>									
	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total*
Proportion of outlet types stocking / providing at least 1 modern contraceptive method on the day of the survey, of all outlets stocking / providing at least 1 modern contraceptive method†:	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
Any method available, including condoms only outlets‡ <b>N=3,547</b>	9.0 (5.6, 14.1)	1.3 (0.3, 6.4)	0.1 (0.0, 0.3)	10.3 (6.4, 16.3)	7.0 (3.1, 14.9)	2.6 (1.4, 4.8)	68.9 (56.6, 79.0)	11.3 (4.5, 25.7)	89.7 (83.8, 93.6)
Any method available, excluding condoms only outlets§ <b>N=2,245</b>	12.8 (6.8, 22.7)	2.0 (0.4, 11.0)	0.1 (0.0, 0.4)	14.9 (7.8, 26.5)	9.0 (5.2, 15.2)	3.7 (1.9, 6.9)	71.6 (64.2, 78.0)	0.9 (0.2, 3.2)	85.1 (73.5, 92.2)
<p>* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>† Family planning commodity stocking outlets have at least one family planning commodity in stock on the day of the survey, verified by the presence of at least one family planning commodity recorded in an audit sheet. There were 44 family planning commodity stocking outlets with partially completed interviews which were thus excluded from the denominator.</p> <p>‡ Includes: male condoms, female condoms, cyclebeads, oral contraceptives, emergency contraceptives, injectables, implants, and IUDs.</p> <p>§ Includes: oral contraceptives, emergency contraceptives, injectables, implants, and IUDs.</p>									
Source: FPwatch Outlet Survey, Nigeria, 2015									

**Table A2: Availability of modern contraceptive method types, among outlets screened, by outlet type – National, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, stocking / providing†:</b>	N=214	N=12	N=15	N=241	N=331	N=229	N=2,802	N=3,362	N=9,762	N=13,365
Any modern method	71.6 (60.3, 80.8)	47.2 (10.7, 86.9)	8.7 (1.5, 36.8)	64.8 (51.4, 76.2)	60.5 (35.3, 81.2)	97.5 (95.0, 98.8)	81.7 (72.2, 88.5)	79.7 (70.0, 86.8)	3.6 (1.3, 9.7)	23.6 (19.8, 27.9)
Any short-acting method	71.6 (60.3, 80.8)	47.2 (10.7, 86.9)	8.7 (1.5, 36.8)	64.8 (51.4, 76.1)	59.1 (33.5, 80.6)	97.5 (95.0, 98.8)	81.7 (72.2, 88.5)	79.5 (69.8, 86.7)	3.6 (1.3, 9.7)	23.5 (19.7, 27.8)
Any LARC method	26.7 (15.6, 41.6)	0.0 -	0.8 (0.1, 6.6)	21.0 (13.0, 32.1)	28.5 (16.5, 44.4)	1.2 (0.4, 3.4)	0.0 (0.0, 0.1)	3.4 (1.5, 7.7)	0.0 -	1.6 (1.1, 2.3)
Any permanent method	1.0 (0.2, 4.8)	0.0 -	0.8 (0.1, 6.9)	0.8 (0.2, 3.8)	10.9 (4.5, 24.1)	0.0 -	0.0 -	1.3 (0.4, 4.2)	0.0 -	0.3 (0.1, 0.9)
Any LARC/PM	27.5 (16.6, 41.9)	0.0 -	0.8 (0.1, 6.6)	21.7 (13.8, 32.3)	30.2 (18.9, 44.6)	1.2 (0.4, 3.4)	0.0 (0.0, 0.1)	3.6 (1.6, 7.7)	0.0 -	1.6 (1.2, 2.3)
* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.										
† The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview).										
Source: FPwatch Outlet Survey, Nigeria, 2015										

**Table A3: Availability of selected contraceptive commodities, among outlets screened, by outlet type – National, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking†:</b>	N=214	N=12	N=15	N=241	N=331	N=229	N=2,802	N=3,362	N=9,762	N=13,365
Male condoms	54.1 (41.4, 66.2)	0.4 (0.0, 4.0)	7.9 (1.4, 34.2)	42.7 (33.5, 52.6)	40.8 (22.2, 62.4)	94.3 (89.5, 97.0)	75.2 (64.5, 83.5)	71.7 (61.9, 79.8)	3.6 (1.3, 9.7)	20.9 (17.6, 24.6)
Female condoms	36.3 (26.0, 48.0)	0.0 -	2.9 (0.3, 22.0)	28.5 (19.0, 40.5)	9.7 (3.2, 25.4)	13.0 (6.2, 25.1)	3.2 (1.4, 7.6)	4.2 (2.4, 7.5)	0.4 (0.1, 2.6)	2.3 (1.4, 3.7)
Cyclebeads	7.2 (3.4, 14.5)	0.0 -	0.1 (0.0, 0.5)	5.7 (2.6, 11.9)	2.6 (0.5, 13.2)	0.1 (0.0, 1.3)	1.2 (0.5, 3.0)	1.3 (0.6, 2.9)	0.0 -	0.5 (0.3, 0.9)
Oral contraceptives	49.5 (37.1, 62.0)	3.8 (0.4, 29.6)	4.5 (0.5, 30.7)	39.8 (26.8, 54.3)	38.8 (19.6, 62.2)	78.0 (65.3, 87.0)	50.9 (34.6, 67.0)	50.2 (34.4, 65.9)	0.2 (0.0, 0.7)	13.3 (10.9, 16.1)
<i>IQA<sup>‡</sup> oral contraceptives</i>	49.5 (37.1, 62.0)	3.8 (0.4, 29.6)	4.5 (0.5, 30.7)	39.8 (26.8, 54.3)	38.6 (19.4, 62.2)	78.0 (65.3, 87.0)	50.7 (34.4, 66.9)	50.0 (34.2, 65.8)	0.2 (0.0, 0.7)	13.2 (10.8, 16.1)
<i>Combined oral contraceptives</i>	44.5 (31.7, 58.0)	3.8 (0.4, 29.6)	4.5 (0.5, 30.7)	35.8 (23.5, 50.3)	38.7 (19.5, 62.2)	78.0 (65.3, 87.0)	50.8 (34.5, 67.0)	50.1 (34.3, 65.9)	0.2 (0.0, 0.7)	13.1 (10.7, 15.9)
<i>Progestin-only pills</i>	38.3 (25.4, 53.1)	0.0 -	4.5 (0.5, 30.7)	30.3 (18.9, 44.6)	0.3 (0.1, 0.9)	0.1 (0.0, 0.6)	0.3 (0.1, 1.1)	0.3 (0.1, 1.0)	0.0 -	1.2 (0.7, 2.2)
Emergency contraceptives	0.0 (0.0, 0.4)	0.0 -	0.0 -	0.0 (0.0, 0.3)	8.4 (2.2, 26.9)	63.8 (52.7, 73.6)	9.8 (4.7, 19.3)	11.1 (5.6, 20.8)	0.0 (0.0, 0.1)	2.6 (1.4, 4.6)
<i>IQA<sup>‡</sup> emergency contraceptives</i>	0.0 (0.0, 0.4)	0.0 -	0.0 -	0.0 (0.0, 0.3)	8.0 (1.9, 28.0)	50.7 (37.8, 63.5)	8.5 (4.0, 17.4)	9.6 (4.6, 18.9)	0.0 (0.0, 0.0)	2.2 (1.2, 4.2)
Contraceptive injectables	58.3 (43.1, 72.1)	42.9 (8.3, 86.2)	5.3 (0.7, 29.3)	53.5 (43.0, 63.6)	32.9 (21.4, 46.8)	61.6 (41.4, 78.5)	5.6 (3.2, 9.5)	10.2 (7.0, 14.7)	0.0 -	4.4 (3.5, 5.5)
<i>Depo-provera injectables</i>	55.7 (40.3, 70.0)	1.0 (0.1, 10.0)	5.3 (0.7, 29.3)	44.1 (29.0, 60.4)	21.7 (15.4, 29.7)	56.5 (37.3, 73.9)	4.8 (2.6, 8.4)	8.1 (5.7, 11.3)	0.0 -	3.5 (2.6, 4.8)
<i>Noristerat injectables</i>	48.4 (35.1, 61.8)	42.9 (8.3, 86.2)	5.3 (0.7, 29.3)	45.6 (35.7, 56.0)	25.3 (12.7, 44.2)	51.3 (30.1, 72.0)	3.7 (1.8, 7.4)	7.5 (4.7, 11.7)	0.0 -	3.5 (2.7, 4.3)
<i>Sayana Press injectables</i>	0.0 -	0.0 -	0.0 -	0.0 -	0.2 (0.0, 1.2)	1.0 (0.3, 3.0)	0.4 (0.1, 1.9)	0.4 (0.1, 1.5)	0.0 -	0.1 (0.0, 0.3)
Implants	23.0 (11.8, 39.9)	0.0 -	0.1 (0.0, 0.5)	18.1 (10.0, 30.5)	24.1 (11.3, 44.2)	0.6 (0.1, 4.0)	0.0 (0.0, 0.1)	2.8 (1.0, 8.0)	0.0 -	1.3 (0.8, 2.1)
<i>Implanon implants</i>	22.6 (11.5, 39.8)	0.0 -	0.1 (0.0, 0.5)	17.8 (9.7, 30.4)	21.1 (7.7, 46.4)	0.0 -	0.0 (0.0, 0.1)	2.5 (0.7, 8.6)	0.0 -	1.2 (0.8, 2.0)
<i>Jadelle implants</i>	15.3 (6.5, 32.0)	0.0 -	0.1 (0.0, 0.5)	12.0 (5.0, 26.3)	24.0 (11.1, 44.2)	0.6 (0.1, 4.0)	0.0 (0.0, 0.1)	2.8 (1.0, 8.0)	0.0 -	1.1 (0.7, 1.8)

IUDs	16.3 (8.0, 30.6)	0.0 -	0.8 (0.1, 6.6)	12.9 (6.7, 23.4)	20.3 (14.1, 28.3)	0.6 (0.2, 1.4)	0.0 (0.0, 0.1)	2.4 (1.4, 4.2)	0.0 -	1.0 (0.7, 1.6)
<p>* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.</p> <p>† The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview).</p> <p>‡ International quality-assured (IQA) contraceptives are defined as those with WHO Prequalification or those on a Stringent Regulatory Authority (SRA) list. See Annex 8 for a list of all brands found in the survey and quality-assurance indications.</p>										
Source: FPwatch Outlet Survey, Nigeria, 2015										

**Table A4: Availability of modern contraceptive method diversity, among outlets screened, by outlet type – National, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking / providing†:</b>	N=214	N=12	N=15	N=241	N=331	N=229	N=2,802	N=3,362	N=9,762	N=13,365
3+ methods‡	47.8 (37.7, 58.1)	0.0 -	5.3 (0.7, 29.3)	37.8 (28.9, 47.6)	29.1 (17.9, 43.6)	75.4 (62.0, 85.2)	11.3 (6.4, 19.2)	15.1 (9.0, 24.4)	0.0 -	4.9 (3.9, 6.1)
3+ methods with LARC	26.6 (15.6, 41.6)	0.0 -	0.8 (0.1, 6.6)	21.0 (13.0, 32.1)	25.6 (13.1, 43.9)	1.2 (0.4, 3.4)	0.0 (0.0, 0.1)	3.0 (1.2, 7.8)	0.0 -	1.5 (1.0, 2.2)
3+ methods with LARC/PM	27.5 (16.6, 41.9)	0.0 -	0.8 (0.1, 6.6)	21.6 (13.8, 32.3)	26.5 (14.3, 43.7)	1.2 (0.4, 3.4)	0.0 (0.0, 0.1)	3.2 (1.2, 7.7)	0.0 -	1.5 (1.1, 2.2)
5+ methods§	23.9 (15.0, 36.0)	0.0 -	0.1 (0.0, 0.5)	18.8 (11.3, 29.5)	12.1 (6.0, 22.7)	6.9 (3.9, 11.7)	0.2 (0.1, 0.7)	1.8 (0.8, 3.9)	0.0 -	1.1 (0.8, 1.6)
<p>* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.</p> <p>† The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview).</p> <p>‡ 3 or more among: male condoms, female condoms, cyclebeads, oral contraceptives, emergency contraceptives, injectables, implants, IUDs commodities and/or male sterilizations, female sterilizations services. No other modern contraceptive methods were found in sampled outlets.</p> <p>§ 5 or more among: male condoms, female condoms, cyclebeads, oral contraceptives, emergency contraceptives, injectables, implants, IUDs commodities and/or male sterilizations, female sterilizations services. No other modern contraceptive methods were found in sampled outlets.</p>										
Source: FPwatch Outlet Survey, Nigeria, 2015										

**Table A5: Current stock out\* of selected modern contraceptive commodities on day of survey, among outlets reportedly stocking method in previous 3 months, by outlet type – National, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total†	Total
Proportion of outlets reportedly stocking method in previous 3 months, currently stocked out of‡:	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)
Oral contraceptives	14.3 <sup>(131)</sup> (4.4, 37.8)	93.7 <sup>(3)</sup> (46.8, 99.6)	0.0 <sup>(2)</sup> -	29.2 <sup>(136)</sup> (12.1, 55.4)	23.8 <sup>(93)</sup> (17.5, 31.5)	7.4 <sup>(185)</sup> (1.9, 25.1)	9.8 <sup>(1,866)</sup> (5.1, 17.8)	44.9 <sup>(32)</sup> (6.0, 91.3)	11.7 <sup>(2,176)</sup> (7.7, 17.4)	14.1 <sup>(2,312)</sup> (9.7, 20.1)
Emergency contraceptives	42.8 <sup>(2)</sup> (2.9, 94.9)	100.0 <sup>(1)</sup> -	- -	98.6 <sup>(3)</sup> (74.2, 99.9)	50.1 <sup>(14)</sup> (48.0, 52.2)	3.5 <sup>(124)</sup> (1.1, 10.2)	30.2 <sup>(491)</sup> (19.3, 43.8)	22.7 <sup>(10)</sup> (4.8, 63.0)	29.7 <sup>(639)</sup> (22.7, 37.8)	31.5 <sup>(642)</sup> (23.7, 40.6)
Contraceptive injectables	10.6 <sup>(144)</sup> (3.3, 29.1)	31.3 <sup>(5)</sup> (3.3, 85.9)	18.1 <sup>(4)</sup> (1.4, 77.2)	14.2 <sup>(153)</sup> (6.7, 27.7)	27.2 <sup>(117)</sup> (18.9, 37.4)	1.3 <sup>(129)</sup> (0.3, 4.8)	57.5 <sup>(388)</sup> (37.0, 75.7)	0.0 <sup>(1)</sup> -	43.5 <sup>(635)</sup> (29.0, 59.3)	33.1 <sup>(788)</sup> (22.2, 46.0)
Implants	5.0 <sup>(64)</sup> (1.0, 21.8)	- -	0.0 <sup>(1)</sup> -	5.0 <sup>(65)</sup> (1.0, 21.8)	4.9 <sup>(47)</sup> (1.0, 21.0)	0.0 <sup>(1)</sup> -	88.5 <sup>(4)</sup> (33.6, 99.2)	- -	7.8 <sup>(52)</sup> (1.7, 30.0)	6.4 <sup>(117)</sup> (2.1, 17.8)
IUDs	4.9 <sup>(54)</sup> (0.6, 31.0)	- -	0.0 <sup>(2)</sup> -	4.9 <sup>(56)</sup> (0.6, 30.8)	9.4 <sup>(81)</sup> (3.5, 22.8)	19.8 <sup>(9)</sup> (3.5, 62.7)	44.6 <sup>(11)</sup> (15.7, 77.7)	- -	10.1 <sup>(101)</sup> (3.9, 23.7)	7.7 <sup>(157)</sup> (2.6, 20.6)

\* This indicator is among all screened outlets. It does not account for whether the outlet is expected to provide the commodity according to national regulations. It is a point-in-time stock out indicator from [http://www.rhsupplies.org/fileadmin/uploads/rhsc/Issues/Addressing\\_Stockouts/Takestock/Documents/Using-the\\_Power\\_of\\_Partnership\\_to\\_Speak\\_the\\_same\\_Languageon\\_Stockouts.pdf](http://www.rhsupplies.org/fileadmin/uploads/rhsc/Issues/Addressing_Stockouts/Takestock/Documents/Using-the_Power_of_Partnership_to_Speak_the_same_Languageon_Stockouts.pdf). It is defined as the percentage of facilities reporting that they have stocked the method in the previous 3 months but were stocked out on the day of the assessment.

† In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.

‡ The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview).

Source: FPwatch Outlet Survey, Nigeria, 2015



**Table A6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – National, 2015**

	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>§</sup>
Median price of method, with interquartile range <sup>¶</sup>	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
<b>Male condoms</b>					
Naira	10.0 <sup>(75)</sup> [0.0, 12.5]	12.5 <sup>(212)</sup> [12.5, 50.0]	12.5 <sup>(2,269)</sup> [10.0, 12.5]	12.5 <sup>(526)</sup> [10.0, 12.5]	12.5 <sup>(3,082)</sup> [10.0, 12.5]
USD	\$ 0.05 <sup>(75)</sup> [0.00, 0.06]	\$ 0.06 <sup>(212)</sup> [0.06, 0.25]	\$ 0.06 <sup>(2,269)</sup> [0.05, 0.06]	\$ 0.06 <sup>(526)</sup> [0.05, 0.06]	\$ 0.06 <sup>(3,082)</sup> [0.05, 0.06]
USD per CYP	\$ 6.00 <sup>(75)</sup> [0.00, 7.50]	\$ 7.50 <sup>(212)</sup> [7.50, 30.00]	\$ 7.50 <sup>(2,269)</sup> [6.00, 30.0]	\$ 7.50 <sup>(526)</sup> [6.00, 7.50]	\$ 7.50 <sup>(3,082)</sup> [6.00, 7.50]
<b>Female condoms</b>					
Naira	0.0 <sup>(19)</sup> [0.0, 0.0]	125.0 <sup>(27)</sup> [50.0, 566.7]	50.0 <sup>(97)</sup> [50.0, 75.0]	20.0 <sup>(7)</sup> [20.0, 20.0]	50.0 <sup>(150)</sup> [20.0, 50.0]
USD	\$ 0.00 <sup>(19)</sup> [0.00, 0.00]	\$ 0.63 <sup>(27)</sup> [0.25, 2.83]	\$ 0.25 <sup>(97)</sup> [0.25, 0.38]	\$ 0.10 <sup>(7)</sup> [0.10, 0.10]	\$ 0.25 <sup>(150)</sup> [0.10, 0.25]
USD per CYP	\$ 0.00 <sup>(19)</sup> [0.00, 0.00]	\$ 75.00 <sup>(27)</sup> [30.00, 340.00]	\$ 30.00 <sup>(97)</sup> [30.00, 45.00]	\$ 12.00 <sup>(7)</sup> [12.00, 12.00]	\$ 30.00 <sup>(150)</sup> [12.00, 30.00]
<b>Cyclebeads</b>					
Naira	0.0 <sup>(4)</sup> [0.0, 0.0]	150.0 <sup>(2)</sup> [150.0, 150.0]	50.0 <sup>(26)</sup> [0.0, 200.0]	-	50.0 <sup>(32)</sup> [0.0, 200.0]
USD	\$ 0.00 <sup>(4)</sup> [0.00, 0.00]	\$ 0.75 <sup>(2)</sup> [0.75, 0.75]	\$ 0.25 <sup>(26)</sup> [0.00, 1.00]	-	\$ 0.25 <sup>(32)</sup> [0.00, 1.00]
USD per CYP	\$ 0.00 <sup>(4)</sup> [0.00, 0.00]	\$ 0.50 <sup>(2)</sup> [0.50, 0.50]	\$ 0.17 <sup>(26)</sup> [0.00, 0.67]	-	\$ 0.16 <sup>(32)</sup> [0.00, 0.67]
<b>Oral contraceptives</b>					
Naira	100.0 <sup>(76)</sup> [70.0, 100.0]	100.0 <sup>(202)</sup> [50.0, 100.0]	80.0 <sup>(1,643)</sup> [50.0 100.0]	60.0 <sup>(28)</sup> [50.0 100.0]	80.0 <sup>(1,949)</sup> [50.0, 100.0]
USD	\$ 0.50 <sup>(76)</sup> [0.35, 0.50]	\$ 0.50 <sup>(202)</sup> [0.25, 0.50]	\$ 0.40 <sup>(1,643)</sup> [0.25, 0.50]	\$ 0.30 <sup>(28)</sup> [0.25, 0.50]	\$ 0.40 <sup>(1,949)</sup> [0.25, 0.50]
USD per CYP	\$ 7.50 <sup>(76)</sup> [5.25, 7.50]	\$ 7.50 <sup>(202)</sup> [3.75, 7.50]	\$ 6.00 <sup>(1,643)</sup> [3.75, 7.50]	\$ 4.50 <sup>(28)</sup> [3.75, 7.50]	\$ 6.00 <sup>(1,949)</sup> [3.75, 7.50]
<b>Combined oral contraceptives</b>					
Naira	100.0 <sup>(69)</sup> [70.0, 100.0]	100.0 <sup>(201)</sup> [50.0, 100.0]	80.0 <sup>(1,631)</sup> [50.0 100.0]	60.0 <sup>(28)</sup> [50.0 100.0]	80.0 <sup>(1,929)</sup> [50.0, 100.0]
USD	\$ 0.50 <sup>(69)</sup> [0.35, 0.50]	\$ 0.50 <sup>(201)</sup> [0.25, 0.50]	\$ 0.40 <sup>(1,631)</sup> [0.25, 0.50]	\$ 0.30 <sup>(28)</sup> [0.25, 0.50]	\$ 0.40 <sup>(1,929)</sup> [0.25, 0.50]
USD per CYP	\$ 7.50 <sup>(69)</sup> [5.25, 7.50]	\$ 7.50 <sup>(201)</sup> [3.75, 7.50]	\$ 6.00 <sup>(1,631)</sup> [3.75, 7.50]	\$ 4.50 <sup>(28)</sup> [3.75, 7.50]	\$ 6.00 <sup>(1,929)</sup> [3.75, 7.50]
<b>Progestin-only pills</b>					

**Table A6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – National, 2015**

	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>§</sup>
Median price of method, with interquartile range <sup>¶</sup>	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
Naira	0.0 <sup>(7)</sup> [0.0, 0.0]	100.0 <sup>(1)</sup> [100.0, 100.0]	70.0 <sup>(12)</sup> [50.0 100.0]	- -	0.70 <sup>(20)</sup> [50.0, 100.0]
USD	\$0.00 <sup>(7)</sup> [0.00, 0.00]	\$ 0.50 <sup>(1)</sup> [0.50, 0.50]	\$ 0.35 <sup>(12)</sup> [0.25, 0.50]	- -	\$ 0.35 <sup>(20)</sup> [0.25, 0.50]
USD per CYP	\$0.00 <sup>(7)</sup> [0.00, 0.00]	\$ 7.50 <sup>(1)</sup> [7.50, 7.50]	\$ 5.25 <sup>(12)</sup> [3.75, 7.50]	- -	\$ 5.25 <sup>(20)</sup> [3.75, 7.50]
<b>Emergency contraceptives</b>					
Naira	300.0 <sup>(6)</sup> [300.0, 500.0]	250.0 <sup>(191)</sup> [50.0, 300.0]	150.0 <sup>(449)</sup> [40.0, 250.0]	200.0 <sup>(8)</sup> [200.0, 300.0]	200.0 <sup>(654)</sup> [40.0, 250.0]
USD	\$1.50 <sup>(6)</sup> [1.50, 2.50]	\$ 1.25 <sup>(191)</sup> [0.25, 1.50]	\$ 0.75 <sup>(449)</sup> [0.20, 1.25]	\$1.00 <sup>(8)</sup> [1.00, 1.50]	\$1.00 <sup>(654)</sup> [0.20, 1.25]
USD per CYP	\$30.00 <sup>(6)</sup> [30.00, 50.00]	\$ 25.00 <sup>(191)</sup> [5.00, 30.00]	\$ 15.00 <sup>(449)</sup> [4.00, 25.00]	\$20.00 <sup>(8)</sup> [20.00, 30.00]	\$20.00 <sup>(654)</sup> [4.00, 25.00]
<b>Contraceptive injectables<sup>  </sup></b>					
Naira	500.0 <sup>(137)</sup> [400.0, 500.0]	200.0 <sup>(217)</sup> [150.0, 300.0]	200.0 <sup>(394)</sup> [150.0, 300.0]	500.0 <sup>(1)</sup> [500.0, 500.0]	300.0 <sup>(749)</sup> [150.0, 500.0]
USD	\$2.50 <sup>(137)</sup> [2.00, 2.50]	\$ 1.00 <sup>(217)</sup> [0.75, 1.50]	\$ 1.00 <sup>(394)</sup> [0.75, 2.00]	\$2.50 <sup>(1)</sup> [2.50, 2.50]	\$1.50 <sup>(749)</sup> [0.75, 2.50]
USD per CYP	\$10.00 <sup>(137)</sup> [10.00, 15.00]	\$ 4.50 <sup>(217)</sup> [3.00, 6.00]	\$4.50 <sup>(394)</sup> [4.00, 8.00]	\$15.00 <sup>(1)</sup> [15.00, 15.00]	\$6.00 <sup>(749)</sup> [4.00, 10.50]
<b>Depo-provera injectables</b>					
Naira	500.0 <sup>(76)</sup> [350.0, 500.0]	200.0 <sup>(114)</sup> [140.0, 300.0]	200.0 <sup>(201)</sup> [150.0, 300.0]	- -	300.0 <sup>(391)</sup> [150.0, 500.0]
USD	\$2.50 <sup>(76)</sup> [1.75, 2.50]	\$ 1.00 <sup>(114)</sup> [0.70, 2.00]	\$ 1.00 <sup>(201)</sup> [0.75, 2.00]	- -	\$1.50 <sup>(391)</sup> [0.75, 2.50]
USD per CYP	\$10.00 <sup>(76)</sup> [7.00, 10.00]	\$ 4.00 <sup>(114)</sup> [2.8, 6.00]	\$ 4.00 <sup>(201)</sup> [3.00, 8.00]	- -	\$6.00 <sup>(391)</sup> [3.00, 10.00]
<b>Noristerat injectables</b>					
Naira	500.0 <sup>(61)</sup> [500.0, 2000.0]	200.0 <sup>(103)</sup> [150.0, 400.0]	200.0 <sup>(193)</sup> [150.0, 300.0]	500.0 <sup>(1)</sup> [500.0, 500.0]	300.0 <sup>(358)</sup> [150.0, 500.0]
USD	\$2.50 <sup>(61)</sup> [2.50, 10.00]	\$ 1.00 <sup>(103)</sup> [0.75, 2.00]	\$ 1.00 <sup>(193)</sup> [0.75, 1.50]	\$2.50 <sup>(1)</sup> [2.50, 2.50]	\$1.50 <sup>(358)</sup> [0.75, 2.50]
USD per CYP	\$15.00 <sup>(61)</sup> [15.00, 60.00]	\$ 6.00 <sup>(103)</sup> [4.50, 12.00]	\$ 6.00 <sup>(193)</sup> [4.50, 9.00]	\$15.00 <sup>(1)</sup> [15.00, 15.00]	\$9.00 <sup>(358)</sup> [4.50, 15.00]
<b>Implants<sup>  </sup></b>					
Naira	1,500.0 <sup>(42)</sup>	1,200.0 <sup>(1)</sup>	500.0 <sup>(3)</sup>	-	1,500.0 <sup>(46)</sup>

**Table A6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – National, 2015**

	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>§</sup>
Median price of method, with interquartile range <sup>¶</sup>	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
	[1000.0, 2000.0]	[1200.0, 1200.0]	[500.0, 500.0]	-	[1000.0, 2000.0]
USD	\$7.50 <sup>(42)</sup> (5.00, 10.00)	\$ 6.00 <sup>(1)</sup> [6.00, 6.00]	\$ 2.50 <sup>(3)</sup> [2.50, 2.50]	-	\$2.00 <sup>(46)</sup> (1.97, 2.63]
USD per CYP	\$2.00 <sup>(42)</sup> (1.97, 2.63]	1.58 <sup>(1)</sup> [1.58, 1.58]	\$ 0.83 <sup>(3)</sup> [0.66, 1.00]	-	\$7.50 <sup>(46)</sup> (5.00, 10.00]
<i>Implanon implants</i>					
Naira	1,000.0 <sup>(14)</sup> [1000.0, 2000.0]	-	500.0 <sup>(1)</sup> [500.0, 500.0]	-	1,000.0 <sup>(15)</sup> [1000.0, 2000.0]
USD	\$5.00 <sup>(14)</sup> (5.00, 10.00]	-	\$ 2.50 <sup>(1)</sup> [2.50, 2.50]	-	\$5.00 <sup>(15)</sup> (5.00, 10.00]
USD per CYP	\$2.00 <sup>(14)</sup> (2.00, 4.00]	-	\$ 1.00 <sup>(1)</sup> [1.00, 1.00]	-	\$2.00 <sup>(15)</sup> (2.00, 4.00]
<i>Jadelle implants</i>					
Naira	1,000.0 <sup>(28)</sup> [1000.0, 1500.0]	1,200.0 <sup>(1)</sup> [1200.0, 1200.0]	500.0 <sup>(2)</sup> [500.0, 500.0]	-	1,500.0 <sup>(31)</sup> [1500.0, 2000.0]
USD	\$7.50 <sup>(28)</sup> (7.50, 10.00]	\$ 6.00 <sup>(1)</sup> [6.00, 6.00]	\$ 2.50 <sup>(2)</sup> [2.50, 2.50]	-	\$7.50 <sup>(31)</sup> (7.50, 10.00]
USD per CYP	\$1.97 <sup>(28)</sup> (1.97, 2.63]	\$ 1.57 <sup>(1)</sup> [1.57, 1.57]	\$ 0.66 <sup>(2)</sup> [0.66, 0.66]	-	\$1.97 <sup>(31)</sup> (1.97, 2.63]
<b>IUDs<sup>  </sup></b>					
Naira	1,000.0 <sup>(62)</sup> [1000.0, 1500.0]	250.0 <sup>(9)</sup> [250.0, 250.0]	160.0 <sup>(8)</sup> [150.0, 200.0]	-	1,000.0 <sup>(79)</sup> [1000.0, 1500.0]
USD	\$5.00 <sup>(62)</sup> (5.00, 7.50]	\$1.25 <sup>(9)</sup> (1.25, 1.25]	\$ 0.80 <sup>(8)</sup> [0.75, 1.00]	-	\$5.00 <sup>(79)</sup> (5.00, 7.50]
USD per CYP	\$1.08 <sup>(62)</sup> (1.09, 1.63]	\$0.27 <sup>(9)</sup> (0.27, 0.27]	\$ 0.17 <sup>(8)</sup> [0.16, 0.21]	-	\$1.09 <sup>(79)</sup> (1.09, 1.63]
<b>Male Sterilization</b>					
Naira	42,000.0 <sup>(4)</sup> [42000.0, 42000.0]	-	-	-	42,000.0 <sup>(4)</sup> [42000.0, 42000.0]
USD	\$ 210.00 <sup>(4)</sup> [210.00, 210.00]	-	-	-	\$ 210.00 <sup>(4)</sup> [210.00, 210.00]
USD per CYP	\$ 22.58 <sup>(4)</sup> [22.58, 22.58]	-	-	-	\$ 22.58 <sup>(4)</sup> [22.58, 22.58]
<b>Female Sterilization</b>					
Naira	15,000.0 <sup>(21)</sup> [15000.0, 15000.0]	-	-	-	15,000.0 <sup>(21)</sup> [15000.0, 15000.0]

**Table A6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – National, 2015**

	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range∞	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
USD	\$ 75.00 <sup>(21)</sup> [75.00, 75.00]	- -	- -	- -	\$ 75.00 <sup>(21)</sup> [75.00, 75.00]
USD per CYP	\$ 8.06 <sup>(21)</sup> [8.06, 8.06]	- -	- -	- -	\$ 8.06 <sup>(21)</sup> [8.06, 8.06]
<p>* Based on the average rate of exchange from August 10 to October 23, 2015 of 500 Naira per 1 USD.</p> <p>† This price is determined for the unit used in CYP conversion factors: condoms: 1 condom; oral contraceptives: 1 cycle or blister package; emergency contraceptives: 1 dose; injectables: 1 dose/injection; implants: 1 implant insertion (1 or 2 rods); IUDs: 1 IUD.</p> <p>‡ CYP – Couple Year Protection is the estimated protection provided by contraceptive methods during a one-year period, based upon the volume of all contraceptives sold or distributed free of charge to clients during that period (see Annex 11).</p> <p>§ In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>∞ The number of family planning products captured in audits sheets with missing price information are as follows: 37 male condoms, 8 female condoms, 22 cycle beads, 13 male vasectomies, 22 female tubal ligations, 47 oral contraceptives, 11 emergency contraceptives, 212 injections, 44 implants and 66 IUDs.</p> <p>    Price for all commodities with a provider-dependent service (injectables, implants, IUDs) may include service charge.</p>					
Source: FPwatch Outlet Survey, Nigeria 2015					

**Table A7: Median markup percentage for selected modern contraceptive commodities with interquartile range, by private outlet type – National, 2015**

	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total*
Median markup percentage <sup>†</sup> of commodity, with interquartile range <sup>‡,§,∞</sup> :	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]
Oral contraceptives	100% <sup>(27)</sup> [100%, 100%]	100% <sup>(99)</sup> [47%, 150%]	75% <sup>(1,272)</sup> [47%, 167%]	100% <sup>(21)</sup> [92%, 116%]	79% <sup>(1,419)</sup> [47%, 150%]
Emergency contraceptives	100% <sup>(2)</sup> [100%, 100%]	50% <sup>(84)</sup> [25%, 100%]	67% <sup>(352)</sup> [45%, 100%]	33% <sup>(6)</sup> [33%, 122%]	67% <sup>(444)</sup> [40%, 100%]
Contraceptive injectables	150% <sup>(80)</sup> [150%, 200%]	100% <sup>(113)</sup> [67%, 150%]	100% <sup>(327)</sup> [58%, 140%]	285% <sup>(1)</sup> [285%, 285%]	133% <sup>(521)</sup> [67%, 150%]
Implants	150% <sup>(12)</sup> [100%, 150%]	- -	- -	- -	150% <sup>(12)</sup> [100%, 150%]
IUDs	3,900% <sup>(22)</sup> [400%, 3900%]	50% <sup>(4)</sup> [50%, 54%]	15% <sup>(6)</sup> [11%, 23%]	- -	3,900% <sup>(32)</sup> [400%, 3,900%]
<p>* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>† To determine median markup percentage, we first determined the profit margin for selected modern contraceptives at private sector outlet categories: retail price – wholesale price. We then determined a profit margin proportion by: profit margin/retail price. Finally, we converted profit margin to markup by: wholesale price/(1- profit margin proportion). We converted to a percentage and determined the median markup with IQR range. Using oral contraceptives sold in private health facilities as an example, this can be interpreted as private health facilities adding 50% to the wholesale costs to set the retail cost.</p> <p>‡ The number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 530 oral contraceptives, 210 emergency contraceptives, 228 injections, 34 implants and 47 IUDs.</p> <p>§ This price is determined for the unit CYP conversion factors: condoms: 1 condom; oral contraceptives: 1 cycle or blister package; emergency contraceptives: 1 does; injectables: 1 dose/injection; implants: 1 implant insertion (1 or 2 rods); IUDs: 1 IUD.</p> <p>∞ Price for all commodities with a provider-dependent service (injectables, implants, IUDs) may include service charge.</p>					
Source: FPwatch Outlet Survey, Nigeria, 2015					

**Table A8: Contraceptive method market share: Relative proportion of total CYP sold/distributed, by method and outlet type – National, 2015**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type as a % of total CYP sold / distributed <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>	TOTAL <sup>§</sup>
	%	%	%	%	%	%	%	%	%	%
<b>1. Male condoms</b>	3.8	0.0	0.0	3.8	0.8	1.1	15.7	1.8	19.4	23.2
<b>2. Female condoms</b>	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2
<b>3. Cyclebeads</b>	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1
<b>4. Oral contraceptives</b>	0.9	0.0	0.0	0.9	0.6	0.3	5.0	0.0	5.9	6.8
IQA <sup>∞</sup> oral contraceptives	0.9	0.0	0.0	0.9	0.6	0.3	5.0	0.0	5.9	6.7
Combined oral contraceptives	0.5	0.0	0.0	0.5	0.6	0.3	5.0	0.0	5.9	6.4
Progestin-only pills	0.3	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.4
<b>5. Emergency contraceptives</b>	0.0	0.0	0.0	0.0	0.0	0.5	2.1	0.0	2.6	2.6
IQA <sup>∞</sup> emergency contraceptives	0.0	0.0	0.0	0.0	0.0	0.2	1.3	0.0	1.6	1.6
<b>6. Contraceptive injectables</b>	4.6	0.1	0.0	4.7	1.2	0.6	2.5	0.0	4.3	9.0
Depo-provera	3.2	0.0	0.0	3.2	0.7	0.3	1.5	0.0	2.5	5.7
Noristerat	1.4	0.1	0.0	1.5	0.5	0.3	1.0	0.0	1.8	3.3
Sayana Press	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1
<b>7. Implants</b>	13.7	0.0	0.0	13.7	28.7	0.0	0.0	0.0	28.7	42.4
Implanon	4.9	0.0	0.0	4.9	17.5	0.0	0.0	0.0	17.5	22.4
Jadelle	8.7	0.0	0.0	8.8	11.2	0.0	0.0	0.0	11.2	20.0
<b>8. IUDs</b>	2.6	0.0	0.0	2.6	12.4	0.0	0.2	0.0	12.6	15.2
<b>9. Male sterilization</b>	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1
<b>10. Female sterilization</b>	0.1	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.3	0.4
<b>OUTLET TYPE TOTAL<sup>§</sup></b>	25.9	0.1	0.0	26.0	44.1	2.5	25.5	1.9	74.0	100.0

\* A total of 964,052 CYP (weighted) were reportedly distributed in the previous 1 month. This is based on the number of commodities reportedly sold for categories 1-8 (not number of services performed for categories 6-8) and number of sterilizations reportedly performed for categories 9-10.

† A total of 4,295 FP products were audited (3,007 contraceptive tablets, 1,004 injection products). In addition, 1,923 outlets were audited for male condoms, 223 for female condoms, 72 for CycleBeads, 37 outlets for female sterilization services and 15 outlets for male sterilization services. A total of 2 injection products and 4 tablet products were excluded from market share analysis due to inconsistent or missing generic names. 56 emergency contraceptive products, 129 oral contraceptives, 205 male condoms, 17 female condoms and 10 CycleBeads were excluded from analysis for missing volume information. 2 male sterilizations and 4 female sterilizations were excluded for similar missing volume information as well. A total of 49 products were excluded due to outlier volumes and prices.

‡ In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs.

§ Row total equals CYP volume for the specified contraceptive method type. Column total equals market share for the specified outlet type method categories 1-10.

∞ Internationally quality-assured (IQA) contraceptives are defined as those with WHO Pre-qualification or those on a Stringent Regulatory authority (SRA) list. See Annex 8 for a list of all quality-assured brands found in the survey.

Source: FPwatch Outlet Survey, Nigeria, 2015

**Table A9: Contraceptive method market share within outlet type: Relative proportion of total CYP sold / distributed within outlet type, by method – National, 2015**

CYP sold or distributed in previous 1-month contraceptive method type as a % of total CYP sold / distributed within outlet type <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>
	%	%	%	%	%	%	%	%	%
<b>1. Male condoms</b>	14.7	2.5	1.0	14.7	1.8	42.5	61.6	98.6	26.2
<b>2. Female condoms</b>	0.7	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.1
<b>3. CycleBeads</b>	0.2	0.0	0.0	0.2	0.1	0.0	0.1	0.0	0.1
<b>4. Oral contraceptives</b>	3.3	0.0	3.4	3.3	1.3	10.9	19.7	1.1	8.0
IQA <sup>§</sup> oral contraceptives	3.3	0.0	3.4	3.3	1.3	10.9	19.6	1.1	7.9
Combined oral contraceptives	2.0	0.0	0.0	2.0	1.3	10.9	19.6	1.1	8.0
Progestin-only pills	1.3	0.0	3.4	1.3	0.0	0.0	0.1	0.0	0.0
<b>5. Emergency contraceptives</b>	0.0	0.0	0.0	0.0	0.0	20.4	8.1	0.2	3.5
IQA <sup>§</sup> emergency contraceptives	0.0	0.0	0.0	0.0	0.0	9.7	5.3	0.1	2.2
<b>6. Contraceptive injectables</b>	17.8	97.5	43.4	18.1	2.8	24.9	9.6	0.0	5.8
Depo-provera	12.3	6.5	30.6	12.4	1.6	12.2	5.8	0.0	3.4
Noristerat	5.5	91.0	12.8	5.8	1.2	12.7	3.8	0.0	2.5
Sayana Press	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.1
<b>7. Implants</b>	52.8	0.0	9.4	52.6	65.1	0.0	0.1	0.0	38.8
Implanon	19.0	0.0	4.6	18.9	39.7	0.0	0.1	0.0	23.7
Jadelle	33.8	0.0	4.9	33.7	25.5	0.0	0.0	0.0	15.2
<b>8. IUDs</b>	9.9	0.0	42.8	10.0	28.1	1.3	0.6	0.0	17.0
<b>9. Male sterilization</b>	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1
<b>10. Female sterilization</b>	0.4	0.0	0.0	0.4	0.6	0.0	0.0	0.0	0.4
<p>* A total of 964,052 CYP (weighted) were reportedly distributed in the previous 1 month. This is based on the number of commodities reportedly sold for categories 1-8 (not number of services performed for categories 6-8) and number of sterilizations reportedly performed for categories 9-10.</p> <p>† A total of 4,295 FP products were audited (3,007 contraceptive tablets, 1,004 injection products). In addition, 1,923 outlets were audited for male condoms, 223 for female condoms, 72 for CycleBeads, 37 outlets for female sterilization services and 15 outlets for male sterilization services. A total of 2 injection products and 4 tablet products were excluded from market share analysis due to inconsistent or missing generic names. 56 emergency contraceptive products, 129 oral contraceptives, 205 male condoms, 17 female condoms and 10 CycleBeads were excluded from analysis for missing volume information. 2 male sterilizations and 4 female sterilizations were excluded for similar missing volume information as well. A total of 49 products were excluded due to outlier volumes and prices.</p> <p>‡ In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs.</p> <p>§ Internationally quality-assured (IQA) contraceptives are defined as those with WHO Pre-qualification or those on a Stringent Regulatory authority (SRA) list. See Annex 8 for a list of all quality-assured brands found in the survey.</p> <p>Categories 1 through 10 sum to 100% within each column.</p>									

Source: FPwatch Outlet Survey, Nigeria, 2015

**Table A10: Availability of selected contraceptive services, among outlets screened, by outlet type – National, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, providing†:</b>	N=214	N=12	N=15	N=241	N=331	N=229	N=2,802	N=3,362	N=9,762	N=13,365
Contraceptive injection service	66.1 (53.0, 77.1)	46.8 (10.4, 86.9)	7.0 (1.3, 29.8)	60.3 (48.5, 71.1)	52.3 (34.8, 69.2)	27.8 (12.1, 51.8)	10.0 (6.6, 14.9)	15.4 (10.6, 21.8)	0.0 -	5.8 (4.6, 7.3)
Implant insertion service	22.0 (12.1, 36.5)	0.0 -	0.1 (0.0, 0.5)	17.3 (9.4, 29.6)	29.4 (17.6, 44.8)	0.4 (0.1, 3.1)	0.1 (0.0, 0.8)	3.5 (1.6, 7.8)	0.0 -	1.5 (1.1, 2.0)
IUD insertion service	19.8 (10.1, 35.2)	0.0 -	1.4 (0.2, 11.3)	15.6 (7.6, 29.4)	35.9 (25.5, 47.9)	0.0 -	0.0 -	4.2 (2.2, 8.0)	0.0 -	1.6 (1.2, 2.1)
Male sterilization service	0.9 (0.1, 5.3)	0.0 -	0.0 -	0.7 (0.1, 4.3)	1.6 (0.6, 4.3)	0.0 -	0.0 -	0.2 (0.1, 0.4)	0.0 -	0.1 (0.0, 0.2)
Female sterilization service	0.2 (0.1, 0.6)	0.0 -	0.8 (0.1, 6.9)	0.2 (0.1, 0.6)	10.6 (4.2, 24.3)	0.0 -	0.0 -	1.2 (0.3, 4.3)	0.0 -	0.3 (0.1, 0.9)
* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.										
† The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview).										
Source: FPwatch Outlet Survey, Nigeria, 2015										



**Table A111: Service readiness\* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – National, 2015**


	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total†
Proportion of outlets offering service, with*:	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)
<b>Contraceptive injection service</b>								
Availability of commodity	88.1 [71.9, 95.5] <sup>(154)</sup>	91.8 [35.2, 99.6] <sup>(3)</sup>	75.2 [24.0, 96.7] <sup>(5)</sup>	88.5 [78.4, 94.2] <sup>(162)</sup>	62.9 [53.4, 71.4] <sup>(150)</sup>	94.1 [79.4, 98.5] <sup>(49)</sup>	33.4 [18.3, 52.9] <sup>(258)</sup>	48.0 [34.1, 62.2] <sup>(459)</sup>
Availability of credentials	71.3 [47.7, 87.1] <sup>(154)</sup>	2.2 [0.1, 35.4] <sup>(3)</sup>	100.0 [100.0, 100.0] <sup>(5)</sup>	62.1 [38.2, 81.3] <sup>(162)</sup>	93.5 [75.6, 98.5] <sup>(150)</sup>	65.4 [30.8, 88.9] <sup>(49)</sup>	40.5 [20.6, 64.1] <sup>(258)</sup>	62.8 [37.0, 82.8] <sup>(459)</sup>
Availability of equipment	86.1 [53.9, 97.1] <sup>(154)</sup>	100.0 [100.0, 100.0] <sup>(3)</sup>	100.0 [100.0, 100.0] <sup>(5)</sup>	88.0 [57.7, 97.5] <sup>(162)</sup>	99.0 [95.4, 99.8] <sup>(150)</sup>	100.0 [100.0, 100.0] <sup>(49)</sup>	93.6 [86.8, 97.0] <sup>(256)</sup>	96.1 [91.7, 98.2] <sup>(457)</sup>
Service readiness	59.8 [36.5, 79.4] <sup>(154)</sup>	2.2 [0.1, 35.4] <sup>(3)</sup>	75.2 [24.0, 96.7] <sup>(5)</sup>	52.1 [26.5, 76.7] <sup>(162)</sup>	59.0 [46.9, 70.0] <sup>(150)</sup>	63.2 [28.2, 88.2] <sup>(49)</sup>	15.1 [7.4, 28.2] <sup>(256)</sup>	34.9 [22.6, 49.6] <sup>(457)</sup>
<b>Implant insertion service</b>								
Availability of commodity	85.5 [64.9, 95.0] <sup>(69)</sup>	- -	100.0 (1)	85.5 [64.9, 95.0] <sup>(70)</sup>	82.2 [50.7, 95.4] <sup>(80)</sup>	0.0 (1)	11.1 [0.6, 71.0] <sup>(4)</sup>	79.8 [45.7, 94.9] <sup>(85)</sup>
Availability of credentials	90.0 [73.4, 96.7] <sup>(69)</sup>	- -	100.0 (1)	90.0 [73.4, 96.7] <sup>(70)</sup>	99.8 [97.7, 100.0] <sup>(80)</sup>	100.0 (1)	92.3 [89.7, 94.3] <sup>(4)</sup>	99.5 [97.5, 99.9] <sup>(85)</sup>
Availability of equipment	94.9 [90.2, 97.4] <sup>(69)</sup>	- -	0.0 (1)	94.9 [90.2, 97.4] <sup>(70)</sup>	98.2 [91.8, 99.6] <sup>(80)</sup>	100.0 (1)	18.5 [3.7, 57.4] <sup>(4)</sup>	95.8 [81.6, 99.1] <sup>(85)</sup>
Service readiness	73.0 [47.9, 88.9] <sup>(69)</sup>	- -	0.0 (1)	73.0 [47.9, 88.9] <sup>(70)</sup>	82.2 [50.6, 95.4] <sup>(80)</sup>	0.0 (1)	11.1 [0.6, 71.0] <sup>(4)</sup>	79.8 [45.7, 94.9] <sup>(85)</sup>
<b>IUD insertion service</b>								
Availability of commodity	59.0 [18.6, 90.1] <sup>(71)</sup>	- -	59.3 [54.5, 64.0] <sup>(3)</sup>	59.0 [18.7, 90.0] <sup>(74)</sup>	56.4 [40.6, 71.0] <sup>(108)</sup>	- -	29.2 [1.6, 91.2] <sup>(2)</sup>	56.4 [40.6, 70.9] <sup>(110)</sup>
Availability of credentials	94.9 [82.0, 98.7] <sup>(71)</sup>	- -	96.4 [51.3, 99.8] <sup>(3)</sup>	94.9 [82.0, 98.7] <sup>(74)</sup>	99.6 [96.8, 100.0] <sup>(108)</sup>	- -	0.0 [0.0, 0.0] <sup>(2)</sup>	99.5 [97.2, 99.9] <sup>(110)</sup>
Availability of equipment	87.0 [67.2, 95.6] <sup>(69)</sup>	- -	96.4 [51.3, 99.8] <sup>(3)</sup>	87.1 [67.3, 95.7] <sup>(72)</sup>	96.9 [90.1, 99.1] <sup>(108)</sup>	- -	70.8 [8.8, 98.4] <sup>(2)</sup>	96.8 [90.0, 99.0] <sup>(110)</sup>
Service readiness	46.7 [11.4, 85.7] <sup>(69)</sup>	- -	55.7 [49.1, 62.1] <sup>(3)</sup>	46.8 [11.5, 85.6] <sup>(72)</sup>	54.9 [39.6, 69.3] <sup>(108)</sup>	- -	0.0 [0.0, 0.0] <sup>(2)</sup>	54.8 [39.6, 69.2] <sup>(110)</sup>
<b>Male sterilization</b>								
Availability of credentials	7.2 [0.3, 65.4] <sup>(2)</sup>	- -	- -	7.2 [0.3, 65.4] <sup>(2)</sup>	100.0 [100.0, 100.0] <sup>(17)</sup>	- -	- -	100.0 [100.0, 100.0] <sup>(17)</sup>
Availability of equipment	7.2 [0.3, 65.4] <sup>(2)</sup>	- -	- -	7.2 [0.3, 65.4] <sup>(2)</sup>	78.1 [33.7, 96.1] <sup>(17)</sup>	- -	- -	78.1 [33.7, 96.1] <sup>(17)</sup>
Service readiness	7.2 [0.3, 65.4] <sup>(2)</sup>	- -	- -	7.2 [0.3, 65.4] <sup>(2)</sup>	78.1 [33.7, 96.1] <sup>(17)</sup>	- -	- -	78.1 [33.7, 96.1] <sup>(17)</sup>

**Table A111: Service readiness\* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – National, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total†
Proportion of outlets offering service, with‡:	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)
<b>Female sterilization</b>								
Credentials	90.1 [42.8, 99.1] <sup>(5)</sup>	- -	100.0 (1)	91.8 [48.0, 99.3] <sup>(6)</sup>	98.4 [84.1, 99.9] <sup>(43)</sup>	- -	- -	98.4 [84.1, 99.9] <sup>(43)</sup>
Equipment	69.4 [22.1, 94.8] <sup>(5)</sup>	- -	0.0 (1)	57.2 [25.0, 84.3] <sup>(6)</sup>	92.4 [64.7, 98.8] <sup>(42)</sup>	- -	- -	92.4 [64.7, 98.8] <sup>(42)</sup>
<i>Service readiness</i>	69.4 [22.1, 94.8] <sup>(5)</sup>	- -	0.0 (1)	57.2 [25.0, 84.3] <sup>(6)</sup>	92.4 [64.7, 98.8] <sup>(42)</sup>	- -	- -	92.4 [64.7, 98.8] <sup>(42)</sup>
<p>* Full service readiness is defined as having available: 1. The commodity (not applicable for male/female sterilization); 2. A provider with credentials meeting the guidelines to perform the service (<a href="http://www.healthpolicyproject.com/ns/docs/CIP_Nigeria.pdf">http://www.healthpolicyproject.com/ns/docs/CIP_Nigeria.pdf</a>); and 3. A minimum set of sentinel equipment (<a href="http://www.cpc.unc.edu/measure/prh/rh_indicators/specific/long-acting-permanent-methods/percent-of-facilities-with-appropriate">http://www.cpc.unc.edu/measure/prh/rh_indicators/specific/long-acting-permanent-methods/percent-of-facilities-with-appropriate</a>) for providing the service. Observations that are missing information for commodity availability, provider credentials, or equipment are excluded from the 'service readiness' denominator.</p> <p>† In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.</p> <p>‡ One rural outlet in the South West region reported offering female tubal ligation, however equipment data was missing for that outlet and was therefore excluded from the denominator.</p>								
Source: FPwatch Outlet Survey, Nigeria, 2015								

**Figure A1. Modern contraceptive method market composition – National, 2015**


*Among all outlets stocking at least 1 modern contraceptive or providing at least 1 contraceptive service, by outlet type*



The private sector accounted for 86 percent of outlets stocking at least one modern contraceptive above the level of condoms only or providing services, the public sector accounted for 15 percent of this contraceptive market composition and the not-for-profit sector accounted for less than 1 percent. The private sector contraceptive market composition was largely PPMVs (72 percent) with an additional 4 percent of the market composition from pharmacies and 9 percent from private facilities. General retailers accounted for an additional 1 percent of the private market composition. Looking at the public sector, 13 percent of the total market composition was from public facilities and 2 percent from CHWs.

**Figure A2. Percentage of modern contraceptive commodity-stocking outlets with selected non-hormonal short-acting contraceptives available – National, 2015**


*Among all screened outlets, by outlet type*



In the Nigerian public sector, slightly more than half of public health facilities had male condoms available and about 40 percent had female condoms and 5 percent cyclebeads available. CHWs and not-for-profit outlets were not commonly stocking non-hormonal short-acting methods. Nearly all pharmacies and over three-quarters of PPMVs stocked male condoms. Over 10 percent of pharmacies stocked female condoms. Less than 5 percent of the numerous general retailers were found to be stocking male condoms.

**Figure A3. Percentage of modern contraceptive commodity-stocking outlets with selected hormonal short-acting contraceptives available – National, 2015**

*Among all screened outlets, by outlet type*



Looking at hormonal short-acting methods, about half of public facilities carried oral contraceptives (both combined and progestin-only pills) and 60 percent stocked injectables on the day of the survey. CHWs did not commonly stock any hormonal short-acting methods other than injectables (40 percent) and less than 5 percent of not-for-profit outlets stocked any hormonal short-acting methods. Emergency contraceptives were not stocked in the public sector. In the private sector, about 40 percent of private facilities, 80 percent of pharmacies and half of PPMVs stocked oral contraceptives but rarely progestin-only pills. Emergency contraceptives were commonly stocked in pharmacies (60 percent) but in less than 10 percent of private facilities or PPMVs. Injectables were commonly stocked in private facilities (about one-third) and pharmacies (almost two-thirds) but rarely in PPMVs (<5 percent).


**Figure A4. Percentage of modern contraceptive commodity-stocking outlets with selected long-acting contraceptives available – National, 2015**  
*Among all screened outlets, by outlet type*



For LARC commodities in the Nigerian public sector, more than 20 percent of public health facilities had implants and nearly 20 percent had IUDs available. Few not-for-profit outlets or pharmacies and no PPMVs were found to be stocking LARCs. A little over 20 percent of not-for-profit outlets stocked either implants or IUDs.

**Figure A5. Percentage of outlets with selected method mixes available – National, 2015**


*Among all screened outlets, by outlet type*



Nearly three-quarters of public facilities and half of CHWs had at least one method in stock whereas less than 10 percent of not-for-profit outlets stocked at least one method. In the private sector, 60 percent of private facilities, nearly all pharmacies and over 80 percent of PPMVs had at least one method in stock on the day of the survey. Looking at method mixes in public sector, nearly half of private facilities had at least three methods in stock and one-quarter had five or more methods available. No CHWs and few not-for-profit outlets had three or more methods available. In the private sector, nearly 30 percent of private facilities had three or more methods available and 15 percent had five or more methods available. Over three-quarters of pharmacies but only about 10 percent of PPMVs had three or more methods available.

**Figure A6. Percentage of outlets with stock outs of selected contraceptive methods – National, 2015**

*Among all outlets reportedly stocking the method at any time in the previous three months, by outlet type*




In previous graphs, availability (and the converse, non-availability) was reported by method and outlet type. In this graph, outlets reportedly stocking the method at any time in the previous three months but currently out of stock of the method is reported. In the public sector, about 15 percent of public health facilities offering oral contraceptives or injectables in the previous three months were out of stock of all brands on the day of the survey. Less than 5 percent of those carrying implants or IUDs were currently out of stock. While very few public facilities reportedly carried emergency contraceptives in the last three months, nearly 40 percent of those that did were currently out of stock. Nearly one-quarter of not-for-profit outlets reportedly stocking the method in the previous three months were currently stocked out of oral contraceptives and injectables while less than 5 and 10 percent were stocked out of implants or IUDs, respectively. Stock outs were rarely reported in pharmacies in Nigeria. For PPMVs, the most numerous outlet type commonly carrying methods, about 10 percent were currently stocked out of oral contraceptives, 30 percent were currently stocked out of emergency contraceptives and nearly 60 percent were stocked out of injectables.



**Figure A7. Price of contraceptive methods in the private sector – National, 2015**


*Median price in USD and USD/CYP with interquartile range, by contraceptive method*



The median price per CYP ranged from \$0.16 for CycleBeads and \$1.09 per CYP for IUDs to \$6.00 per CYP for contraceptive injectables and \$7.50 per CYP for male condoms and implants. Female condoms were rare and emergency contraceptives were priced very high, \$20.00 per CYP compared to other methods. With some variation, prices tended to be lower for a given method in PPMVs compared to pharmacies and private health facilities.

**Figure A8. Percentage market share for contraceptives methods – National, 2015**


*As a % of total CYP sold/distributed, by outlet type and sector*



As a proportion of the total volume of CYP for all methods, the public sector accounts for about one-quarter of total volume of CYP, almost entirely from public health facilities. Implants (14 percent), followed by contraceptive injectables (5 percent) and male condoms (4 percent) are the primary contributors in the public sector, of total CYP. The private sector accounted for nearly three-quarters of the total volume of CYP reportedly distributed in the previous month. This share came largely from private facilities (44 percent) with a large contribution also from PPMVs (26 percent). In the private sector, 29 percent of the total volume reportedly distributed came from implants distributed by private facilities and a further 12 percent came from IUDs distributed in private facilities. In PPMVs, 16 percent of the total volume of CYP distributed in Nigeria was from male condoms distributed at PPMVs and a further 5 percent was from oral contraceptives. Pharmacies accounted for only about 3 percent of the total CYP volume and general retailers for about 2 percent of the total CYP volume, with both mostly from distribution of male condoms.

**Figure A9. Within outlet market share for contraceptive methods – National, 2015**


*As a % of total CYP sold/distributed within outlet type and sector, by outlet type and sector*



Of the total volume within outlet types, LARCs (implants, 53 percent; and IUDs, 10 percent) account for more than 60 percent of public sector outlet CYP. CHWs and not-for-profit outlets contributed only a very small proportion (< 0.1 percent) of the total volume of CYP in Nigeria. The majority of CYP volume in private facilities was from implants (65 percent) and IUDs (28 percent); in PPMVs from male condoms (62 percent) and oral contraceptives (20 percent); and in pharmacies from male condoms (43 percent) and oral and emergency contraceptives (20 percent each). LARCs account for over 60 percent of the total CYP volume distributed within public sector outlets and nearly 60 percent of the total CYP volume distributed in private sector outlets.

**Figure A10. Percentage of outlets with selected contraceptive services available – National, 2015**


*Among all screened outlets, by outlet type*



Two-thirds of public sector facilities offered contraceptive injection services, while only about 20 percent offer implant or IUD insertion procedures. Male or female sterilizations were rarely offered, with less than 1 percent of public health facilities reportedly offering either male or female sterilizations. Over half of all private health facilities screened offered contraceptive injection services while about one-third offered implant and/or IUD insertions services. Over 10 percent also offered female sterilization services. In addition, over one-quarter of pharmacies and 10 percent of PPMVs reported offering contraceptive injection services.

**Figure A11. Service readiness to offer provider-dependent contraceptive services – National, 2015**

*Among outlets reportedly offering the service, by outlet type*



For injection services, nearly 60 percent of public and private health facilities, over 60 percent of pharmacies and 15 percent of PPMVs reportedly offering contraceptive injection services were found to meet service readiness requirements. Service readiness for implant insertion services was relatively high for public and private facilities, with over 70 percent of those providing services meeting conditions. Only about 45 percent of all public health facilities and slightly over half of private health facilities met conditions for service readiness for IUD insertions.

## Results Section B: Core Indicators by Geopolitical Zone

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total*
Proportion of outlet types stocking / providing at least 1 modern contraceptive method on the day of the survey, of all outlets stocking / providing at least 1 modern contraceptive method <sup>†</sup> :	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<i>Any method available, including condoms only outlets<sup>‡</sup></i>									
North Central; <b>N=540</b>	11.4 (6.6, 19.0)	5.3 (1.5, 16.5)	0.1 (0.0, 2.4)	16.8 (13.2, 21.1)	6.2 (2.5, 14.9)	1.4 (0.2, 9.2)	50 (29.8, 70.3)	25.6 (8.4, 56.4)	83.2 (78.9, 86.8)
North East; <b>N=130</b>	24.6 (7.3, 57.4)	- -	0.0 (0.0, 0.3)	24.6 (7.3, 57.4)	0.3 (0.0, 4.8)	1.2 (0.1, 9.6)	64.9 (28.6, 89.5)	9.1 (1.3, 43.1)	75.4 (42.6, 92.7)
North West; <b>N=255</b>	26.7 (9.0, 57.3)	0.0 -	0.0 -	26.7 (9.0, 57.3)	1.5 (0.4, 5.7)	0.4 (0.1, 2.1)	71.0 (43.4, 88.6)	0.5 (0.1, 2.3)	73.3 (42.7, 91.0)
South East; <b>N=331</b>	8.3 (2.5, 24.1)	0.0 -	0.0 -	8.3 (2.5, 24.1)	6.3 (5.5, 7.4)	2.2 (0.5, 8.4)	75.4 (55.3, 88.4)	7.8 (3.7, 15.7)	91.7 (75.9, 97.5)
South South; <b>N=233</b>	7.0 (1.4, 29.4)	0.0 -	0.0 -	7.0 (1.4, 29.4)	12.6 (3.4, 37.0)	2.0 (0.6, 6.6)	76.8 (73.6, 79.7)	1.6 (0.2, 14.0)	93.0 (70.6, 98.7)
South West; <b>N=2,058</b>	2.2 (0.8, 6.0)	0.4 (0.0, 4.1)	0.1 (0.0, 1.1)	2.7 (0.9, 8.1)	3.3 (1.4, 7.5)	5.3 (1.8, 14.8)	73.1 (30.2, 94.5)	15.5 (2.5, 56.8)	97.3 (91.9, 99.1)
<i>Any method available, excluding condoms only outlets<sup>§</sup></i>									
North Central; <b>N=376</b>	16.8 (10.8, 25.3)	9.4 (1.9, 36.5)	0.2 (0.0, 3.8)	26.5 (17.4, 38.1)	10.8 (4.9, 21.9)	2.2 (0.3, 13.1)	60.1 (50.5, 69.1)	0.4 (0.0, 4.1)	73.5 (61.9, 82.6)
North East; <b>N=107</b>	35.2 (8.2, 76.8)	- -	0.0 (0.0, 0.4)	35.2 (8.2, 76.8)	0.4 (0.0, 7.5)	0.4 (0.0, 9.8)	64.0 (23.5, 91.2)	0.0 -	64.8 (23.2, 91.8)
North West; <b>N=229</b>	28.8 (10.2, 59.0)	0.0 -	0.0 -	28.8 (10.2, 59.0)	1.6 (0.4, 6.6)	0.4 (0.1, 2.4)	69.2 (41.4, 87.7)	0.0 -	71.2 (41.0, 89.8)
South East; <b>N=195</b>	9.4 (4.7, 17.8)	0.0 -	0.0 -	9.4 (4.7, 17.8)	9.5 (8.2, 11.1)	3.3 (1.0, 10.6)	72.2 (54.5, 84.9)	5.6 (0.6, 35.9)	90.6 (82.2, 95.3)

**Table B1: Modern contraceptive method market composition: Relative proportion of outlets with 1 or more methods, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total*
Proportion of outlet types stocking / providing at least 1 modern contraceptive method on the day of the survey, of all outlets stocking / providing at least 1 modern contraceptive method <sup>†</sup> :	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
South South; <b>N=157</b>	10.1 (1.0, 56.9)	0.0 -	0.0 -	10.1 (1.0, 56.9)	14.1 (7.4, 25.0)	2.5 (1.1, 5.8)	73.3 (55.6, 85.8)	0.0 -	89.9 (43.1, 99.1)
South West; <b>N=1,181</b>	3.4 (1.3, 8.8)	0.8 (0.1, 7.3)	0.0 (0.0, 0.4)	4.2 (1.4, 12.2)	4.7 (1.8, 11.7)	8.9 (3.0, 24.0)	81.1 (57.4, 93.2)	1.1 (0.4, 2.5)	95.8 (87.8, 98.6)
<p>* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>† Family planning commodity stocking outlets have at least one family planning commodity in stock on the day of the survey, verified by the presence of at least one family planning commodity recorded in an audit sheet. There were 44 family planning commodity stocking outlets with partially completed interviews which were thus excluded from the denominator. In Region 1 (NC), there were 9 incomplete interviews. In Region 2 (NE), there were 8 incomplete interviews. In Region 3 (NW), there were 2 incomplete interviews. In Region 4 (SE), there were 44 incomplete interviews. In Region 5 (SS), there were 6 incomplete interviews. In Region 6 (SW), there were 39 incomplete interviews.</p> <p>‡ Includes: male condoms, female condoms, oral contraceptives, emergency contraceptives, injectables, implants, and IUDs.</p> <p>§ Includes: oral contraceptives, emergency contraceptives, injectables, implants, and IUDs.</p>									
Source: FPwatch Outlet Survey, Nigeria, 2015									

**Table B2: Availability of modern contraceptive method types, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, stocking / providing†:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
<b>Any modern method</b>										
North Central	66.8 (44.5, 83.4)	100.0 -	100.0 -	74.7 (46.1, 91.1)	62.1 (39.3, 80.5)	100.0 -	90.3 (73.2, 96.9)	86.3 (77.9, 91.8)	12.9 (3.2, 40.2)	34.9 (22.8, 49.2)
North East	59.1 (48.8, 68.6)	- -	100.0 -	59.1 (48.8, 68.7)	3.2 (0.1, 43.1)	82.1 (39.7, 97.0)	60.6 (20.6, 90.1)	56.4 (26.8, 82.1)	2.9 (0.3, 20.8)	21.1 (15.6, 27.8)
North West	58.3 (28.3, 83.2)	0.0 -	0.0 -	58.0 (28.3, 82.9)	28.8 (17.0, 44.3)	100.0 -	48.2 (24.3, 72.9)	47.6 (25.2, 71.1)	0.1 (0.0, 0.5)	11.2 (5.5, 21.7)
South East	88.1 (37.1, 98.9)	0.0 -	0.0 -	50.8 (9.2, 91.3)	49.6 (37.6, 61.6)	92.5 (61.3, 99.0)	76.3 (72.2, 80.0)	73.6 (68.8, 77.9)	2.9 (1.4, 5.9)	24.9 (19.9, 30.8)
South South	94.9 (76.0, 99.1)	0.0 -	0.0 -	84.8 (75.0, 91.2)	75.9 (23.1, 97.1)	99.0 (90.9, 99.9)	88.7 (52.7, 98.2)	86.9 (50.5, 97.7)	0.4 (0.0, 4.8)	20.8 (18.1, 23.7)
South West	89.3 (68.6, 96.9)	11.2 (0.5, 76.5)	14.2 (0.4, 87.4)	38.5 (10.1, 77.9)	41.4 (21.8, 64.1)	97.7 (92.5, 99.3)	92.3 (90.4, 93.9)	88.2 (83.8, 91.5)	6.4 (1.5, 23.0)	29.2 (23.4, 35.9)
<b>Any short-acting method</b>										
North Central	66.8 (44.5, 83.4)	100.0 -	100.0 -	74.7 (46.1, 91.1)	62.1 (39.3, 80.5)	100.0 -	90.3 (73.2, 96.9)	86.3 (77.9, 91.8)	12.9 (3.2, 40.2)	34.9 (22.8, 49.2)
North East	59.1 (48.8, 68.6)	- -	100.0 -	59.1 (48.8, 68.7)	0.4 (0.2, 1.2)	82.1 (39.7, 97.0)	60.6 (20.6, 90.1)	56.2 (26.8, 81.8)	2.9 (0.3, 20.8)	21.0 (15.5, 27.9)
North West	58.3 (28.3, 83.2)	0.0 -	0.0 -	58.0 (28.3, 82.9)	28.8 (17.0, 44.3)	100.0 -	48.2 (24.3, 72.9)	47.6 (25.2, 71.1)	0.1 (0.0, 0.5)	11.2 (5.5, 21.7)
South East	88.1 (37.1, 98.9)	0.0 -	0.0 -	50.8 (9.2, 91.3)	46.6 (33.5, 60.1)	92.5 (61.3, 99.0)	76.3 (72.2, 80.0)	73.3 (68.8, 77.4)	2.9 (1.4, 5.9)	24.8 (19.8, 30.7)
South South	94.9 (76.0, 99.1)	0.0 -	0.0 -	84.8 (75.0, 91.2)	75.9 (23.1, 97.1)	99.0 (90.9, 99.9)	88.7 (52.7, 98.2)	86.9 (50.5, 97.7)	0.4 (0.0, 4.8)	20.8 (18.1, 23.7)
South West	89.1 (68.3, 96.9)	11.2 (0.5, 76.5)	14.2 (0.4, 87.4)	38.5 (10.1, 77.7)	36.0 (17.5, 59.8)	97.7 (92.5, 99.3)	92.3 (90.4, 93.9)	87.7 (83.2, 91.1)	6.4 (1.5, 23.0)	29.1 (23.3, 35.7)
<b>Any LARC method</b>										



**Table B2: Availability of modern contraceptive method types, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, stocking / providing†:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
North Central	26.7 (8.0, 60.5)	0.0 -	0.0 -	20.3 (9.6, 37.9)	29.5 (8.1, 66.7)	0.3 (0.0, 5.8)	0.1 (0.0, 0.9)	4.5 (1.7, 11.2)	0.0 -	2.6 (1.2, 5.8)
North East	16.7 (0.9, 81.2)	- -	100.0 -	16.7 (0.9, 81.2)	0.4 (0.2, 1.2)	0.0 -	0.1 (0.0, 1.4)	0.1 (0.0, 1.2)	0.0 -	1.5 (0.1, 15.9)
North West	7.7 (2.2, 24.0)	0.0 -	0.0 -	7.7 (2.2, 23.7)	0.0 -	0.0 -	0.0 (0.0, 0.4)	0.0 (0.0, 0.4)	0.0 -	0.4 (0.1, 1.1)
South East	2.0 (0.3, 13.7)	0.0 -	0.0 -	1.2 (0.1, 13.3)	15.9 (2.2, 61.7)	1.3 (0.1, 16.1)	0.1 (0.0, 1.7)	1.9 (0.3, 12.1)	0.0 -	0.6 (0.1, 3.4)
South South	63.8 (31.5, 87.1)	0.0 -	0.0 -	57.0 (25.2, 83.8)	40.0 (26.0, 55.8)	2.5 (0.5, 12.8)	0.0 (0.0, 0.5)	6.4 (2.1, 18.1)	0.0 -	2.4 (1.6, 3.4)
South West	57.5 (18.2, 89.1)	0.0 -	2.7 (0.1, 42.3)	20.2 (7.3, 44.9)	16.2 (5.8, 37.9)	0.8 (0.2, 3.5)	0.0 -	1.5 (0.5, 4.2)	0.0 -	0.8 (0.5, 1.2)
<b>Any permanent method</b>										
North Central	0.1 (0.0, 2.0)	0.0 -	0.0 -	0.1 (0.0, 1.7)	2.9 (0.5, 15.9)	0.0 -	0.0 -	0.4 (0.1, 2.5)	0.0 -	0.1 (0.0, 0.7)
North East	7.6 (0.8, 47.2)	- -	0.0 -	7.6 (0.7, 47.2)	2.8 (0.1, 55.0)	0.0 -	0.0 -	0.2 (0.0, 6.1)	0.0 -	0.7 (0.0, 11.4)
North West	0.4 (0.1, 2.4)	0.0 -	0.0 -	0.4 (0.1, 2.3)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 (0.0, 0.1)
South East	0.0 -	0.0 -	0.0 -	0.0 -	10.4 (5.1, 20.0)	0.0 -	0.0 -	1.2 (0.7, 1.8)	0.0 -	0.3 (0.2, 0.7)
South South	0.0 -	0.0 -	0.0 -	0.0 -	17.9 (7.9, 35.7)	0.0 -	0.0 -	2.8 (0.6, 11.9)	0.0 -	0.6 (0.2, 2.3)
South West	1.1 (0.2, 7.1)	0.0 -	2.7 (0.1, 42.3)	0.7 (0.1, 7.4)	5.7 (0.9, 28.4)	0.0 -	0.0 -	0.5 (0.0, 5.3)	0.0 -	0.1 (0.0, 1.1)
<b>Any LARC/PM</b>										
North Central	26.7 (8.0, 60.5)	0.0 -	0.0 -	20.3 (9.6, 37.9)	31.4 (9.5, 66.6)	0.3 (0.0, 5.8)	0.1 (0.0, 0.9)	4.8 (2.0, 11.1)	0.0 -	2.7 (1.3, 5.7)

**Table B2: Availability of modern contraceptive method types, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, stocking / providing†:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
North East	24.3 (6.7, 58.9)	- -	100.0 -	24.3 (6.7, 58.9)	3.2 (0.1, 43.1)	0.0 -	0.1 (0.0, 1.4)	0.3 (0.0, 3.0)	0.0 -	2.2 (0.4, 10.2)
North West	7.8 (2.2, 24.2)	0.0 -	0.0 -	7.8 (2.2, 23.9)	0.0 -	0.0 -	0.0 (0.0, 0.4)	0.0 (0.0, 0.4)	0.0 -	0.4 (0.1, 1.1)
South East	2.0 (0.3, 13.7)	0.0 -	0.0 -	1.2 (0.1, 13.3)	23.3 (6.9, 55.6)	1.3 (0.1, 16.1)	0.1 (0.0, 1.7)	2.7 (0.8, 9.1)	0.0 -	0.8 (0.3, 2.6)
South South	63.8 (31.5, 87.1)	0.0 -	0.0 -	57.0 (25.2, 83.8)	40.0 (26.0, 55.8)	2.5 (0.5, 12.8)	0.0 (0.0, 0.5)	6.4 (2.1, 18.1)	0.0 -	2.4 (1.6, 3.4)
South West	58.6 (19.7, 89.1)	0.0 -	2.7 (0.1, 42.3)	20.6 (7.5, 45.3)	18.3 (6.3, 42.9)	0.8 (0.2, 3.5)	0.0 -	1.7 (0.5, 5.3)	0.0 -	0.9 (0.5, 1.4)
<p>* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.</p> <p>† The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview). In Region 1 (NC), the denominator includes 9 outlets that met screening criteria for a full interview but did not complete the interview. In Region 2 (NE), the denominator includes 8 outlets that met screening criteria for a full interview but did not complete the interview. In Region 3 (NW), the denominator includes 2 outlets that met screening criteria for a full interview but did not complete the interview. In Region 4 (SE), the denominator includes 4 outlets that met screening criteria for a full interview but did not complete the interview. In Region 5 (SS), the denominator includes 6 outlets that met screening criteria for a full interview but did not complete the interview. In Region 6 (SW), the denominator includes 39 outlets that met screening criteria for a full interview but did not complete the interview.</p>										
Source: FPwatch Outlet Survey, Nigeria, 2015										

**Table B3: Availability of selected contraceptive methods, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking<sup>†</sup>:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
<b>Male condoms</b>										
North Central	55.3 (29.8, 78.3)	0.9 (0.0, 26.1)	100.0 -	42.9 (32.1, 54.4)	32.0 (14.1, 57.5)	96.1 (71.7, 99.6)	79.7 (70.6, 86.5)	72.9 (64.2, 80.1)	12.9 (3.2, 40.3)	29.2 (20.5, 39.7)
North East	56.3 (42.8, 69.0)	- -	100.0 -	56.4 (42.8, 69.0)	0.3 (0.1, 1.9)	82.1 (39.7, 97.0)	56.9 (22.9, 85.5)	52.8 (28.2, 76.2)	2.9 (0.3, 20.8)	20.0 (13.8, 27.9)
North West	22.2 (13.1, 35.1)	0.0 -	0.0 -	22.1 (13.1, 34.8)	4.7 (3.2, 6.8)	72.5 (62.5, 80.7)	23.3 (7.4, 53.7)	22.8 (7.6, 51.2)	0.1 (0.0, 0.5)	5.1 (1.9, 13.3)
South East	73.3 (32.6, 94.0)	0.0 -	0.0 -	42.2 (7.1, 87.5)	27.8 (24.0, 31.9)	85.6 (58.3, 96.2)	72.7 (68.3, 76.7)	67.9 (63.4, 72.1)	2.9 (1.4, 5.9)	23.0 (18.3, 28.5)
South South	93.4 (71.8, 98.7)	0.0 -	0.0 -	82.5 (69.1, 90.8)	58.0 (29.4, 82.1)	93.7 (56.5, 99.4)	88.3 (54.0, 98.0)	83.6 (59.2, 94.7)	0.4 (0.0, 4.8)	19.9 (17.0, 23.3)
South West	54.6 (18.0, 86.9)	0.0 -	11.6 (0.3, 83.1)	20.2 (5.8, 51.0)	28.7 (11.3, 56.0)	96.7 (89.6, 99.0)	88.2 (84.0, 91.5)	83.6 (80.4, 86.3)	6.4 (1.5, 23.0)	27.6 (22.3, 33.6)
<b>Female condoms</b>										
North Central	20.2 (12.4, 31.2)	0.0 -	0.0 -	15.3 (7.0, 30.5)	0.7 (0.0, 9.3)	14.1 (3.6, 42.2)	11.7 (2.9, 36.6)	10.1 (2.8, 30.4)	2.6 (0.5, 12.4)	5.3 (2.1, 13.0)
North East	51.7 (33.0, 70.0)	- -	100.0 -	51.8 (33.0, 70.0)	0.0 -	17.2 (2.3, 64.7)	0.2 (0.0, 5.6)	0.4 (0.0, 10.5)	0.0 -	4.7 (0.9, 20.1)
North West	12.1 (3.3, 35.8)	0.0 -	0.0 -	12.0 (3.3, 35.6)	0.0 -	34.8 (24.3, 47.1)	1.4 (0.5, 3.5)	1.4 (0.6, 3.5)	0.0 (0.0, 0.1)	0.9 (0.2, 3.3)
South East	50.3 (11.2, 89.1)	0.0 -	0.0 -	29.0 (3.8, 80.8)	4.8 (0.8, 23.6)	5.2 (0.6, 32.6)	3.0 (0.9, 9.5)	3.2 (0.9, 10.9)	0.0 -	2.1 (0.8, 5.3)
South South	85.4 (69.1, 93.8)	0.0 -	0.0 -	75.4 (47.2, 91.3)	17.7 (7.4, 36.7)	8.2 (1.1, 42.3)	1.5 (0.3, 6.5)	4.2 (1.4, 11.7)	0.0 -	2.1 (1.1, 4.0)
South West	52.4 (17.6, 85.0)	0.0 -	9.6 (0.3, 78.7)	19.2 (5.2, 50.7)	5.8 (1.7, 18.1)	15.8 (5.2, 39.3)	1.9 (1.0, 3.5)	3.0 (1.3, 7.0)	0.1 (0.0, 0.4)	1.3 (0.8, 1.9)
<b>Cyclebeads</b>										
North Central	0.2 (0.0, 3.3)	0.0 -	0.0 -	0.2 (0.0, 2.8)	0.0 -	0.0 -	0.3 (0.1, 0.8)	0.2 (0.1, 0.6)	0.0 -	0.1 (0.0, 0.1)

**Table B3: Availability of selected contraceptive methods, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking<sup>†</sup>:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
North East	0.0 -	- -	100.0 -	0.0 (0.0, 0.6)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 (0.0, 0.1)
North West	13.2 (4.4, 33.5)	0.0 -	0.0 -	13.2 (4.4, 33.3)	0.0 -	0.0 -	1.4 (0.5, 4.4)	1.4 (0.5, 4.0)	0.0 -	0.9 (0.3, 2.6)
South East	9.1 (0.7, 59.0)	0.0 -	0.0 -	5.2 (0.4, 45.6)	5.0 (0.8, 26.7)	0.0 -	5.2 (0.6, 34.0)	5.1 (0.7, 27.8)	0.0 -	1.7 (0.4, 7.2)
South South	12.1 (1.0, 64.6)	0.0 -	0.0 -	10.8 (0.9, 61.5)	4.4 (0.2, 55.6)	0.0 -	0.4 (0.1, 2.0)	1.1 (0.2, 6.5)	0.0 -	0.4 (0.1, 1.5)
South West	11.9 (1.5, 53.9)	0.0 -	0.0 -	4.1 (0.3, 35.6)	0.1 (0.0, 1.0)	0.3 (0.0, 6.5)	0.7 (0.1, 4.2)	0.6 (0.1, 3.1)	0.0 -	0.2 (0.1, 1.2)
<b>Oral contraceptives</b>										
North Central	33.6 (16.1, 57.0)	0.0 -	100.0 -	26.1 (8.3, 57.9)	42.4 (22.1, 65.6)	81.4 (52.5, 94.5)	57.9 (40.4, 73.6)	56.1 (40.6, 70.4)	0.1 (0.0, 1.0)	15.2 (11.8, 19.3)
North East	48.3 (27.4, 69.7)	- -	100.0 -	48.3 (27.5, 69.7)	0.4 (0.2, 1.2)	17.9 (3.0, 60.3)	39.5 (11.0, 77.5)	36.2 (12.9, 68.5)	0.0 -	13.2 (7.8, 21.4)
North West	35.3 (22.1, 51.2)	0.0 -	0.0 -	35.2 (22.0, 51.0)	3.2 (0.1, 53.1)	100.0 -	35.8 (20.4, 54.7)	34.8 (20.8, 52.0)	0.0 -	7.8 (4.2, 14.1)
South East	43.0 (16.3, 74.5)	0.0 -	0.0 -	24.8 (4.5, 69.5)	11.8 (3.5, 32.8)	66.9 (20.0, 94.2)	38.9 (18.6, 64.0)	36.4 (18.4, 59.4)	1.1 (0.1, 13.0)	12.1 (6.8, 20.8)
South South	93.9 (71.4, 98.9)	0.0 -	0.0 -	83.8 (73.5, 90.7)	58.0 (29.6, 82.0)	83.5 (40.5, 97.4)	55.6 (9.6, 93.6)	56.4 (12.0, 92.5)	0.0 -	13.8 (7.8, 23.1)
South West	79.2 (44.3, 94.8)	11.2 (0.5, 76.5)	0.0 -	33.5 (8.3, 73.5)	16.8 (8.7, 30.0)	78.5 (53.4, 92.0)	57.2 (38.2, 74.2)	54.9 (41.8, 67.4)	0.2 (0.1, 0.4)	15.7 (12.7, 19.4)
<b>IQA<sup>†</sup> oral contraceptives</b>										
North Central	33.6 (16.1, 57.0)	0.0 -	100.0 -	26.1 (8.3, 57.9)	42.4 (22.1, 65.6)	81.4 (52.5, 94.5)	57.9 (40.4, 73.6)	56.0 (40.6, 70.4)	0.1 (0.0, 1.0)	15.2 (11.8, 19.3)
North East	48.3	-	100.0	48.3	0.4	17.9	39.5	36.2	0.0	13.2

**Table B3: Availability of selected contraceptive methods, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking<sup>†</sup>:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
	(27.4, 69.7)	-	-	(27.5, 69.7)	(0.2, 1.2)	(3.0, 60.3)	(11.0, 77.5)	(12.9, 68.5)	-	(7.8, 21.4)
North West	35.3 (22.1, 51.2)	0.0 -	0.0 -	35.2 (22.0, 51.0)	3.2 (0.1, 53.1)	100.0 -	35.8 (20.4, 54.7)	34.8 (20.8, 52.0)	0.0 -	7.8 (4.2, 14.1)
South East	43.0 (16.3, 74.5)	0.0 -	0.0 -	24.8 (4.5, 69.5)	11.1 (3.0, 33.4)	66.9 (20.0, 94.2)	38.9 (18.6, 64.0)	36.4 (18.4, 59.1)	1.1 (0.1, 13.0)	12.1 (6.8, 20.7)
South South	93.9 (71.4, 98.9)	0.0 -	0.0 -	83.8 (73.5, 90.7)	58.0 (29.6, 82.0)	83.5 (40.5, 97.4)	55.6 (9.6, 93.6)	56.4 (12.0, 92.5)	0.0 -	13.8 (7.8, 23.1)
South West	79.2 (44.3, 94.8)	11.2 (0.5, 76.5)	0.0 -	33.5 (8.3, 73.5)	16.3 (8.5, 29.1)	78.5 (53.5, 92.1)	56.4 (38.9, 72.4)	54.2 (42.2, 65.8)	0.2 (0.1, 0.4)	15.5 (12.3, 19.4)
<i>Combined oral contraceptives</i>										
North Central	29.5 (12.3, 55.5)	0.0 -	100.0 -	23.0 (7.0, 54.2)	42.4 (22.1, 65.6)	81.4 (52.5, 94.5)	57.8 (40.2, 73.6)	56.0 (40.4, 70.5)	0.1 (0.0, 1.0)	14.9 (11.6, 19.0)
North East	48.3 (27.4, 69.7)	- -	100.0 -	48.3 (27.5, 69.7)	0.4 (0.2, 1.2)	17.9 (3.0, 60.3)	39.5 (11.0, 77.5)	36.2 (12.9, 68.5)	0.0 -	13.2 (7.8, 21.4)
North West	33.3 (21.0, 48.4)	0.0 -	0.0 -	33.1 (20.8, 48.3)	3.2 (0.1, 53.1)	100.0 -	35.3 (20.5, 53.7)	34.4 (20.8, 51.1)	0.0 -	7.6 (4.1, 13.7)
South East	32.3 (9.6, 68.3)	0.0 -	0.0 -	18.6 (3.1, 62.1)	11.1 (3.0, 33.4)	66.9 (20.0, 94.2)	38.9 (18.6, 64.0)	36.4 (18.4, 59.1)	1.1 (0.1, 13.0)	11.9 (6.6, 20.4)
South South	89.2 (43.5, 98.9)	0.0 -	0.0 -	79.7 (57.3, 92.0)	58.0 (29.6, 82.0)	83.5 (40.5, 97.4)	55.6 (9.6, 93.6)	56.4 (12.0, 92.5)	0.0 -	13.7 (7.8, 22.9)
South West	49.4 (15.9, 83.5)	11.2 (0.5, 76.5)	0.0 -	23.1 (5.6, 60.6)	16.8 (8.7, 30.0)	78.5 (53.4, 92.0)	57.2 (38.2, 74.2)	54.9 (41.8, 67.4)	0.2 (0.1, 0.4)	15.5 (12.2, 19.5)
<i>Progestin-only pills</i>										
North Central	26.5 (11.4, 50.2)	0.0 -	100.0 -	20.7 (6.6, 49.2)	0.0 -	0.6 (0.0, 11.5)	0.1 (0.0, 1.4)	0.1 (0.0, 1.0)	0.0 -	1.7 (0.7, 4.1)
North East	14.0 (1.2, 68.9)	- -	100.0 -	14.0 (1.2, 68.9)	0.1 (0.0, 5.1)	0.0 -	0.0 -	0.0 (0.0, 0.3)	0.0 -	1.2 (0.2, 7.2)
North West	18.9	0.0	0.0	18.8	0.0	0.0	2.4	2.3	0.0	1.4

**Table B3: Availability of selected contraceptive methods, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking<sup>†</sup>:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
	(8.4, 37.4)	-	-	(8.4, 37.1)	-	-	(0.6, 9.1)	(0.6, 8.4)	-	(0.4, 4.2)
South East	34.9 (12.9, 66.1)	0.0 -	0.0 -	20.1 (3.6, 62.9)	2.3 (0.4, 12.8)	0.0 -	0.0 (0.0, 0.8)	0.3 (0.0, 1.8)	0.0 -	0.9 (0.2, 3.8)
South South	93.2 (70.6, 98.7)	0.0 -	0.0 -	83.2 (72.0, 90.5)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	1.4 (0.2, 7.8)
South West	74.9 (42.6, 92.3)	0.0 -	0.0 -	25.9 (9.3, 54.4)	0.2 (0.0, 1.0)	0.0 -	0.0 (0.0, 0.1)	0.0 (0.0, 0.1)	0.0 -	0.5 (0.2, 1.2)
<b>Emergency contraceptives</b>										
North Central	0.0 -	0.0 -	0.0 -	0.0 -	1.7 (0.3, 9.1)	55.5 (29.1, 79.1)	13.2 (5.5, 28.4)	12.3 (5.5, 25.2)	0.0 -	2.9 (1.6, 5.0)
North East	0.5 (0.0, 22.3)	- -	0.0 -	0.5 (0.0, 22.3)	0.0 -	17.9 (3.0, 60.3)	3.2 (0.7, 13.7)	3.1 (0.7, 12.5)	0.0 -	0.8 (0.3, 2.6)
North West	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	43.8 (26.7, 62.5)	2.9 (0.7, 10.8)	2.9 (0.8, 10.3)	0.0 -	0.5 (0.1, 2.1)
South East	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	51.6 (12.1, 89.1)	5.8 (3.3, 10.0)	6.1 (2.9, 12.1)	0.0 (0.0, 1.1)	1.8 (0.8, 3.7)
South South	0.0 -	0.0 -	0.0 -	0.0 -	17.7 (7.4, 36.7)	70.0 (23.0, 94.8)	16.1 (3.6, 49.6)	17.3 (4.4, 48.6)	0.0 -	3.8 (1.3, 10.6)
South West	0.0 -	0.0 -	0.0 -	0.0 -	1.0 (0.1, 7.1)	67.1 (53.7, 78.3)	6.3 (2.5, 14.8)	9.4 (3.7, 22.2)	0.1 (0.0, 0.4)	2.6 (1.6, 4.2)
<b>IQA<sup>‡</sup> emergency contraceptives</b>										
North Central	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	47.0 (25.0, 70.1)	11.4 (3.8, 29.8)	10.4 (3.8, 25.5)	0.0 -	2.4 (1.1, 5.2)
North East	0.5 (0.0, 22.3)	- -	0.0 -	0.5 (0.0, 22.3)	0.0 -	17.9 (3.0, 60.3)	3.2 (0.7, 13.7)	3.1 (0.7, 12.5)	0.0 -	0.8 (0.3, 2.6)
North West	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	43.8 (26.7, 62.5)	2.5 (0.6, 10.1)	2.6 (0.6, 9.7)	0.0 -	0.4 (0.1, 2.0)

**Table B3: Availability of selected contraceptive methods, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking<sup>†</sup>:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
South East	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	51.6 (12.1, 89.1)	4.9 (3.3, 7.1)	5.3 (2.9, 9.4)	0.0 (0.0, 1.1)	1.5 (0.8, 2.9)
South South	0.0 -	0.0 -	0.0 -	0.0 -	17.7 (7.4, 36.7)	70.0 (23.0, 94.8)	14.4 (3.3, 45.7)	16.0 (4.2, 45.6)	0.0 -	3.5 (1.2, 9.8)
South West	0.0 -	0.0 -	0.0 -	0.0 -	0.4 (0.1, 2.8)	43.7 (34.4, 53.4)	5.0 (2.5, 9.9)	6.9 (3.1, 14.6)	0.0 (0.0, 0.1)	1.9 (1.3, 2.8)
<b>Contraceptive injectables</b>										
North Central	41.4 (18.3, 69.0)	99.1 (73.9, 100.0)	100.0 -	55.2 (44.0, 65.9)	38.6 (7.1, 83.7)	74.9 (62.4, 84.3)	4.5 (1.5, 12.6)	11.0 (3.4, 30.6)	0.0 -	6.9 (4.3, 10.8)
North East	56.3 (42.8, 69.0)	- -	100.0 -	56.4 (42.8, 69.0)	0.0 -	17.9 (3.0, 60.3)	11.8 (2.2, 44.4)	10.9 (2.1, 40.8)	0.0 -	7.6 (2.4, 21.8)
North West	54.2 (20.4, 84.5)	0.0 -	0.0 -	54.0 (20.5, 84.3)	28.8 (17.0, 44.3)	72.5 (62.5, 80.7)	26.3 (15.8, 40.4)	26.5 (16.2, 40.2)	0.0 -	7.3 (3.5, 14.8)
South East	48.2 (31.0, 65.9)	0.0 -	0.0 -	27.8 (8.2, 62.3)	22.9 (8.4, 49.0)	16.5 (2.5, 60.0)	1.2 (0.4, 3.2)	3.9 (1.9, 8.0)	0.0 -	2.2 (1.2, 4.1)
South South	93.9 (71.4, 98.9)	0.0 -	0.0 -	83.8 (73.5, 90.7)	40.3 (26.8, 55.5)	75.4 (21.7, 97.1)	1.7 (0.5, 5.5)	9.2 (3.2, 23.4)	0.0 -	3.5 (2.7, 4.5)
South West	78.2 (45.6, 93.9)	0.0 -	2.7 (0.1, 42.3)	27.4 (9.6, 57.2)	19.7 (9.4, 36.9)	62.1 (23.9, 89.6)	1.3 (0.2, 7.5)	6.5 (2.4, 16.4)	0.0 -	2.3 (1.3, 4.0)
<b>Depo-provera injectables</b>										
North Central	39.4 (16.6, 67.8)	2.3 (0.1, 49.1)	100.0 -	31.1 (8.7, 68.0)	27.1 (4.5, 74.5)	60.5 (42.2, 76.3)	3.5 (1.3, 9.0)	8.2 (2.7, 22.5)	0.0 -	4.3 (1.5, 11.8)
North East	47.8 (25.0, 71.5)	- -	100.0 -	47.8 (25.0, 71.5)	0.0 -	17.9 (3.0, 60.3)	5.9 (1.7, 18.7)	5.6 (1.6, 18.0)	0.0 -	5.6 (2.0, 14.4)
North West	53.9 (20.3, 84.3)	0.0 -	0.0 -	53.6 (20.3, 84.0)	16.5 (5.3, 41.2)	37.7 (20.0, 59.4)	23.7 (13.8, 37.6)	23.5 (14.3, 36.1)	0.0 -	6.8 (3.2, 13.9)
South East	46.2	0.0	0.0	26.6	22.9	16.5	1.2	3.9	0.0	2.2

**Table B3: Availability of selected contraceptive methods, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking<sup>†</sup>:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
	(28.2, 65.2)	-	-	(8.1, 59.8)	(8.4, 49.0)	(2.5, 60.0)	(0.4, 3.2)	(1.9, 8.0)	-	(1.2, 4.1)
South South	93.9 (71.4, 98.9)	0.0 -	0.0 -	83.8 (73.5, 90.7)	22.1 (18.6, 26.0)	65.0 (14.5, 95.3)	1.6 (0.5, 5.3)	6.0 (2.5, 13.7)	0.0 -	2.8 (1.5, 4.9)
South West	59.6 (19.8, 89.9)	0.0 -	2.7 (0.1, 42.3)	20.9 (7.8, 45.2)	17.8 (8.3, 34.2)	61.1 (22.7, 89.4)	1.1 (0.1, 7.6)	6.1 (2.3, 15.1)	0.0 -	2.1 (1.3, 3.3)
<i>Noristerat injectables</i>										
North Central	36.7 (16.4, 63.2)	99.1 (73.9, 100.0)	100.0 -	51.7 (37.6, 65.4)	21.5 (3.2, 69.3)	66.6 (56.0, 75.7)	3.5 (1.0, 11.0)	7.5 (1.9, 25.1)	0.0 -	5.8 (3.9, 8.6)
North East	46.2 (24.6, 69.3)	- -	100.0 -	46.2 (24.7, 69.2)	0.0 -	17.2 (2.3, 64.7)	9.6 (1.2, 48.1)	9.0 (1.2, 43.8)	0.0 -	6.3 (2.1, 17.2)
North West	31.1 (14.9, 53.8)	0.0 -	0.0 -	31.0 (14.9, 53.6)	25.6 (17.7, 35.5)	72.5 (62.5, 80.7)	19.5 (8.1, 40.1)	19.9 (8.4, 40.2)	0.0 -	5.0 (2.2, 11.0)
South East	39.6 (15.3, 70.4)	0.0 -	0.0 -	22.8 (3.9, 68.1)	5.2 (2.0, 12.6)	2.6 (0.2, 28.7)	0.1 (0.0, 1.6)	0.7 (0.2, 2.2)	0.0 -	1.1 (0.3, 4.3)
South South	91.8 (58.6, 98.9)	0.0 -	0.0 -	82.0 (67.6, 90.9)	40.3 (26.8, 55.5)	75.4 (21.7, 97.1)	0.3 (0.1, 0.6)	8.0 (2.8, 20.7)	0.0 -	3.2 (2.2, 4.5)
South West	76.8 (44.2, 93.2)	0.0 -	2.7 (0.1, 42.3)	26.9 (9.6, 56.0)	9.1 (3.4, 22.1)	46.8 (14.9, 81.5)	0.6 (0.1, 4.9)	4.1 (1.8, 9.1)	0.0 -	1.7 (1.1, 2.6)
<i>Sayana Press injectables</i>										
North Central	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	1.6 (0.1, 17.9)	0.0 -	0.0 (0.0, 0.5)	0.0 -	0.0 (0.0, 0.1)
North East	0.0 -	- -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
North West	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
South East	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.4 (0.0, 10.0)	0.4 (0.0, 8.6)	0.0 -	0.1 (0.0, 2.1)



**Table B3: Availability of selected contraceptive methods, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking<sup>†</sup>:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
South South	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	1.1 (0.2, 5.8)	0.9 (0.2, 4.2)	0.0 -	0.2 (0.1, 0.8)
South West	0.0 -	0.0 -	0.0 -	0.0 -	1.1 (0.2, 5.6)	1.6 (0.5, 4.7)	0.1 (0.0, 1.0)	0.3 (0.0, 2.7)	0.0 -	0.1 (0.0, 0.5)
<b>Implants</b>										
North Central	21.4 (3.9, 64.6)	0.0 -	0.0 -	16.3 (5.0, 41.6)	20.1 (3.2, 65.9)	0.0 -	0.0 -	3.0 (0.5, 14.9)	0.0 -	2.0 (0.5, 7.1)
North East	16.7 (0.9, 81.2)	- -	100.0 -	16.7 (0.9, 81.2)	0.1 (0.0, 5.1)	0.0 -	0.0 -	0.0 (0.0, 0.3)	0.0 -	1.5 (0.1, 16.4)
North West	7.7 (2.2, 24.0)	0.0 -	0.0 -	7.7 (2.2, 23.7)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.4 (0.1, 1.1)
South East	2.0 (0.3, 13.7)	0.0 -	0.0 -	1.2 (0.1, 13.3)	14.0 (1.2, 68.1)	0.0 -	0.0 -	1.6 (0.1, 15.8)	0.0 -	0.5 (0.1, 4.6)
South South	59.1 (23.0, 87.5)	0.0 -	0.0 -	52.8 (19.8, 83.5)	39.7 (25.3, 56.2)	2.5 (0.5, 12.8)	0.0 (0.0, 0.5)	6.3 (2.0, 18.3)	0.0 -	2.3 (1.5, 3.4)
South West	33.0 (9.3, 70.2)	0.0 -	0.0 -	11.4 (5.4, 22.4)	4.1 (0.7, 19.5)	0.0 -	0.0 (0.0, 0.1)	0.4 (0.0, 3.6)	0.0 -	0.3 (0.1, 0.8)
<b>Implanon implants</b>										
North Central	21.3 (3.8, 64.8)	0.0 -	0.0 -	16.2 (4.9, 41.8)	19.6 (2.9, 66.4)	0.0 -	0.0 -	2.9 (0.5, 15.4)	0.0 -	2.0 (0.5, 7.2)
North East	16.5 (0.9, 81.8)	- -	100.0 -	16.6 (0.9, 81.8)	0.1 (0.0, 5.1)	0.0 -	0.0 -	0.0 (0.0, 0.3)	0.0 -	1.5 (0.1, 16.8)
North West	6.9 (1.5, 26.2)	0.0 -	0.0 -	6.9 (1.5, 25.9)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.4 (0.1, 1.1)
South East	2.0 (0.3, 13.7)	0.0 -	0.0 -	1.2 (0.1, 13.3)	11.0 (1.1, 58.8)	0.0 -	0.0 -	1.2 (0.1, 12.3)	0.0 -	0.4 (0.0, 3.6)
South South	59.1 (23.0, 87.5)	0.0 -	0.0 -	52.8 (19.8, 83.5)	35.4 (13.4, 66.0)	0.0 -	0.0 (0.0, 0.5)	5.6 (1.2, 23.0)	0.0 -	2.1 (1.4, 3.1)
South West	31.3	0.0	0.0	10.8	0.6	0.0	0.0	0.1	0.0	0.2

**Table B3: Availability of selected contraceptive methods, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking†:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
	(8.2, 69.9)	-	-	(5.2, 21.2)	(0.2, 1.8)	-	-	(0.0, 0.4)	-	(0.1, 0.5)
<i>Jadelle implants</i>										
North Central	3.0 (0.4, 20.5)	0.0 -	0.0 -	2.3 (0.3, 17.6)	19.6 (2.9, 66.5)	0.0 -	0.0 -	2.9 (0.5, 15.4)	0.0 -	0.9 (0.3, 2.6)
North East	1.9 (0.3, 11.6)	- -	100.0 -	1.9 (0.3, 11.9)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.2 (0.0, 1.8)
North West	7.5 (2.2, 22.9)	0.0 -	0.0 -	7.5 (2.2, 22.6)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.4 (0.1, 1.1)
South East	2.0 (0.3, 13.7)	0.0 -	0.0 -	1.2 (0.1, 13.3)	14.0 (1.2, 68.1)	0.0 -	0.0 -	1.6 (0.1, 15.8)	0.0 -	0.5 (0.1, 4.6)
South South	59.1 (23.0, 87.5)	0.0 -	0.0 -	52.8 (19.8, 83.5)	39.7 (25.3, 56.2)	2.5 (0.5, 12.8)	0.0 (0.0, 0.5)	6.3 (2.0, 18.3)	0.0 -	2.3 (1.5, 3.4)
South West	24.7 (4.1, 71.6)	0.0 -	0.0 -	8.6 (3.3, 20.4)	3.5 (0.6, 18.5)	0.0 -	0.0 (0.0, 0.1)	0.3 (0.0, 3.3)	0.0 -	0.3 (0.1, 0.6)
<i>IUDs</i>										
North Central	19.0 (5.9, 46.7)	0.0 -	0.0 -	14.4 (6.6, 28.7)	29.5 (8.0, 66.7)	0.3 (0.0, 5.8)	0.1 (0.0, 0.9)	4.5 (1.7, 11.3)	0.0 -	2.2 (0.9, 5.1)
North East	4.3 (0.3, 39.1)	- -	100.0 -	4.3 (0.3, 39.0)	0.4 (0.2, 1.2)	0.0 -	0.1 (0.0, 1.4)	0.1 (0.0, 1.2)	0.0 -	0.4 (0.1, 1.9)
North West	3.5 (0.5, 21.7)	0.0 -	0.0 -	3.5 (0.5, 21.4)	0.0 -	0.0 -	0.0 (0.0, 0.4)	0.0 (0.0, 0.4)	0.0 -	0.2 (0.0, 0.9)
South East	2.0 (0.3, 13.7)	0.0 -	0.0 -	1.2 (0.1, 13.3)	14.4 (2.2, 55.8)	1.3 (0.1, 16.1)	0.1 (0.0, 1.7)	1.7 (0.3, 10.4)	0.0 -	0.5 (0.1, 3.0)
South South	34.6 (5.8, 82.0)	0.0 -	0.0 -	30.9 (6.5, 74.1)	22.3 (18.8, 26.2)	0.0 -	0.0 -	3.5 (1.6, 7.7)	0.0 -	1.3 (0.6, 2.8)
South West	53.9 (14.5, 89.0)	0.0 -	2.7 (0.1, 42.3)	18.9 (6.6, 43.4)	15.6 (5.5, 37.0)	0.8 (0.2, 3.5)	0.0 -	1.4 (0.5, 3.9)	0.0 -	0.8 (0.5, 1.1)

\* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.

† The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview). In Region 1 (NC), the denominator includes 9 outlets that met screening criteria for a full interview but did not complete the interview. In Region 2 (NE), the

**Table B3: Availability of selected contraceptive methods, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking<sup>†</sup>:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
<p>denominator includes 8 outlets that met screening criteria for a full interview but did not complete the interview. In Region 3 (NW), the denominator includes 2 outlets that met screening criteria for a full interview but did not complete the interview. In Region 4 (SE), the denominator includes 4 outlets that met screening criteria for a full interview but did not complete the interview. In Region 5 (SS), the denominator includes 6 outlets that met screening criteria for a full interview but did not complete the interview. In Region 6 (SW), the denominator includes 39 outlets that met screening criteria for a full interview but did not complete the interview.</p> <p>* International quality-assured (IQA) contraceptives are defined as those with WHO Prequalification or those on a Stringent Regulatory Authority (SRA) list. See Annex 8 for a list of all brands found in survey and quality-assurance indications.</p>										
Source: FPwatch Outlet Survey, Nigeria, 2015										

**Table B4: Availability of modern contraceptive method diversity, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking / providing†:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
<b>3+ methods‡</b>										
North Central	44.3 (28.4, 61.5)	0.0 -	100.0 -	34.3 (21.5, 49.8)	30.8 (13.6, 55.6)	82.3 (43.1, 96.6)	14.0 (6.4, 28.1)	17.9 (8.7, 33.3)	0.0 -	6.9 (5.2, 8.9)
North East	56.3 (42.8, 69.0)	- -	100.0 -	56.4 (42.8, 69.0)	0.4 (0.2, 1.2)	17.9 (3.0, 60.3)	10.7 (1.3, 52.1)	10.0 (1.3, 47.7)	0.0 -	7.4 (2.2, 22.5)
North West	24.0 (13.5, 39.0)	0.0 -	0.0 -	23.9 (13.5, 38.7)	0.0 -	72.5 (62.5, 80.7)	12.2 (4.0, 31.8)	12.0 (4.2, 29.9)	0.0 -	3.3 (1.3, 8.0)
South East	40.6 (13.7, 74.7)	0.0 -	0.0 -	23.4 (4.2, 68.1)	23.1 (9.8, 45.3)	47.0 (6.0, 92.5)	7.3 (2.3, 20.8)	9.9 (3.6, 24.2)	0.0 -	3.8 (1.6, 8.5)
South South	84.5 (70.1, 92.6)	0.0 -	0.0 -	75.4 (52.1, 89.7)	40.3 (26.8, 55.5)	72.9 (25.9, 95.4)	14.5 (3.3, 45.3)	19.6 (5.7, 49.8)	0.0 -	5.6 (3.9, 8.0)
South West	60.7 (21.5, 89.7)	0.0 -	2.7 (0.1, 42.3)	21.3 (8.1, 45.4)	12.3 (3.8, 33.3)	82.4 (58.3, 94.0)	7.2 (2.6, 18.5)	12.1 (4.4, 29.2)	0.0 (0.0, 0.1)	3.7 (2.3, 6.1)
<b>3+ methods with LARC</b>										
North Central	26.7 (8.0, 60.5)	0.0 -	0.0 -	20.3 (9.6, 37.9)	20.9 (3.6, 65.2)	0.3 (0.0, 5.8)	0.1 (0.0, 0.9)	3.2 (0.7, 13.9)	0.0 -	2.3 (0.9, 5.8)
North East	16.7 (0.9, 81.2)	- -	100.0 -	16.7 (0.9, 81.2)	0.4 (0.2, 1.2)	0.0 -	0.1 (0.0, 1.4)	0.1 (0.0, 1.2)	0.0 -	1.5 (0.1, 15.9)
North West	7.7 (2.2, 24.0)	0.0 -	0.0 -	7.7 (2.2, 23.7)	0.0 -	0.0 -	0.0 (0.0, 0.4)	0.0 (0.0, 0.4)	0.0 -	0.4 (0.1, 1.1)
South East	2.0 (0.3, 13.7)	0.0 -	0.0 -	1.2 (0.1, 13.3)	14.4 (2.2, 55.8)	1.3 (0.1, 16.1)	0.0 -	1.6 (0.2, 10.5)	0.0 -	0.5 (0.1, 3.1)
South South	63.8 (31.5, 87.1)	0.0 -	0.0 -	57.0 (25.2, 83.8)	40.0 (26.0, 55.8)	2.5 (0.5, 12.8)	0.0 (0.0, 0.5)	6.4 (2.1, 18.1)	0.0 -	2.4 (1.6, 3.4)
South West	57.3 (18.0, 89.1)	0.0 -	2.7 (0.1, 42.3)	20.1 (7.3, 44.8)	10.6 (3.4, 28.3)	0.8 (0.2, 3.5)	0.0 -	1.0 (0.3, 3.7)	0.0 -	0.7 (0.4, 1.2)
<b>3+ methods with</b>										

**Table B4: Availability of modern contraceptive method diversity, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking / providing†:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
<b>LARC/PM</b>										
North Central	26.7 (8.0, 60.5)	0.0 -	0.0 -	20.3 (9.6, 37.9)	22.3 (4.6, 63.2)	0.3 (0.0, 5.8)	0.1 (0.0, 0.9)	3.4 (0.8, 13.1)	0.0 -	2.4 (1.0, 5.7)
North East	24.3 (6.7, 58.9)	- -	100.0 -	24.3 (6.7, 58.9)	0.4 (0.2, 1.2)	0.0 -	0.1 (0.0, 1.4)	0.1 (0.0, 1.2)	0.0 -	2.2 (0.4, 10.6)
North West	7.7 (2.2, 24.0)	0.0 -	0.0 -	7.7 (2.2, 23.7)	0.0 -	0.0 -	0.0 (0.0, 0.4)	0.0 (0.0, 0.4)	0.0 -	0.4 (0.1, 1.1)
South East	2.0 (0.3, 13.7)	0.0 -	0.0 -	1.2 (0.1, 13.3)	18.4 (6.2, 43.7)	1.3 (0.1, 16.1)	0.0 -	2.1 (0.6, 7.0)	0.0 -	0.6 (0.2, 2.1)
South South	63.8 (31.5, 87.1)	0.0 -	0.0 -	57.0 (25.2, 83.8)	40.0 (26.0, 55.8)	2.5 (0.5, 12.8)	0.0 (0.0, 0.5)	6.4 (2.1, 18.1)	0.0 -	2.4 (1.6, 3.4)
South West	58.4 (19.4, 89.1)	0.0 -	2.7 (0.1, 42.3)	20.5 (7.5, 45.2)	11.2 (3.5, 30.5)	0.8 (0.2, 3.5)	0.0 -	1.0 (0.3, 4.2)	0.0 -	0.7 (0.4, 1.3)
<b>5+ methods§</b>										
North Central	14.2 (5.9, 30.3)	0.0 -	0.0 -	10.8 (4.4, 24.1)	2.2 (0.3, 15.1)	10.9 (3.0, 32.4)	0.2 (0.0, 0.5)	0.7 (0.1, 3.8)	0.0 -	1.0 (0.5, 2.0)
North East	12.1 (3.6, 33.7)	- -	100.0 -	12.1 (3.6, 33.6)	0.0 -	17.2 (2.3, 64.7)	0.2 (0.0, 3.3)	0.4 (0.0, 7.7)	0.0 -	1.2 (0.2, 5.9)
North West	11.0 (2.7, 35.7)	0.0 -	0.0 -	11.0 (2.7, 35.5)	0.0 -	34.8 (24.3, 47.1)	0.0 (0.0, 0.4)	0.1 (0.0, 0.6)	0.0 -	0.6 (0.1, 3.4)
South East	2.0 (0.3, 13.7)	0.0 -	0.0 -	1.2 (0.1, 13.3)	3.2 (0.8, 12.1)	1.3 (0.1, 16.1)	0.0 -	0.4 (0.1, 1.6)	0.0 -	0.2 (0.1, 0.4)
South South	71.1 (43.7, 88.6)	0.0 -	0.0 -	63.5 (33.1, 85.9)	22.1 (18.6, 26.0)	4.4 (0.9, 19.1)	0.5 (0.1, 4.2)	4.0 (1.9, 7.9)	0.0 -	2.0 (0.9, 4.2)
South West	45.2 (12.4, 82.8)	0.0 -	0.0 -	15.6 (3.5, 48.5)	8.1 (2.8, 21.2)	7.2 (2.9, 16.6)	0.0 (0.0, 0.2)	1.1 (0.2, 5.4)	0.0 -	0.6 (0.3, 1.2)

\* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.

† The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview). In Region 1 (NC), the denominator includes 9 outlets that met screening criteria for a full interview but did not complete the interview. In Region 2 (NE), the

**Table B4: Availability of modern contraceptive method diversity, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking / providing†:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
<p>denominator includes 8 outlets that met screening criteria for a full interview but did not complete the interview. In Region 3 (NW), the denominator includes 2 outlets that met screening criteria for a full interview but did not complete the interview. In Region 4 (SE), the denominator includes 4 outlets that met screening criteria for a full interview but did not complete the interview. In Region 5 (SS), the denominator includes 6 outlets that met screening criteria for a full interview but did not complete the interview. In Region 6 (SW), the denominator includes 39 outlets that met screening criteria for a full interview but did not complete the interview.</p> <p>‡ 3 or more among: male condoms, female condoms, cyclebeads, oral contraceptives, emergency contraceptives, injectables, implants, IUDs commodities and/or male sterilizations, female sterilizations services. No other modern contraceptive methods were found in sampled outlets.</p> <p>§ 5 or more among: male condoms, female condoms, cyclebeads, oral contraceptives, emergency contraceptives, injectables, implants, IUDs commodities and/or male sterilizations, female sterilizations services. No other modern contraceptive methods were found in sampled outlets.</p>										
Source: FPwatch Outlet Survey, Nigeria, 2015										

**Table B5: Current stock out\* of selected modern contraceptive commodities on day of survey, among outlets reportedly stocking method in previous 3 months, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total†	Total
Proportion of outlets reportedly stocking method in previous 3 months, currently stocked out of:	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)
<b>Oral contraceptives</b>										
North Central	19.6 <sup>(31)</sup> (4.4, 56.6)	100.0 <sup>(1)</sup> -	0.0 <sup>(1)</sup> -	52.5 <sup>(33)</sup> (14.4, 87.9)	17.8 <sup>(17)</sup> (2.1, 68.5)	14.0 <sup>(40)</sup> (2.6, 49.4)	12.3 <sup>(310)</sup> (2.6, 42.6)	0.0 <sup>(5)</sup> -	12.9 <sup>(372)</sup> (2.9, 42.3)	21.7 <sup>(405)</sup> (11.8, 36.5)
North East	0.0 <sup>(15)</sup> -	-	0.0 <sup>(1)</sup> -	0.0 <sup>(16)</sup> -	96.9 <sup>(4)</sup> (90.1, 99.1)	43.3 <sup>(3)</sup> (38.2, 48.6)	16.7 <sup>(87)</sup> (3.1, 55.7)	-	18.9 <sup>(94)</sup> (5.1, 50.2)	13.7 <sup>(110)</sup> (3.0, 44.8)
North West	34.8 <sup>(29)</sup> (5.4, 83.3)	-	-	34.8 <sup>(29)</sup> (5.4, 83.3)	79.6 <sup>(2)</sup> (8.7, 99.4)	0.0 <sup>(4)</sup> -	22.1 <sup>(202)</sup> (12.1, 36.7)	-	22.6 <sup>(208)</sup> (12.1, 38.2)	25.8 <sup>(237)</sup> (11.6, 48.1)
South East	11.7 <sup>(9)</sup> (0.4, 80.9)	-	-	11.7 <sup>(9)</sup> (0.4, 80.9)	46.1 <sup>(15)</sup> (15.8, 79.7)	4.2 <sup>(14)</sup> (0.2, 44.3)	5.1 <sup>(139)</sup> (1.0, 22.9)	0.0 <sup>(3)</sup> -	7.1 <sup>(171)</sup> (1.4, 29.7)	7.5 <sup>(180)</sup> (1.3, 33.5)
South South	0.0 <sup>(15)</sup> -	-	-	0.0 <sup>(15)</sup> -	23.4 <sup>(8)</sup> (18.0, 29.7)	0.0 <sup>(16)</sup> -	3.0 <sup>(113)</sup> (0.3, 24.6)	-	6.9 <sup>(137)</sup> (4.4, 10.8)	6.2 <sup>(152)</sup> (4.4, 8.8)
South West	2.8 <sup>(32)</sup> (0.1, 36.5)	80.1 <sup>(2)</sup> (7.6, 99.5)	-	42.9 <sup>(34)</sup> (4.2, 92.8)	12.1 <sup>(47)</sup> (4.0, 31.2)	9.3 <sup>(108)</sup> (0.6, 62.0)	12.2 <sup>(1015)</sup> (6.6, 21.3)	77.1 <sup>(24)</sup> (11.8, 98.8)	14.3 <sup>(1194)</sup> (8.8, 22.5)	16.2 <sup>(1228)</sup> (8.7, 27.9)
<b>Emergency contraceptives</b>										
North Central	-	-	-	-	0.0 <sup>(2)</sup> -	0.5 <sup>(23)</sup> (0.0, 12.6)	19.3 <sup>(113)</sup> (4.3, 55.9)	100.0 <sup>(1)</sup> -	17.8 <sup>(139)</sup> (4.6, 49.6)	17.8 <sup>(139)</sup> (4.6, 49.6)
North East	0.0 <sup>(1)</sup> -	-	-	0.0 <sup>(1)</sup> -	-	0.0 <sup>(2)</sup> -	16.9 <sup>(14)</sup> (2.7, 59.9)	-	15.9 <sup>(16)</sup> (2.4, 58.8)	15.2 <sup>(17)</sup> (2.2, 58.3)
North West	-	-	-	-	-	39.6 <sup>(3)</sup> (23.5, 58.4)	17.2 <sup>(24)</sup> (9.3, 29.6)	-	18.2 <sup>(27)</sup> (9.9, 31.1)	18.2 <sup>(27)</sup> (9.9, 31.1)
South East	-	-	-	-	100.0 <sup>(3)</sup> -	2.5 <sup>(10)</sup> (0.4, 13.1)	34.1 <sup>(49)</sup> (14.5, 61.1)	0.0 <sup>(1)</sup> -	32.3 <sup>(63)</sup> (12.0, 62.6)	32.3 <sup>(63)</sup> (12.0, 62.6)
South South	-	-	-	-	50.0 <sup>(2)</sup> (50.0, 50.0)	0.0 <sup>(7)</sup> -	25.1 <sup>(56)</sup> (12.6, 43.9)	-	29.4 <sup>(65)</sup> (20.7, 39.9)	29.4 <sup>(65)</sup> (20.7, 39.9)
South West	100.0 <sup>(1)</sup> -	100.0 <sup>(1)</sup> -	-	100.0 <sup>(2)</sup> -	51.4 <sup>(7)</sup> (22.5, 79.4)	5.0 <sup>(79)</sup> (1.4, 16.6)	51.5 <sup>(235)</sup> (28.1, 74.2)	11.7 <sup>(8)</sup> (11.7, 11.7)	38.7 <sup>(329)</sup> (17.7, 65.0)	45.2 <sup>(331)</sup> (20.9, 72.1)
<b>Contraceptive injectables</b>										

**Table B5: Current stock out\* of selected modern contraceptive commodities on day of survey, among outlets reportedly stocking method in previous 3 months, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total†	Total
Proportion of outlets reportedly stocking method in previous 3 months, currently stocked out of:	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)
North Central	29.1 <sup>(34)</sup> (5.9, 72.8)	0.0 <sup>(2)</sup> -	0.0 <sup>(1)</sup> -	18.9 <sup>(37)</sup> (7.9, 38.9)	19.1 <sup>(19)</sup> (4.5, 54.0)	0.0 <sup>(34)</sup> -	82.5 <sup>(84)</sup> (34.8, 97.7)	- -	63.0 <sup>(137)</sup> (17.4, 93.2)	43.8 <sup>(174)</sup> (18.1, 73.4)
North East	0.0 <sup>(1)</sup> -	- -	0.0 <sup>(1)</sup> -	0.0 <sup>(18)</sup> -	100.0 <sup>(5)</sup> -	43.3 <sup>(3)</sup> (38.2, 48.6)	26.0 <sup>(39)</sup> (1.6, 88.6)	- -	41.1 <sup>(47)</sup> (3.4, 93.4)	19.8 <sup>(65)</sup> (1.0, 85.4)
North West	4.3 <sup>(29)</sup> (0.3, 37.0)	100.0 <sup>(1)</sup> -	100.0 <sup>(1)</sup> -	5.0 <sup>(31)</sup> (0.5, 34.1)	0.0 <sup>(5)</sup> -	0.0 <sup>(3)</sup> -	21.4 <sup>(141)</sup> (14.4, 30.4)	- -	20.6 <sup>(149)</sup> (14.3, 28.8)	15.3 <sup>(180)</sup> (7.2, 29.6)
South East	14.4 <sup>(11)</sup> (0.7, 78.9)	- -	- -	14.4 <sup>(11)</sup> (0.7, 78.9)	14.9 <sup>(17)</sup> (1.5, 67.3)	0.0 <sup>(5)</sup> -	57.7 <sup>(14)</sup> (26.5, 83.8)	- -	32.1 <sup>(36)</sup> (13.6, 58.7)	24.2 <sup>(47)</sup> (5.7, 62.8)
South South	0.0 <sup>(15)</sup> -	- -	- -	0.0 <sup>(15)</sup> -	30.5 <sup>(7)</sup> (21.5, 41.3)	1.5 <sup>(12)</sup> (0.1, 17.4)	72.9 <sup>(13)</sup> (56.1, 84.9)	- -	41.6 <sup>(32)</sup> (37.4, 46.0)	29.4 <sup>(47)</sup> (11.6, 56.9)
South West	7.7 <sup>(38)</sup> (1.2, 35.7)	100.0 <sup>(2)</sup> -	0.0 <sup>(1)</sup> -	54.4 <sup>(41)</sup> (14.4, 89.4)	20.7 <sup>(64)</sup> (6.4, 50.0)	0.9 <sup>(72)</sup> (0.0, 15.5)	84.8 <sup>(97)</sup> (40.6, 97.8)	0.0 <sup>(1)</sup> -	50.0 <sup>(234)</sup> (18.1, 82.0)	51.2 <sup>(275)</sup> (22.2, 79.4)
<b>Implants</b>										
North Central	4.2 <sup>(16)</sup> (0.2, 48.4)	- -	- -	4.2 <sup>(16)</sup> (0.2, 48.4)	10.9 <sup>(9)</sup> (1.0, 60.5)	- -	100.0 <sup>(1)</sup> -	- -	12.4 <sup>(10)</sup> (1.2, 62.8)	7.3 <sup>(26)</sup> (0.6, 50.9)
North East	3.5 <sup>(9)</sup> (0.0, 73.2)	- -	0.0 <sup>(1)</sup> -	3.5 <sup>(10)</sup> (0.0, 73.2)	72.5 <sup>(2)</sup> (1.5, 99.8)	- -	- -	- -	72.5 <sup>(2)</sup> (1.5, 99.8)	3.9 <sup>(12)</sup> (0.1, 70.5)
North West	0.0 <sup>(15)</sup> -	- -	- -	0.0 <sup>(15)</sup> -	- -	- -	100.0 <sup>(1)</sup> -	- -	100.0 <sup>(1)</sup> -	24.3 <sup>(16)</sup> (5.8, 62.8)
South East	0.0 <sup>(1)</sup> -	- -	- -	0.0 <sup>(1)</sup> -	23.6 <sup>(9)</sup> (0.9, 91.6)	- -	- -	- -	23.6 <sup>(9)</sup> (0.9, 91.6)	21.8 <sup>(10)</sup> (0.8, 91.1)
South South	0.0 <sup>(4)</sup> -	- -	- -	0.0 <sup>(4)</sup> -	0.0 <sup>(4)</sup> -	0.0 <sup>(1)</sup> -	0.0 <sup>(1)</sup> -	- -	0.0 <sup>(6)</sup> -	0.0 <sup>(10)</sup> -
South West	34.8 <sup>(19)</sup> (5.4, 83.5)	- -	- -	34.8 <sup>(19)</sup> (5.4, 83.5)	24.0 <sup>(23)</sup> (19.8, 28.8)	- -	0.0 <sup>(1)</sup> -	- -	23.9 <sup>(24)</sup> (19.5, 28.8)	32.0 <sup>(43)</sup> (8.5, 70.3)
<b>IUDs</b>										
North Central	0.0 <sup>(12)</sup> -	- -	- -	0.0 <sup>(12)</sup> -	4.9 <sup>(12)</sup> (1.8, 12.8)	0.0 <sup>(1)</sup> -	0.0 <sup>(1)</sup> -	- -	4.8 <sup>(14)</sup> (1.8, 12.2)	2.4 <sup>(26)</sup> (0.9, 6.3)
North East	0.0 <sup>(5)</sup> -	- -	0.0 <sup>(1)</sup> -	0.0 <sup>(6)</sup> -	0.0 <sup>(2)</sup> -	- -	50.0 <sup>(2)</sup> (50.0, 50.0)	- -	37.4 <sup>(4)</sup> (25.2, 51.5)	3.0 <sup>(10)</sup> (0.0, 68.3)



**Table B5: Current stock out\* of selected modern contraceptive commodities on day of survey, among outlets reportedly stocking method in previous 3 months, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total†	Total
Proportion of outlets reportedly stocking method in previous 3 months, currently stocked out of‡:	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)
North West	0.0 <sup>(7)</sup> -	- -	- -	0.0 <sup>(7)</sup> -	100.0 <sup>(1)</sup> -	- -	0.0 <sup>(1)</sup> -	- -	95.2 <sup>(2)</sup> (32.4, 99.9)	27.9 <sup>(9)</sup> (11.4, 53.8)
South East	0.0 <sup>(1)</sup> -	- -	- -	0.0 <sup>(1)</sup> -	15.1 <sup>(11)</sup> (8.1, 26.4)	0.0 <sup>(1)</sup> -	61.9 <sup>(3)</sup> (5.1, 98.0)	- -	18.4 <sup>(15)</sup> (11.0, 29.2)	17.1 <sup>(16)</sup> (10.2, 27.2)
South South	0.0 <sup>(4)</sup> -	- -	- -	0.0 <sup>(4)</sup> -	0.0 <sup>(4)</sup> -	- -	- -	- -	0.0 <sup>(4)</sup> -	0.0 <sup>(8)</sup> -
South West	24.5 <sup>(25)</sup> (2.2, 82.1)	- -	0.0 <sup>(1)</sup> -	24.2 <sup>(26)</sup> (2.3, 81.3)	28.5 <sup>(51)</sup> (27.2, 29.9)	25.5 <sup>(7)</sup> (3.7, 75.1)	62.1 <sup>(4)</sup> (43.8, 77.5)	- -	29.0 <sup>(62)</sup> (26.9, 31.2)	26.7 <sup>(88)</sup> (9.5, 55.6)
<p>* This indicator is among all screened outlets. It does not account for whether the outlet is expected to provide the commodity according to national regulations. It is a point-in-time stock out indicator from <a href="http://www.rhsupplies.org/fileadmin/uploads/rhsc/Issues/Addressing_Stockouts/Takestock/Documents/Using-the_Power_of_Partnership_to_Speak_the_same_Languageoon_Stockouts.pdf">http://www.rhsupplies.org/fileadmin/uploads/rhsc/Issues/Addressing_Stockouts/Takestock/Documents/Using-the_Power_of_Partnership_to_Speak_the_same_Languageoon_Stockouts.pdf</a>. It is defined as the percentage of facilities reporting that they have stocked the method in the previous 3 months but were stocked out on the day of the assessment.</p> <p>† In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>‡ The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview). In Region 1 (NC), the denominator includes 9 outlets that met screening criteria for a full interview but did not complete the interview. In Region 2 (NE), the denominator includes 8 outlets that met screening criteria for a full interview but did not complete the interview. In Region 3 (NW), the denominator includes 2 outlets that met screening criteria for a full interview but did not complete the interview. In Region 4 (SE), the denominator includes 4 outlets that met screening criteria for a full interview but did not complete the interview. In Region 5 (SS), the denominator includes 6 outlets that met screening criteria for a full interview but did not complete the interview. In Region 6 (SW), the denominator includes 39 outlets that met screening criteria for a full interview but did not complete the interview.</p>										

Source: FPwatch Outlet Survey, Nigeria, 2015

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
<b>Male condoms</b>						
North Central	Naira	0.00 <sup>(15)</sup> [0.00-0.00]	33.33 <sup>(41)</sup> [10.00-133.33]	10.00 <sup>(370)</sup> [7.50-12.50]	10.00 <sup>(45)</sup> [7.50-12.50]	10.00 <sup>(471)</sup> [7.50-12.50]
	USD	\$0.00 <sup>(15)</sup> [0.00-0.00]	\$0.17 <sup>(41)</sup> [0.05-0.67]	\$0.05 <sup>(370)</sup> [0.04-0.06]	\$0.05 <sup>(45)</sup> [0.04-0.06]	\$0.05 <sup>(471)</sup> [0.04-0.06]
	USD per CYP	\$0.00 <sup>(15)</sup> [0.00-0.00]	\$20.00 <sup>(41)</sup> [6.00-80.00]	\$6.00 <sup>(370)</sup> [4.50-7.50]	\$6.00 <sup>(45)</sup> [4.50-7.50]	\$6.00 <sup>(471)</sup> [4.50-7.50]
North East	Naira	0.00 <sup>(1)</sup> -	\$12.50 <sup>(5)</sup> [12.50-33.33]	10.00 <sup>(88)</sup> [7.50-12.50]	7.50 <sup>(3)</sup> [7.50-7.50]	10.00 <sup>(97)</sup> [7.50-12.50]
	USD	\$0.00 <sup>(1)</sup> -	\$0.06 <sup>(5)</sup> [0.06-0.17]	\$0.05 <sup>(88)</sup> [0.04-0.06]	\$0.04 <sup>(3)</sup> [0.04-0.04]	\$0.05 <sup>(97)</sup> [0.04-0.06]
	USD per CYP	\$0.00 <sup>(1)</sup> -	\$7.50 <sup>(5)</sup> [7.50-20.00]	\$6.00 <sup>(88)</sup> [4.50-7.50]	\$4.50 <sup>(3)</sup> [4.50-4.50]	\$6.00 <sup>(97)</sup> [4.50-7.50]
North West	Naira	0.00 <sup>(1)</sup> -	12.50 <sup>(3)</sup> [10.00-33.33]	12.50 <sup>(106)</sup> [7.50-16.67]	12.50 <sup>(4)</sup> [12.50-33.33]	12.50 <sup>(114)</sup> [7.50-16.67]
	USD	\$0.00 <sup>(1)</sup> -	\$0.06 <sup>(3)</sup> [0.05-0.17]	\$0.06 <sup>(106)</sup> [0.04-0.08]	\$0.06 <sup>(4)</sup> [0.06-0.17]	\$0.06 <sup>(114)</sup> [0.04-0.08]
	USD per CYP	\$0.00 <sup>(1)</sup> -	\$7.50 <sup>(3)</sup> [6.00-20.00]	\$7.50 <sup>(106)</sup> [4.50-10.00]	\$7.50 <sup>(4)</sup> [7.50-20.00]	\$7.50 <sup>(114)</sup> [4.50-10.00]
South East	Naira	0.00 <sup>(9)</sup> [0.00-5.00]	12.50 <sup>(17)</sup> [12.50-23.33]	12.50 <sup>(236)</sup> [10.00-12.50]	12.50 <sup>(21)</sup> [7.50-16.67]	12.50 <sup>(283)</sup> [7.50-12.50]
	USD	\$0.00 <sup>(9)</sup> [0.00-0.03]	\$0.06 <sup>(17)</sup> [0.06-0.12]	\$0.06 <sup>(236)</sup> [0.05-0.06]	\$0.06 <sup>(21)</sup> [0.04-0.08]	\$0.06 <sup>(283)</sup> [0.04-0.06]
	USD per CYP	\$0.00 <sup>(9)</sup> [0.00-3.00]	\$7.50 <sup>(17)</sup> [7.50-14.00]	\$7.50 <sup>(236)</sup> [6.00-7.50]	\$7.50 <sup>(21)</sup> [4.50-10.00]	\$7.50 <sup>(283)</sup> [4.50-7.50]
South South	Naira	12.50 <sup>(8)</sup> [0.00-12.50]	12.50 <sup>(18)</sup> [12.50-12.50]	12.50 <sup>(179)</sup> [12.50-12.50]	12.50 <sup>(6)</sup> [12.50-12.50]	12.50 <sup>(211)</sup> [12.50-12.50]
	USD	\$0.06 <sup>(8)</sup> [0.00-0.06]	\$0.06 <sup>(18)</sup> [0.06-0.06]	\$0.06 <sup>(179)</sup> [0.06-0.06]	\$0.06 <sup>(6)</sup> [0.06-0.06]	\$0.06 <sup>(211)</sup> [0.06-0.06]
	USD per CYP	\$7.50 <sup>(8)</sup> [0.00-7.50]	\$7.50 <sup>(18)</sup> [7.50-7.50]	\$7.50 <sup>(179)</sup> [7.50-7.50]	\$7.50 <sup>(6)</sup> [7.50-7.50]	\$7.50 <sup>(211)</sup> [7.50-7.50]
South West	Naira	0.00 <sup>(42)</sup> [0.00-16.67]	12.50 <sup>(128)</sup> [12.50-133.33]	12.50 <sup>(1,290)</sup> [10.00-12.50]	12.50 <sup>(447)</sup> [12.50-12.50]	12.50 <sup>(1,907)</sup> [10.00-12.50]
	USD	\$0.00 <sup>(42)</sup> [0.00-0.08]	\$0.06 <sup>(128)</sup> [0.06-0.67]	\$0.06 <sup>(1,290)</sup> [0.05-0.06]	\$0.06 <sup>(447)</sup> [0.06-0.06]	\$0.06 <sup>(1,907)</sup> [0.05-0.06]
	USD per CYP	\$0.00 <sup>(42)</sup>	\$7.50 <sup>(128)</sup>	\$7.50 <sup>(1,290)</sup>	\$7.50 <sup>(447)</sup>	\$7.50 <sup>(1,907)</sup>

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
		[0.00-10.00]	[7.50-80.00]	[6.00-7.50]	[7.50-7.50]	[6.00-7.50]
<b>Female condoms</b>						
North Central	Naira	0.00 <sup>(3)</sup> [0.00-0.00]	237.50 <sup>(5)</sup> [87.50-375.00]	50.00 <sup>(16)</sup> [50.00-50.00]	20.00 <sup>(1)</sup> -	50.00 <sup>(25)</sup> [20.00-50.00]
	USD	\$0.00 <sup>(3)</sup> [0.00-0.00]	\$1.19 <sup>(5)</sup> [0.44-1.88]	\$0.25 <sup>(16)</sup> [0.25-0.25]	\$0.10 <sup>(1)</sup> -	\$0.25 <sup>(25)</sup> [0.10-0.25]
	USD per CYP	\$0.00 <sup>(3)</sup> [0.00-0.00]	\$142.50 <sup>(5)</sup> [52.50-225.00]	\$30.00 <sup>(16)</sup> [30.00-30.00]	\$12.00 <sup>(1)</sup> -	\$30.00 <sup>(25)</sup> [12.00-30.00]
North East	Naira	- -	50.00 <sup>(1)</sup> -	50.00 <sup>(1)</sup> -	- -	50.00 <sup>(2)</sup> [50.00-50.00]
	USD	- -	\$0.25 <sup>(1)</sup> -	\$0.25 <sup>(1)</sup> -	- -	\$0.25 <sup>(2)</sup> [0.25-0.25]
	USD per CYP	- -	\$30.00 <sup>(1)</sup> -	\$30.00 <sup>(1)</sup> -	- -	\$30.00 <sup>(2)</sup> [30.00-30.00]
North West	Naira	- -	200.00 <sup>(1)</sup> -	50.00 <sup>(5)</sup> [50.00-100.00]	30.00 <sup>(1)</sup> -	50.00 <sup>(7)</sup> [50.00-100.00]
	USD	- -	\$1.00 <sup>(1)</sup> -	\$0.25 <sup>(5)</sup> [0.25-0.50]	\$0.15 <sup>(1)</sup> -	\$0.25 <sup>(7)</sup> [0.25-0.50]
	USD per CYP	- -	\$120.00 <sup>(1)</sup> -	\$30.00 <sup>(5)</sup> [30.00-60.00]	\$18.00 <sup>(1)</sup> -	\$30.00 <sup>(7)</sup> [30.00-60.00]
South East	Naira	0.00 <sup>(5)</sup> [0.00-0.00]	100.00 <sup>(2)</sup> [100.00-100.00]	100.00 <sup>(14)</sup> [50.00-150.00]	- -	50.00 <sup>(21)</sup> [25.00-100.00]
	USD	\$0.00 <sup>(5)</sup> [0.00-0.00]	\$0.50 <sup>(2)</sup> [0.50-0.50]	\$0.50 <sup>(14)</sup> [0.25-0.75]	- -	\$0.25 <sup>(21)</sup> [0.13-0.50]
	USD per CYP	\$0.00 <sup>(5)</sup> [0.00-0.00]	\$60.00 <sup>(2)</sup> [60.00-60.00]	\$60.00 <sup>(14)</sup> [30.00-90.00]	- -	\$30.00 <sup>(21)</sup> [15.00-60.00]
South South	Naira	0.00 <sup>(1)</sup> [0.00-0.00]	25.00 <sup>(3)</sup> [25.00-100.00]	50.00 <sup>(14)</sup> [50.00-100.00]	- -	0.00 <sup>(18)</sup> [0.00-50.00]
	USD	\$0.00 <sup>(1)</sup> [0.00-0.00]	\$0.13 <sup>(3)</sup> [0.13-0.50]	\$0.25 <sup>(14)</sup> [0.25-0.50]	- -	\$0.00 <sup>(18)</sup> [0.00-0.25]
	USD per CYP	\$0.00 <sup>(1)</sup> [0.00-0.00]	\$15.00 <sup>(3)</sup> [15.00-60.00]	\$30.00 <sup>(14)</sup> [30.00-60.00]	- -	\$0.00 <sup>(18)</sup> [0.00-30.00]
South West	Naira	0.00 <sup>(10)</sup> [0.00-0.00]	566.67 <sup>(15)</sup> [100.00-566.67]	60.00 <sup>(47)</sup> [25.00-100.00]	75.00 <sup>(5)</sup> [50.00-75.00]	75.00 <sup>(77)</sup> [25.00-150.00]
	USD	\$0.00 <sup>(10)</sup> [0.00-0.00]	\$2.83 <sup>(15)</sup> [0.50-2.83]	\$0.30 <sup>(47)</sup> [0.13-0.50]	\$0.38 <sup>(5)</sup> [0.25-0.38]	\$0.38 <sup>(77)</sup> [0.13-0.75]

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP<sup>†‡</sup>, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>§</sup>
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
	USD per CYP	\$0.00 <sup>(10)</sup> [0.00-0.00]	\$340.00 <sup>(15)</sup> [60.00-340.00]	\$36.00 <sup>(47)</sup> [15.00-60.00]	\$45.00 <sup>(5)</sup> [30.00-45.00]	\$45.00 <sup>(77)</sup> [15.00-90.00]
<b>Cyclebeads</b>						
North Central	Naira	- -	- -	150.00 <sup>(7)</sup> [0.00-200.00]	- -	150.00 <sup>(7)</sup> [0.00-200.00]
	USD	- -	- -	\$0.75 <sup>(7)</sup> [0.00-1.00]	- -	\$0.75 <sup>(7)</sup> [0.00-1.00]
	USD per CYP	- -	- -	\$0.50 <sup>(7)</sup> [0.00-0.67]	- -	\$0.50 <sup>(7)</sup> [0.00-0.67]
North East	Naira	- -	- -	- -	- -	- -
	USD	- -	- -	- -	- -	- -
	USD per CYP	- -	- -	- -	- -	- -
North West	Naira	- -	- -	50.00 <sup>(2)</sup> [50.00-50.00]	- -	50.00 <sup>(2)</sup> [50.00-50.00]
	USD	- -	- -	\$0.25 <sup>(2)</sup> [0.25-0.25]	- -	\$0.25 <sup>(2)</sup> [0.25-0.25]
	USD per CYP	- -	- -	\$0.17 <sup>(2)</sup> [0.17-0.17]	- -	\$0.17 <sup>(2)</sup> [0.17-0.17]
South East	Naira	0.00 <sup>(2)</sup> [0.00-0.00]	- -	0.00 <sup>(2)</sup> [0.00-0.00]	- -	0.00 <sup>(4)</sup> [0.00-0.00]
	USD	\$0.00 <sup>(2)</sup> [0.00-0.00]	- -	\$0.00 <sup>(2)</sup> [0.00-0.00]	- -	\$0.00 <sup>(4)</sup> [0.00-0.00]
	USD per CYP	\$0.00 <sup>(2)</sup> [0.00-0.00]	- -	\$0.00 <sup>(2)</sup> [0.00-0.00]	- -	\$0.00 <sup>(4)</sup> [0.00-0.00]
South South	Naira	- -	- -	500.00 <sup>(3)</sup> [150.00-500.00]	- -	500.00 <sup>(3)</sup> [150.00-500.00]
	USD	- -	- -	\$2.50 <sup>(3)</sup> [0.75-2.50]	- -	\$2.50 <sup>(3)</sup> [0.75-2.50]
	USD per CYP	- -	- -	\$1.67 <sup>(3)</sup> [0.50-1.67]	- -	\$1.67 <sup>(3)</sup> [0.50-1.67]
South West	Naira	0.00 <sup>(2)</sup> [0.00-0.00]	150.00 <sup>(2)</sup> [150.00-150.00]	100.00 <sup>(12)</sup> [0.00-200.00]	- -	100.00 <sup>(16)</sup> [0.00-200.00]
	USD	\$0.00 <sup>(2)</sup>	\$0.75 <sup>(2)</sup>	\$0.50 <sup>(12)</sup>	-	\$0.50 <sup>(16)</sup>

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
		[0.00-0.00]	[0.75-0.75]	[0.00-1.00]	-	[0.00-1.00]
	USD per CYP	\$0.00 <sup>(2)</sup> [0.00-0.00]	\$0.50 <sup>(2)</sup> [0.50-0.50]	\$0.33 <sup>(12)</sup> [0.00-0.67]	-	\$0.33 <sup>(16)</sup> [0.00-0.67]
<b>Oral contraceptives</b>						
North Central	Naira	100.00 <sup>(14)</sup> [98.00-100.00]	50.00 <sup>(41)</sup> [50.00-100.00]	50.00 <sup>(263)</sup> [50.00-100.00]	100.00 <sup>(5)</sup> [60.00-200.00]	50.00 <sup>(323)</sup> [50.00-100.00]
	USD	\$0.50 <sup>(14)</sup> [0.49-0.50]	\$0.25 <sup>(41)</sup> [0.25-0.50]	\$0.25 <sup>(263)</sup> [0.25-0.50]	\$0.50 <sup>(5)</sup> [0.30-1.00]	\$0.25 <sup>(323)</sup> [0.25-0.50]
	USD per CYP	\$7.50 <sup>(14)</sup> [7.35-7.50]	\$3.75 <sup>(41)</sup> [3.75-7.50]	\$3.75 <sup>(263)</sup> [3.75-7.50]	\$7.50 <sup>(5)</sup> [4.50-15.00]	\$3.75 <sup>(323)</sup> [3.75-7.50]
North East	Naira	150.00 <sup>(3)</sup> [150.00-150.00]	50.00 <sup>(3)</sup> [50.00-50.00]	70.00 <sup>(80)</sup> [50.00-100.00]	-	70.00 <sup>(86)</sup> [50.00-100.00]
	USD	\$0.75 <sup>(3)</sup> [0.75-0.75]	\$0.25 <sup>(3)</sup> [0.25-0.25]	\$0.35 <sup>(80)</sup> [0.25-0.50]	-	\$0.35 <sup>(86)</sup> [0.25-0.50]
	USD per CYP	\$11.25 <sup>(3)</sup> [11.25-11.25]	\$3.75 <sup>(3)</sup> [3.75-3.75]	\$5.25 <sup>(80)</sup> [3.75-7.50]	-	\$5.25 <sup>(86)</sup> [3.75-7.50]
North West	Naira	50.00 <sup>(1)</sup> -	50.00 <sup>(4)</sup> [50.00-100.00]	70.00 <sup>(172)</sup> [50.00-80.00]	-	70.00 <sup>(177)</sup> [50.00-80.00]
	USD	\$0.25 <sup>(1)</sup> -	\$0.25 <sup>(4)</sup> [0.25-0.50]	\$0.35 <sup>(172)</sup> [0.25-0.40]	-	\$0.35 <sup>(177)</sup> [0.25-0.40]
	USD per CYP	\$3.75 <sup>(1)</sup> -	\$3.75 <sup>(4)</sup> [3.75-7.50]	\$5.25 <sup>(172)</sup> [3.75-6.00]	-	\$5.25 <sup>(177)</sup> [3.75-6.00]
South East	Naira	0.00 <sup>(12)</sup> [0.00-200.00]	100.00 <sup>(14)</sup> [100.00-150.00]	100.00 <sup>(131)</sup> [50.00-100.00]	50.00 <sup>(3)</sup> [50.00-100.00]	100.00 <sup>(160)</sup> [50.00-100.00]
	USD	\$0.00 <sup>(12)</sup> [0.00-1.00]	\$0.50 <sup>(14)</sup> [0.50-0.75]	\$0.50 <sup>(131)</sup> [0.25-0.50]	\$0.25 <sup>(3)</sup> [0.25-0.50]	\$0.50 <sup>(160)</sup> [0.25-0.50]
	USD per CYP	\$0.00 <sup>(12)</sup> [0.00-15.00]	\$7.50 <sup>(14)</sup> [7.50-11.25]	\$7.50 <sup>(131)</sup> [3.75-7.50]	\$3.75 <sup>(3)</sup> [3.75-7.50]	\$7.50 <sup>(160)</sup> [3.75-7.50]
South South	Naira	100.00 <sup>(7)</sup> [70.00-300.00]	100.00 <sup>(17)</sup> [100.00-150.00]	100.00 <sup>(105)</sup> [80.00-100.00]	-	100.00 <sup>(129)</sup> [80.00-100.00]
	USD	\$0.50 <sup>(7)</sup> [0.35-1.50]	\$0.50 <sup>(17)</sup> [0.50-0.75]	\$0.50 <sup>(105)</sup> [0.40-0.50]	-	\$0.50 <sup>(129)</sup> [0.40-0.50]
	USD per CYP	\$7.50 <sup>(7)</sup> [5.25-22.50]	\$7.50 <sup>(17)</sup> [7.50-11.25]	\$7.50 <sup>(105)</sup> [6.00-7.50]	-	\$7.50 <sup>(129)</sup> [6.00-7.50]
South West	Naira	80.00 <sup>(40)</sup> [80.00-100.00]	70.00 <sup>(123)</sup> [50.00-100.00]	70.00 <sup>(892)</sup> [50.00-100.00]	80.00 <sup>(20)</sup> [70.00-80.00]	70.00 <sup>(1,075)</sup> [50.00-100.00]

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>¶</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
	USD	\$0.40 <sup>(40)</sup> [0.40-0.50]	\$0.35 <sup>(123)</sup> [0.25-0.50]	\$0.35 <sup>(892)</sup> [0.25-0.50]	\$0.40 <sup>(20)</sup> [0.35-0.40]	\$0.35 <sup>(1,075)</sup> [0.25-0.50]
	USD per CYP	\$6.00 <sup>(40)</sup> [6.00-7.50]	\$5.25 <sup>(123)</sup> [3.75-7.50]	\$5.25 <sup>(892)</sup> [3.75-7.50]	\$6.00 <sup>(20)</sup> [5.25-6.00]	\$5.25 <sup>(1,075)</sup> [3.75-7.50]
<i>Combined oral contraceptives</i>						
North Central	Naira	100.00 <sup>(14)</sup> [98.00-100.00]	50.00 <sup>(40)</sup> [50.00-100.00]	50.00 <sup>(261)</sup> [50.00-100.00]	100.00 <sup>(5)</sup> [60.00-200.00]	50.00 <sup>(320)</sup> [50.00-100.00]
	USD	\$0.50 <sup>(14)</sup> [0.49-0.50]	\$0.25 <sup>(40)</sup> [0.25-0.50]	\$0.25 <sup>(261)</sup> [0.25-0.50]	\$0.50 <sup>(5)</sup> [0.30-1.00]	\$0.25 <sup>(320)</sup> [0.25-0.50]
	USD per CYP	\$7.50 <sup>(14)</sup> [7.35-7.50]	\$3.75 <sup>(40)</sup> [3.75-7.50]	\$3.75 <sup>(261)</sup> [3.75-7.50]	\$7.50 <sup>(5)</sup> [4.50-15.00]	\$3.75 <sup>(320)</sup> [3.75-7.50]
North East	Naira	150.00 <sup>(2)</sup> [150.00-150.00]	50.00 <sup>(3)</sup> [50.00-50.00]	70.00 <sup>(80)</sup> [50.00-100.00]	- -	70.00 <sup>(85)</sup> [50.00-100.00]
	USD	\$0.75 <sup>(2)</sup> [0.75-0.75]	\$0.25 <sup>(3)</sup> [0.25-0.25]	\$0.35 <sup>(80)</sup> [0.25-0.50]	- -	\$0.35 <sup>(85)</sup> [0.25-0.50]
	USD per CYP	\$11.25 <sup>(2)</sup> [11.25-11.25]	\$3.75 <sup>(3)</sup> [3.75-3.75]	\$5.25 <sup>(80)</sup> [3.75-7.50]	- -	\$5.25 <sup>(85)</sup> [3.75-7.50]
North West	Naira	50.00 <sup>(1)</sup> -	50.00 <sup>(4)</sup> [50.00-100.00]	70.00 <sup>(164)</sup> [50.00-80.00]	- -	70.00 <sup>(169)</sup> [50.00-80.00]
	USD	\$0.25 <sup>(1)</sup> -	\$0.25 <sup>(4)</sup> [0.25-0.50]	\$0.35 <sup>(164)</sup> [0.25-0.40]	- -	\$0.35 <sup>(169)</sup> [0.25-0.40]
	USD per CYP	\$3.75 <sup>(1)</sup> -	\$3.75 <sup>(4)</sup> [3.75-7.50]	\$5.25 <sup>(164)</sup> [3.75-6.00]	- -	\$5.25 <sup>(169)</sup> [3.75-6.00]
South East	Naira	0.00 <sup>(9)</sup> [0.00-200.00]	100.00 <sup>(14)</sup> [100.00-150.00]	100.00 <sup>(130)</sup> [50.00-100.00]	50.00 <sup>(3)</sup> [50.00-100.00]	100.00 <sup>(156)</sup> [50.00-100.00]
	USD	\$0.00 <sup>(9)</sup> [0.00-1.00]	\$0.50 <sup>(14)</sup> [0.50-0.75]	\$0.50 <sup>(130)</sup> [0.25-0.50]	\$0.25 <sup>(3)</sup> [0.25-0.50]	\$0.50 <sup>(156)</sup> [0.25-0.50]
	USD per CYP	\$0.00 <sup>(9)</sup> [0.00-15.00]	\$7.50 <sup>(14)</sup> [7.50-11.25]	\$7.50 <sup>(130)</sup> [3.75-7.50]	\$3.75 <sup>(3)</sup> [3.75-7.50]	\$7.50 <sup>(156)</sup> [3.75-7.50]
South South	Naira	100.00 <sup>(7)</sup> [70.00-300.00]	100.00 <sup>(17)</sup> [100.00-150.00]	100.00 <sup>(105)</sup> [80.00-100.00]	- -	100.00 <sup>(129)</sup> [80.00-100.00]
	USD	\$0.50 <sup>(7)</sup> [0.35-1.50]	\$0.50 <sup>(17)</sup> [0.50-0.75]	\$0.50 <sup>(105)</sup> [0.40-0.50]	- -	\$0.50 <sup>(129)</sup> [0.40-0.50]
	USD per CYP	\$7.50 <sup>(7)</sup> [5.25-22.50]	\$7.50 <sup>(17)</sup> [7.50-11.25]	\$7.50 <sup>(105)</sup> [6.00-7.50]	- -	\$7.50 <sup>(129)</sup> [6.00-7.50]
South West	Naira	80.00 <sup>(37)</sup>	70.00 <sup>(123)</sup>	70.00 <sup>(891)</sup>	80.00 <sup>(20)</sup>	70.00 <sup>(1,071)</sup>

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
		[80.00-100.00]	[50.00-100.00]	[50.00-100.00]	[70.00-80.00]	[50.00-100.00]
	USD	\$0.40 <sup>(37)</sup> [0.40-0.50]	\$0.35 <sup>(123)</sup> [0.25-0.50]	\$0.35 <sup>(891)</sup> [0.25-0.50]	\$0.40 <sup>(20)</sup> [0.35-0.40]	\$0.35 <sup>(1,071)</sup> [0.25-0.50]
	USD per CYP	\$6.00 <sup>(37)</sup> [6.00-7.50]	\$5.25 <sup>(123)</sup> [3.75-7.50]	\$5.25 <sup>(891)</sup> [3.75-7.50]	\$6.00 <sup>(20)</sup> [5.25-6.00]	\$5.25 <sup>(1,071)</sup> [3.75-7.50]
<i>Progestin-only pills</i>						
North Central	Naira	- -	100.00 <sup>(1)</sup> -	30.00 <sup>(2)</sup> [30.00-30.00]	- -	30.00 <sup>(3)</sup> [30.00-30.00]
	USD	- -	\$0.50 <sup>(1)</sup> -	\$0.15 <sup>(2)</sup> [0.15-0.15]	- -	\$0.15 <sup>(3)</sup> [0.15-0.15]
	USD per CYP	- -	\$7.50 <sup>(1)</sup> -	\$2.25 <sup>(2)</sup> [2.25-2.25]	- -	\$2.25 <sup>(3)</sup> [2.25-2.25]
North East	Naira	150.00 <sup>(1)</sup> -	- -	- -	- -	150.00 <sup>(1)</sup> -
	USD	\$0.75 <sup>(1)</sup> -	- -	- -	- -	\$0.75 <sup>(1)</sup> -
	USD per CYP	\$11.25 <sup>(1)</sup> -	- -	- -	- -	\$11.25 <sup>(1)</sup> -
North West	Naira	- -	- -	70.00 <sup>(8)</sup> [70.00-100.00]	- -	70.00 <sup>(8)</sup> [70.00-100.00]
	USD	- -	- -	\$0.35 <sup>(8)</sup> [0.35-0.50]	- -	\$0.35 <sup>(8)</sup> [0.35-0.50]
	USD per CYP	- -	- -	\$5.25 <sup>(8)</sup> [5.25-7.50]	- -	\$5.25 <sup>(8)</sup> [5.25-7.50]
South East	Naira	0.00 <sup>(3)</sup> [0.00-0.00]	- -	16.67 <sup>(1)</sup> -	- -	0.00 <sup>(4)</sup> [0.00-0.00]
	USD	\$0.00 <sup>(3)</sup> [0.00-0.00]	- -	\$0.08 <sup>(1)</sup> -	- -	\$0.00 <sup>(4)</sup> [0.00-0.00]
	USD per CYP	\$0.00 <sup>(3)</sup> [0.00-0.00]	- -	\$1.25 <sup>(1)</sup> -	- -	\$0.00 <sup>(4)</sup> [0.00-0.00]
South South	Naira	- -	- -	- -	- -	- -
	USD	- -	- -	- -	- -	- -
	USD per CYP	- -	- -	- -	- -	- -

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
South West	Naira	100.00 <sup>(3)</sup> [50.00-100.00]	-	100.00 <sup>(1)</sup>	-	100.00 <sup>(4)</sup> [50.00-100.00]
	USD	\$0.50 <sup>(3)</sup> [0.25-0.50]	-	\$0.50 <sup>(1)</sup> -	-	\$0.50 <sup>(4)</sup> [0.25-0.50]
	USD per CYP	\$7.50 <sup>(3)</sup> [3.75-7.50]	-	\$7.50 <sup>(1)</sup> -	-	\$7.50 <sup>(4)</sup> [3.75-7.50]
Emergency contraceptives						
North Central	Naira	300.00 <sup>(2)</sup> [200.00-300.00]	300.00 <sup>(32)</sup> [200.00-350.00]	120.00 <sup>(93)</sup> [40.00-200.00]	-	150.00 <sup>(127)</sup> [40.00-200.00]
	USD	\$1.50 <sup>(2)</sup> [1.00-1.50]	\$1.50 <sup>(32)</sup> [1.00-1.75]	\$0.60 <sup>(93)</sup> [0.20-1.00]	-	\$0.75 <sup>(127)</sup> [0.20-1.00]
	USD per CYP	\$30.00 <sup>(2)</sup> [20.00-30.00]	\$30.00 <sup>(32)</sup> [20.00-35.00]	\$12.00 <sup>(93)</sup> [4.00-20.00]	-	\$15.00 <sup>(127)</sup> [4.00-20.00]
North East	Naira	-	175.00 <sup>(6)</sup> [100.00-300.00]	200.00 <sup>(15)</sup> [40.00-250.00]	-	200.00 <sup>(21)</sup> [40.00-250.00]
	USD	-	\$0.88 <sup>(6)</sup> [0.50-1.50]	\$1.00 <sup>(15)</sup> [0.20-1.25]	-	\$1.00 <sup>(21)</sup> [0.20-1.25]
	USD per CYP	-	\$17.50 <sup>(6)</sup> [10.00-30.00]	\$20.00 <sup>(15)</sup> [4.00-25.00]	-	\$20.00 <sup>(21)</sup> [4.00-25.00]
North West	Naira	-	200.00 <sup>(2)</sup> [200.00-200.00]	250.00 <sup>(21)</sup> [150.00-250.00]	-	250.00 <sup>(23)</sup> [150.00-250.00]
	USD	-	\$1.00 <sup>(2)</sup> [1.00-1.00]	\$1.25 <sup>(21)</sup> [0.75-1.25]	-	\$1.25 <sup>(23)</sup> [0.75-1.25]
	USD per CYP	-	\$20.00 <sup>(2)</sup> [20.00-20.00]	\$25.00 <sup>(21)</sup> [15.00-25.00]	-	\$25.00 <sup>(23)</sup> [15.00-25.00]
South East	Naira	-	200.00 <sup>(15)</sup> [150.00-300.00]	200.00 <sup>(38)</sup> [200.00-250.00]	300.00 <sup>(1)</sup> -	200.00 <sup>(54)</sup> [150.00-250.00]
	USD	-	\$1.00 <sup>(15)</sup> [0.75-1.50]	\$1.00 <sup>(38)</sup> [1.00-1.25]	\$1.50 <sup>(1)</sup> -	\$1.00 <sup>(54)</sup> [0.75-1.25]
	USD per CYP	-	\$20.00 <sup>(15)</sup> [15.00-30.00]	\$20.00 <sup>(38)</sup> [20.00-25.00]	\$30.00 <sup>(1)</sup> -	\$20.00 <sup>(54)</sup> [15.00-25.00]
South South	Naira	0.00 <sup>(1)</sup> -	250.00 <sup>(11)</sup> [50.00-300.00]	150.00 <sup>(67)</sup> [40.00-250.00]	-	150.00 <sup>(79)</sup> [40.00-250.00]
	USD	\$0.00 <sup>(1)</sup> -	\$1.25 <sup>(11)</sup> [0.25-1.50]	\$0.75 <sup>(67)</sup> [0.20-1.25]	-	\$0.75 <sup>(79)</sup> [0.20-1.25]
	USD per CYP	\$0.00 <sup>(1)</sup>	\$25.00 <sup>(11)</sup>	\$15.00 <sup>(67)</sup>	-	\$15.00 <sup>(79)</sup>



**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>¶</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
South West		-	[5.00-30.00]	[4.00-25.00]	-	[4.00-25.00]
	Naira	500.00 <sup>(4)</sup> [50.00-500.00]	250.00 <sup>(125)</sup> [50.00-350.00]	80.00 <sup>(214)</sup> [40.00-250.00]	200.00 <sup>(7)</sup> [200.00-200.00]	150.00 <sup>(350)</sup> [40.00-300.00]
	USD	\$2.50 <sup>(4)</sup> [0.25-2.50]	\$1.25 <sup>(125)</sup> [0.25-1.75]	\$0.40 <sup>(214)</sup> [0.20-1.25]	\$1.00 <sup>(7)</sup> [1.00-1.00]	\$0.75 <sup>(350)</sup> [0.20-1.50]
	USD per CYP	\$50.00 <sup>(4)</sup> [5.00-50.00]	\$25.00 <sup>(125)</sup> [5.00-35.00]	\$8.00 <sup>(214)</sup> [4.00-25.00]	\$20.00 <sup>(7)</sup> [20.00-20.00]	\$15.00 <sup>(350)</sup> [4.00-30.00]
Contraceptive injectables <sup>  </sup>						
North Central	Naira	350.00 <sup>(21)</sup> [200.00-350.00]	200.00 <sup>(61)</sup> [150.00-400.00]	250.00 <sup>(82)</sup> [150.00-300.00]	-	300.00 <sup>(164)</sup> [180.00-350.00]
	USD	\$1.75 <sup>(21)</sup> [1.00-1.75]	\$1.00 <sup>(61)</sup> [0.75-2.00]	\$1.25 <sup>(82)</sup> [0.75-1.50]	-	\$1.50 <sup>(164)</sup> [0.90-1.75]
	USD per CYP	\$7.00 <sup>(21)</sup> [6.00-10.00]	\$6.00 <sup>(61)</sup> [4.00-9.00]	\$6.00 <sup>(82)</sup> [3.90-9.00]	-	\$6.00 <sup>(164)</sup> [4.00-10.00]
North East	Naira	-	200.00 <sup>(3)</sup> [200.00-200.00]	250.00 <sup>(48)</sup> [200.00-300.00]	-	250.00 <sup>(51)</sup> [200.00-300.00]
	USD	-	\$1.00 <sup>(3)</sup> [1.00-1.00]	\$1.25 <sup>(48)</sup> [1.00-1.50]	-	\$1.25 <sup>(51)</sup> [1.00-1.50]
	USD per CYP	-	\$5.00 <sup>(3)</sup> [4.00-6.00]	\$6.00 <sup>(48)</sup> [4.50-9.00]	-	\$6.00 <sup>(51)</sup> [4.50-9.00]
North West	Naira	300.00 <sup>(8)</sup> [200.00-600.00]	120.00 <sup>(5)</sup> [100.00-400.00]	200.00 <sup>(179)</sup> [150.00-250.00]	-	200.00 <sup>(192)</sup> [150.00-250.00]
	USD	\$1.50 <sup>(8)</sup> [1.00-3.00]	\$0.60 <sup>(5)</sup> [0.50-2.00]	\$1.00 <sup>(179)</sup> [0.75-1.25]	-	\$1.00 <sup>(192)</sup> [0.75-1.25]
	USD per CYP	6.00 <sup>(8)</sup> [4.50-18.00]	3.00 <sup>(5)</sup> [2.40-12.00]	4.50 <sup>(179)</sup> [3.60-6.00]	-	4.50 <sup>(192)</sup> [3.60-6.00]
South East	Naira	\$500.00 <sup>(22)</sup> [200.00-500.00]	\$100.00 <sup>(7)</sup> [100.00-150.00]	\$1000.00 <sup>(9)</sup> [800.00-1500.00]	-	\$500.00 <sup>(38)</sup> [200.00-800.00]
	USD	\$2.50 <sup>(22)</sup> [1.00-2.50]	\$0.50 <sup>(7)</sup> [0.50-0.75]	\$5.00 <sup>(9)</sup> [4.00-7.50]	-	\$2.50 <sup>(38)</sup> [1.00-4.00]
	USD per CYP	\$10.00 <sup>(22)</sup> [6.00-10.00]	\$2.00 <sup>(7)</sup> [2.00-3.00]	\$20.00 <sup>(9)</sup> [16.00-30.00]	-	\$10.00 <sup>(38)</sup> [6.00-16.00]
South South	Naira	500.00 <sup>(9)</sup> [500.00-2000.00]	300.00 <sup>(17)</sup> [300.00-400.00]	1500.00 <sup>(8)</sup> [500.00-1500.00]	-	500.00 <sup>(34)</sup> [500.00-1500.00]
	USD	\$2.50 <sup>(9)</sup> [2.50-10.00]	\$1.50 <sup>(17)</sup> [1.50-2.00]	\$7.50 <sup>(8)</sup> [2.50-7.50]	-	\$2.50 <sup>(34)</sup> [2.50-7.50]

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>¶</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
	USD per CYP	\$15.00 <sup>(9)</sup> [10.00-60.00]	\$6.00 <sup>(17)</sup> [6.00-12.00]	\$30.00 <sup>(8)</sup> [10.00-30.00]	-	\$15.00 <sup>(34)</sup> [10.00-30.00]
South West	Naira	500.00 <sup>(77)</sup> [400.00-500.00]	150.00 <sup>(124)</sup> [130.00-200.00]	200.00 <sup>(67)</sup> [150.00-500.00]	500.00 <sup>(1)</sup> -	180.00 <sup>(269)</sup> [140.00-400.00]
	USD	\$2.50 <sup>(77)</sup> [2.00-2.50]	\$0.75 <sup>(124)</sup> [0.65-1.00]	\$1.00 <sup>(67)</sup> [0.75-2.50]	\$2.50 <sup>(1)</sup> -	\$0.90 <sup>(269)</sup> [0.70-2.00]
	USD per CYP	\$10.00 <sup>(77)</sup> [8.00-15.00]	\$3.90 <sup>(124)</sup> [3.00-4.50]	\$6.00 <sup>(67)</sup> [4.00-10.00]	\$15.00 <sup>(1)</sup> -	\$4.50 <sup>(269)</sup> [3.00-8.00]
<i>Depo-provera injectables</i>						
North Central	Naira	350.00 <sup>(11)</sup> [150.00-500.00]	200.00 <sup>(30)</sup> [150.00-300.00]	250.00 <sup>(37)</sup> [150.00-306.00]	-	300.00 <sup>(78)</sup> [150.00-500.00]
	USD	\$1.75 <sup>(11)</sup> [0.75-2.50]	\$1.00 <sup>(30)</sup> [0.75-1.50]	\$1.25 <sup>(37)</sup> [0.75-1.53]	-	\$1.50 <sup>(78)</sup> [0.75-2.50]
	USD per CYP	\$7.00 <sup>(11)</sup> [3.00-10.00]	\$4.00 <sup>(30)</sup> [3.00-6.00]	\$5.00 <sup>(37)</sup> [3.00-6.12]	-	\$6.00 <sup>(78)</sup> [3.00-10.00]
North East	Naira	-	200.00 <sup>(2)</sup> [200.00-200.00]	200.00 <sup>(22)</sup> [150.00-300.00]	-	200.00 <sup>(24)</sup> [150.00-300.00]
	USD	-	\$1.00 <sup>(2)</sup> [1.00-1.00]	\$1.00 <sup>(22)</sup> [0.75-1.50]	-	\$1.00 <sup>(24)</sup> [0.75-1.50]
	USD per CYP	-	\$4.00 <sup>(2)</sup> [4.00-4.00]	\$4.00 <sup>(22)</sup> [3.00-6.00]	-	\$4.00 <sup>(24)</sup> [3.00-6.00]
North West	Naira	200.00 <sup>(4)</sup> [200.00-300.00]	120.00 <sup>(2)</sup> [120.00-120.00]	200.00 <sup>(94)</sup> [150.00-300.00]	-	200.00 <sup>(100)</sup> [150.00-300.00]
	USD	\$1.00 <sup>(4)</sup> [1.00-1.50]	\$0.60 <sup>(2)</sup> [0.60-0.60]	\$1.00 <sup>(94)</sup> [0.75-1.50]	-	\$1.00 <sup>(100)</sup> [0.75-1.50]
	USD per CYP	\$4.00 <sup>(4)</sup> [4.00-6.00]	\$2.40 <sup>(2)</sup> [2.40-2.40]	\$4.00 <sup>(94)</sup> [3.00-6.00]	-	\$4.00 <sup>(100)</sup> [3.00-6.00]
South East	Naira	500.00 <sup>(16)</sup> [300.00-500.00]	100.00 <sup>(5)</sup> [100.00-150.00]	1000.00 <sup>(7)</sup> [800.00-1500.00]	-	500.00 <sup>(28)</sup> [300.00-800.00]
	USD	\$2.50 <sup>(16)</sup> [1.50-2.50]	\$0.50 <sup>(5)</sup> [0.50-0.75]	\$5.00 <sup>(7)</sup> [4.00-7.50]	-	\$2.50 <sup>(28)</sup> [1.50-4.00]
	USD per CYP	\$10.00 <sup>(16)</sup> [6.00-10.00]	\$2.00 <sup>(5)</sup> [2.00-3.00]	\$20.00 <sup>(7)</sup> [16.00-30.00]	-	\$10.00 <sup>(28)</sup> [6.00-16.00]
South South	Naira	500.00 <sup>(3)</sup> [500.00-500.00]	300.00 <sup>(7)</sup> [300.00-300.00]	1500.00 <sup>(4)</sup> [500.00-1500.00]	-	500.00 <sup>(14)</sup> [500.00-500.00]
	USD	\$2.50 <sup>(3)</sup>	\$1.50 <sup>(7)</sup>	\$7.50 <sup>(4)</sup>	-	\$2.50 <sup>(14)</sup>

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
		[2.50-2.50]	[1.50-1.50]	[2.50-7.50]	-	[2.50-2.50]
	USD per CYP	\$10.00 <sup>(3)</sup> [10.00-10.00]	\$6.00 <sup>(7)</sup> [6.00-6.00]	\$30.00 <sup>(4)</sup> [10.00-30.00]	-	\$10.00 <sup>(14)</sup> [10.00-10.00]
South West	Naira	400.00 <sup>(43)</sup> [400.00-500.00]	150.00 <sup>(68)</sup> [130.00-200.00]	500.00 <sup>(36)</sup> [200.00-500.00]	-	200.00 <sup>(147)</sup> [140.00-500.00]
	USD	\$2.00 <sup>(43)</sup> [2.00-2.50]	\$0.75 <sup>(68)</sup> [0.65-1.00]	\$2.50 <sup>(36)</sup> [1.00-2.50]	-	\$1.00 <sup>(147)</sup> [0.70-2.50]
	USD per CYP	\$8.00 <sup>(43)</sup> [8.00-10.00]	\$3.00 <sup>(68)</sup> [2.60-4.00]	\$10.00 <sup>(36)</sup> [4.00-10.00]	-	\$4.00 <sup>(147)</sup> [2.80-10.00]
<i>Noristerat injectables</i>						
North Central	Naira	200.00 <sup>(10)</sup> [200.00-350.00]	200.00 <sup>(31)</sup> [150.00-400.00]	250.00 <sup>(45)</sup> [150.00-300.00]	-	200.00 <sup>(86)</sup> [200.00-300.00]
	USD	\$1.00 <sup>(10)</sup> [1.00-1.75]	\$1.00 <sup>(31)</sup> [0.75-2.00]	\$1.25 <sup>(45)</sup> [0.75-1.50]	-	\$1.00 <sup>(86)</sup> [1.00-1.50]
	USD per CYP	\$6.00 <sup>(10)</sup> [6.00-10.50]	\$6.00 <sup>(31)</sup> [4.50-12.00]	\$7.50 <sup>(45)</sup> [4.50-9.00]	-	\$6.00 <sup>(86)</sup> [6.00-9.00]
North East	Naira	- -	200.00 <sup>(1)</sup> -	250.00 <sup>(26)</sup> [200.00-300.00]	-	250.00 <sup>(27)</sup> [200.00-300.00]
	USD	- -	\$1.00 <sup>(1)</sup> -	\$1.25 <sup>(26)</sup> [1.00-1.50]	-	\$1.25 <sup>(27)</sup> [1.00-1.50]
	USD per CYP	- -	\$6.00 <sup>(1)</sup> -	\$7.50 <sup>(26)</sup> [6.00-9.00]	-	\$7.50 <sup>(27)</sup> [6.00-9.00]
North West	Naira	450.00 <sup>(4)</sup> [200.00-600.00]	400.00 <sup>(3)</sup> [100.00-400.00]	150.00 <sup>(85)</sup> [150.00-200.00]	-	150.00 <sup>(92)</sup> [150.00-200.00]
	USD	\$2.25 <sup>(4)</sup> [1.00-3.00]	\$2.00 <sup>(3)</sup> [0.50-2.00]	\$0.75 <sup>(85)</sup> [0.75-1.00]	-	\$0.75 <sup>(92)</sup> [0.75-1.00]
	USD per CYP	\$13.50 <sup>(4)</sup> [6.00-18.00]	\$12.00 <sup>(3)</sup> [3.00-12.00]	\$4.50 <sup>(85)</sup> [4.50-6.00]	-	\$4.50 <sup>(92)</sup> [4.50-6.00]
South East	Naira	200.00 <sup>(6)</sup> [200.00-500.00]	675.00 <sup>(2)</sup> [150.00-1200.00]	150.00 <sup>(2)</sup> [150.00-150.00]	-	200.00 <sup>(10)</sup> [150.00-250.00]
	USD	\$1.00 <sup>(6)</sup> [1.00-2.50]	\$3.38 <sup>(2)</sup> [0.75-6.00]	\$0.75 <sup>(2)</sup> [0.75-0.75]	-	\$1.00 <sup>(10)</sup> [0.75-1.25]
	USD per CYP	\$6.00 <sup>(6)</sup> [6.00-15.00]	\$20.25 <sup>(2)</sup> [4.50-36.00]	\$4.50 <sup>(2)</sup> [4.50-4.50]	-	\$6.00 <sup>(10)</sup> [4.50-7.50]
South South	Naira	500.00 <sup>(6)</sup> [500.00-2000.00]	400.00 <sup>(10)</sup> [200.00-400.00]	500.00 <sup>(4)</sup> [500.00-500.00]	-	500.00 <sup>(20)</sup> [500.00-2000.00]

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
	USD	\$2.50 <sup>(6)</sup> [2.50-10.00]	\$2.00 <sup>(10)</sup> [1.00-2.00]	\$2.50 <sup>(4)</sup> [2.50-2.50]	-	\$2.50 <sup>(20)</sup> [2.50-10.00]
	USD per CYP	\$15.00 <sup>(6)</sup> [15.00-60.00]	\$12.00 <sup>(10)</sup> [6.00-12.00]	\$15.00 <sup>(4)</sup> [15.00-15.00]	-	\$15.00 <sup>(20)</sup> [15.00-60.00]
South West	Naira	500.00 <sup>(34)</sup> [500.00-1000.00]	150.00 <sup>(56)</sup> [130.00-180.00]	200.00 <sup>(31)</sup> [150.00-200.00]	500.00 <sup>(1)</sup> -	150.00 <sup>(122)</sup> [150.00-200.00]
	USD	\$2.50 <sup>(34)</sup> [2.50-5.00]	\$0.75 <sup>(56)</sup> [0.65-0.90]	\$1.00 <sup>(31)</sup> [0.75-1.00]	\$2.50 <sup>(1)</sup> -	\$0.75 <sup>(122)</sup> [0.75-1.00]
	USD per CYP	\$15.00 <sup>(34)</sup> [15.00-30.00]	\$4.50 <sup>(56)</sup> [3.90-5.40]	\$6.00 <sup>(31)</sup> [4.50-6.00]	\$15.00 <sup>(1)</sup> -	\$4.50 <sup>(122)</sup> [4.50-6.00]
<b>Implants<sup>  </sup></b>						
North Central	Naira	1000.00 <sup>(5)</sup> [1000.00-1000.00]	-	-	-	1000.00 <sup>(5)</sup> [1000.00-1000.00]
	USD	\$5.00 <sup>(5)</sup> [5.00-5.00]	-	-	-	\$5.00 <sup>(5)</sup> [5.00-5.00]
	USD per CYP	\$1.32 <sup>(5)</sup> [1.32-2.00]	-	-	-	\$1.32 <sup>(5)</sup> [1.32-2.00]
North East	Naira	1600.00 <sup>(1)</sup> -	-	-	-	1600.00 <sup>(1)</sup> -
	USD	\$8.00 <sup>(1)</sup> -	-	-	-	\$8.00 <sup>(1)</sup> -
	USD per CYP	\$3.20 <sup>(1)</sup> -	-	-	-	\$3.20 <sup>(1)</sup> -
North West	Naira	-	-	-	-	-
	USD	-	-	-	-	-
	USD per CYP	-	-	-	-	-
South East	Naira	0.00 <sup>(11)</sup> [0.00-1500.00]	-	-	-	0.00 <sup>(11)</sup> [0.00-1500.00]
	USD	\$0.00 <sup>(11)</sup> [0.00-7.50]	-	-	-	\$0.00 <sup>(11)</sup> [0.00-7.50]
	USD per CYP	\$0.00 <sup>(11)</sup> [0.00-1.97]	-	-	-	\$0.00 <sup>(11)</sup> [0.00-1.97]
South South	Naira	1500.00 <sup>(6)</sup>	1200.00 <sup>(1)</sup>	500.00 <sup>(2)</sup>	-	1500.00 <sup>(9)</sup>

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
		[1500.00-2000.00]		[500.00-500.00]	-	[1500.00-2000.00]
	USD	\$7.50 <sup>(6)</sup> [7.50-10.00]	\$6.00 <sup>(1)</sup>	\$2.50 <sup>(2)</sup> [2.50-2.50]	-	\$7.50 <sup>(9)</sup> [7.50-10.00]
	USD per CYP	\$2.00 <sup>(6)</sup> [1.97-2.63]	\$1.58 <sup>(1)</sup>	\$0.83 <sup>(2)</sup> [0.66-1.00]	-	\$2.00 <sup>(9)</sup> [1.97-2.63]
South West	Naira	1500.00 <sup>(19)</sup> [1000.00-5000.00]	-	0.00 <sup>(1)</sup> -	-	1500.00 <sup>(20)</sup> [1000.00-5000.00]
	USD	\$7.50 <sup>(19)</sup> [5.00-25.00]	-	\$0.00 <sup>(1)</sup> -	-	\$7.50 <sup>(20)</sup> [5.00-25.00]
	USD per CYP	\$1.97 <sup>(19)</sup> [1.32-6.58]	-	\$0.00 <sup>(1)</sup> -	-	\$1.97 <sup>(20)</sup> [1.32-6.58]
<i>Implanon implants</i>						
North Central	Naira	1000.00 <sup>(3)</sup> [1000.00-1000.00]	-	-	-	1000.00 <sup>(3)</sup> [1000.00-1000.00]
	USD	\$5.00 <sup>(3)</sup> [5.00-5.00]	-	-	-	\$5.00 <sup>(3)</sup> [5.00-5.00]
	USD per CYP	\$2.00 <sup>(3)</sup> [2.00-2.00]	-	-	-	\$2.00 <sup>(3)</sup> [2.00-2.00]
North East	Naira	1600.00 <sup>(1)</sup> -	-	-	-	1600.00 <sup>(1)</sup> -
	USD	\$8.00 <sup>(1)</sup> -	-	-	-	\$8.00 <sup>(1)</sup> -
	USD per CYP	\$3.20 <sup>(1)</sup> -	-	-	-	\$3.20 <sup>(1)</sup> -
North West	Naira	- -	-	-	-	- -
	USD	- -	-	-	-	- -
	USD per CYP	- -	-	-	-	- -
South East	Naira	0.00 <sup>(4)</sup> [0.00-1500.00]	-	-	-	0.00 <sup>(4)</sup> [0.00-1500.00]
	USD	\$0.00 <sup>(4)</sup> [0.00-7.50]	-	-	-	\$0.00 <sup>(4)</sup> [0.00-7.50]
	USD per CYP	\$0.00 <sup>(4)</sup> [0.00-3.00]	-	-	-	\$0.00 <sup>(4)</sup> [0.00-3.00]

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
South South	Naira	1500.00 <sup>(2)</sup> [1000.00-2000.00]	-	500.00 <sup>(1)</sup> -	-	1000.00 <sup>(3)</sup> [1000.00-2000.00]
	USD	\$7.50 <sup>(2)</sup> [5.00-10.00]	-	\$2.50 <sup>(1)</sup> -	-	\$5.00 <sup>(3)</sup> [5.00-10.00]
	USD per CYP	\$3.00 <sup>(2)</sup> [2.00-4.00]	-	\$1.00 <sup>(1)</sup> -	-	\$2.00 <sup>(3)</sup> [2.00-4.00]
South West	Naira	5000.00 <sup>(4)</sup> [5000.00-7500.00]	-	-	-	5000.00 <sup>(4)</sup> [5000.00-7500.00]
	USD	\$25.00 <sup>(4)</sup> [25.00-37.50]	-	-	-	\$25.00 <sup>(4)</sup> [25.00-37.50]
	USD per CYP	\$10.00 <sup>(4)</sup> [10.00-15.00]	-	-	-	\$10.00 <sup>(4)</sup> [10.00-15.00]
<i>Jadelle implants</i>						
North Central	Naira	1000.00 <sup>(2)</sup> [1000.00-1000.00]	-	-	-	1000.00 <sup>(2)</sup> [1000.00-1000.00]
	USD	\$5.00 <sup>(2)</sup> [5.00-5.00]	-	-	-	\$5.00 <sup>(2)</sup> [5.00-5.00]
	USD per CYP	\$1.32 <sup>(2)</sup> [1.32-1.32]	-	-	-	\$1.32 <sup>(2)</sup> [1.32-1.32]
North East	Naira	-	-	-	-	-
	USD	-	-	-	-	-
	USD per CYP	-	-	-	-	-
North West	Naira	-	-	-	-	-
	USD	-	-	-	-	-
	USD per CYP	-	-	-	-	-
South East	Naira	1500.00 <sup>(7)</sup> [0.00-1500.00]	-	-	-	1500.00 <sup>(7)</sup> [0.00-1500.00]
	USD	\$7.50 <sup>(7)</sup> [0.00-7.50]	-	-	-	\$7.50 <sup>(7)</sup> [0.00-7.50]
	USD per CYP	\$1.97 <sup>(7)</sup>	-	-	-	\$1.97 <sup>(7)</sup>

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
South South		[0.00-1.97]	-	-	-	[0.00-1.97]
	Naira	1500.00 <sup>(4)</sup> [1500.00-2000.00]	1200.00 <sup>(1)</sup> -	500.00 <sup>(1)</sup> -	-	1500.00 <sup>(6)</sup> [1500.00-2000.00]
	USD	\$7.50 <sup>(4)</sup> [7.50-10.00]	\$6.00 <sup>(1)</sup> -	\$2.50 <sup>(1)</sup> -	-	\$7.50 <sup>(6)</sup> [7.50-10.00]
	USD per CYP	\$1.97 <sup>(4)</sup> [1.97-2.63]	\$1.58 <sup>(1)</sup> -	\$0.66 <sup>(1)</sup> -	-	\$1.97 <sup>(6)</sup> [1.97-2.63]
South West	Naira	1500.00 <sup>(15)</sup> [1000.00-4000.00]	-	0.00 <sup>(1)</sup> -	-	1500.00 <sup>(16)</sup> [1000.00-4000.00]
	USD	\$7.50 <sup>(15)</sup> [5.00-20.00]	-	\$0.00 <sup>(1)</sup> -	-	\$7.50 <sup>(16)</sup> [5.00-20.00]
	USD per CYP	\$1.97 <sup>(15)</sup> [1.32-5.26]	-	\$0.00 <sup>(1)</sup> -	-	\$1.97 <sup>(16)</sup> [1.32-5.26]
IUDs						
North Central	Naira	1000.00 <sup>(7)</sup> [1000.00-1500.00]	250.00 <sup>(1)</sup> -	155.00 <sup>(2)</sup> [150.00-160.00]	-	1000.00 <sup>(10)</sup> [1000.00-1500.00]
	USD	\$5.00 <sup>(7)</sup> [5.00-7.50]	\$1.25 <sup>(1)</sup> -	\$0.77 <sup>(2)</sup> [0.75-0.80]	-	\$5.00 <sup>(10)</sup> [5.00-7.50]
	USD per CYP	\$1.09 <sup>(7)</sup> [1.09-1.63]	\$0.27 <sup>(1)</sup> -	\$0.17 <sup>(2)</sup> [0.16-0.17]	-	\$1.09 <sup>(10)</sup> [1.09-1.63]
North East	Naira	1500.00 <sup>(2)</sup> [800.00-1500.00]	-	2500.00 <sup>(1)</sup> -	-	2500.00 <sup>(3)</sup> [1500.00-2500.00]
	USD	\$7.50 <sup>(2)</sup> [4.00-7.50]	-	\$12.50 <sup>(1)</sup> -	-	\$12.50 <sup>(3)</sup> [7.50-12.50]
	USD per CYP	\$1.63 <sup>(2)</sup> [0.87-1.63]	-	\$2.72 <sup>(1)</sup> -	-	\$2.72 <sup>(3)</sup> [1.63-2.72]
North West	Naira	-	-	500.00 <sup>(1)</sup> -	-	500.00 <sup>(1)</sup> -
	USD	-	-	\$2.50 <sup>(1)</sup> -	-	\$2.50 <sup>(1)</sup> -
	USD per CYP	-	-	\$0.54 <sup>(1)</sup> -	-	\$0.54 <sup>(1)</sup> -
South East	Naira	2000.00 <sup>(8)</sup> [500.00-2000.00]	250.00 <sup>(1)</sup> -	200.00 <sup>(1)</sup> -	-	500.00 <sup>(10)</sup> [500.00-2000.00]
	USD	\$10.00 <sup>(8)</sup> [2.50-10.00]	\$1.25 <sup>(1)</sup> -	\$1.00 <sup>(1)</sup> -	-	\$2.50 <sup>(10)</sup> [2.50-10.00]

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
	USD per CYP	\$2.17 <sup>(8)</sup> [0.54-2.17]	\$0.27 <sup>(1)</sup> -	\$0.22 <sup>(1)</sup> -	- -	\$0.54 <sup>(10)</sup> [0.54-2.17]
South South	Naira	1000.00 <sup>(4)</sup> [1000.00-1000.00]	- -	- -	- -	1000.00 <sup>(4)</sup> [1000.00-1000.00]
	USD	\$5.00 <sup>(4)</sup> [5.00-5.00]	- -	- -	- -	\$5.00 <sup>(4)</sup> [5.00-5.00]
	USD per CYP	\$1.09 <sup>(4)</sup> [1.09-1.09]	- -	- -	- -	\$1.09 <sup>(4)</sup> [1.09-1.09]
South West	Naira	500.00 <sup>(41)</sup> [500.00-2400.00]	250.00 <sup>(7)</sup> [250.00-250.00]	250.00 <sup>(3)</sup> [250.00-250.00]	- -	500.00 <sup>(51)</sup> [500.00-2400.00]
	USD	\$2.50 <sup>(41)</sup> [2.50-12.00]	\$1.25 <sup>(7)</sup> [1.25-1.25]	\$1.25 <sup>(3)</sup> [1.25-1.25]	- -	\$2.50 <sup>(51)</sup> [2.50-12.00]
	USD per CYP	\$0.54 <sup>(41)</sup> [0.54-2.61]	\$0.27 <sup>(7)</sup> [0.27-0.27]	\$0.27 <sup>(3)</sup> [0.27-0.27]	- -	\$0.54 <sup>(51)</sup> [0.54-2.61]
<b>Male Sterilization</b>						
North Central	Naira	- -	- -	- -	- -	- -
	USD	- -	- -	- -	- -	- -
	USD per CYP	- -	- -	- -	- -	- -
North East	Naira	20000.00 <sup>(1)</sup> -	- -	- -	- -	20000.00 <sup>(1)</sup> -
	USD	\$100.00 <sup>(1)</sup> -	- -	- -	- -	\$100.00 <sup>(1)</sup> -
	USD per CYP	\$10.75 <sup>(1)</sup> -	- -	- -	- -	\$10.75 <sup>(1)</sup> -
North West	Naira	- -	- -	- -	- -	- -
	USD	- -	- -	- -	- -	- -
	USD per CYP	- -	- -	- -	- -	- -
South East	Naira	42000.00 <sup>(1)</sup> -	- -	- -	- -	42000.00 <sup>(1)</sup> -
	USD	\$210.00 <sup>(1)</sup>	-	-	-	\$210.00 <sup>(1)</sup>



**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
		-	-	-	-	-
	USD per CYP	\$22.58 <sup>(1)</sup> -	-	-	-	\$22.58 <sup>(1)</sup> -
South South	Naira	-	-	-	-	-
	USD	-	-	-	-	-
	USD per CYP	-	-	-	-	-
South West	Naira	150000.00 <sup>(2)</sup> [150000.00-150000.00]	-	-	-	150000.00 <sup>(2)</sup> [150000.00-150000.00]
	USD	\$750.00 <sup>(2)</sup> [750.00-750.00]	-	-	-	\$750.00 <sup>(2)</sup> [750.00-750.00]
	USD per CYP	\$80.65 <sup>(2)</sup> [80.65-80.65]	-	-	-	\$80.65 <sup>(2)</sup> [80.65-80.65]
<b>Female Sterilization</b>						
North Central	Naira	60000.00 <sup>(3)</sup> [60000.00-150000.00]	-	-	-	60000.00 <sup>(3)</sup> [60000.00-150000.00]
	USD	\$300.00 <sup>(3)</sup> [300.00-750.00]	-	-	-	\$300.00 <sup>(3)</sup> [300.00-750.00]
	USD per CYP	\$32.26 <sup>(3)</sup> [32.26-80.65]	-	-	-	\$32.26 <sup>(3)</sup> [32.26-80.65]
North East	Naira	20000.00 <sup>(1)</sup> -	-	-	-	20000.00 <sup>(1)</sup> -
	USD	\$100.00 <sup>(1)</sup> -	-	-	-	\$100.00 <sup>(1)</sup> -
	USD per CYP	\$10.75 <sup>(1)</sup> -	-	-	-	\$10.75 <sup>(1)</sup> -
North West	Naira	-	-	-	-	-
	USD	-	-	-	-	-
	USD per CYP	-	-	-	-	-
South East	Naira	42000.00 <sup>(2)</sup> [0.00-42000.00]	-	-	-	42000.00 <sup>(2)</sup> [0.00-42000.00]

**Table B6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – by Geopolitical Zone, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>§</sup>
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
	USD	\$210.00 <sup>(2)</sup> [0.00-210.00]	- -	- -	- -	\$210.00 <sup>(2)</sup> [0.00-210.00]
	USD per CYP	\$22.58 <sup>(2)</sup> [0.00-22.58]	- -	- -	- -	\$22.58 <sup>(2)</sup> [0.00-22.58]
South South	Naira	15000.00 <sup>(3)</sup> [15000.00-15000.00]	- -	- -	- -	15000.00 <sup>(3)</sup> [15000.00-15000.00]
	USD	\$75.00 <sup>(3)</sup> [75.00-75.00]	- -	- -	- -	\$75.00 <sup>(3)</sup> [75.00-75.00]
	USD per CYP	\$8.06 <sup>(3)</sup> [8.06-8.06]	- -	- -	- -	\$8.06 <sup>(3)</sup> [8.06-8.06]
South West	Naira	25000.00 <sup>(12)</sup> [7000.00-50000.00]	- -	- -	- -	25000.00 <sup>(12)</sup> [7000.00-50000.00]
	USD	\$125.00 <sup>(12)</sup> [35.00-250.00]	- -	- -	- -	\$125.00 <sup>(12)</sup> [35.00-250.00]
	USD per CYP	\$13.44 <sup>(12)</sup> [3.76-26.88]	- -	- -	- -	\$13.44 <sup>(12)</sup> [3.76-26.88]
<p>* Based on the average rate of exchange from August 10 to October 23, 2015 of 500 Naira per 1 USD.</p> <p>† CYP – Couple Year Protection is the estimated protection provided by contraceptive methods during a one-year period, based upon the volume of all contraceptives sold or distributed free of charge to clients during that period (see Annex 11).</p> <p>‡ This price is determined for the unit used in CYP conversion factors: condoms: 1 condom; oral contraceptives: 1 cycle or blister package; emergency contraceptives: 1 dose; injectables: 1 dose/injection; implants: 1 implant insertion (1 or 2 rods); IUDs: 1 IUD.</p> <p>§ In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>∞ In Region 1 (NC), the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 79 oral contraceptives, 34 emergency contraceptives, 38 injections, 2 implants and 5 IUDs. In Region 2(NE), the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 15 oral contraceptives, 0 emergency contraceptives, 8 injections, 0 implants and 1 IUD. In Region 3 (NW), the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 41 oral contraceptives, 4 emergency contraceptives, 43 injections, 0 implants and 0 IUDs. In Region 4 (SE), the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 54 oral contraceptives, 27 emergency contraceptives, 18 injections, 7 implants and 6 IUDs. In Region 5 (SS), the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 36 oral contraceptives, 26 emergency contraceptives, 7injections, 6 implants and 2 IUDs. In Region 6, (SW) the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 305 oral contraceptives, 119 emergency contraceptives, 114 injections, 19 implants and 33 IUDs.</p> <p>    Price for all commodities with provider-dependent service (injectables, implants, IUDs) may include service charge.</p>						
Source: FPwatch Outlet Survey, Nigeria, 2015						

**Table B7: Median markup percentage for selected modern contraceptive commodities with interquartile range, by private outlet type – by Geopolitical Zone, 2015**

	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total*
Median markup percentage <sup>†</sup> of commodity, with interquartile range <sup>‡,§</sup> :	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]
<b>Oral contraceptives</b>					
North Central	70% <sup>(244)</sup> [40%, 100%]	100% <sup>(5)</sup> [100%, 100%]	90% <sup>(27)</sup> [50%, 100%]	70% <sup>(207)</sup> [40%, 100%]	240% <sup>(5)</sup> [200%, 400%]
North East	70% <sup>(71)</sup> [50%, 190%]	50% <sup>(2)</sup> [50%, 4570%]	70% <sup>(3)</sup> [70%, 70%]	60% <sup>(66)</sup> [50%, 190%]	- -
North West	70% <sup>(136)</sup> [50%, 130%]	- -	20% <sup>(2)</sup> [20%, 90%]	70% <sup>(134)</sup> [50%, 130%]	- -
South East	80% <sup>(106)</sup> [50%, 140%]	0% <sup>(6)</sup> [0%, 100%]	50% <sup>(5)</sup> [10%, 320%]	70% <sup>(92)</sup> [50%, 150%]	100% <sup>(3)</sup> [90%, 120%]
South South	100% <sup>(93)</sup> [40%, 210%]	100% <sup>(5)</sup> [100%, 100%]	200% <sup>(9)</sup> [130%, 230%]	150% <sup>(79)</sup> [40%, 210%]	- -
South West	70% <sup>(770)</sup> [70%, 130%]	50% <sup>(10)</sup> [0%, 150%]	100% <sup>(53)</sup> [40%, 120%]	70% <sup>(694)</sup> [70%, 130%]	90% <sup>(13)</sup> [60%, 170%]
<b>Emergency contraceptives</b>					
North Central	70% <sup>(93)</sup> [20%, 70%]	100% <sup>(2)</sup> [100%, 100%]	60% <sup>(16)</sup> [50%, 70%]	70% <sup>(75)</sup> [20%, 70%]	- -
North East	70% <sup>(21)</sup> [50%, 70%]	- -	70% <sup>(6)</sup> [50%, 200%]	70% <sup>(15)</sup> [70%, 70%]	- -
North West	100% <sup>(19)</sup> [40%, 130%]	- -	10% <sup>(1)</sup> [10%, 10%]	100% <sup>(18)</sup> [40%, 130%]	- -
South East	30% <sup>(27)</sup> [30%, 100%]	- -	120% <sup>(1)</sup> [120%, 120%]	30% <sup>(26)</sup> [30%, 100%]	- -
South South	70% <sup>(53)</sup> [50%, 70%]	- -	90% <sup>(4)</sup> [10%, 150%]	70% <sup>(49)</sup> [50%, 70%]	- -
South West	80% <sup>(231)</sup> [30%, 150%]	60% <sup>(1)</sup> [60%, 60%]	50% <sup>(56)</sup> [30%, 100%]	90% <sup>(168)</sup> [50%, 190%]	30% <sup>(6)</sup> [30%, 120%]
<b>Contraceptive injectables<sup>∞</sup></b>					
North Central	100% <sup>(126)</sup> [50%, 140%]	130% <sup>(14)</sup> [30%, 130%]	150% <sup>(44)</sup> [100%, 300%]	100% <sup>(68)</sup> [50%, 150%]	- -
North East	110% <sup>(43)</sup> [80%, 200%]	- -	190% <sup>(1)</sup> [190%, 190%]	110% <sup>(42)</sup> [70%, 200%]	- -
North West	70% <sup>(149)</sup> [50%, 120%]	100% <sup>(4)</sup> [50%, 160%]	30% <sup>(3)</sup> [30%, 110%]	70% <sup>(142)</sup> [50%, 120%]	- -
South East	230% <sup>(20)</sup> [70%, 860%]	100% <sup>(12)</sup> [30%, 230%]	- -	860% <sup>(8)</sup> [570%, 1500%]	- -

**Table B7: Median markup percentage for selected modern contraceptive commodities with interquartile range, by private outlet type – by Geopolitical Zone, 2015**

	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total*
Median markup percentage <sup>†</sup> of commodity, with interquartile range <sup>‡,§</sup> :	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]
South South	150% <sup>(27)</sup> [150%, 230%]	150% <sup>(9)</sup> [150%, 2400%]	70% <sup>(10)</sup> [70%, 110%]	110% <sup>(8)</sup> [110%, 230%]	- -
South West	100% <sup>(155)</sup> [70%, 130%]	100% <sup>(41)</sup> [100%, 400%]	70% <sup>(55)</sup> [40%, 130%]	100% <sup>(58)</sup> [50%, 100%]	280% <sup>(1)</sup> [280%, 280%]
<b>Implants<sup>∞</sup></b>					
North Central	100% <sup>(3)</sup> [100%, 100%]	100% <sup>(3)</sup> [100%, 100%]	- -	- -	- -
North East	30% <sup>(1)</sup> [30%, 30%]	30% <sup>(1)</sup> [30%, 30%]	- -	- -	- -
North West	- -	- -	- -	- -	- -
South East	0% <sup>(4)</sup> [0%, 50%]	0% <sup>(4)</sup> [0%, 50%]	- -	- -	- -
South South	150% <sup>(3)</sup> [150%, 150%]	150% <sup>(3)</sup> [150%, 150%]	- -	- -	- -
South West	200% <sup>(1)</sup> [200%, 200%]	200% <sup>(1)</sup> [200%, 200%]	- -	- -	- -
<b>IUDs<sup>∞</sup></b>					
North Central	400% <sup>(5)</sup> [400%, 400%]	400% <sup>(2)</sup> [400%, 400%]	30% <sup>(1)</sup> [30%, 30%]	20% <sup>(2)</sup> [20%, 20%]	- -
North East	190% <sup>(2)</sup> [190%, 900%]	900% <sup>(1)</sup> [900%, 900%]	- -	190% <sup>(1)</sup> [190%, 190%]	- -
North West	10% <sup>(1)</sup> [10%, 10%]	- -	- -	10% <sup>(1)</sup> [10%, 10%]	- -
South East	30% <sup>(4)</sup> [30%, 900%]	30% <sup>(3)</sup> [30%, 900%]	- -	10% <sup>(1)</sup> [10%, 10%]	- -
South South	3900% <sup>(2)</sup> [3900%, 3900%]	3900% <sup>(2)</sup> [3900%, 3900%]	- -	- -	- -
South West	170% <sup>(18)</sup> [110%, 1230%]	170% <sup>(14)</sup> [110%, 1330%]	50% <sup>(3)</sup> [50%, 50%]	30% <sup>(1)</sup> [30%, 30%]	- -
<p>* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>† To determine median markup percentage, we first determined the profit margin for selected modern contraceptives at private sector outlet categories: retail price – wholesale price. We then determined a profit margin proportion by: profit margin/retail price. Finally, we converted profit margin to markup by: wholesale price/(1- profit margin proportion). We converted to a percentage and determined the median markup with IQR range. Using oral contraceptives sold in private health facilities as an example, this can be interpreted as private health facilities adding 50% to the wholesale costs to set the retail cost.</p> <p>‡ In Region 1 (NC), The number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 79 oral</p>					

**Table B7: Median markup percentage for selected modern contraceptive commodities with interquartile range, by private outlet type – by Geopolitical Zone, 2015**

	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total*
Median markup percentage <sup>†</sup> of commodity, with interquartile range <sup>‡,§</sup> :	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]
<p>contraceptives, 34 emergency contraceptives, 38 injections, 2 implants and 5 IUDs. In Region 2 (NE), the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 15 oral contraceptives, 0 emergency contraceptives, 8 injections, 0 implants and 1 IUDs. In Region 3 (NW), the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 41 oral contraceptives, 4 emergency contraceptives, 43 injections, 0 implants and 0 IUDs. In Region 4 (SE), the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 54 oral contraceptives, 27 emergency contraceptives, 18 injections, 7 implants and 6 IUDs. In Region 5 (SS), the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 36 oral contraceptives, 26 emergency contraceptives, 7injections, 6 implants and 2 IUDs. In Region 6 (SW), the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 305 oral contraceptives, 119 emergency contraceptives, 114 injections, 19 implants and 33 IUDs.</p> <p>§ This price is determined for the unit CYP conversion factors: condoms: 1 condom; oral contraceptives: 1 cycle or blister package; emergency contraceptives: 1 does; injectables: 1 dose/injection; implants: 1 implant insertion (1 or 2 rods): IUDs: 1 IUD.</p> <p>∞ Price for all commodities with provider-dependent service (injectables, implants, IUDs) may include service charge.</p>					
Source: FPwatch Outlet Survey, Nigeria, 2015					

**Table B8: Contraceptive method market share: Relative proportion of total CYP sold/distributed, by method and outlet type – by Geopolitical Zone, 2015**

CYP sold or distributed in previous 1-month contraceptive method type as a % of total CYP sold / distributed within outlet type <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>	TOTAL <sup>§</sup>
	%	%	%	%	%	%	%	%	%	%
<b>1. Male condoms</b>										
North Central	2.2	0.0	0.0	2.2	0.5	0.8	10.4	3.2	14.8	17.1
North East	4.3	0.0	0.0	4.3	0.0	0.9	24.8	0.7	26.5	30.8
North West	2.1	0.0	0.0	2.1	0.4	0.1	5.9	0.0	6.5	8.6
South East	0.7	0.0	0.0	0.7	0.9	2.4	41.8	4.1	49.1	49.9
South South	6.4	0.0	0.0	6.4	0.9	0.5	11.7	0.1	13.2	19.6
South West	0.9	0.0	0.0	0.9	1.4	4.2	38.9	5.6	50.0	51.0
<b>2. Female condoms</b>										
North Central	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North East	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2
North West	0.5	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.1	0.6
South East	0.3	0.0	0.0	0.3	0.0	0.0	0.3	0.0	0.3	0.6
South South	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.3
South West	0.2	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.3
<b>3. Cyclebeads</b>										
North Central	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North East	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North West	0.5	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.5
South East	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
South South	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
South West	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.6	0.6
<b>4. Oral contraceptives</b>										
North Central	0.5	0.0	0.0	0.5	0.3	0.2	4.2	0.0	4.7	5.2
North East	3.0	0.0	0.0	3.0	0.0	0.1	9.5	0.0	9.6	12.7
North West	3.0	0.0	0.0	3.0	0.0	0.1	7.2	0.0	7.2	10.2
South East	0.8	0.0	0.0	0.8	0.2	0.4	11.2	0.2	11.9	12.8
South South	0.6	0.0	0.0	0.6	1.1	0.1	2.6	0.0	3.8	4.4
South West	0.6	0.0	0.0	0.6	0.2	1.3	11.2	0.1	12.8	13.3
<i>IQA<sup>∞</sup> oral contraceptives</i>										
North Central	0.5	0.0	0.0	0.5	0.3	0.2	4.2	0.0	4.7	5.2
North East	3.0	0.0	0.0	3.0	0.0	0.1	9.5	0.0	9.6	12.6
North West	3.0	0.0	0.0	3.0	0.0	0.1	7.2	0.0	7.2	10.2
South East	0.6	0.0	0.0	0.6	1.1	0.1	2.6	0.0	3.8	4.4
South South	0.6	0.0	0.0	0.6	1.1	0.1	2.5	0.0	3.7	4.3

**Table B8: Contraceptive method market share: Relative proportion of total CYP sold/distributed, by method and outlet type – by Geopolitical Zone, 2015**

CYP sold or distributed in previous 1-month contraceptive method type as a % of total CYP sold / distributed within outlet type <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>	TOTAL <sup>§</sup>
	%	%	%	%	%	%	%	%	%	%
South West	0.6	0.0	0.0	0.6	0.2	1.3	11.1	0.1	12.7	13.2
<i>Combined oral contraceptives</i>										
North Central	0.3	0.0	0.0	0.3	0.3	0.2	4.2	0.0	4.7	5.0
North East	2.3	0.0	0.0	2.3	0.0	0.1	9.5	0.0	9.6	11.9
North West	1.9	0.0	0.0	1.9	0.0	0.1	7.0	0.0	7.0	8.9
South East	0.3	0.0	0.0	0.3	0.1	0.4	11.2	0.2	11.9	12.2
South South	0.4	0.0	0.0	0.4	1.1	0.1	2.6	0.0	3.8	4.2
South West	0.1	0.0	0.0	0.1	0.2	1.3	11.2	0.1	12.8	12.9
<i>Progestin-only pills</i>										
North Central	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2
North East	0.8	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.8
North West	1.0	0.0	0.0	1.0	0.0	0.0	0.2	0.0	0.2	1.3
South East	0.5	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.5
South South	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2
South West	0.5	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.5
<b>5. Emergency contraceptives</b>										
North Central	0.0	0.0	0.0	0.0	0.0	0.2	2.6	0.0	2.7	2.7
North East	0.0	0.0	0.0	0.0	0.0	0.2	1.9	0.0	2.1	2.2
North West	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.2
South East	0.0	0.0	0.0	0.0	0.0	0.3	1.4	0.0	1.8	1.8
South South	0.0	0.0	0.0	0.0	0.0	0.4	2.0	0.0	2.5	2.5
South West	0.0	0.0	0.0	0.0	0.0	2.2	2.7	0.0	4.9	4.9
<i>IQA<sup>∞</sup> emergency contraceptives</i>										
North Central	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.7	0.7
North East	0.0	0.0	0.0	0.0	0.0	0.2	1.8	0.0	2.0	2.0
North West	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.2
South East	0.0	0.0	0.0	0.0	0.0	0.3	1.2	0.0	1.6	1.6
South South	0.0	0.0	0.0	0.0	0.0	0.2	1.9	0.0	2.1	2.1
South West	0.0	0.0	0.0	0.0	0.0	0.9	2.2	0.0	3.1	3.1
<b>6. Contraceptive injectables</b>										
North Central	2.7	0.3	0.0	3.1	0.8	0.7	1.1	0.0	2.5	5.6
North East	22.7	0.0	0.0	22.7	0.0	0.2	4.4	0.0	4.7	27.4
North West	16.4	0.0	0.0	16.4	0.8	0.1	20.0	0.0	20.9	37.3

**Table B8: Contraceptive method market share: Relative proportion of total CYP sold/distributed, by method and outlet type – by Geopolitical Zone, 2015**

CYP sold or distributed in previous 1-month contraceptive method type as a % of total CYP sold / distributed within outlet type <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>	TOTAL <sup>§</sup>
	%	%	%	%	%	%	%	%	%	%
South East	4.0	0.0	0.0	4.0	1.7	0.2	2.3	0.0	4.2	8.2
South South	3.1	0.0	0.0	3.1	1.8	0.2	0.2	0.0	2.2	5.2
South West	3.1	0.0	0.0	3.1	0.7	2.7	0.8	0.0	4.1	7.2
<i>Depo-provera injectables</i>										
North Central	1.6	0.0	0.0	1.6	0.6	0.2	0.6	0.0	1.4	3.1
North East	15.0	0.0	0.0	15.0	0.0	0.0	2.0	0.0	2.0	17.0
North West	13.7	0.0	0.0	13.7	0.3	0.0	11.7	0.0	12.0	25.8
South East	3.2	0.0	0.0	3.2	1.5	0.2	2.2	0.0	3.9	7.1
South South	1.9	0.0	0.0	1.9	0.9	0.1	0.1	0.0	1.1	3.0
South West	1.7	0.0	0.0	1.7	0.4	1.6	0.5	0.0	2.6	4.3
<i>Noristerat injectables</i>										
North Central	1.2	0.3	0.0	1.4	0.2	0.4	0.5	0.0	1.0	2.5
North East	7.7	0.0	0.0	7.7	0.0	0.2	2.4	0.0	2.6	10.3
North West	2.6	0.0	0.0	2.6	0.5	0.0	8.3	0.0	8.9	11.5
South East	0.9	0.0	0.0	0.9	0.1	0.0	0.1	0.0	0.2	1.1
South South	1.1	0.0	0.0	1.1	0.9	0.2	0.0	0.0	1.1	2.2
South West	1.3	0.0	0.0	1.4	0.2	1.0	0.3	0.0	1.5	2.9
<i>Sayana Press injectables</i>										
North Central	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North East	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North West	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
South East	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	1.9	1.9
South South	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
South West	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>7. Implants</b>										
North Central	9.7	0.0	0.0	9.7	23.9	0.0	0.0	0.0	23.9	33.6
North East	20.9	0.0	0.2	21.0	0.1	0.0	0.0	0.0	0.1	21.1
North West	40.0	0.0	0.0	40.0	0.0	0.0	0.0	0.0	0.0	40.0
South East	5.4	0.0	0.0	5.4	8.0	0.0	0.0	0.0	8.0	13.4
South South	13.1	0.0	0.0	13.1	49.4	0.0	0.0	0.0	49.4	62.6
South West	7.6	0.0	0.0	7.6	0.4	0.0	0.0	0.0	0.4	7.9
<i>Implanon implants</i>										
North Central	5.3	0.0	0.0	5.3	23.9	0.0	0.0	0.0	23.9	29.2
North East	17.8	0.0	0.1	17.9	0.1	0.0	0.0	0.0	0.1	17.9



**Table B8: Contraceptive method market share: Relative proportion of total CYP sold/distributed, by method and outlet type – by Geopolitical Zone, 2015**

CYP sold or distributed in previous 1-month contraceptive method type as a % of total CYP sold / distributed within outlet type <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>	TOTAL <sup>§</sup>
	%	%	%	%	%	%	%	%	%	%
North West	15.7	0.0	0.0	15.7	0.0	0.0	0.0	0.0	0.0	15.7
South East	1.9	0.0	0.0	1.9	1.1	0.0	0.0	0.0	1.1	3.0
South South	2.4	0.0	0.0	2.4	24.2	0.0	0.0	0.0	24.2	26.6
South West	3.9	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	3.9
<i>Jadelle implants</i>										
North Central	4.4	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	4.4
North East	3.1	0.0	0.1	3.2	0.0	0.0	0.0	0.0	0.0	3.2
North West	24.3	0.0	0.0	24.3	0.0	0.0	0.0	0.0	0.0	24.3
South East	3.5	0.0	0.0	3.5	6.9	0.0	0.0	0.0	6.9	10.4
South South	10.8	0.0	0.0	10.8	25.2	0.0	0.0	0.0	25.2	35.9
South West	3.7	0.0	0.0	3.7	0.4	0.0	0.0	0.0	0.4	4.0
<b>8. IUDs</b>										
North Central	0.2	0.0	0.0	0.2	35.1	0.0	0.4	0.0	35.5	35.7
North East	5.3	0.0	0.1	5.4	0.2	0.0	0.0	0.0	0.2	5.6
North West	2.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	2.0
South East	0.0	0.0	0.0	0.0	9.5	0.4	0.8	0.0	10.7	10.7
South South	4.3	0.0	0.0	4.3	1.2	0.0	0.0	0.0	1.2	5.5
South West	3.2	0.0	0.1	3.3	9.7	0.1	0.2	0.0	9.9	13.2
<b>9. Male sterilization</b>										
North Central	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North East	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North West	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
South East	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	1.1	1.1
South South	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
South West	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1
<b>10. Female sterilization</b>										
North Central	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2
North East	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North West	0.8	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.8
South East	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	1.6	1.6
South South	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
South West	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	1.5	1.5
<b>OUTLET TYPE TOTAL<sup>∞</sup></b>										
North Central	15.5	0.3	0.1	15.9	60.6	1.8	18.5	3.2	84.1	100.0

**Table B8: Contraceptive method market share: Relative proportion of total CYP sold/distributed, by method and outlet type – by Geopolitical Zone, 2015**

CYP sold or distributed in previous 1-month contraceptive method type as a % of total CYP sold / distributed within outlet type <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>	TOTAL <sup>§</sup>
	%	%	%	%	%	%	%	%	%	%
North East	56.6	0.0	0.3	56.9	0.3	1.5	40.6	0.7	43.1	100.0
North West	65.1	0.0	0.0	65.1	1.3	0.3	33.4	0.0	34.9	100.0
South East	11.2	0.0	0.0	11.2	22.9	3.7	57.8	4.4	88.8	100.0
South South	27.7	0.0	0.0	27.7	54.4	1.3	16.6	0.1	72.3	100.0
South West	15.5	0.0	0.1	15.6	14.4	10.3	54.0	5.7	84.4	100.0
<p>* A total of 282,359 CYP (weighted) in NC, 21,041 CYP (weighted) in NE, 85,545 CYP (weighted) in NW, 44,189 in SE, 416,181 CYP (weighted) in SS &amp; 114,734 CYP (weighted) in SW were reportedly distributed in the previous 1 month. This is based on the number of commodities reportedly sold for categories 1-8 (not the number of services performed for categories 6-8) and the number of sterilizations reportedly performed for categories 9-10. See Annex 11 for a description of CYP calculation and Annex 12 for CYP numbers by outlet type and method category.</p> <p>† A total of 2 (NC region) injection products and 4 tablet products (SW region), were excluded from market share analysis due to inconsistent or missing generic names. A total of 56 emergency contraceptive products (6, 2, 1, 11 &amp; 36 in NC, NW, SE, SS &amp; SW regions, respectively), 129 oral contraceptives (10, 6, 6, 8 &amp; 99 in NC, NW, SE, SS &amp; SW regions, respectively), 205 male condoms (21, 4, 12, 14, 11 &amp; 143 in NC, NE, NW, SE, SS &amp; SW regions, respectively), 17 female condoms (2, 1, 1, 1, 1 &amp; 11 in NC, NE, NW, SE, SS &amp; SW regions, respectively) and 10 CycleBeads (8 in SE and 2 in SW) were excluded from market share analysis for missing volume information. 2 male sterilizations and 4 female sterilizations were excluded for missing volume information as well. A total of 179 products were excluded due to outlier volumes and prices (45, 1, 30, 14, 1 &amp; 88 in NC, NE, NW, SE, SS &amp; SW regions, respectively).</p> <p>‡ In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>§ Row total equals CYP volume for the specified contraceptive method type. Column total equals market share for the specified outlet type method categories 1-10.</p> <p>∞ Internationally quality-assured (IQA) contraceptives are defined as those with WHO Pre-qualification or those on a Stringent Regulatory authority (SRA) list. See Annex for a list of all quality assured brands found in the survey.</p>										

Source: FPwatch Outlet Survey, Nigeria, 2015

**Table B9: Contraceptive method market share within outlet type: Relative proportion of total CYP sold / distributed within outlet type, by method – by Geopolitical Zone, 2015**

CYP sold or distributed in previous 1-month contraceptive method type as a % of total CYP sold / distributed within outlet type <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>
	%	%	%	%	%	%	%	%	%
<b>1. Male condoms</b>									
North Central	14.2	2.5	0.0	13.9	0.8	45.0	56.0	99.9	17.7
North East	7.7	0.0	3.9	7.6	1.5	60.6	61.1	100.0	61.4
North West	3.2	0.0	0.0	3.2	35.2	45.3	17.7	100.0	18.6
South East	6.5	0.0	0.0	6.5	3.8	64.3	72.3	94.5	55.4
South South	23.0	0.0	0.0	23.0	1.7	36.9	70.8	100.0	18.2
South West	5.9	0.0	0.7	5.8	9.6	40.3	72.1	97.9	59.3
<b>2. Female condoms</b>									
North Central	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0
North East	0.4	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0
North West	0.8	0.0	0.0	0.8	0.0	0.0	0.2	0.0	0.2
South East	2.5	0.0	0.0	2.5	0.2	0.0	0.5	0.0	0.4
South South	0.9	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0
South West	1.1	0.0	0.0	1.1	0.1	0.0	0.1	0.0	0.1
<b>3. Cyclebeads</b>									
North Central	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North East	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North West	0.7	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0
South East	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
South South	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0
South West	0.2	0.0	0.0	0.2	3.5	0.1	0.1	0.0	0.7
<b>4. Oral contraceptives</b>									
North Central	3.2	0.0	7.6	3.2	0.6	8.3	22.5	0.1	5.6
North East	5.4	0.0	1.6	5.4	5.3	7.9	23.4	0.0	22.3
North West	4.5	0.0	0.0	4.5	0.3	21.0	21.5	0.0	20.7
South East	7.4	0.0	0.0	7.4	0.7	10.4	19.4	4.5	13.5
South South	2.3	0.0	0.0	2.3	2.0	10.0	15.5	0.0	5.2
South West	3.7	0.0	0.0	3.7	1.2	12.3	20.8	1.7	15.1
<i>IQA<sup>§</sup> oral contraceptives</i>									
North Central	3.2	0.0	7.6	3.2	0.6	8.3	22.4	0.1	5.5
North East	5.4	0.0	1.6	5.4	5.3	7.9	23.3	0.0	22.2
North West	4.5	0.0	0.0	4.5	0.3	21.0	21.5	0.0	20.7
South East	7.4	0.0	0.0	7.4	0.7	10.4	19.4	4.5	13.5
South South	2.3	0.0	0.0	2.3	2.0	10.0	15.3	0.0	5.2

**Table B9: Contraceptive method market share within outlet type: Relative proportion of total CYP sold / distributed within outlet type, by method – by Geopolitical Zone, 2015**

CYP sold or distributed in previous 1-month contraceptive method type as a % of total CYP sold / distributed within outlet type <sup>*,†</sup>	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>
%	%	%	%	%	%	%	%	%	%
South West	3.7	0.0	0.0	3.7	1.2	12.3	20.6	1.7	15.0
<i>Combined oral contraceptives</i>									
North Central	2.0	0.0	0.0	1.9	0.6	8.3	22.5	0.1	5.5
North East	4.0	0.0	0.2	4.0	4.1	7.9	23.4	0.0	22.3
North West	2.9	0.0	0.0	2.9	0.3	21.0	20.8	0.0	20.1
South East	2.8	0.0	0.0	2.8	0.6	10.4	19.4	4.5	13.4
South South	1.5	0.0	0.0	1.5	2.0	10.0	15.5	0.0	5.2
South West	0.8	0.0	0.0	0.8	1.2	12.3	20.8	1.7	15.1
<i>Progestin-only pills</i>									
North Central	1.3	0.0	7.6	1.2	0.0	0.0	0.0	0.0	0.0
North East	1.4	0.0	1.4	1.4	1.2	0.0	0.0	0.0	0.0
North West	1.6	0.0	0.0	1.6	0.0	0.0	0.6	0.0	0.6
South East	4.6	0.0	0.0	4.6	0.1	0.0	0.0	0.0	0.0
South South	0.7	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0
South West	2.9	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0
<b>5. Emergency contraceptives</b>									
North Central	0.0	0.0	0.0	0.0	0.0	8.8	13.8	0.0	3.2
North East	0.1	0.0	0.0	0.1	0.0	15.6	4.7	0.0	4.9
North West	0.0	0.0	0.0	0.0	0.0	7.2	0.7	0.0	0.7
South East	0.0	0.0	0.0	0.0	0.0	8.6	2.5	0.9	2.0
South South	0.0	0.0	0.0	0.0	0.0	34.7	12.3	0.0	3.4
South West	0.0	0.0	0.0	0.0	0.0	21.0	5.1	0.4	5.8
<i>IQA<sup>§</sup> emergency contraceptives</i>									
North Central	0.0	0.0	0.0	0.0	0.0	6.4	3.1	0.0	0.8
North East	0.1	0.0	0.0	0.1	0.0	12.0	4.5	0.0	4.6
North West	0.0	0.0	0.0	0.0	0.0	7.2	0.5	0.0	0.5
South East	0.0	0.0	0.0	0.0	0.0	7.6	2.1	0.9	1.7
South South	0.0	0.0	0.0	0.0	0.0	15.6	11.3	0.0	2.9
South West	0.0	0.0	0.0	0.0	0.0	8.8	4.1	0.1	3.7
<b>6. Contraceptive injectables</b>									
North Central	17.6	97.5	92.4	19.3	1.2	36.4	5.8	0.0	3.0
North East	40.1	0.0	14.7	40.0	0.0	15.9	10.9	0.0	10.8
North West	25.1	0.0	0.0	25.1	64.5	26.5	60.0	0.0	59.9
South East	35.8	0.0	0.0	35.8	7.3	5.4	4.0	0.0	4.7

**Table B9: Contraceptive method market share within outlet type: Relative proportion of total CYP sold / distributed within outlet type, by method – by Geopolitical Zone, 2015**

CYP sold or distributed in previous 1-month contraceptive method type as a % of total CYP sold / distributed within outlet type <sup>*,†</sup>	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>
	%	%	%	%	%	%	%	%	%
South South	11.0	0.0	0.0	11.0	3.3	18.5	1.0	0.0	3.0
South West	19.8	0.0	6.7	19.7	4.6	25.7	1.4	0.0	4.9
<i>Depo-provera injectables</i>									
North Central	10.1	6.5	66.9	10.3	1.0	13.3	3.3	0.0	1.7
North East	26.5	0.0	9.4	26.4	0.0	0.2	5.0	0.0	4.7
North West	21.1	0.0	0.0	21.1	25.7	12.1	34.9	0.0	34.4
South East	28.0	0.0	0.0	28.0	6.6	5.0	3.9	0.0	4.4
South South	7.0	0.0	0.0	7.0	1.6	6.2	0.9	0.0	1.5
South West	11.1	0.0	3.4	11.0	3.1	15.7	1.0	0.0	3.1
<i>Noristerat injectables</i>									
North Central	7.5	91.0	25.5	9.1	0.3	23.0	2.5	0.0	1.2
North East	13.6	0.0	5.3	13.5	0.0	15.7	5.9	0.0	6.1
North West	4.0	0.0	0.0	4.0	38.8	14.4	25.0	0.0	25.4
South East	7.8	0.0	0.0	7.8	0.6	0.4	0.1	0.0	0.3
South South	4.0	0.0	0.0	4.0	1.7	12.3	0.1	0.0	1.5
South West	8.7	0.0	3.4	8.7	1.4	10.1	0.5	0.0	1.8
<i>Sayana Press injectables</i>									
North Central	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0
North East	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North West	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
South East	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	2.1
South South	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0
South West	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1
<b>7. Implants</b>									
North Central	62.6	0.0	0.0	61.2	39.4	0.0	0.0	0.0	28.4
North East	36.9	0.0	55.2	37.0	22.7	0.0	0.0	0.0	0.1
North West	61.4	0.0	0.0	61.4	0.0	0.0	0.0	0.0	0.0
South East	47.8	0.0	0.0	47.8	35.0	0.0	0.0	0.0	9.0
South South	47.5	0.0	0.0	47.5	90.7	0.0	0.2	0.0	68.3
South West	48.9	0.0	0.0	48.5	2.7	0.0	0.0	0.0	0.5
<i>Implanon implants</i>									
North Central	34.2	0.0	0.0	33.5	39.4	0.0	0.0	0.0	28.4
North East	31.5	0.0	26.7	31.4	22.7	0.0	0.0	0.0	0.1
North West	24.1	0.0	0.0	24.1	0.0	0.0	0.0	0.0	0.0

**Table B9: Contraceptive method market share within outlet type: Relative proportion of total CYP sold / distributed within outlet type, by method – by Geopolitical Zone, 2015**

CYP sold or distributed in previous 1-month contraceptive method type as a % of total CYP sold / distributed within outlet type <sup>*,†</sup>	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>
	%	%	%	%	%	%	%	%	%
South East	16.5	0.0	0.0	16.5	4.9	0.0	0.0	0.0	1.3
South South	8.6	0.0	0.0	8.6	44.5	0.0	0.2	0.0	33.5
South West	25.3	0.0	0.0	25.0	0.1	0.0	0.0	0.0	0.0
<i>Jadelle implants</i>									
North Central	28.4	0.0	0.0	27.7	0.0	0.0	0.0	0.0	0.0
North East	5.5	0.0	28.5	5.6	0.0	0.0	0.0	0.0	0.0
North West	37.3	0.0	0.0	37.3	0.0	0.0	0.0	0.0	0.0
South East	31.3	0.0	0.0	31.3	30.1	0.0	0.0	0.0	7.8
South South	38.8	0.0	0.0	38.8	46.3	0.0	0.0	0.0	34.8
South West	23.6	0.0	0.0	23.4	2.6	0.0	0.0	0.0	0.4
<b>8. IUDs</b>									
North Central	1.3	0.0	0.0	1.3	58.0	1.4	1.9	0.0	42.2
North East	9.4	0.0	24.6	9.5	70.6	0.0	0.0	0.0	0.5
North West	3.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0
South East	0.0	0.0	0.0	0.0	41.5	11.2	1.3	0.0	12.0
South South	15.4	0.0	0.0	15.4	2.2	0.0	0.0	0.0	1.7
South West	20.4	0.0	92.6	21.0	67.4	0.6	0.3	0.0	11.8
<b>9. Male sterilization</b>									
North Central	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North East	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North West	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
South East	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	1.2
South South	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
South West	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.1
<b>10. Female sterilization</b>									
North Central	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0
North East	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
North West	1.2	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0
South East	0.0	0.0	0.0	0.0	6.8	0.0	0.0	0.0	1.8
South South	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
South West	0.0	0.0	0.0	0.0	10.5	0.0	0.0	0.0	1.8

**Table B9: Contraceptive method market share within outlet type: Relative proportion of total CYP sold / distributed within outlet type, by method – by Geopolitical Zone, 2015**

CYP sold or distributed in previous 1-month contraceptive method type as a % of total CYP sold / distributed within outlet type <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>
	%	%	%	%	%	%	%	%	%
<p>* A total of 282,359 CYP (weighted) in NC, 21,041 CYP (weighted) in NE, 85,545 CYP (weighted) in NW, 44,189 in SE, 416,181 CYP (weighted) in SS &amp; 114,734 CYP (weighted) in SW were reportedly distributed in the previous 1 month. This is based on the number of commodities reportedly sold for categories 1-8 (not the number of services performed for categories 6-8) and the number of sterilizations reportedly performed for categories 9-10. See Annex 11 for a description of CYP calculation and Annex 12 for CYP numbers by outlet type and method category.</p> <p>† A total of 2 (NC region) injection products and 4 tablet products (SW region), were excluded from market share analysis due to inconsistent or missing generic names. A total of 56 emergency contraceptive products (6, 2, 1, 11 &amp; 36 in NC, NW, SE, SS &amp; SW regions, respectively), 129 oral contraceptives (10, 6, 6, 8 &amp; 99 in NC, NW, SE, SS &amp; SW regions, respectively), 205 male condoms (21, 4, 12, 14, 11 &amp; 143 in NC, NE, NW, SE, SS &amp; SW regions, respectively), 17 female condoms (2, 1, 1, 1, 1 &amp; 11 in NC, NE, NW, SE, SS &amp; SW regions, respectively) and 10 CycleBeads (8 in SE and 2 in SW) were excluded from market share analysis for missing volume information. 2 male sterilizations and 4 female sterilizations were excluded for missing volume information as well. A total of 179 products were excluded due to outlier volumes and prices (45, 1, 30, 14, 1 &amp; 88 in NC, NE, NW, SE, SS &amp; SW regions, respectively).</p> <p>‡ In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>§ Internationally quality-assured (IQA) contraceptives are defined as those with WHO Pre-qualification or those on a Stringent Regulatory authority (SRA) list. See Annex for a list of all quality assured brands found in the survey.</p> <p>Categories 1 through 10 sum to 100% within each column.</p>									
Source: FPwatch Outlet Survey, Nigeria, 2015									

Table B10: Availability of selected contraceptive services, among outlets screened, by outlet type – by Geopolitical Zone, 2015										
	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, providing†:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
<b>Contraceptive injection service</b>										
North Central	62.1 (39.0, 80.8)	99.1 (73.9, 100.0)	100.0 -	71.0 (52.2, 84.6)	49.4 (7.5, 92.2)	53.8 (42.3, 65.0)	18.3 (5.6, 45.8)	23.7 (14.5, 36.4)	0.0 (0.0, 0.3)	11.1 (7.3, 16.5)
North East	56.3 (42.8, 69.0)	- -	100.0 -	56.4 (42.8, 69.0)	47.7 (15.0, 82.4)	48.7 (3.2, 96.5)	9.5 (1.5, 42.1)	12.9 (3.8, 36.0)	0.0 -	8.1 (3.2, 19.1)
North West	56.8 (22.2, 85.8)	0.0 -	100.0 -	56.8 (22.3, 85.7)	87.0 (64.4, 96.1)	34.8 (24.3, 47.1)	20.0 (10.3, 35.1)	22.3 (10.2, 41.9)	0.0 -	6.8 (3.0, 14.7)
South East	50.8 (33.4, 68.0)	0.0 -	0.0 -	29.3 (8.6, 64.5)	26.9 (11.7, 50.6)	15.8 (2.1, 62.6)	3.7 (1.0, 12.8)	6.5 (2.7, 14.8)	0.0 -	3.0 (1.6, 5.9)
South South	93.9 (71.4, 98.9)	0.0 -	0.0 -	83.8 (73.5, 90.7)	58.0 (29.6, 82.0)	56.8 (8.9, 94.6)	6.1 (2.2, 16.0)	15.3 (4.7, 39.6)	0.0 -	4.8 (3.9, 5.9)
South West	87.6 (61.9, 96.9)	11.2 (0.5, 76.5)	4.6 (0.2, 58.1)	36.9 (10.1, 75.2)	52.8 (32.8, 71.9)	10.0 (5.2, 18.7)	7.9 (3.9, 15.1)	11.9 (6.6, 20.5)	0.0 -	4.0 (2.5, 6.3)
<b>Implant insertion service</b>										
North Central	10.0 (3.4, 26.3)	0.0 -	0.0 -	7.6 (3.3, 16.5)	22.9 (5.0, 62.5)	3.4 (0.9, 11.8)	0.0 -	3.5 (0.9, 12.7)	0.0 -	1.4 (0.6, 3.4)
North East	15.7 (1.1, 76.5)	- -	100.0 -	15.7 (1.1, 76.5)	3.2 (0.1, 43.1)	0.0 -	0.0 -	0.2 (0.0, 4.1)	0.0 -	1.4 (0.2, 11.6)
North West	7.8 (2.2, 24.2)	0.0 -	0.0 -	7.8 (2.2, 23.9)	34.2 (22.9, 47.7)	0.0 -	0.8 (0.1, 7.1)	2.0 (0.2, 14.8)	0.0 -	0.7 (0.2, 3.3)
South East	10.1 (1.0, 56.9)	0.0 -	0.0 -	5.8 (0.4, 46.9)	27.5 (2.6, 84.3)	0.0 -	0.0 -	3.1 (0.4, 21.9)	0.0 -	1.1 (0.2, 5.6)
South South	59.1 (23.0, 87.5)	0.0 -	0.0 -	52.8 (19.8, 83.5)	39.7 (25.3, 56.2)	0.0 -	0.0 (0.0, 0.5)	6.3 (2.0, 18.1)	0.0 -	2.3 (1.5, 3.4)
South West	72.9 (40.7, 91.3)	0.0 -	0.0 -	25.2 (8.7, 54.6)	14.4 (4.2, 39.1)	0.0 -	0.0 -	1.2 (0.2, 6.4)	0.0 -	0.9 (0.4, 1.9)
<b>IUD insertion service</b>										
North Central	7.7	0.0	0.0	5.8	31.4	0.0	0.0	4.7	0.0	1.6



**Table B10: Availability of selected contraceptive services, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, providing†:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
	(1.4, 32.3)	-	-	(0.8, 31.3)	(9.7, 66.0)	-	-	(2.0, 11.0)	-	(0.7, 3.5)
North East	4.3 (0.3, 39.1)	-	100.0	4.3 (0.3, 39.0)	0.4 (0.2, 1.2)	0.0	0.1 (0.0, 1.4)	0.1 (0.0, 1.2)	0.0	0.4 (0.1, 1.9)
North West	5.3 (1.3, 19.7)	0.0	0.0	5.3 (1.3, 19.5)	34.2 (22.9, 47.7)	0.0	0.0	1.2 (0.1, 9.1)	0.0	0.5 (0.1, 2.1)
South East	10.1 (1.0, 56.9)	0.0	0.0	5.8 (0.4, 46.9)	30.9 (3.4, 84.9)	0.0	0.0	3.5 (0.5, 21.1)	0.0	1.2 (0.3, 5.5)
South South	59.1 (23.0, 87.5)	0.0	0.0	52.8 (19.8, 83.5)	40.0 (26.0, 55.8)	0.0	0.0	6.3 (2.0, 18.1)	0.0	2.3 (1.5, 3.4)
South West	81.9 (51.9, 95.0)	0.0	4.6 (0.2, 58.1)	28.9 (10.3, 59.0)	39.9 (16.6, 68.8)	0.0	0.0 (0.0, 0.4)	3.5 (0.9, 12.0)	0.0	1.5 (0.7, 3.3)
<b>Male sterilization service</b>										
North Central	0.0 -	0.0 -	0.0 -	0.0 -	1.2 (0.1, 15.0)	0.0 -	0.0 -	0.2 (0.0, 3.0)	0.0 -	0.0 (0.0, 0.7)
North East	7.6 (0.8, 47.2)	-	0.0 -	7.6 (0.7, 47.2)	2.8 (0.1, 55.0)	0.0 -	0.0 -	0.2 (0.0, 6.1)	0.0 -	0.7 (0.0, 11.4)
North West	0.2 (0.0, 3.0)	0.0 -	0.0 -	0.2 (0.0, 2.9)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 (0.0, 0.1)
South East	0.0 -	0.0 -	0.0 -	0.0 -	7.6 (2.3, 22.1)	0.0 -	0.0 -	0.8 (0.3, 2.1)	0.0 -	0.2 (0.1, 0.7)
South South	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
South West	0.0 -	0.0 -	0.0 -	0.0 -	2.1 (0.3, 13.4)	0.0 -	0.0 -	0.2 (0.0, 2.3)	0.0 -	0.0 (0.0, 0.4)
<b>Female sterilization service</b>										
North Central	0.1 (0.0, 2.0)	0.0 -	0.0 -	0.1 (0.0, 1.7)	2.9 (0.5, 15.9)	0.0 -	0.0 -	0.4 (0.1, 2.5)	0.0 -	0.1 (0.0, 0.7)
North East	0.0	-	0.0	0.0	2.8	0.0	0.0	0.2	0.0	0.1

**Table B10: Availability of selected contraceptive services, among outlets screened, by outlet type – by Geopolitical Zone, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, providing†:</b>	NC: N=48 NE: N=25 NW: N=44 SE: N=21 SS: N=19 SW: N=56	NC: N=3 NE: N=0 NW: N=1 SE: N=3 SS: N=1 SW: N=4	NC: N=1 NE: N=1 NW: N=1 SE: N=4 SS: N=1 SW: N=7	NC: N=52 NE: N=26 NW: N=46 SE: N=28 SS: N=21 SW: N=67	NC: N=51 NE: N=13 NW: N=15 SE: N=53 SS: N=28 SW: N=171	NC: N=43 NE: N=7 NW: N=4 SE: N=20 SS: N=21 SW: N=134	NC: N=415 NE: N=127 NW: N=285 SE: N=329 SS: N=195 SW: N=1,451	NC: N=1,253 NE: N=394 NW: N=927 SE: N=1,091 SS: N=879 SW: N=5,212	NC: N=509 NE: N=147 NW: N=304 SE: N=402 SS: N=244 SW: N=1,756	NC: N=1,814 NE: N=567 NW: N=1,277 SE: N=1,521 SS: N=1,144 SW: N=7,035
	-	-	-	-	(0.1, 55.0)	-	-	(0.0, 6.1)	-	(0.0, 1.2)
North West	0.4 (0.1, 2.4)	0.0 -	0.0 -	0.4 (0.1, 2.3)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 (0.0, 0.1)
South East	0.0 -	0.0 -	0.0 -	0.0 -	7.6 (2.8, 19.1)	0.0 -	0.0 -	0.9 (0.3, 2.2)	0.0 -	0.2 (0.1, 0.8)
South South	0.0 -	0.0 -	0.0 -	0.0 -	17.9 (7.9, 35.7)	0.0 -	0.0 -	2.8 (0.6, 11.9)	0.0 -	0.6 (0.2, 2.3)
South West	1.1 (0.2, 7.1)	0.0 -	2.7 (0.1, 42.3)	0.7 (0.1, 7.4)	5.7 (0.9, 28.4)	0.0 -	0.0 -	0.5 (0.0, 5.3)	0.0 -	0.1 (0.0, 1.1)
<p>* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.</p> <p>† The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview). In Region 1 (NC), the denominator includes 9 outlets that met screening criteria for a full interview but did not complete the interview. In Region 2 (NE), the denominator includes 8 outlets that met screening criteria for a full interview but did not complete the interview. In Region 3 (NW), the denominator includes 2 outlets that met screening criteria for a full interview but did not complete the interview. In Region 4 (SE), the denominator includes 4 outlets that met screening criteria for a full interview but did not complete the interview. In Region 5 (SS), the denominator includes 6 outlets that met screening criteria for a full interview but did not complete the interview. In Region 6 (SW), the denominator includes 39 outlets that met screening criteria for a full interview but did not complete the interview.</p>										
Source: FPwatch Outlet Survey, Nigeria, 2015										

**Table B11: Service readiness\* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – by Geopolitical Zone, 2015**

		Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total†
Proportion of outlets offering service, with‡:		% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)
<b>Contraceptive injection service</b>									
North Central	Availability of commodity	66.6 [31.5, 89.6] (36)	100.0 [100,100] (2)	100.0 (1)	77.8 [63.9, 87.4] (39)	78.1 [48.2, 93.2] (22)	94.7 [85.6, 98.2] (21)	13.3 [1.1, 66.8] (45)	37.3 [6.4, 83.8] (89)
	Availability of credentials	84.9 [63.1, 94.9] (36)	2.4 [0.1,49.8] (2)	100.0 (1)	58.1 [17.2, 90.3] (39)	79.3 [18.1, 98.5] (22)	65.8 [43.2, 83.0] (21)	19.9 [1.9, 76.2] (45)	40.8 [6.4, 87.5] (89)
	Availability of equipment	99.2 [92.0, 99.9] (36)	100.0 [100,100] (2)	100.0 (1)	99.5 [92.7, 100.0] (39)	99.8 [96.9, 100.0] (22)	100.0 [0.0, 0.0] (21)	96.6 [79.5, 99.5] (45)	97.8 [90.9, 99.5] (89)
	Service readiness	57.7 [16.5, 90.4] (36)	2.4 [0.1,49.8] (2)	100.0 (1)	40.0 [5.7, 88.0] (39)	60.5 [22.2, 89.2] (22)	61.1 [37.6, 80.4] (21)	7.7 [0.4, 61.3] (45)	26.7 [4.3, 74.7] (89)
North East	Availability of commodity	100.0 [100.0,100.0] (17)	- -	100.0 (1)	100.0 [100.0,100.0] (18)	0.0 [0.0, 0.0] (6)	36.7 [31.9, 41.8] (4)	98.0 [75.6, 99.9] (26)	67.0 [8.9, 97.7] (36)
	Availability of credentials	100.0 [100.0,100.0] (17)	- -	100.0 (1)	100.0 [100.0,100.0] (18)	100.0 [100.0,100.0] (6)	28.1 [25.9, 30.3] (4)	39.1 [6.8, 84.9] (26)	56.1 [6.5, 95.9] (36)
	Availability of equipment	82.0 [11.1, 99.4] (17)	- -	100.0 (1)	82.0 [11.1, 99.4] (18)	100.0 [100.0,100.0] (6)	100.0 [100.0,100.0] (4)	99.9 [99.4, 100.0] (26)	99.9 [99.1, 100.0] (36)
	Service readiness	82.0 [11.1, 99.4] (17)	- -	100.0 (1)	82.0 [11.1, 99.4] (18)	0.0 [0.0, 0.0] (6)	0.0 [0.0, 0.0] (4)	37.1 [6.6, 83.1] (26)	24.7 [15.6, 36.9] (36)
North West	Availability of commodity	95.4 [64.7, 99.6] (31)	- -	0.0 (1)	95.1 [66.2, 99.5] (32)	33.1 [18.3, 52.2] (10)	100.0 (1)	68.2 [51.9, 81.0] (80)	63.7 [44.7, 79.2] (91)
	Availability of credentials	52.7 [6.8, 94.4] (31)	- -	100.0 (1)	52.8 [6.8, 94.5] (32)	97.7 [97.0, 98.2] (10)	100.0 (1)	51.2 [35.8, 66.3] (80)	57.5 [40.7, 72.7] (91)
	Availability of equipment	55.4 [5.7, 96.2] (31)	- -	100.0 (1)	55.6 [5.8, 96.2] (32)	100.0 [100.0,100.0] (10)	100.0 (1)	94.5 [76.5, 98.9] (80)	95.2 [82.6, 98.8] (91)
	Service readiness	49.2 [5.9, 93.8] (31)	- -	0.0 (1)	49.0 [5.9, 93.6] (32)	33.1 [18.3, 52.2] (10)	100.0 (1)	31.2 [15.0, 53.8] (80)	31.7 [16.9, 51.5] (91)
South East	Availability of commodity	94.9 [45.7, 99.8] (11)	- -	- -	94.9 [45.7, 99.8] (11)	85.1 [32.7, 98.5] (17)	56.4 [1.6, 99.0] (2)	28.5 [7.5, 66.3] (16)	56.0 [38.6, 72.1] (35)
	Availability of credentials	88.7 [19.2, 99.6] (11)	- -	- -	88.7 [19.2, 99.6] (11)	91.5 [51.9, 99.1] (17)	0.0 [0.0, 0.0] (2)	51.3 [32.5, 69.8] (16)	67.3 [57.8, 75.6] (35)
	Availability of equipment	100.0 [100.0,100.0] (11)	- -	- -	100.0 [100.0,100.0] (11)	91.5 [51.9, 99.1] (17)	100.0 [100.0,100.0] (2)	77.2 [11.9, 98.8] (16)	84.9 [42.6, 97.7] (35)
	Service readiness	83.7 [24.7, 98.8] (11)	- -	- -	83.7 [24.7, 98.8] (11)	76.6 [17.4, 98.1] (17)	0.0 [0.0, 0.0] (2)	28.5 [7.5, 66.3] (16)	49.3 [30.0, 68.8] (35)

**Table B11: Service readiness\* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – by Geopolitical Zone, 2015**

		Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total†
Proportion of outlets offering service, with*:		% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)
South South	Availability of commodity	100.0 [100.0,100.0] <sup>(15)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(15)</sup>	69.5 [58.7, 78.5] <sup>(7)</sup>	99.5 [83.1, 100.0] <sup>(7)</sup>	27.7 [15.2, 45.1] <sup>(11)</sup>	57.9 [53.6, 62.0] <sup>(25)</sup>
	Availability of credentials	51.5 [8.4, 92.5] <sup>(15)</sup>	- -	- -	51.5 [8.4, 92.5] <sup>(15)</sup>	100.0 [100.0,100.0] <sup>(7)</sup>	89.4 [15.9, 99.7] <sup>(7)</sup>	67.4 [30.8, 90.6] <sup>(11)</sup>	88.5 [63.9, 97.1] <sup>(25)</sup>
	Availability of equipment	93.9 [37.3, 99.7] <sup>(15)</sup>	- -	- -	93.9 [37.3, 99.7] <sup>(15)</sup>	100.0 [100.0,100.0] <sup>(7)</sup>	100.0 [100.0,100.0] <sup>(7)</sup>	97.8 [95.5, 99.0] <sup>(11)</sup>	99.3 [98.9, 99.5] <sup>(25)</sup>
	Service readiness	51.5 [8.4, 92.5] <sup>(15)</sup>	- -	- -	51.5 [8.4, 92.5] <sup>(15)</sup>	69.5 [58.7, 78.5] <sup>(7)</sup>	88.9 [16.3, 99.7] <sup>(7)</sup>	8.8 [0.9, 51.1] <sup>(11)</sup>	50.8 [46.7, 55.0] <sup>(25)</sup>
South West	Availability of commodity	87.4 [54.0, 97.6] <sup>(44)</sup>	0.0 (1)	57.8 [57.8, 57.8] <sup>(2)</sup>	72.6 [40.9, 91.1] <sup>(47)</sup>	37.4 [12.6, 71.3] <sup>(88)</sup>	100.0 [100.0,100.0] <sup>(14)</sup>	7.9 [0.8, 47.3] <sup>(80)</sup>	23.9 [7.2, 55.9] <sup>(183)</sup>
	Availability of credentials	99.6 [93.6, 100.0] <sup>(44)</sup>	0.0 (1)	100.0 [0.0, 0.0] <sup>(2)</sup>	83.3 [43.5, 97.0] <sup>(47)</sup>	89.0 [49.9, 98.5] <sup>(88)</sup>	25.8 [4.0, 74.5] <sup>(14)</sup>	24.8 [1.8, 85.7] <sup>(80)</sup>	49.6 [11.7, 88.0] <sup>(183)</sup>
	Availability of equipment	99.7 [94.5, 100.0] <sup>(44)</sup>	100.0 (1)	100.0 [0.0, 0.0] <sup>(2)</sup>	99.7 [94.9, 100.0] <sup>(47)</sup>	97.8 [86.9, 99.7] <sup>(88)</sup>	100.0 [100.0,100.0] <sup>(14)</sup>	85.8 [69.7, 94.1] <sup>(78)</sup>	91.3 [76.2, 97.2] <sup>(181)</sup>
	Service readiness	86.9 [52.7, 97.6] <sup>(44)</sup>	0.0 (1)	57.8 [57.8, 57.8] <sup>(2)</sup>	72.3 [40.7, 90.8] <sup>(47)</sup>	37.1 [12.5, 70.9] <sup>(88)</sup>	25.8 [4.0, 74.5] <sup>(14)</sup>	0.9 [0.1, 7.0] <sup>(78)</sup>	16.7 [3.6, 51.6] <sup>(181)</sup>
Implant insertion service									
North Central	Availability of commodity	90.6 [39.3, 99.3] <sup>(14)</sup>	- -	- -	90.6 [39.3, 99.3] <sup>(14)</sup>	87.8 [28.1, 99.3] <sup>(12)</sup>	0.0 (1)	- -	86.0 [26.0, 99.1] <sup>(13)</sup>
	Availability of credentials	96.0 [76.3, 99.4] <sup>(14)</sup>	- -	- -	96.0 [76.3, 99.4] <sup>(14)</sup>	99.9 [97.9, 100.0] <sup>(12)</sup>	100.0 (1)	- -	99.9 [98.0, 100.0] <sup>(13)</sup>
	Availability of equipment	90.7 [80.2, 95.9] <sup>(14)</sup>	- -	- -	90.7 [80.2, 95.9] <sup>(14)</sup>	93.2 [36.2, 99.7] <sup>(12)</sup>	100.0 (1)	- -	93.3 [37.5, 99.7] <sup>(13)</sup>
	Service readiness	81.4 [41.0, 96.5] <sup>(14)</sup>	- -	- -	81.4 [41.0, 96.5] <sup>(14)</sup>	87.7 [27.8, 99.3] <sup>(12)</sup>	0.0 (1)	- -	86.0 [25.7, 99.1] <sup>(13)</sup>
North East	Availability of commodity	93.1 [16.8, 99.9] <sup>(9)</sup>	- -	100.0 (1)	93.1 [16.8, 99.9] <sup>(10)</sup>	3.7 [0.0, 84.4] <sup>(3)</sup>	- -	- -	3.7 [0.0, 84.4] <sup>(3)</sup>
	Availability of credentials	15.4 [4.2, 43.3] <sup>(9)</sup>	- -	100.0 (1)	15.6 [4.3, 42.9] <sup>(10)</sup>	13.5 [0.2, 94.2] <sup>(3)</sup>	- -	- -	13.5 [0.2, 94.2] <sup>(3)</sup>
	Availability of equipment	87.8 [86.0, 89.3] <sup>(9)</sup>	- -	0.0 (1)	87.6 [85.9, 89.2] <sup>(10)</sup>	13.5 [0.2, 94.2] <sup>(3)</sup>	- -	- -	13.5 [0.2, 94.2] <sup>(3)</sup>
	Service readiness	4.1 [0.1, 59.0] <sup>(9)</sup>	- -	0.0 (1)	4.1 [0.1, 59.0] <sup>(10)</sup>	3.7 [0.0, 84.4] <sup>(3)</sup>	- -	- -	3.7 [0.0, 84.4] <sup>(3)</sup>
North West	Availability of commodity	99.1 [87.6, 99.9] <sup>(16)</sup>	- -	- -	99.1 [87.6, 99.9] <sup>(16)</sup>	0.0 [0.0, 0.0] <sup>(2)</sup>	- -	0.0 [0.0, 0.0] <sup>(2)</sup>	0.0 [0.0, 0.0] <sup>(4)</sup>

**Table B11: Service readiness\* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – by Geopolitical Zone, 2015**

		Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total†
Proportion of outlets offering service, with*:		% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)
	Availability of credentials	73.4 [37.1, 92.8] <sup>(16)</sup>	- -	- -	73.4 [37.1, 92.8] <sup>(16)</sup>	100.0 [100.0,100.0] <sup>(2)</sup>	- -	91.6 [91.6, 91.6] <sup>(2)</sup>	96.6 [96.6, 96.6] <sup>(4)</sup>
	Availability of equipment	87.4 [71.5, 95.1] <sup>(16)</sup>	- -	- -	87.4 [71.5, 95.1] <sup>(16)</sup>	100.0 [100.0,100.0] <sup>(2)</sup>	- -	8.4 [8.4, 8.4] <sup>(2)</sup>	62.3 [62.3, 62.3] <sup>(4)</sup>
	Service readiness	66.2 [35.4, 87.5] <sup>(16)</sup>	- -	- -	66.2 [35.4, 87.5] <sup>(16)</sup>	0.0 [0.0, 0.0] <sup>(2)</sup>	- -	0.0 [0.0, 0.0] <sup>(2)</sup>	0.0 [0.0, 0.0] <sup>(4)</sup>
South East	Availability of commodity	20.1 [0.3, 95.1] <sup>(2)</sup>	- -	- -	20.1 [0.3, 95.1] <sup>(2)</sup>	51.1 [25.1, 76.4] <sup>(10)</sup>	- -	- -	51.1 [25.1, 76.4] <sup>(10)</sup>
	Availability of credentials	100.0 [100.0,100.0] <sup>(2)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(2)</sup>	100.0 [100.0,100.0] <sup>(10)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(10)</sup>
	Availability of equipment	100.0 [100.0,100.0] <sup>(2)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(2)</sup>	100.0 [100.0,100.0] <sup>(10)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(10)</sup>
	Service readiness	20.1 [0.3, 95.1] <sup>(2)</sup>	- -	- -	20.1 [0.3, 95.1] <sup>(2)</sup>	51.1 [25.1, 76.4] <sup>(10)</sup>	- -	- -	51.1 [25.1, 76.4] <sup>(10)</sup>
South South	Availability of commodity	100.0 [100.0,100.0] <sup>(4)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(4)</sup>	100.0 [100.0,100.0] <sup>(4)</sup>	- -	100.0 <sup>(1)</sup>	100.0 [100.0,100.0] <sup>(5)</sup>
	Availability of credentials	99.1 [94.1, 99.9] <sup>(4)</sup>	- -	- -	99.1 [94.1, 99.9] <sup>(4)</sup>	100.0 [100.0,100.0] <sup>(4)</sup>	- -	100.0 <sup>(1)</sup>	100.0 [100.0,100.0] <sup>(5)</sup>
	Availability of equipment	99.1 [94.1, 99.9] <sup>(4)</sup>	- -	- -	99.1 [94.1, 99.9] <sup>(4)</sup>	100.0 [100.0,100.0] <sup>(4)</sup>	- -	100.0 <sup>(1)</sup>	100.0 [100.0,100.0] <sup>(5)</sup>
	Service readiness	99.1 [94.1, 99.9] <sup>(4)</sup>	- -	- -	99.1 [94.1, 99.9] <sup>(4)</sup>	100.0 [100.0,100.0] <sup>(4)</sup>	- -	100.0 <sup>(1)</sup>	100.0 [100.0,100.0] <sup>(5)</sup>
South West	Availability of commodity	40.8 [9.2, 82.4] <sup>(24)</sup>	- -	- -	40.8 [9.2, 82.4] <sup>(24)</sup>	28.4 [12.5, 52.5] <sup>(49)</sup>	- -	0.0 <sup>(1)</sup>	28.4 [12.5, 52.5] <sup>(50)</sup>
	Availability of credentials	99.0 [81.7,100.0] <sup>(24)</sup>	- -	- -	99.0 [81.7, 100.0] <sup>(24)</sup>	100.0 [100.0,100.0] <sup>(49)</sup>	- -	0.0 <sup>(1)</sup>	99.9 [97.3, 100.0] <sup>(50)</sup>
	Availability of equipment	92.5 [74.6,98.1] <sup>(24)</sup>	- -	- -	92.5 [74.6, 98.1] <sup>(24)</sup>	93.5 [92.2, 94.5] <sup>(49)</sup>	- -	0.0 <sup>(1)</sup>	93.4 [92.4, 94.3] <sup>(50)</sup>
	Service readiness	34.9 [5.6, 82.8] <sup>(24)</sup>	- -	- -	34.9 [5.6, 82.8] <sup>(24)</sup>	28.4 [12.5, 52.5] <sup>(49)</sup>	- -	0.0 <sup>(1)</sup>	28.4 [12.5, 52.5] <sup>(50)</sup>
<b>IUD insertions</b>									
North Central	Availability of commodity	87.4 [30.4, 99.1] <sup>(13)</sup>	- -	- -	87.4 [30.4, 99.1] <sup>(13)</sup>	94.0 [48.7, 99.6] <sup>(12)</sup>	- -	- -	94.0 [48.7, 99.6] <sup>(12)</sup>
	Availability of credentials	100.0 [100.0,100.0] <sup>(13)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(13)</sup>	98.0 [68.1, 99.9] <sup>(12)</sup>	- -	- -	98.0 [68.1, 99.9] <sup>(12)</sup>

**Table B11: Service readiness\* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – by Geopolitical Zone, 2015**

		Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total†
Proportion of outlets offering service, with*:		% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)	% <sup>(n)</sup> (95% CI)
	Availability of equipment	49.4 [17.9, 81.5] <sup>(12)</sup>	- -	- -	49.4 [17.9, 81.5] <sup>(12)</sup>	94.8 [54.1, 99.7] <sup>(12)</sup>	- -	- -	94.8 [54.1, 99.7] <sup>(12)</sup>
	Service readiness	41.4 [15.7, 72.8] <sup>(12)</sup>	- -	- -	41.4 [15.7, 72.8] <sup>(12)</sup>	93.0 [47.6, 99.5] <sup>(12)</sup>	- -	- -	93.0 [47.6, 99.5] <sup>(12)</sup>
North East	Availability of commodity	100.0 [100.0,100.0] <sup>(5)</sup>	- -	100.0 (1)	100.0 [100.0,100.0] <sup>(6)</sup>	100.0 [100.0,100.0] <sup>(2)</sup>	- -	100.0 (1)	100.0 [100.0,100.0] <sup>(3)</sup>
	Availability of credentials	51.2 [2.3, 97.9] <sup>(5)</sup>	- -	0.0 (1)	50.9 [2.5, 97.7] <sup>(6)</sup>	100.0 [100.0,100.0] <sup>(2)</sup>	- -	0.0 (1)	40.2 [13.9, 73.6] <sup>(3)</sup>
	Availability of equipment	10.9 [1.4, 51.8] <sup>(5)</sup>	- -	0.0 (1)	10.8 [1.3, 52.1] <sup>(6)</sup>	27.5 [0.2, 98.5] <sup>(2)</sup>	- -	0.0 (1)	11.0 [0.1, 95.7] <sup>(3)</sup>
	Service readiness	10.9 [1.4, 51.8] <sup>(5)</sup>	- -	0.0 (1)	10.8 [1.3, 52.1] <sup>(6)</sup>	27.5 [0.2, 98.5] <sup>(2)</sup>	- -	0.0 (1)	11.0 [0.1, 95.7] <sup>(3)</sup>
North West	Availability of commodity	66.2 [12.7, 96.3] <sup>(11)</sup>	- -	- -	66.2 [12.7, 96.3] <sup>(11)</sup>	0.0 [0.0, 0.0] <sup>(2)</sup>	- -	- -	0.0 [0.0, 0.0] <sup>(2)</sup>
	Availability of credentials	86.0 [21.5, 99.3] <sup>(11)</sup>	- -	- -	86.0 [21.5, 99.3] <sup>(11)</sup>	100.0 [100.0,100.0] <sup>(2)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(2)</sup>
	Availability of equipment	87.7 [51.0, 98.0] <sup>(10)</sup>	- -	- -	87.7 [51.0, 98.0] <sup>(10)</sup>	100.0 [100.0,100.0] <sup>(2)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(2)</sup>
	Service readiness	43.5 [4.5, 92.6] <sup>(10)</sup>	- -	- -	43.5 [4.5, 92.6] <sup>(10)</sup>	0.0 [0.0, 0.0] <sup>(2)</sup>	- -	- -	0.0 [0.0, 0.0] <sup>(2)</sup>
South East	Availability of commodity	20.1 [0.3, 95.1] <sup>(2)</sup>	- -	- -	20.1 [0.3, 95.1] <sup>(2)</sup>	46.7 [29.8, 64.5] <sup>(13)</sup>	- -	- -	46.7 [29.8, 64.5] <sup>(13)</sup>
	Availability of credentials	100.0 [100.0,100.0] <sup>(2)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(2)</sup>	100.0 [100.0,100.0] <sup>(13)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(13)</sup>
	Availability of equipment	20.1 [0.3, 95.1] <sup>(2)</sup>	- -	- -	20.1 [0.3, 95.1] <sup>(2)</sup>	90.8 [64.6, 98.1] <sup>(13)</sup>	- -	- -	90.8 [64.6, 98.1] <sup>(13)</sup>
	Service readiness	20.1 [0.3, 95.1] <sup>(2)</sup>	- -	- -	20.1 [0.3, 95.1] <sup>(2)</sup>	42.3 [23.4, 63.9] <sup>(13)</sup>	- -	- -	42.3 [23.4, 63.9] <sup>(13)</sup>
South South	Availability of commodity	50.6 [1.9, 98.2] <sup>(4)</sup>	- -	- -	50.6 [1.9, 98.2] <sup>(4)</sup>	55.8 [35.7, 74.1] <sup>(5)</sup>	- -	- -	55.8 [35.7, 74.1] <sup>(5)</sup>
	Availability of credentials	100.0 [100.0,100.0] <sup>(4)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(4)</sup>	100.0 [100.0,100.0] <sup>(5)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(5)</sup>
	Availability of equipment	100.0 [100.0,100.0] <sup>(4)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(4)</sup>	100.0 [100.0,100.0] <sup>(5)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(5)</sup>

**Table B11: Service readiness\* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – by Geopolitical Zone, 2015**

		Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total†
Proportion of outlets offering service, with‡:		% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)
	<i>Service readiness</i>	50.6 [1.9, 98.2] <sup>(4)</sup>	- -	- -	50.6 [1.9, 98.2] <sup>(4)</sup>	55.8 [35.7, 74.1] <sup>(5)</sup>	- -	- -	55.8 [35.7, 74.1] <sup>(5)</sup>
South West	Availability of commodity	65.8 [18.4, 94.2] <sup>(36)</sup>	- -	57.8 [57.8, 57.8] <sup>(2)</sup>	65.6 [18.8, 94.0] <sup>(38)</sup>	39.0 [8.3, 81.8] <sup>(74)</sup>	- -	0.0 (1)	38.8 [8.4, 81.4] <sup>(75)</sup>
	Availability of credentials	84.9 [29.1, 98.7] <sup>(36)</sup>	- -	100.0 [100.0, 100] <sup>(2)</sup>	85.2 [29.5, 98.8] <sup>(38)</sup>	100.0 [0.0, 0.0] <sup>(74)</sup>	- -	0.0 (1)	99.4 [95.7, 99.9] <sup>(75)</sup>
	Availability of equipment	82.0 [33.5, 97.6] <sup>(36)</sup>	- -	100.0 [100.0, 100] <sup>(2)</sup>	82.3 [33.9, 97.7] <sup>(38)</sup>	93.5 [74.5, 98.6] <sup>(74)</sup>	- -	100.0 (1)	93.6 [74.9, 98.6] <sup>(75)</sup>
	<i>Service readiness</i>	48.2 [10.6, 88.0] <sup>(36)</sup>	- -	57.8 [57.8, 57.8] <sup>(2)</sup>	48.4 [11.1, 87.5] <sup>(38)</sup>	34.4 [7.5, 77.2] <sup>(74)</sup>	- -	0.0 (1)	34.2 [7.5, 76.8] <sup>(75)</sup>
<b>Male sterilization</b>									
North Central	Availability of credentials	- -	- -	- -	- -	100.0 (1)	- -	- -	100.0 (1)
	Availability of equipment	- -	- -	- -	- -	0.0 (1)	- -	- -	0.0 (1)
	<i>Service readiness</i>	- -	- -	- -	- -	0.0 (1)	- -	- -	0.0 (1)
North East	Availability of credentials	0.0 (1)	- -	- -	0.0 (1)	100.0 (1)	- -	- -	100.0 (1)
	Availability of equipment	0.0 (1)	- -	- -	0.0 (1)	100.0 (1)	- -	- -	100.0 (1)
	<i>Service readiness</i>	0.0 (1)	- -	- -	0.0 (1)	100.0 (1)	- -	- -	100.0 (1)
North West	Availability of credentials	100.0 (1)	- -	- -	100.0 (1)	- -	- -	- -	- -
	Availability of equipment	100.0 (1)	- -	- -	100.0 (1)	- -	- -	- -	- -
	<i>Service readiness</i>	100.0 (1)	- -	- -	100.0 (1)	- -	- -	- -	- -
South East	Availability of credentials	- -	- -	- -	- -	100.0 [100.0, 100.0] <sup>(5)</sup>	- -	- -	100.0 [100.0, 100.0] <sup>(5)</sup>
	Availability of equipment	- -	- -	- -	- -	88.3 [16.9, 99.6] <sup>(5)</sup>	- -	- -	88.3 [16.9, 99.6] <sup>(5)</sup>
	<i>Service readiness</i>	- -	- -	- -	- -	88.3 [16.9, 99.6] <sup>(5)</sup>	- -	- -	88.3 [16.9, 99.6] <sup>(5)</sup>

**Table B11: Service readiness\* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – by Geopolitical Zone, 2015**

		Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total†
Proportion of outlets offering service, with*:		% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)
South South	Availability of credentials	- -	- -	- -	- -	- -	- -	- -	- -
	Availability of equipment	- -	- -	- -	- -	- -	- -	- -	- -
	Service readiness	- -	- -	- -	- -	- -	- -	- -	- -
South West	Availability of credentials	- -	- -	- -	- -	100.0 [100.0,100.0] <sup>(10)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(10)</sup>
	Availability of equipment	- -	- -	- -	- -	100.0 [100.0,100.0] <sup>(10)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(10)</sup>
	Service readiness	- -	- -	- -	- -	100.0 [100.0,100.0] <sup>(10)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(10)</sup>
<b>Female sterilization</b>									
North Central	Availability of credentials	100.0 (1)	- -	- -	100.0 (1)	100.0 [100.0,100.0] <sup>(7)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(7)</sup>
	Availability of equipment	0.0 (1)	- -	- -	0.0 (1)	30.7 [9.8, 64.6] <sup>(6)</sup>	- -	- -	30.7 [9.8, 64.6] <sup>(6)</sup>
	Service readiness	0.0 (1)	- -	- -	0.0 (1)	30.7 [9.8, 64.6] <sup>(6)</sup>	- -	- -	30.7 [9.8, 64.6] <sup>(6)</sup>
North East	Availability of credentials	- -	- -	- -	- -	100.0 (1)	- -	- -	100.0 (1)
	Availability of equipment	- -	- -	- -	- -	0.0 (1)	- -	- -	0.0 (1)
	Service readiness	- -	- -	- -	- -	0.0 (1)	- -	- -	0.0 (1)
North West	Availability of credentials	81.0 [13.0, 99.2] <sup>(3)</sup>	- -	- -	81.0 [13.0, 99.2] <sup>(3)</sup>	- -	- -	- -	- -
	Availability of equipment	81.0 [13.0, 99.2] <sup>(3)</sup>	- -	- -	81.0 [13.0, 99.2] <sup>(3)</sup>	- -	- -	- -	- -
	Service readiness	81.0 [13.0, 99.2] <sup>(3)</sup>	- -	- -	81.0 [13.0, 99.2] <sup>(3)</sup>	- -	- -	- -	- -
South East	Availability of credentials	- -	- -	- -	- -	100.0 [100.0,100.0] <sup>(5)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(5)</sup>
	Availability of equipment	- -	- -	- -	- -	80.4 [6.4, 99.6] <sup>(5)</sup>	- -	- -	80.4 [6.4, 99.6] <sup>(5)</sup>




**Table B11: Service readiness\* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – by Geopolitical Zone, 2015**

		Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total†
Proportion of outlets offering service, with‡:		% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)
	<i>Service readiness</i>	- -	- -	- -	- -	80.4 [6.4, 99.6] <sup>(5)</sup>	- -	- -	80.4 [6.4, 99.6] <sup>(5)</sup>
South South	Availability of credentials	- -	- -	- -	- -	100.0 [100.0,100.0] <sup>(3)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(3)</sup>
	Availability of equipment	- -	- -	- -	- -	100.0 [0.0, 0.0] <sup>(3)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(3)</sup>
	<i>Service readiness</i>	- -	- -	- -	- -	100.0 [100.0,100.0] <sup>(3)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(3)</sup>
South West	Availability of credentials	100.0 <sup>(1)</sup>	- -	100.0 <sup>(1)</sup>	100.0 [100.0,100.0] <sup>(2)</sup>	82.9 [79.1, 86.2] <sup>(27)</sup>	- -	- -	82.9 [79.1, 86.2] <sup>(27)</sup>
	Availability of equipment	100.0 <sup>(1)</sup>	- -	0.0 <sup>(1)</sup>	56.2 [56.2, 56.2] <sup>(2)</sup>	79.5 [72.2, 85.4] <sup>(27)</sup>	- -	- -	79.5 [72.2, 85.4] <sup>(27)</sup>
	<i>Service readiness</i>	100.0 <sup>(1)</sup>	- -	0.0 <sup>(1)</sup>	56.2 [56.2, 56.2] <sup>(2)</sup>	79.5 [72.2, 85.4] <sup>(27)</sup>	- -	- -	79.5 [72.2, 85.4] <sup>(27)</sup>
<p>* Full service readiness is defined as having available: 1. The commodity (not applicable for male/female sterilization); 2. A provider with credentials meeting the guidelines to perform the service (<a href="http://www.healthpolicyproject.com/ns/docs/CIP_Nigeria.pdf">http://www.healthpolicyproject.com/ns/docs/CIP_Nigeria.pdf</a>); and 3. A minimum set of sentinel equipment (<a href="http://www.cpc.unc.edu/measure/prh/rh_indicators/specific/long-acting-permanent-methods/percent-of-facilities-with-appropriate">http://www.cpc.unc.edu/measure/prh/rh_indicators/specific/long-acting-permanent-methods/percent-of-facilities-with-appropriate</a>) for providing the service. Observations that are missing information for commodity availability, provider credentials, or equipment are excluded from the 'service readiness' denominator.</p> <p>† In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.</p> <p>‡ One rural outlet in the South West region reported offering female tubal ligation, however equipment data is missing for that outlet and is therefore excluded from the denominator.</p>									

Source: FPwatch Outlet Survey, Nigeria, 2015

**Figure B1. Modern contraceptive method market composition – Geopolitical Zones, 2015**


*Among all outlets stocking at least 1 modern contraceptive or providing at least 1 contraceptive service, by outlet type*



Comparing contraceptive market composition by geopolitical zones, the private sector accounted for a higher range of the market composition in the Southern zones (91 – 96 percent) compared to Northern zones (65 – 74 percent). In the Southern zones, PPMVs accounted for about three-quarters of market composition compared to about two-thirds in Northern zones. Public facilities comprised about one-third of the market composition particularly in the North East and North West zones. CHWs were only an appreciable portion of the market composition in the South East zone and general retailers commonly stocked at least one method above the level of condoms in the South East (6 percent).

**Figure B2. Percentage of modern contraceptive commodity-stocking outlets with selected non-hormonal short-acting contraceptives available – Geopolitical Zones, 2015**


*Among all screened outlets, by outlet type*



There were few general trends in availability of non-hormonal short-acting methods by sector comparing the zones. Availability of male and female condoms was the lowest in the public sector outlets of the North West and South West zones. However, there was higher availability of cyclebeads in the public sector of the North West compared to other zones. There was also lower availability of most non-hormonal short-acting methods in the private sector in the North West zone compared to others.

**Figure B3. Percentage of modern contraceptive commodity-stocking outlets with selected hormonal short-acting contraceptives available – Geopolitical Zones, 2015**


*Among all screened outlets, by outlet type*



Comparing availability of hormonal short-acting methods between zones, there was higher availability of all methods in the public sector of the North East and South South zones while most methods were less commonly stocked in the South East and South West public sectors. Comparatively, the private sectors in the North East and South East zones appeared to have lower availability across hormonal short-acting methods.

**Figure B4. Percentage of modern contraceptive commodity-stocking outlets with selected long-acting contraceptives available – Geopolitical Zones, 2015**


*Among all screened outlets, by outlet type*



LARC methods only appeared available to an appreciable degree in the public sector in the South South zone. Very few public or private sector outlets had LARC methods available in either the North West or South East zones.

**Figure B5. Percentage of outlets with selected method mixes available – Geopolitical Zones, 2015**


*Among all screened outlets, by outlet type*



The majority of public sector outlets in the North East zone had three or more methods available compared to one-third or less of public sector outlets in the North Central and North West zones. In the South South zone, more than three-quarters of public sector outlets had three or more methods available and nearly two-quarters had five or methods available, considerably higher compared to all other regions. About 20 percent of private sector outlets had three or more methods available in the South South zone compared to 10 percent for South East and South West zones.

**Figure B6. Percentage of outlets with stock outs of selected contraceptive methods – Geopolitical Zones, 2015**


*Among all outlets reportedly stocking the method at any time in the previous three months, by outlet type*




For those methods with higher availability (less variation in 95% CIs), there were considerably higher reports of stock outs for oral contraceptives (> 25 percent) in public sector outlets in the North Central, North West and South West zones compared to others. There were also considerably higher reported stock outs of contraceptive injectables (> 50 percent) in the public sector of the South West zone and in the private sector of the North Central and South West zones.

**Figure B7. Price of contraceptive methods in the private sector – Geopolitical Zones, 2015**

*Median price in USD and USD/CYP with interquartile range, by contraceptive method*








While prices were generally comparable across zones, prices tended to be higher in Southern zones compared to other zones, particularly for oral contraceptives, emergency contraceptives and injectables.

**Figure B8. Percentage market share for contraceptives methods – Geopolitical Zones, 2015**


*As a % of total CYP sold/distributed, by outlet type and sector*



In the North Central, South East and South West zones, the public sector accounted for less than 20 percent of the CYP volume reportedly distributed in the zone with the private sector accounting for over 80 percent. In the South South, the public sector accounted for about one-quarter of the total CYP volume compared to three-quarters from the private sector. In the North East and North West, the public sector was dominant, accounting for nearly 60 percent and two-thirds of the total CYP volume, respectively. By method, in the North West and North East, the market share was highest for public sector implants and injectables. In the private sector, male condoms accounted for a much higher market share in the North East, South East and South West zones. Variance was seen in the remaining private sectors with implants dominant in the South South, injectables in the North West and a much higher share of IUDs in the North Central zone.

**Figure B9. Within outlet market share for contraceptive methods – Geopolitical Zones, 2015**


*As a % of total CYP sold/distributed within outlet type and sector, by outlet type and sector*



Comparing within sector market share by zones, the public sector in the North Central zone was very dominated by distribution of injectables and from a combination of injectables and implants in the other Northern zones. In the South, the within market share for the South East was largely from injectables and implants, in the South South from implants and male condoms and in the South West from injectables, implants and IUDs. In the private sector, the North Central zone market share came largely from a combination of IUDs and implants, injectables in the North East zone and male condoms and injectables in the North West. In the South East and South West private sectors, the majority of within sector market share came from male condoms while it predominantly came from implants in the South South.

**Figure B10. Percentage of outlets with selected contraceptive services available – Geopolitical Zones, 2015**


*Among all screened outlets, by outlet type*



Availability of contraceptive injections was above 50 percent in northern zone public sectors. The highest availability of injection, implant and IUD services was observed in the public sector of the South South zone. Low service availability was seen in the private sectors across zones. Availability of implant insertion only surpassed 20% in the public sectors of the South South zone and the South West zone (half and one-quarter, respectively). The only appreciable percentage of male sterilization services was observed in the public sector of the North East.

**Figure B11. Service readiness to offer provider-dependent contraceptive services among outlets reportedly offering services, by sector – Geopolitical Zones, 2015**

*Among all screened outlets reportedly offering services*



Among outlets reportedly offering the respective contraceptive services, service readiness for injections, implant insertion and IUD insertion varied widely across regions and sectors. Service readiness for male sterilization was high in the private sector of all zones except for North Central and South South, and female sterilization was high in the private sectors of the South East, South South, and South West zones. Across methods, service readiness was particularly low in the private sector of the North West zone.

## Results Section C: Core Indicators by Urban vs. Rural Stratification

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total*
Proportion of outlet types stocking / providing at least 1 modern contraceptive method on the day of the survey, of all outlets stocking / providing at least 1 modern contraceptive method <sup>†</sup> :	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<i>Any method available, including condoms only outlets<sup>‡</sup></i>									
Urban; N=2,926	2.5 (1.3,4.8)	0.0 (0.0,0.3)	0.1 (0.0,0.5)	2.6 (1.4,5.0)	3.0 (1.9,4.8)	6.3 (3.5,11.2)	75.5 (50.8,90.3)	12.5 (3.4,36.7)	97.4 (95.1,98.7)
Rural; N=621	12.2 (7.3,19.7)	1.9 (0.4,8.8)	0.0 (0.0,0.4)	14.2 (8.8,22.2)	8.9 (3.5,21.1)	0.7 (0.2,2.3)	65.5 (52.8,76.4)	10.7 (3.1,31.4)	85.8 (77.9,91.2)
<i>Any method available, excluding condoms only outlets<sup>§</sup></i>									
Urban; N=1,821	3.9 (2.2,6.9)	0.0 -	0.0 (0.0,0.2)	3.9 (2.2,6.9)	4.6 (2.7,7.7)	10.2 (5.7,17.7)	80.3 (69.8,87.8)	1.0 (0.5,1.9)	96.1 (93.1,97.8)
Rural; N=424	16.8 (8.0,32.0)	3.0 (0.5,15.3)	0.1 (0.0,0.6)	19.8 (9.4,37.0)	11.0 (6.0,19.4)	0.7 (0.2,2.5)	67.6 (58.0,76.0)	0.8 (0.1,5.6)	80.2 (63.0,90.6)
<p>* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>† Family planning commodity stocking outlets have at least one family planning commodity in stock on the day of the survey, verified by the presence of at least one family planning commodity recorded in an audit sheet. There were 44 family planning commodity stocking outlets with partially completed interviews, which were thus excluded from the denominator. In urban areas, there were 37 incomplete interviews. In rural areas there were 7 incomplete interviews.</p> <p>‡ Includes: male condoms, female condoms, oral contraceptives, emergency contraceptives, injectables, implants, and IUDs.</p> <p>§ Includes: oral contraceptives, emergency contraceptives, injectables, implants, and IUDs.</p>									
Source: FPwatch Outlet Survey, Nigeria, 2015									

**Table C2: Availability of modern contraceptive method types, among outlets screened, by outlet type – Urban/Rural, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, stocking / providing†:</b>	U: N=107 R: N=107	U: N=2 R: N=10	U: N=11 R: N= 4	U: N=120 R: N= 121	U: N=274 R: N= 59	U: N=214 R: N=16	U: N=2,231 R: N= 570	U: N=2,719 R: N=645	U: N=7,829 R: N= 1,933	U: N=10,668 R: N= 2,699
<b>Any modern method</b>										
Urban	72.1 (51.2, 86.5)	58.0 (6.1, 96.7)	8.5 (0.7, 55.8)	57.9 (34.0, 78.6)	37.5 (26.8, 49.6)	97.0 (94.0, 98.5)	89.4 (85.2, 92.5)	85.6 (80.9, 89.3)	4.6 (1.5, 13.8)	26.8 (21.2, 33.3)
Rural	71.6 (59.4, 81.3)	47.1 (10.3, 87.4)	8.8 (0.7, 57.9)	65.5 (51.8, 77.0)	67.7 (32.9, 89.9)	100.0 -	77.9 (64.6, 87.1)	76.7 (62.4, 86.7)	3.2 (0.8, 12.4)	22.2 (17.7, 27.5)
<b>Any short-acting method</b>										
Urban	72.1 (51.1, 86.4)	58.0 (6.1, 96.7)	8.5 (0.7, 55.8)	57.9 (34.0, 78.6)	31.7 (22.2, 43.0)	97.0 (94.0, 98.5)	89.4 (85.2, 92.5)	85.1 (80.5, 88.9)	4.6 (1.5, 13.8)	26.7 (21.1, 33.1)
Rural	71.6 (59.4, 81.3)	47.1 (10.3, 87.4)	8.8 (0.7, 57.9)	65.5 (51.8, 77.0)	67.7 (32.9, 89.9)	100.0 -	77.9 (64.6, 87.1)	76.7 (62.4, 86.7)	3.2 (0.8, 12.4)	22.2 (17.7, 27.5)
<b>Any LARC method</b>										
Urban	40.3 (26.4, 56.0)	0.0 -	1.7 (0.2, 15.0)	31.3 (20.0, 45.5)	16.6 (9.5, 27.2)	1.4 (0.5, 4.2)	0.1 (0.0, 0.4)	1.6 (0.8, 2.9)	0.0 -	0.8 (0.5, 1.2)
Rural	25.3 (13.5, 42.2)	0.0 -	0.0 -	19.9 (11.4, 32.4)	32.2 (17.5, 51.5)	0.0 -	0.0 -	4.3 (1.6, 10.9)	0.0 -	1.9 (1.3, 2.8)
<b>Any permanent method</b>										
Urban	2.1 (0.9, 4.7)	0.0 -	1.6 (0.1, 15.5)	2.0 (0.8, 5.0)	10.3 (5.5, 18.4)	0.0 -	0.0 -	0.8 (0.3, 2.3)	0.0 -	0.2 (0.1, 0.6)
Rural	0.9 (0.1, 6.1)	0.0 -	0.0 -	0.7 (0.1, 5.0)	11.1 (3.3, 31.2)	0.0 -	0.0 -	1.5 (0.3, 6.9)	0.0 -	0.4 (0.1, 1.4)
<b>Any LARC/PM</b>										
Urban	41.1 (27.0, 56.9)	0.0 -	1.7 (0.2, 15.0)	31.9 (20.3, 46.3)	22.5 (14.9, 32.5)	1.4 (0.5, 4.2)	0.1 (0.0, 0.4)	2.1 (1.1, 3.8)	0.0 -	0.9 (0.6, 1.4)
Rural	26.1 (14.6, 42.4)	0.0 -	0.0 -	20.6 (12.2, 32.6)	32.6 (18.0, 51.6)	0.0 -	0.0 -	4.4 (1.7, 10.8)	0.0 -	1.9 (1.3, 2.8)

\* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.

† The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview). The denominator includes 58 urban outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview) and 10 rural outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview).



**Table C2: Availability of modern contraceptive method types, among outlets screened, by outlet type – Urban/Rural, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, stocking / providing†:</b>	U: N=107 R: N=107	U: N=2 R: N=10	U: N=11 R: N= 4	U: N=120 R: N= 121	U: N=274 R: N= 59	U: N=214 R: N=16	U: N=2,231 R: N= 570	U: N=2,719 R: N=645	U: N=7,829 R: N= 1,933	U: N=10,668 R: N= 2,699
interview).										
Source: FPwatch Outlet Survey, Nigeria, 2015										

**Table C3: Availability of selected contraceptive methods, among outlets screened, by outlet type – Urban/Rural, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking†:</b>	U: N=107 R: N=107	U: N=2 R: N=10	U: N=11 R: N= 4	U: N=120 R: N= 121	U: N=274 R: N= 59	U: N=214 R: N=16	U: N=2,231 R: N= 570	U: N=2,719 R: N=645	U: N=7,829 R: N= 1,933	U: N=10,668 R: N= 2,699
<b>Male condoms</b>										
Urban	59.6 (41.9, 75.1)	58.0 (6.1, 96.7)	7.0 (0.6, 49.1)	48.0 (28.7, 67.8)	19.0 (12.5, 27.7)	93.5 (86.1, 97.1)	83.3 (77.2, 88.1)	78.7 (72.1, 84.0)	4.6 (1.5, 13.8)	24.9 (19.6, 31.0)
Rural	53.5 (39.6, 66.9)	0.0 -	8.8 (0.7, 57.9)	42.2 (32.5, 52.6)	47.6 (24.6, 71.6)	98.4 (85.6, 99.8)	71.1 (56.7, 82.2)	68.1 (54.7, 79.1)	3.2 (0.8, 12.4)	19.2 (15.5, 23.7)
<b>Female condoms</b>										
Urban	47.8 (31.3, 64.8)	0.0 -	5.8 (0.5, 43.3)	38.0 (23.0, 55.6)	5.7 (2.5, 12.3)	15.3 (7.4, 29.1)	2.9 (1.7, 5.0)	4.0 (2.3, 6.8)	0.0 (0.0, 0.2)	1.5 (1.1, 2.2)
Rural	35.1 (24.5, 47.4)	0.0 -	0.0 -	27.5 (17.8, 40.1)	10.9 (3.1, 31.6)	1.6 (0.2, 14.1)	3.4 (1.0, 10.6)	4.4 (1.9, 9.7)	0.5 (0.1, 3.6)	2.7 (1.5, 4.6)
<b>Cyclebeads</b>										
Urban	22.4 (10.6, 41.4)	0.0 -	0.1 (0.0, 1.2)	17.2 (7.1, 36.2)	0.1 (0.0, 0.5)	0.2 (0.0, 1.7)	1.1 (0.4, 2.9)	0.9 (0.4, 2.3)	0.0 -	0.5 (0.2, 0.9)
Rural	5.7 (2.3, 13.3)	0.0 -	0.0 -	4.5 (1.8, 10.9)	3.4 (0.6, 17.6)	0.0 -	1.3 (0.4, 3.7)	1.5 (0.6, 3.6)	0.0 -	0.6 (0.3, 1.1)
<b>Oral contraceptives</b>										
Urban	60.3 (42.4, 75.9)	0.0 -	0.1 (0.0, 1.2)	46.3 (29.1, 64.4)	15.8 (10.1, 24.0)	83.5 (72.2, 90.9)	51.6 (44.4, 58.8)	50.8 (44.6, 56.9)	0.2 (0.1, 0.4)	14.2 (11.5, 17.4)
Rural	48.4 (35.5, 61.6)	3.9 (0.4, 30.5)	8.8 (0.7, 57.9)	39.1 (25.6, 54.4)	45.9 (22.3, 71.6)	50.5 (24.0, 76.7)	50.6 (27.5, 73.4)	49.9 (27.4, 72.5)	0.2 (0.0, 1.2)	12.9 (9.3, 17.5)
<b>Combined oral contraceptives</b>										
Urban	56.6 (40.0, 71.9)	0.0 -	0.1 (0.0, 1.2)	43.5 (27.7, 60.7)	15.5 (9.8, 23.7)	83.5 (72.2, 90.9)	51.6 (44.4, 58.8)	50.7 (44.6, 56.8)	0.2 (0.1, 0.4)	14.2 (11.4, 17.4)
Rural	43.3 (29.8, 57.8)	3.9 (0.4, 30.5)	8.8 (0.7, 57.9)	35.0 (22.2, 50.5)	45.9 (22.3, 71.6)	50.5 (24.0, 76.7)	50.4 (27.4, 73.3)	49.8 (27.3, 72.4)	0.2 (0.0, 1.2)	12.6 (9.1, 17.3)
<b>Progestin-only pills</b>										
Urban	51.8 (34.9, 68.2)	0.0 -	0.1 (0.0, 1.2)	39.8 (24.7, 57.0)	0.9 (0.3, 2.7)	0.1 (0.0, 0.8)	0.4 (0.1, 2.2)	0.4 (0.1, 1.8)	0.0 -	0.6 (0.3, 1.1)
Rural	36.9	0.0	8.8	29.3	0.1	0.0	0.3	0.3	0.0	1.5

**Table C3: Availability of selected contraceptive methods, among outlets screened, by outlet type – Urban/Rural, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking†:</b>	U: N=107 R: N=107	U: N=2 R: N=10	U: N=11 R: N= 4	U: N=120 R: N= 121	U: N=274 R: N= 59	U: N=214 R: N=16	U: N=2,231 R: N= 570	U: N=2,719 R: N=645	U: N=7,829 R: N= 1,933	U: N=10,668 R: N= 2,699
	(23.2, 53.1)	-	(0.7, 57.9)	(17.4, 44.8)	(0.0, 1.3)	-	(0.1, 1.1)	(0.1, 1.0)	-	(0.8, 2.8)
<b>Emergency contraceptives</b>										
Urban	0.0 -	0.0 -	0.0 -	0.0 -	2.2 (0.8, 6.3)	63.0 (50.7, 73.8)	10.0 (4.9, 19.6)	12.9 (6.8, 23.1)	0.0 (0.0, 0.2)	3.5 (2.4, 4.9)
Rural	0.1 (0.0, 0.4)	0.0 -	0.0 -	0.0 (0.0, 0.4)	10.3 (2.7, 32.5)	67.9 (45.3, 84.4)	9.7 (3.9, 21.9)	10.1 (4.1, 22.7)	0.0 -	2.2 (1.0, 4.9)
<b>Contraceptive injectables</b>										
Urban	64.0 (45.9, 78.9)	0.0 -	1.7 (0.2, 15.0)	49.5 (30.6, 68.6)	20.7 (14.6, 28.7)	63.1 (38.6, 82.3)	7.3 (2.7, 18.6)	12.1 (6.3, 22.0)	0.0 -	3.8 (2.6, 5.6)
Rural	57.8 (41.4, 72.6)	43.2 (8.2, 86.7)	8.8 (0.7, 57.9)	53.9 (43.1, 64.3)	36.6 (22.0, 54.3)	54.2 (28.0, 78.3)	4.7 (2.4, 9.0)	9.3 (6.0, 14.0)	0.0 -	4.6 (3.5, 6.0)
<i>Depo-provera injectables</i>										
Urban	60.1 (42.5, 75.4)	0.0 -	1.7 (0.2, 15.0)	46.5 (28.9, 64.9)	17.8 (12.7, 24.3)	58.7 (36.0, 78.2)	6.2 (2.2, 16.7)	10.7 (5.5, 19.5)	0.0 -	3.4 (2.3, 4.9)
Rural	55.2 (38.8, 70.5)	1.0 (0.1, 10.4)	8.8 (0.7, 57.9)	43.9 (27.8, 61.3)	22.9 (14.7, 34.0)	45.7 (21.1, 72.7)	4.0 (1.9, 8.1)	6.8 (4.6, 10.1)	0.0 -	3.6 (2.4, 5.4)
<i>Noristerat injectables</i>										
Urban	59.7 (42.4, 74.9)	0.0 -	1.7 (0.2, 15.0)	46.1 (28.5, 64.8)	12.9 (8.3, 19.3)	51.0 (26.4, 75.1)	5.2 (1.7, 14.9)	8.8 (4.5, 16.5)	0.0 -	2.9 (1.9, 4.5)
Rural	47.2 (33.3, 61.5)	43.2 (8.2, 86.7)	8.8 (0.7, 57.9)	45.6 (35.4, 56.2)	29.2 (13.6, 52.0)	52.6 (26.5, 77.4)	3.0 (1.5, 5.9)	6.8 (3.8, 11.8)	0.0 -	3.7 (2.9, 4.6)
<i>Sayana Press injectables</i>										
Urban	0.0 -	0.0 -	0.0 -	0.0 -	0.8 (0.2, 3.1)	1.2 (0.5, 3.3)	1.1 (0.2, 7.4)	1.1 (0.2, 5.6)	0.0 -	0.3 (0.1, 1.3)
Rural	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.1 (0.0, 0.7)	0.1 (0.0, 0.6)	0.0 -	0.0 (0.0, 0.1)

**Table C3: Availability of selected contraceptive methods, among outlets screened, by outlet type – Urban/Rural, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking†:</b>	U: N=107 R: N=107	U: N=2 R: N=10	U: N=11 R: N= 4	U: N=120 R: N= 121	U: N=274 R: N= 59	U: N=214 R: N=16	U: N=2,231 R: N= 570	U: N=2,719 R: N=645	U: N=7,829 R: N= 1,933	U: N=10,668 R: N= 2,699
<b>Implants</b>										
Urban	37.8 (23.9, 54.1)	0.0 -	0.1 (0.0, 1.2)	29.0 (18.1, 43.1)	6.5 (2.8, 14.6)	0.7 (0.1, 4.7)	0.0 (0.0, 0.4)	0.6 (0.2, 1.8)	0.0 -	0.5 (0.3, 0.9)
Rural	21.5 (9.8, 40.7)	0.0 -	0.0 -	16.9 (8.4, 31.1)	29.6 (14.4, 51.3)	0.0 -	0.0 -	4.0 (1.4, 11.1)	0.0 -	1.7 (1.1, 2.7)
<i>Implanon implants</i>										
Urban	36.3 (22.4, 52.9)	0.0 -	0.1 (0.0, 1.2)	27.9 (17.1, 41.9)	2.0 (0.8, 5.0)	0.0 -	0.0 (0.0, 0.4)	0.2 (0.1, 0.6)	0.0 -	0.4 (0.2, 0.7)
Rural	21.2 (9.6, 40.7)	0.0 -	0.0 -	16.7 (8.2, 31.1)	27.1 (10.6, 53.9)	0.0 -	0.0 -	3.6 (1.0, 12.2)	0.0 -	1.6 (1.0, 2.6)
<i>Jadelle implants</i>										
Urban	31.8 (18.7, 48.6)	0.0 -	0.1 (0.0, 1.2)	24.4 (14.7, 37.8)	5.7 (2.3, 13.5)	0.7 (0.1, 4.7)	0.0 (0.0, 0.4)	0.6 (0.2, 1.7)	0.0 -	0.4 (0.3, 0.8)
Rural	13.6 (4.8, 33.0)	0.0 -	0.0 -	10.7 (3.7, 27.4)	29.6 (14.4, 51.3)	0.0 -	0.0 -	4.0 (1.4, 11.1)	0.0 -	1.4 (0.8, 2.3)
<b>IUDs</b>										
Urban	23.0 (13.6, 36.4)	0.0 -	1.7 (0.2, 15.0)	18.1 (11.5, 27.3)	15.3 (8.7, 25.5)	0.7 (0.3, 1.9)	0.1 (0.0, 0.3)	1.4 (0.7, 2.6)	0.0 -	0.6 (0.4, 0.9)
Rural	15.7 (6.9, 31.9)	0.0 -	0.0 -	12.3 (5.8, 24.3)	21.8 (14.3, 31.9)	0.0 -	0.0 -	2.9 (1.5, 5.7)	0.0 -	1.2 (0.7, 2.0)
<p>* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.</p> <p>† The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview). The denominator includes 58 urban outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview) and 10 rural outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview).</p>										
Source: FPwatch Outlet Survey, Nigeria, 2015										

**Table C4: Availability of modern contraceptive method diversity, among outlets screened, by outlet type – Urban/Rural, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, currently stocking / providing<sup>†</sup>:</b>	U: N=107 R: N=107	U: N=2 R: N=10	U: N=11 R: N= 4	U: N=120 R: N= 121	U: N=274 R: N= 59	U: N=214 R: N=16	U: N=2,231 R: N= 570	U: N=2,719 R: N=645	U: N=7,829 R: N= 1,9333	U: N=10,666 R: N= 2,699
<b>3+ methods<sup>‡</sup></b>										
Urban	64.5 (46.7, 78.9)	0.0 -	1.7 (0.2, 15.0)	49.8 (30.9, 68.8)	18.3 (12.3, 26.3)	76.6 (62.4, 86.5)	11.5 (6.0, 20.9)	16.3 (9.4, 26.9)	0.0 -	4.9 (3.8, 6.4)
Rural	46.1 (35.0, 57.6)	0.0 -	8.8 (0.7, 57.9)	36.5 (27.2, 47.0)	32.4 (18.3, 50.6)	69.5 (45.9, 86.0)	11.3 (5.4, 22.1)	14.5 (7.0, 27.6)	0.0 -	4.9 (3.6, 6.6)
<b>3+ methods with LARC</b>										
Urban	40.3 (26.4, 56.0)	0.0 -	1.7 (0.2, 15.0)	31.3 (20.0, 45.4)	11.7 (6.6, 19.8)	1.4 (0.5, 4.2)	0.1 (0.0, 0.4)	1.1 (0.5, 2.3)	0.0 -	0.7 (0.4, 1.1)
Rural	25.3 (13.5, 42.2)	0.0 -	0.0 -	19.9 (11.4, 32.4)	29.9 (14.8, 51.2)	0.0 -	0.0 -	4.0 (1.4, 11.1)	0.0 -	1.8 (1.2, 2.8)
<b>3+ methods with LARC/PM</b>										
Urban	41.0 (26.8, 56.8)	0.0 -	1.7 (0.2, 15.0)	31.8 (20.2, 46.2)	16.6 (10.7, 24.9)	1.4 (0.5, 4.2)	0.1 (0.0, 0.4)	1.5 (0.7, 2.8)	0.0 -	0.8 (0.5, 1.2)
Rural	26.1 (14.6, 42.4)	0.0 -	0.0 -	20.6 (12.2, 32.6)	30.8 (15.5, 51.7)	0.0 -	0.0 -	4.0 (1.4, 11.1)	0.0 -	1.9 (1.3, 2.8)
<b>5+ methods<sup>§</sup></b>										
Urban	36.3 (23.4, 51.5)	0.0 -	0.1 (0.0, 1.2)	27.9 (18.0, 40.4)	8.3 (4.6, 14.5)	7.9 (4.7, 12.9)	0.2 (0.1, 0.9)	1.4 (0.6, 3.1)	0.0 -	0.7 (0.5, 1.1)
Rural	22.7 (13.3, 36.0)	0.0 -	0.0 -	17.9 (10.0, 29.8)	13.3 (5.9, 27.3)	1.6 (0.2, 14.1)	0.2 (0.0, 1.5)	1.9 (0.7, 5.3)	0.0 -	1.3 (0.9, 1.9)
<p>* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.</p> <p>† The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview). The denominator includes 58 urban outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview) and 10 rural outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview).</p> <p>‡ 3 or more among: male condoms, female condoms, cyclebeads, oral contraceptives, emergency contraceptives, injectables, implants, IUDs commodities and/or male sterilizations, female sterilizations services. No other modern contraceptive methods were found in sampled outlets.</p> <p>§ 5 or more among: male condoms, female condoms, cyclebeads, oral contraceptives, emergency contraceptives, injectables, implants, IUDs commodities and/or male sterilizations, female sterilizations services. No other modern contraceptive methods were found in sampled outlets.</p>										

Source: FPwatch Outlet Survey, Nigeria, 2015

**Table C5: Current stock out\* of selected modern contraceptive commodities on day of survey, among outlets reportedly stocking method in previous 3 months, by outlet type – Urban/Rural, 2015**

	Public Health Facility	Community Health Workers	Private Not- For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer / Kiosk	Private Total†	Total
Proportion of outlets stocking method in previous 3 months, stocked out of‡:	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)
<b>Oral contraceptives</b>										
Urban	2.1 <sup>(70)</sup> (0.5, 8.2)	- -	0.0 <sup>(1)</sup> -	2.1 <sup>(71)</sup> (0.5, 8.2)	23.1 <sup>(70)</sup> (10.6, 43.2)	2.3 <sup>(173)</sup> (1.1, 4.9)	13.4 <sup>(1533)</sup> (9.5, 18.7)	6.3 <sup>(27)</sup> (1.4, 23.6)	12.6 <sup>(1803)</sup> (8.8, 17.6)	12.2 <sup>(1874)</sup> (8.5, 17.2)
Rural	15.6 <sup>(61)</sup> (4.8, 40.7)	93.7 <sup>(3)</sup> (46.8, 99.6)	0.0 <sup>(1)</sup> -	31.5 <sup>(65)</sup> (13.2, 58.2)	23.9 <sup>(23)</sup> (17.4, 31.9)	35.1 <sup>(12)</sup> (6.4, 81.2)	7.8 <sup>(333)</sup> (3.1, 18.1)	54.2 <sup>(5)</sup> (4.9, 96.4)	11.3 <sup>(373)</sup> (6.6, 18.6)	15.0 <sup>(438)</sup> (9.3, 23.3)
<b>Emergency contraceptives</b>										
Urban	100.0 <sup>(1)</sup> -	- -	- -	100.0 <sup>(1)</sup> -	33.2 <sup>(10)</sup> (12.4, 63.5)	4.2 <sup>(113)</sup> (1.4, 11.5)	28.3 <sup>(409)</sup> (13.6, 49.7)	29.2 <sup>(9)</sup> (4.9, 76.7)	22.1 <sup>(541)</sup> (11.1, 39.3)	22.2 <sup>(542)</sup> (11.1, 39.3)
Rural	0.0 <sup>(1)</sup> -	100.0 <sup>(1)</sup> -	- -	98.6 <sup>(2)</sup> (73.6, 99.9)	50.9 <sup>(4)</sup> (48.4, 53.4)	0.0 <sup>(10)</sup> -	31.1 <sup>(82)</sup> (18.2, 47.9)	0.0 <sup>(1)</sup> -	33.8 <sup>(97)</sup> (24.3, 44.9)	36.5 <sup>(99)</sup> (25.7, 48.8)
<b>Contraceptive injectables</b>										
Urban	3.2 <sup>(75)</sup> (1.3, 7.3)	100.0 <sup>(1)</sup> -	58.2 <sup>(3)</sup> (7.1, 96.2)	5.0 <sup>(79)</sup> (1.6, 14.8)	22.5 <sup>(92)</sup> (10.7, 41.4)	1.0 <sup>(120)</sup> (0.2, 4.7)	39.0 <sup>(279)</sup> (14.9, 70.0)	0.0 <sup>(1)</sup> -	27.2 <sup>(492)</sup> (11.5, 51.8)	24.5 <sup>(571)</sup> (10.6, 47.1)
Rural	11.3 <sup>(69)</sup> (3.4, 31.5)	31.0 <sup>(4)</sup> (2.9, 87.2)	0.0 <sup>(1)</sup> -	15.0 <sup>(74)</sup> (7.0, 29.3)	27.9 <sup>(25)</sup> (19.3, 38.6)	2.9 <sup>(9)</sup> (0.3, 25.9)	65.8 <sup>(109)</sup> (39.9, 84.7)	- -	50.9 <sup>(143)</sup> (32.8, 68.7)	35.6 <sup>(217)</sup> (22.7, 51.0)
<b>Implants</b>										
Urban	2.0 <sup>(43)</sup> (0.3, 12.5)	- -	0.0 <sup>(1)</sup> -	2.0 <sup>(44)</sup> (0.3, 12.5)	34.2 <sup>(40)</sup> (15.0, 60.4)	0.0 <sup>(1)</sup> -	88.5 <sup>(4)</sup> (33.6, 99.2)	- -	47.5 <sup>(45)</sup> (20.4, 76.1)	23.3 <sup>(89)</sup> (10.8, 43.3)
Rural	5.5 <sup>(21)</sup> (0.9, 26.8)	- -	- -	5.5 <sup>(21)</sup> (0.9, 26.8)	1.9 <sup>(7)</sup> (0.1, 21.1)	- -	- -	- -	1.9 <sup>(7)</sup> (0.1, 21.1)	3.7 <sup>(28)</sup> (0.8, 15.2)
<b>IUDs</b>										
Urban	0.0 <sup>(39)</sup> -	- -	0.0 <sup>(2)</sup> -	0.0 <sup>(41)</sup> -	30.0 <sup>(70)</sup> (24.5, 36.1)	19.8 <sup>(9)</sup> (3.5, 62.7)	44.6 <sup>(11)</sup> (15.7, 77.7)	- -	30.6 <sup>(90)</sup> (24.6, 37.4)	21.7 <sup>(131)</sup> (17.0, 27.2)
Rural	5.6 <sup>(15)</sup> (0.6, 36.3)	- -	- -	5.6 <sup>(15)</sup> (0.6, 36.3)	3.2 <sup>(11)</sup> (0.5, 18.3)	- -	- -	- -	3.2 <sup>(11)</sup> (0.5, 18.3)	4.4 <sup>(26)</sup> (0.9, 18.8)

\* This indicator is among all screened outlets. It does not account for whether the outlet is expected to provide the commodity according to national regulations. It is a point-in-time stock out indicator from [http://www.rhsupplies.org/fileadmin/uploads/rhsc/Issues/Addressing\\_Stockouts/Takestock/Documents/Using-the\\_Power\\_of\\_Partnership\\_to\\_Speak\\_the\\_same\\_Languageon\\_Stockouts.pdf](http://www.rhsupplies.org/fileadmin/uploads/rhsc/Issues/Addressing_Stockouts/Takestock/Documents/Using-the_Power_of_Partnership_to_Speak_the_same_Languageon_Stockouts.pdf). It is defined as the percentage of facilities reporting that they have stocked the method in the previous 3 months but were stocked out on the day of the assessment.

**Table C5: Current stock out\* of selected modern contraceptive commodities on day of survey, among outlets reportedly stocking method in previous 3 months, by outlet type – Urban/Rural, 2015**

	Public Health Facility	Community Health Workers	Private Not- For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer / Kiosk	Private Total†	Total
Proportion of outlets stocking method in previous 3 months, stocked out of‡:	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)	% (n) (95% CI)
<p>† In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>‡ The denominator includes 68 outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview). The denominator includes 58 urban outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview) and 10 rural outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview).</p>										
Source: FPwatch Outlet Survey, Nigeria, 2015										

**Table C6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – Urban/Rural, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>¶</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
<b>Male condoms</b>						
Urban	Naira	\$0.00 <sup>(57)</sup> [0.00-12.50]	\$12.50 <sup>(197)</sup> [12.50-116.67]	\$12.50 <sup>(1,872)</sup> [10.00-12.50]	\$12.50 <sup>(488)</sup> [12.50-12.50]	\$12.50 <sup>(2,614)</sup> [10.00-12.50]
	USD	\$0.00 <sup>(57)</sup> [0.00-0.06]	\$0.06 <sup>(197)</sup> [0.06-0.58]	\$0.06 <sup>(1,872)</sup> [0.05-0.06]	\$0.06 <sup>(488)</sup> [0.06-0.06]	\$0.06 <sup>(2,614)</sup> [0.05-0.06]
	USD per CYP	\$0.00 <sup>(57)</sup> [0.00-7.50]	\$7.50 <sup>(197)</sup> [7.50-70.00]	\$7.50 <sup>(1,872)</sup> [6.00-7.50]	\$7.50 <sup>(488)</sup> [7.50-7.50]	\$7.50 <sup>(2,614)</sup> [6.00-7.50]
Rural	Naira	\$12.50 <sup>(19)</sup> [0.00-12.50]	\$12.50 <sup>(15)</sup> [12.50-23.33]	\$12.50 <sup>(397)</sup> [10.00-12.50]	\$10.00 <sup>(38)</sup> [7.50-12.50]	\$12.50 <sup>(469)</sup> [10.00-12.50]
	USD	\$0.06 <sup>(19)</sup> [0.00-0.06]	\$0.06 <sup>(15)</sup> [0.06-0.12]	\$0.06 <sup>(397)</sup> [0.05-0.06]	\$0.05 <sup>(38)</sup> [0.04-0.06]	\$0.06 <sup>(469)</sup> [0.05-0.06]
	USD per CYP	\$7.50 <sup>(19)</sup> [0.00-7.50]	\$7.50 <sup>(15)</sup> [7.50-14.00]	\$7.50 <sup>(397)</sup> [6.00-7.50]	\$6.00 <sup>(38)</sup> [4.50-7.50]	\$7.50 <sup>(469)</sup> [6.00-7.50]
<b>Female condoms</b>						
Urban	Naira	\$0.00 <sup>(14)</sup> [0.00-0.00]	\$150.00 <sup>(26)</sup> [50.00-566.67]	\$60.00 <sup>(80)</sup> [50.00-125.00]	\$50.00 <sup>(6)</sup> [30.00-75.00]	\$60.00 <sup>(126)</sup> [30.00-150.00]
	USD	\$0.00 <sup>(14)</sup> [0.00-0.00]	\$0.75 <sup>(26)</sup> [0.25-2.83]	\$0.30 <sup>(80)</sup> [0.25-0.63]	\$0.25 <sup>(6)</sup> [0.15-0.38]	\$0.30 <sup>(126)</sup> [0.15-0.75]
	USD per CYP	\$0.00 <sup>(14)</sup> [0.00-0.00]	\$90.00 <sup>(26)</sup> [30.00-340.00]	\$36.00 <sup>(80)</sup> [30.00-75.00]	\$30.00 <sup>(6)</sup> [18.00-45.00]	\$36.00 <sup>(126)</sup> [18.00-90.00]
Rural	Naira	\$0.00 <sup>(5)</sup> [0.00-0.00]	\$50.00 <sup>(1)</sup> -	\$50.00 <sup>(17)</sup> [50.00-50.00]	\$20.00 <sup>(1)</sup>	\$20.00 <sup>(24)</sup> [0.00-50.00]
	USD	\$0.00 <sup>(5)</sup> [0.00-0.00]	\$0.25 <sup>(1)</sup> -	\$0.25 <sup>(17)</sup> [0.25-0.25]	\$0.10 <sup>(1)</sup>	\$0.10 <sup>(24)</sup> [0.00-0.25]
	USD per CYP	\$0.00 <sup>(5)</sup> [0.00-0.00]	\$30.00 <sup>(1)</sup> -	\$30.00 <sup>(17)</sup> [30.00-30.00]	\$12.00 <sup>(1)</sup>	\$12.00 <sup>(24)</sup> [0.00-30.00]
<b>CycleBeads</b>						
Urban	Naira	\$0.00 <sup>(2)</sup> [0.00-0.00]	\$150.00 <sup>(2)</sup> [150.00-150.00]	\$150.00 <sup>(24)</sup> [0.00-300.00]	- -	\$150.00 <sup>(28)</sup> [0.00-300.00]
	USD	\$0.00 <sup>(2)</sup> [0.00-0.00]	\$0.75 <sup>(2)</sup> [0.75-0.75]	\$0.75 <sup>(24)</sup> [0.00-1.50]	- -	\$0.75 <sup>(28)</sup> [0.00-1.50]
	USD per CYP	\$0.00 <sup>(2)</sup> [0.00-0.00]	\$0.50 <sup>(2)</sup> [0.50-0.50]	\$0.50 <sup>(24)</sup> [0.00-1.00]	- -	\$0.50 <sup>(28)</sup> [0.00-1.00]
Rural	Naira	\$0.00 <sup>(2)</sup> [0.00-0.00]	- -	\$50.00 <sup>(2)</sup> [50.00-50.00]	- -	\$50.00 <sup>(4)</sup> [0.00-50.00]
	USD	\$0.00 <sup>(2)</sup>	-	\$0.25 <sup>(2)</sup>	-	\$0.25 <sup>(4)</sup>



**Table C6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – Urban/Rural, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>¶</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
		[0.00-0.00]	-	[0.25-0.25]	-	[0.00-0.25]
	USD per CYP	\$0.00 <sup>(2)</sup> [0.00-0.00]	-	\$0.17 <sup>(2)</sup> [0.17-0.17]	-	\$0.17 <sup>(4)</sup> [0.00-0.17]
<b>Oral contraceptives</b>						
Urban	Naira	\$100.00 <sup>(61)</sup> [0.00-150.00]	\$100.00 <sup>(191)</sup> [50.00-100.00]	\$70.00 <sup>(1,356)</sup> [50.00-100.00]	\$80.00 <sup>(24)</sup> [70.00-80.00]	\$70.00 <sup>(1,632)</sup> [50.00-100.00]
	USD	\$0.50 <sup>(61)</sup> [0.00-0.75]	\$0.50 <sup>(191)</sup> [0.25-0.50]	\$0.35 <sup>(1,356)</sup> [0.25-0.50]	\$0.40 <sup>(24)</sup> [0.35-0.40]	\$0.35 <sup>(1,632)</sup> [0.25-0.50]
	USD per CYP	\$7.50 <sup>(61)</sup> [0.00-11.25]	\$7.50 <sup>(191)</sup> [3.75-7.50]	\$5.25 <sup>(1,356)</sup> [3.75-7.50]	\$6.00 <sup>(24)</sup> [5.25-6.00]	\$5.25 <sup>(1,632)</sup> [3.75-7.50]
Rural	Naira	\$100.00 <sup>(16)</sup> [70.00-100.00]	\$100.00 <sup>(11)</sup> [100.00-150.00]	\$80.00 <sup>(287)</sup> [50.00-100.00]	\$50.00 <sup>(4)</sup> [50.00-100.00]	\$100.00 <sup>(318)</sup> [50.00-100.00]
	USD	\$0.50 <sup>(16)</sup> [0.35-0.50]	\$0.50 <sup>(11)</sup> [0.50-0.75]	\$0.40 <sup>(287)</sup> [0.25-0.50]	\$0.25 <sup>(4)</sup> [0.25-0.50]	\$0.50 <sup>(318)</sup> [0.25-0.50]
	USD per CYP	\$7.50 <sup>(16)</sup> [5.25-7.50]	\$7.50 <sup>(11)</sup> [7.50-11.25]	\$6.00 <sup>(287)</sup> [3.75-7.50]	\$3.75 <sup>(4)</sup> [3.75-7.50]	\$7.50 <sup>(318)</sup> [3.75-7.50]
<b>Combined oral contraceptives</b>						
Urban	Naira	\$100.00 <sup>(55)</sup> [50.00-200.00]	\$100.00 <sup>(190)</sup> [50.00-100.00]	\$70.00 <sup>(1,347)</sup> [50.00-100.00]	\$80.00 <sup>(24)</sup> [70.00-80.00]	\$70.00 <sup>(1,616)</sup> [50.00-100.00]
	USD	\$0.50 <sup>(55)</sup> [0.25-1.00]	\$0.50 <sup>(190)</sup> [0.25-0.50]	\$0.35 <sup>(1,347)</sup> [0.25-0.50]	\$0.40 <sup>(24)</sup> [0.35-0.40]	\$0.35 <sup>(1,616)</sup> [0.25-0.50]
	USD per CYP	\$7.50 <sup>(55)</sup> [3.75-15.00]	\$7.50 <sup>(190)</sup> [3.75-7.50]	\$5.25 <sup>(1,347)</sup> [3.75-7.50]	\$6.00 <sup>(24)</sup> [5.25-6.00]	\$5.25 <sup>(1,616)</sup> [3.75-7.50]
Rural	Naira	\$100.00 <sup>(15)</sup> [70.00-100.00]	\$100.00 <sup>(11)</sup> [100.00-150.00]	\$80.00 <sup>(284)</sup> [50.00-100.00]	\$50.00 <sup>(4)</sup> [50.00-100.00]	\$100.00 <sup>(314)</sup> [50.00-100.00]
	USD	\$0.50 <sup>(15)</sup> [0.35-0.50]	\$0.50 <sup>(11)</sup> [0.50-0.75]	\$0.40 <sup>(284)</sup> [0.25-0.50]	\$0.25 <sup>(4)</sup> [0.25-0.50]	\$0.50 <sup>(314)</sup> [0.25-0.50]
	USD per CYP	\$7.50 <sup>(15)</sup> [5.25-7.50]	\$7.50 <sup>(11)</sup> [7.50-11.25]	\$6.00 <sup>(284)</sup> [3.75-7.50]	\$3.75 <sup>(4)</sup> [3.75-7.50]	\$7.50 <sup>(314)</sup> [3.75-7.50]
<b>Progestin-only pills</b>						
Urban	Naira	\$0.00 <sup>(6)</sup> [0.00-100.00]	\$100.00 <sup>(1)</sup> -	\$100.00 <sup>(9)</sup> [100.00-100.00]	-	\$100.00 <sup>(16)</sup> [100.00-100.00]
	USD	\$0.00 <sup>(6)</sup> [0.00-0.50]	\$0.50 <sup>(1)</sup> -	\$0.50 <sup>(9)</sup> [0.50-0.50]	-	\$0.50 <sup>(16)</sup> [0.50-0.50]
	USD per CYP	\$0.00 <sup>(6)</sup>	\$7.50 <sup>(1)</sup>	\$7.50 <sup>(9)</sup>	-	\$7.50 <sup>(16)</sup>

**Table C6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP\*\*, by private outlet type – Urban/Rural, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>§</sup>
Median price of method, with interquartile range <sup>∞</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
Rural		[0.00-7.50]	-	[7.50-7.50]	-	[7.50-7.50]
	Naira	\$0.00 <sup>(1)</sup> -	- -	\$70.00 <sup>(3)</sup> [50.00-70.00]	- -	\$70.00 <sup>(4)</sup> [50.00-70.00]
	USD	\$0.00 <sup>(1)</sup> -	- -	\$0.35 <sup>(3)</sup> [0.25-0.35]	- -	\$0.35 <sup>(4)</sup> [0.25-0.35]
	USD per CYP	\$0.00 <sup>(1)</sup> -	- -	\$5.25 <sup>(3)</sup> [3.75-5.25]	- -	\$5.25 <sup>(4)</sup> [3.75-5.25]
<b>Emergency contraceptives</b>						
Urban	Naira	\$300.00 <sup>(6)</sup> [200.00-300.00]	\$300.00 <sup>(177)</sup> [50.00-300.00]	\$250.00 <sup>(381)</sup> [60.00-300.00]	\$200.00 <sup>(7)</sup> [200.00-200.00]	\$250.00 <sup>(571)</sup> [60.00-300.00]
	USD	\$1.50 <sup>(6)</sup> [1.00-1.50]	\$1.50 <sup>(177)</sup> [0.25-1.50]	\$1.25 <sup>(381)</sup> [0.30-1.50]	\$1.00 <sup>(7)</sup> [1.00-1.00]	\$1.25 <sup>(571)</sup> [0.30-1.50]
	USD per CYP	\$30.00 <sup>(6)</sup> [20.00-30.00]	\$30.00 <sup>(177)</sup> [5.00-30.00]	\$25.00 <sup>(381)</sup> [6.00-30.00]	\$20.00 <sup>(7)</sup> [20.00-20.00]	\$25.00 <sup>(571)</sup> [6.00-30.00]
Rural	Naira	\$0.00 <sup>(1)</sup> -	\$150.00 <sup>(14)</sup> [50.00-250.00]	\$150.00 <sup>(67)</sup> [40.00-200.00]	\$300.00 <sup>(1)</sup> -	\$150.00 <sup>(83)</sup> [40.00-200.00]
	USD	\$0.00 <sup>(1)</sup> -	\$0.75 <sup>(14)</sup> [0.25-1.25]	\$0.75 <sup>(67)</sup> [0.20-1.00]	\$1.50 <sup>(1)</sup> -	\$0.75 <sup>(83)</sup> [0.20-1.00]
	USD per CYP	\$0.00 <sup>(1)</sup> -	\$15.00 <sup>(14)</sup> [5.00-25.00]	\$15.00 <sup>(67)</sup> [4.00-20.00]	\$30.00 <sup>(1)</sup> -	\$15.00 <sup>(83)</sup> [4.00-20.00]
<b>Contraceptive injectables<sup>†</sup></b>						
Urban	Naira	\$500.00 <sup>(115)</sup> [300.00-500.00]	\$200.00 <sup>(203)</sup> [140.00-300.00]	\$300.00 <sup>(292)</sup> [150.00-400.00]	\$500.00 <sup>(1)</sup>	\$250.00 <sup>(611)</sup> [150.00-400.00]
	USD	\$2.50 <sup>(115)</sup> [1.50-2.50]	\$1.00 <sup>(203)</sup> [0.70-1.50]	\$1.50 <sup>(292)</sup> [0.75-2.00]	\$2.50 <sup>(1)</sup> -	\$1.25 <sup>(611)</sup> [0.75-2.00]
	USD per CYP	\$10.00 <sup>(115)</sup> [6.00-15.00]	\$4.50 <sup>(203)</sup> [3.60-6.00]	\$7.50 <sup>(292)</sup> [4.00-10.00]	\$15.00 <sup>(1)</sup> -	\$6.00 <sup>(611)</sup> [4.00-10.00]
Rural	Naira	\$500.00 <sup>(115)</sup> [300.00-500.00]	\$200.00 <sup>(203)</sup> [140.00-300.00]	\$300.00 <sup>(292)</sup> [150.00-400.00]	\$500.00 <sup>(1)</sup> -	\$250.00 <sup>(611)</sup> [150.00-400.00]
	USD	\$2.50 <sup>(115)</sup> [1.50-2.50]	\$1.00 <sup>(203)</sup> [0.70-1.50]	\$1.50 <sup>(292)</sup> [0.75-2.00]	\$2.50 <sup>(1)</sup> -	\$1.25 <sup>(611)</sup> [0.75-2.00]
	USD per CYP	\$10.00 <sup>(115)</sup> [6.00-15.00]	\$4.50 <sup>(203)</sup> [3.60-6.00]	\$7.50 <sup>(292)</sup> [4.00-10.00]	\$15.00 <sup>(1)</sup> -	\$6.00 <sup>(611)</sup> [4.00-10.00]
<b>Depo-provera injectables</b>						
Urban	Naira	\$500.00 <sup>(64)</sup> [300.00-500.00]	\$200.00 <sup>(107)</sup> [140.00-300.00]	\$400.00 <sup>(146)</sup> [200.00-500.00]	- -	\$300.00 <sup>(317)</sup> [150.00-500.00]

**Table C6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – Urban/Rural, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range∞		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
	USD	\$2.50 <sup>(64)</sup> [1.50-2.50]	\$1.00 <sup>(107)</sup> [0.70-1.50]	\$2.00 <sup>(146)</sup> [1.00-2.50]	- -	\$1.50 <sup>(317)</sup> [0.75-2.50]
	USD per CYP	\$10.00 <sup>(64)</sup> [6.00-10.00]	\$4.00 <sup>(107)</sup> [2.80-6.00]	\$8.00 <sup>(146)</sup> [4.00-10.00]	- -	\$6.00 <sup>(317)</sup> [3.00-10.00]
Rural	Naira	\$500.00 <sup>(13)</sup> [400.00-500.00]	\$150.00 <sup>(7)</sup> [150.00-200.00]	\$200.00 <sup>(54)</sup> [150.00-250.00]	- -	\$300.00 <sup>(74)</sup> [170.00-500.00]
	USD	\$2.50 <sup>(13)</sup> [2.00-2.50]	\$0.75 <sup>(7)</sup> [0.75-1.00]	\$1.00 <sup>(54)</sup> [0.75-1.25]	- -	\$1.50 <sup>(74)</sup> [0.85-2.50]
	USD per CYP	\$10.00 <sup>(13)</sup> [8.00-10.00]	\$3.00 <sup>(7)</sup> [3.00-4.00]	\$4.00 <sup>(54)</sup> [3.00-5.00]	- -	\$6.00 <sup>(74)</sup> [3.40-10.00]
<i>Noristerat injectables</i>						
Urban	Naira	\$500.00 <sup>(51)</sup> [250.00-700.00]	\$200.00 <sup>(96)</sup> [150.00-400.00]	\$250.00 <sup>(146)</sup> [150.00-400.00]	\$500.00 <sup>(1)</sup> -	\$250.00 <sup>(294)</sup> [150.00-400.00]
	USD	\$2.50 <sup>(51)</sup> [1.25-3.50]	\$1.00 <sup>(96)</sup> [0.75-2.00]	\$1.25 <sup>(146)</sup> [0.75-2.00]	\$2.50 <sup>(1)</sup> -	\$1.25 <sup>(294)</sup> [0.75-2.00]
	USD per CYP	\$15.00 <sup>(51)</sup> [7.50-21.00]	\$6.00 <sup>(96)</sup> [4.50-12.00]	\$7.50 <sup>(146)</sup> [4.50-12.00]	\$15.00 <sup>(1)</sup> -	\$7.50 <sup>(294)</sup> [4.50-12.00]
Rural	Naira	\$500.00 <sup>(9)</sup> [500.00-2000.00]	\$150.00 <sup>(7)</sup> [150.00-200.00]	\$150.00 <sup>(47)</sup> [150.00-200.00]	- -	\$350.00 <sup>(63)</sup> [200.00-500.00]
	USD	\$2.50 <sup>(9)</sup> [2.50-10.00]	\$0.75 <sup>(7)</sup> [0.75-1.00]	\$0.75 <sup>(47)</sup> [0.75-1.00]	- -	\$1.75 <sup>(63)</sup> [1.00-2.50]
	USD per CYP	\$15.00 <sup>(9)</sup> [15.00-60.00]	\$4.50 <sup>(7)</sup> [4.50-6.00]	\$4.50 <sup>(47)</sup> [4.50-6.00]	- -	\$10.50 <sup>(63)</sup> [6.00-15.00]
<i>Implants†</i>						
Urban	Naira	\$1500.00 <sup>(31)</sup> [1000.00-5000.00]	\$1200.00 <sup>(1)</sup> -	\$500.00 <sup>(3)</sup> [500.00-500.00]	- -	\$1500.00 <sup>(35)</sup> [1000.00-1500.00]
	USD	\$7.50 <sup>(31)</sup> [5.00-25.00]	\$6.00 <sup>(1)</sup> -	\$2.50 <sup>(3)</sup> [2.50-2.50]	- -	\$7.50 <sup>(35)</sup> [5.00-7.50]
	USD per CYP	\$1.97 <sup>(31)</sup> [1.32-6.58]	\$1.58 <sup>(1)</sup> -	\$0.83 <sup>(3)</sup> [0.66-1.00]	- -	\$1.97 <sup>(35)</sup> [1.32-3.00]
Rural	Naira	\$1500.00 <sup>(11)</sup> [1000.00-2000.00]	- -	- -	- -	\$1500.00 <sup>(11)</sup> [1000.00-2000.00]
	USD	\$7.50 <sup>(11)</sup> [5.00-10.00]	- -	- -	- -	\$7.50 <sup>(11)</sup> [5.00-10.00]
	USD per CYP	\$2.00 <sup>(11)</sup> [1.97-2.63]	- -	- -	- -	\$2.00 <sup>(11)</sup> [1.97-2.63]

**Table C6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – Urban/Rural, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range∞		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
<i>Implanon implants</i>						
Urban	Naira	\$1600.00 <sup>(9)</sup> [1500.00-5000.00]	- -	\$500.00 <sup>(1)</sup>	- -	\$1500.00 <sup>(10)</sup> [500.00-5000.00]
	USD	\$8.00 <sup>(9)</sup> [7.50-25.00]	- -	\$2.50 <sup>(1)</sup> -	- -	\$7.50 <sup>(10)</sup> [2.50-25.00]
	USD per CYP	\$3.20 <sup>(9)</sup> [3.00-10.00]	- -	\$1.00 <sup>(1)</sup> -	- -	\$3.00 <sup>(10)</sup> [1.00-10.00]
Rural	Naira	\$1000.00 <sup>(5)</sup> [1000.00-2000.00]	- -	- -	- -	\$1000.00 <sup>(5)</sup> [1000.00-2000.00]
	USD	\$5.00 <sup>(5)</sup> [5.00-10.00]	- -	- -	- -	\$5.00 <sup>(5)</sup> [5.00-10.00]
	USD per CYP	\$2.00 <sup>(5)</sup> [2.00-4.00]	- -	- -	- -	\$2.00 <sup>(5)</sup> [2.00-4.00]
<i>Jadelle implants</i>						
Urban	Naira	\$1500.00 <sup>(22)</sup> [1000.00-2000.00]	\$1200.00 <sup>(1)</sup> -	\$500.00 <sup>(2)</sup> [500.00-500.00]	- -	\$1200.00 <sup>(25)</sup> [1000.00-1500.00]
	USD	\$7.50 <sup>(22)</sup> [5.00-10.00]	\$6.00 <sup>(1)</sup> -	\$2.50 <sup>(2)</sup> [2.50-2.50]	- -	\$6.00 <sup>(25)</sup> [5.00-7.50]
	USD per CYP	\$1.97 <sup>(22)</sup> [1.32-2.63]	\$1.58 <sup>(1)</sup> -	\$0.66 <sup>(2)</sup> [0.66-0.66]	- -	\$1.58 <sup>(25)</sup> [1.32-1.97]
Rural	Naira	\$1500.00 <sup>(6)</sup> [1500.00-2000.00]	- -	- -	- -	\$1500.00 <sup>(6)</sup> [1500.00-2000.00]
	USD	\$7.50 <sup>(6)</sup> [7.50-10.00]	- -	- -	- -	\$7.50 <sup>(6)</sup> [7.50-10.00]
	USD per CYP	\$1.97 <sup>(6)</sup> [1.97-2.63]	- -	- -	- -	\$1.97 <sup>(6)</sup> [1.97-2.63]
<i>IUDs†</i>						
Urban	Naira	\$500.00 <sup>(54)</sup> [500.00-2000.00]	\$250.00 <sup>(9)</sup> [250.00-250.00]	\$160.00 <sup>(8)</sup> [150.00-200.00]	- -	\$500.00 <sup>(71)</sup> [500.00-2000.00]
	USD	\$2.50 <sup>(54)</sup> [2.50-10.00]	\$1.25 <sup>(9)</sup> [1.25-1.25]	\$0.80 <sup>(8)</sup> [0.75-1.00]	- -	\$2.50 <sup>(71)</sup> [2.50-10.00]
	USD per CYP	\$0.54 <sup>(54)</sup> [0.54-2.17]	\$0.27 <sup>(9)</sup> [0.27-0.27]	\$0.17 <sup>(8)</sup> [0.16-0.22]	- -	\$0.54 <sup>(71)</sup> [0.54-2.17]
Rural	Naira	\$1000.00 <sup>(8)</sup> [1000.00-1500.00]	- -	- -	- -	\$1000.00 <sup>(8)</sup> [1000.00-1500.00]
	USD	\$5.00 <sup>(8)</sup>	-	-	-	\$5.00 <sup>(8)</sup>

**Table C6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – Urban/Rural, 2015**

		Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range <sup>¶</sup>		Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
		[5.00-7.50]	-	-	-	[5.00-7.50]
	USD per CYP	\$1.09 <sup>(8)</sup> [1.09-1.63]	-	-	-	\$1.09 <sup>(8)</sup> [1.09-1.63]
<b>Male Sterilization</b>						
Urban	Naira	\$42000.00 <sup>(4)</sup> [42000.00-42000.00]	-	-	-	\$42000.00 <sup>(4)</sup> [42000.00-42000.00]
	USD	\$210.00 <sup>(4)</sup> [210.00-210.00]	-	-	-	\$210.00 <sup>(4)</sup> [210.00-210.00]
	USD per CYP	\$22.58 <sup>(4)</sup> [22.58-22.58]	-	-	-	\$22.58 <sup>(4)</sup> [22.58-22.58]
Rural	Naira	-	-	-	-	-
	USD	-	-	-	-	-
	USD per CYP	-	-	-	-	-
<b>Female Sterilization</b>						
Urban	Naira	\$42000.00 <sup>(20)</sup> [20000.00-60000.00]	-	-	-	\$42000.00 <sup>(20)</sup> [20000.00-60000.00]
	USD	\$210.00 <sup>(20)</sup> [100.00-300.00]	-	-	-	\$210.00 <sup>(20)</sup> [100.00-300.00]
	USD per CYP	\$22.58 <sup>(20)</sup> [10.75-32.26]	-	-	-	\$22.58 <sup>(20)</sup> [10.75-32.26]
Rural	Naira	\$15000.00 <sup>(1)</sup> -	-	-	-	\$15000.00 <sup>(1)</sup> -
	USD	\$75.00 <sup>(1)</sup> -	-	-	-	\$75.00 <sup>(1)</sup> -
	USD per CYP	\$8.06 <sup>(1)</sup> -	-	-	-	\$8.06 <sup>(1)</sup> -

**Table C6: Median price of selected modern contraceptive methods in Nigerian Naira, USD\*, and USD per CYP†‡, by private outlet type – Urban/Rural, 2015**

	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total§
Median price of method, with interquartile range∞	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]	Median <sup>(N)</sup> [IQR]
<p>* Based on the average rate of exchange from August 10 to October 23, 2015 of 500 Naira per 1 USD.</p> <p>† This price is determined for the unit used in CYP conversion factors: condoms: 1 condom; oral contraceptives: 1 cycle or blister package; emergency contraceptives: 1 dose; injectables: 1 dose/injection; implants: 1 implant insertion (1 or 2 rods); IUDs: 1 IUD.</p> <p>‡ CYP – Couple Year Protection is the estimated protection provided by contraceptive methods during a one-year period, based upon the volume of all contraceptives sold or distributed free of charge to clients during that period (see Annex 11).</p> <p>§ In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>∞ In urban areas, the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 444 oral contraceptives, 181 emergency contraceptives, 197 injections, 29 implants and 43 IUDs. In urban areas, the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 86 oral contraceptives, 29 emergency contraceptives, 31 injections, 5 implants and 4 IUDs.</p> <p>    Price for all commodities with a provider-dependent service (injectables, implants, IUDs) may include service charge.</p>					
Source: FPwatch Outlet Survey, Nigeria, 2015					

**Table C7: Median markup percentage for selected modern contraceptive commodities with interquartile range, by private outlet type – Urban/Rural, 2015**

	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total*
Median markup percentage <sup>†</sup> of commodity, with interquartile range <sup>‡,§,∞</sup> :	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]
<b>Oral contraceptives</b>					
Urban	150% <sup>(21)</sup> (0%, 200%)	90% <sup>(93)</sup> (40%, 130%)	80% <sup>(1,057)</sup> (70%, 140%)	200% <sup>(17)</sup> (90%, 400%)	90% <sup>(1,188)</sup> (70%, 140%)
Rural	100% <sup>(7)</sup> (100%, 100%)	230% <sup>(6)</sup> (100%, 260%)	70% <sup>(215)</sup> (40%, 190%)	100 <sup>(4)</sup> (90%, 120%)	70% <sup>(232)</sup> (40%, 180%)
<b>Emergency contraceptives</b>					
Urban	100% <sup>(3)</sup> (100%, 100%)	50% <sup>(78)</sup> (30%, 100%)	70% <sup>(303)</sup> (50%, 110%)	30% <sup>(6)</sup> (30%, 120%)	70% <sup>(390)</sup> (40%, 100%)
Rural	- -	110% <sup>(6)</sup> (10%, 150%)	70% <sup>(48)</sup> (40%, 70%)	- -	70% <sup>(54)</sup> (30%, 70%)
<b>Contraceptive injectables</b>					
Urban	200% <sup>(66)</sup> (70%, 280%)	100% <sup>(78)</sup> (50%, 150%)	110% <sup>(244)</sup> (70%, 150%)	280% <sup>(1)</sup> (280%, 280%)	110% <sup>(414)</sup> (70%, 190%)
Rural	150% <sup>(14)</sup> (150%, 150%)	80% <sup>(10)</sup> (70%, 150%)	70% <sup>(82)</sup> (50%, 120%)	- -	150% <sup>(106)</sup> (70%, 150%)
<b>Implants</b>					
Urban	50% <sup>(6)</sup> (50%, 50%)	- -	- -	- -	50% <sup>(6)</sup> (50%, 50%)
Rural	150% <sup>(6)</sup> (100%, 150%)	- -	- -	- -	150% <sup>(6)</sup> (100%, 150%)
<b>IUDs</b>					
Urban	170% <sup>(18)</sup> (100%, 1,230%)	50% <sup>(4)</sup> (50%, 50%)	20% <sup>(6)</sup> (10%, 20%)	- -	110% <sup>(28)</sup> (30%, 250%)
Rural	3,900% <sup>(4)</sup> (400%, 3,900)	- -	- -	- -	3,900% <sup>(4)</sup> (400%, 3,900)
<p>* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies, PPMVs and General Retailer/Kiosks.</p> <p>† To determine median markup percentage, we first determined the profit margin for selected modern contraceptives at private sector outlet categories: retail price – wholesale price. We then determined a profit margin proportion by: profit margin/retail price. Finally, we converted profit margin to markup by: wholesale price/(1- profit margin proportion). We converted to a percentage and determined the median markup with IQR range. Using oral contraceptives sold in private health facilities as an example, this can be interpreted as private health facilities adding 50% to the wholesale costs to set the retail cost.</p> <p>‡ In urban areas, the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 444 oral contraceptives, 181 emergency contraceptives, 197 injections, 29 implants and 43 IUDs. In urban areas, the number of family planning products captured in audit sheets with missing retail and/or wholesale price information are as follows: 86 oral contraceptives, 29 emergency contraceptives, 31 injections, 5 implants and 4 IUDs.</p> <p>§ This price is determined for the unit CYP conversion factors: condoms: 1 condom; oral contraceptives: 1 cycle or blister package; emergency contraceptives: 1 does; injectables: 1 dose/injection; implants: 1 implant insertion (1 or 2 rods); IUDs: 1 IUD.</p> <p>∞ Price for all commodities with a provider-dependent service (injectables, implants, IUDs) may include service charge.</p>					

**Table C7: Median markup percentage for selected modern contraceptive commodities with interquartile range, by private outlet type – Urban/Rural, 2015**

	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total*
Median markup percentage <sup>†</sup> of commodity, with interquartile range <sup>‡,§,∞</sup> :	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]	Median % <sup>(N)</sup> [IQR %]

Source: FPwatch Outlet Survey, Nigeria, 2015



**Table C8: Contraceptive method market share: Relative proportion of total CYP sold/distributed, by method and outlet type – Urban/Rural, 2015**

CYPs sold or distributed in previous 1 month by outlet type and contraceptive method type as a % of total CYPs sold / distributed <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>	TOTAL <sup>§</sup>
	%	%	%	%	%	%	%	%	%	%
<b>1. Male condoms</b>										
Urban	0.8	0.0	0.0	0.9	0.6	3.5	27.4	3.6	35.1	36.0
Rural	4.7	0.0	0.0	4.7	0.8	0.3	12.1	1.3	14.5	19.2
<b>2. Female condoms</b>										
Urban	0.2	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.3
Rural	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2
<b>3. Cyclebeads</b>										
Urban	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.3	0.4
Rural	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1
<b>4. Oral contraceptives</b>										
Urban	0.7	0.0	0.0	0.7	0.1	1.1	7.1	0.1	8.4	9.1
Rural	0.9	0.0	0.0	0.9	0.7	0.0	4.4	0.0	5.1	6.0
<i>Combined oral contraceptives</i>										
Urban	0.4	0.0	0.0	0.4	0.1	1.1	7.1	0.1	8.3	8.7
Rural	0.6	0.0	0.0	0.6	0.7	0.0	4.3	0.0	5.1	5.7
<i>Progestin-only pills</i>										
Urban	0.3	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.4
Rural	0.3	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.3
<b>5. Emergency contraceptives</b>										
Urban	0.0	0.0	0.0	0.0	0.0	2.1	1.8	0.0	3.9	3.9
Rural	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	2.2	2.2
<b>6. Contraceptive injectables</b>										
Urban	4.1	0.0	0.0	4.1	0.8	2.1	3.8	0.0	6.7	10.8
Rural	4.8	0.1	0.0	4.9	1.3	0.2	2.0	0.0	3.6	8.5
<i>Depo-provera injectables</i>										
Urban	3.0	0.0	0.0	3.0	0.6	1.2	2.3	0.0	4.0	7.0
Rural	3.3	0.0	0.0	3.3	0.7	0.0	1.2	0.0	2.0	5.3
<i>Noristerat injectables</i>										
Urban	1.1	0.0	0.0	1.1	0.2	0.9	1.5	0.0	2.7	3.8
Rural	1.5	0.1	0.0	1.6	0.6	0.1	0.8	0.0	1.5	3.2
<i>Sayana Press injectables</i>										
Urban	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1
Rural	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1
<b>7. Implants</b>										
Urban	27.0	0.0	0.0	27.1	1.6	0.0	0.1	0.0	1.6	28.7

**Table C8: Contraceptive method market share: Relative proportion of total CYP sold/distributed, by method and outlet type – Urban/Rural, 2015**

CYPs sold or distributed in previous 1 month by outlet type and contraceptive method type as a % of total CYPs sold / distributed <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>	TOTAL <sup>§</sup>
	%	%	%	%	%	%	%	%	%	%
Rural	9.5	0.0	0.0	9.5	37.2	0.0	0.0	0.0	37.2	46.7
<i>Implanon implants</i>										
Urban	12.3	0.0	0.0	12.3	0.2	0.0	0.1	0.0	0.3	12.7
Rural	2.6	0.0	0.0	2.6	22.9	0.0	0.0	0.0	22.9	25.5
<i>Jadelle implants</i>										
Urban	14.7	0.0	0.0	14.7	1.3	0.0	0.0	0.0	1.3	16.0
Rural	6.9	0.0	0.0	6.9	14.3	0.0	0.0	0.0	14.3	21.2
<b>8. IUDs</b>										
Urban	1.9	0.0	0.1	2.0	6.8	0.1	0.7	0.0	7.6	9.6
Rural	2.8	0.0	0.0	2.8	14.1	0.0	0.0	0.0	14.1	16.9
<b>9. Male sterilization</b>										
Urban	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Rural	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1
<b>10. Female sterilization</b>										
Urban	0.5	0.0	0.0	0.5	0.8	0.0	0.0	0.0	0.8	1.3
Rural	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1
<b>OUTLET TYPE TOTAL<sup>§</sup></b>										
Urban	35.3	0.0	0.1	35.4	11.1	8.9	41.0	3.6	64.6	100.0
Rural	22.9	0.1	0.0	23.1	54.4	0.5	20.6	1.3	76.9	100.0

\* A total 734,541 and 229,511 CYP (weighted) were reportedly distributed in the previous 1 month in rural and urban areas, respectively. This is based on the number of commodities reportedly sold for categories 1-8 (not number of services performed for categories 6-8) and number of sterilizations reportedly performed for categories 9-10. See Annex 11 for a description of CYP calculation and Annex 12 for CYP numbers by outlet type and method category.

† The total number of FP products audited (oral contraceptive, injection and insertion products) in rural and urban areas were 886 and 3,449 respectively. A total of 2 injection products and 4 tablet products were excluded from market share analysis due to inconsistent or missing generic names, 56 emergency contraceptive products (6 rural & 50 urban), 129 oral contraceptives (12 rural & 117 urban), 205 male condoms (27 rural & 178 urban), 17 female condoms (1 rural & 16 urban) and 10 cyclebeads (5 rural & 5 urban), were excluded from market share analysis for missing volume information. 2 male sterilizations and 4 female sterilizations were excluded for missing volume information as well. A total of 179 products were excluded due to outlier volumes and prices (7 rural & 172 urban).

‡ In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs.

§ Row total equals CYP volume for the specified contraceptive method type. Column total equals market share for the specified outlet type method categories 1-10.

∞ Internationally quality-assured (IQA) contraceptives are defined as those with WHO Pre-qualification or those on a Stringent Regulatory authority (SRA) list. See Annex 8 for a list of all quality-assured brands found in the survey.

Source: FPwatch Outlet Survey, Nigeria, 2015

**Table C9: Contraceptive method market share within outlet type: Relative proportion of total CYP sold / distributed within outlet type, by method – Urban/Rural, 2015**

CYPs sold or distributed in previous 1-month contraceptive method type as a % of total CYPs sold / distributed within outlet type <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>
	%	%	%	%	%	%	%	%	%
<b>1. Male condoms</b>									
Urban	2.4	100.0	1.6	2.4	5.6	39.5	66.8	98.3	54.3
Rural	20.7	0.0	0.0	20.5	1.5	58.0	58.4	98.9	18.8
<b>2. Female condoms</b>									
Urban	0.4	0.0	0.0	0.4	0.1	0.0	0.2	0.0	0.2
Rural	0.9	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0
<b>3. Cyclebeads</b>									
Urban	0.0	0.0	0.0	0.0	2.3	0.0	0.2	0.0	0.5
Rural	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0
<b>4. Oral contraceptives</b>									
Urban	2.0	0.0	0.5	2.0	1.0	12.1	17.3	1.4	12.9
Rural	3.9	0.0	7.6	3.9	1.4	4.6	21.2	0.9	6.7
<i>Combined oral contraceptives</i>									
Urban	1.1	0.0	0.1	1.1	1.0	12.1	17.3	1.4	12.9
Rural	2.5	0.0	0.0	2.4	1.4	4.6	21.1	0.9	6.7
<i>Progestin-only pills</i>									
Urban	1.0	0.0	0.4	1.0	0.0	0.0	0.1	0.0	0.0
Rural	1.4	0.0	7.6	1.4	0.0	0.0	0.1	0.0	0.0
<b>5. Emergency contraceptives</b>									
Urban	0.0	0.0	0.0	0.0	0.0	23.1	4.4	0.3	6.0
Rural	0.0	0.0	0.0	0.0	0.0	5.9	10.5	0.2	2.9
<b>6. Contraceptive injectables</b>									
Urban	11.6	0.0	9.0	11.5	7.5	23.7	9.2	0.0	10.4
Rural	20.9	100.0	92.4	21.3	2.5	31.5	9.9	0.0	4.6
<i>Depo-provera injectables</i>									
Urban	8.5	0.0	5.1	8.5	5.3	13.1	5.5	0.0	6.2
Rural	14.2	6.6	66.9	14.2	1.3	7.2	6.0	0.0	2.6
<i>Noristerat injectables</i>									
Urban	3.1	0.0	3.9	3.1	2.2	10.5	3.7	0.0	4.2
Rural	6.6	93.4	25.5	7.1	1.1	24.3	3.9	0.0	2.0
<i>Sayana Press injectables</i>									
Urban	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.0	0.1
Rural	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1
<b>7. Implants</b>									

**Table C9: Contraceptive method market share within outlet type: Relative proportion of total CYP sold / distributed within outlet type, by method – Urban/Rural, 2015**

CYPs sold or distributed in previous 1-month contraceptive method type as a % of total CYPs sold / distributed within outlet type <sup>*,†</sup> :	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total <sup>‡</sup>
	%	%	%	%	%	%	%	%	%
Urban	76.7	0.0	16.1	76.5	14.2	0.0	0.2	0.0	2.5
Rural	41.4	0.0	0.0	41.2	68.3	0.0	0.0	0.0	48.4
<i>Implanon implants</i>									
Urban	35.0	0.0	7.8	34.9	2.1	0.0	0.2	0.0	0.5
Rural	11.4	0.0	0.0	11.3	42.0	0.0	0.0	0.0	29.8
<i>Jadelle implants</i>									
Urban	41.7	0.0	8.3	41.6	12.1	0.0	0.0	0.0	2.1
Rural	30.0	0.0	0.0	29.9	26.3	0.0	0.0	0.0	18.6
<b>8. IUDs</b>									
Urban	5.5	0.0	72.8	5.7	61.7	1.6	1.6	0.0	11.8
Rural	12.1	0.0	0.0	12.0	26.0	0.0	0.0	0.0	18.4
<b>9. Male sterilization</b>									
Urban	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1
Rural	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1
<b>10. Female sterilization</b>									
Urban	1.4	0.0	0.0	1.4	7.2	0.0	0.0	0.0	1.2
Rural	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1

\* A total 734,541 and 229,511 CYP (weighted) were reportedly distributed in the previous 1 month in rural and urban areas, respectively. This is based on the number of commodities reportedly sold for categories 1-8 (not number of services performed for categories 6-8) and number of sterilizations reportedly performed for categories 9-10. See Annex 11 for a description of CYP calculation and Annex 12 for CYP numbers by outlet type and method category.

† The total number of FP products audited (oral contraceptive, injection and insertion products) in rural and urban areas were 886 and 3,449 respectively. A total of 2 injection products and 4 tablet products were excluded from market share analysis due to inconsistent or missing generic names, 56 emergency contraceptive products (6 rural & 50 urban), 129 oral contraceptives (12 rural & 117 urban), 205 male condoms (27 rural & 178 urban), 17 female condoms (1 rural & 16 urban) and 10 CycleBeads (5 rural & 5 urban), were excluded from market share analysis for missing volume information. 2 male sterilizations and 4 female sterilizations were excluded for missing volume information as well. A total of 179 products were excluded due to outlier volumes and prices (7 rural & 172 urban).

‡ In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs.

§ Internationally quality-assured (IQA) contraceptives are defined as those with WHO Pre-qualification or those on a Stringent Regulatory authority (SRA) list. See Annex 8 for a list of all quality-assured brands found in the survey. Categories 1 through 10 sum to 100% within each column.

Source: FPwatch Outlet Survey, Nigeria, 2015

**Table C10: Availability of selected contraceptive services, among outlets screened, by outlet type – Urban vs. Rural, 2015**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total*	General Retailer	Total
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Proportion of outlets screened, providing†:</b>	U: N=107 R: N=107	U: N=2 R: N=10	U: N=11 R: N= 4	U: N=120 R: N= 121	U: N=274 R: N= 59	U: N=214 R: N=16	U: N=2,231 R: N= 570	U: N=2719 R: N=645	U: N=7,829 R: N= 1,9333	U: N=10,666 R: N= 2,699
<b>Contraceptive injection service</b>										
Urban	69.0 (50.9, 82.7)	0.0 -	5.2 (0.7, 28.4)	54.1 (33.4, 73.4)	37.3 (25.6, 50.7)	30.7 (11.8, 59.6)	10.0 (5.9, 16.3)	13.6 (9.0, 20.0)	0.0 (0.0, 0.1)	4.3 (3.1, 5.9)
Rural	65.8 (51.7, 77.6)	47.1 (10.3, 87.4)	8.8 (0.7, 57.9)	61.0 (48.8, 72.0)	57.0 (33.4, 77.8)	13.3 (5.5, 28.7)	10.0 (5.8, 16.7)	16.3 (10.6, 24.2)	0.0 -	6.5 (5.0, 8.3)
<b>Implant insertion service</b>										
Urban	39.5 (26.1, 54.7)	0.0 -	0.1 (0.0, 1.2)	30.3 (19.5, 43.9)	19.0 (11.0, 30.6)	0.5 (0.1, 3.7)	0.4 (0.1, 2.5)	1.9 (0.8, 4.7)	0.0 -	0.9 (0.5, 1.6)
Rural	20.2 (10.1, 36.4)	0.0 -	0.0 -	15.9 (7.8, 29.6)	32.6 (17.9, 51.7)	0.0 -	0.0 -	4.4 (1.7, 10.9)	0.0 -	1.7 (1.2, 2.5)
<b>IUD insertion service</b>										
Urban	32.5 (20.9, 46.7)	0.0 -	2.8 (0.3, 24.5)	25.5 (16.3, 37.7)	28.5 (17.6, 42.7)	0.0 -	0.0 (0.0, 0.1)	2.4 (1.2, 4.7)	0.0 -	0.9 (0.6, 1.5)
Rural	18.5 (8.4, 36.2)	0.0 -	0.0 -	14.6 (6.3, 30.3)	38.3 (24.8, 53.8)	0.0 -	0.0 -	5.1 (2.3, 10.9)	0.0 -	1.8 (1.3, 2.5)
<b>Male sterilization</b>										
Urban	0.7 (0.1, 4.1)	0.0 -	0.0 -	0.5 (0.1, 3.3)	5.3 (2.2, 12.4)	0.0 -	0.0 -	0.4 (0.1, 1.4)	0.0 -	0.1 (0.0, 0.3)
Rural	0.9 (0.1, 6.1)	0.0 -	0.0 -	0.7 (0.1, 5.0)	0.4 (0.1, 2.3)	0.0 -	0.0 -	0.1 (0.0, 0.3)	0.0 -	0.0 (0.0, 0.2)
<b>Female sterilization</b>										
Urban	2.1 (0.9, 4.7)	0.0 -	1.6 (0.1, 15.5)	2.0 (0.8, 5.0)	10.3 (5.5, 18.4)	0.0 -	0.0 -	0.8 (0.3, 2.3)	0.0 -	0.2 (0.1, 0.6)
Rural	0.0 -	0.0 -	0.0 -	0.0 -	10.7 (3.0, 31.9)	0.0 -	0.0 -	1.4 (0.3, 7.1)	0.0 -	0.3 (0.1, 1.5)

\* In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.

† The denominator includes 58 urban outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview) and 10 rural outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview)

Source: FPwatch Outlet Survey, Nigeria, 2015

**Table C111: Service readiness\* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – Urban/Rural**

		Public Health Facility	Community Health Workers	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total†
Proportion of outlets offering service, with‡:		% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
<b>Contraceptive injections</b>									
Urban	Availability of commodity	92.8 [85.0, 96.7] <sup>(84)</sup>	- -	32.5 [6.6, 76.6] <sup>(4)</sup>	91.6 [83.0, 96.0] <sup>(88)</sup>	55.6 [43.4, 67.2] <sup>(119)</sup>	93.6 [76.9, 98.5] <sup>(46)</sup>	47.3 [19.7, 76.7] <sup>(189)</sup>	56.0 [32.1, 77.4] <sup>(356)</sup>
	Availability of credentials	95.6 [87.4, 98.5] <sup>(84)</sup>	- -	100.0 [100.0, 100.0] <sup>(4)</sup>	95.7 [87.6, 98.6] <sup>(88)</sup>	96.8 [92.6, 98.6] <sup>(119)</sup>	69.0 [34.5, 90.4] <sup>(46)</sup>	31.9 [14.3, 56.8] <sup>(189)</sup>	52.2 [32.4, 71.3] <sup>(356)</sup>
	Availability of equipment	99.4 [97.5, 99.9] <sup>(84)</sup>	- -	100.0 [100.0, 100.0] <sup>(4)</sup>	99.4 [97.5, 99.9] <sup>(88)</sup>	97.6 [92.6, 99.2] <sup>(119)</sup>	100.0 [100.0, 100.0] <sup>(46)</sup>	85.8 [80.4, 89.9] <sup>(187)</sup>	90.7 [85.4, 94.2] <sup>(354)</sup>
	Service readiness	89.1 [78.8, 94.7] <sup>(84)</sup>	- -	32.5 [6.6, 76.6] <sup>(4)</sup>	87.9 [77.5, 93.9] <sup>(88)</sup>	55.3 [43.3, 66.7] <sup>(119)</sup>	66.6 [31.2, 89.7] <sup>(46)</sup>	19.3 [8.1, 39.4] <sup>(187)</sup>	34.8 [20.0, 53.2] <sup>(354)</sup>
Rural	Availability of commodity	87.6 [69.7, 95.6] <sup>(70)</sup>	91.8 [35.2, 99.6] <sup>(3)</sup>	100.0 (1)	88.2 [77.3, 94.3] <sup>(74)</sup>	64.3 [53.7, 73.7] <sup>(31)</sup>	100.0 [100.0, 100.0] <sup>(3)</sup>	26.4 [10.5, 52.4] <sup>(69)</sup>	44.6 [28.8, 61.6] <sup>(103)</sup>
	Availability of credentials	68.7 [44.1, 85.9] <sup>(70)</sup>	2.2 [0.1, 35.4] <sup>(3)</sup>	100.0 (1)	59.1 [34.9, 79.5] <sup>(74)</sup>	92.9 [69.1, 98.7] <sup>(31)</sup>	24.0 [1.7, 85.5] <sup>(3)</sup>	44.8 [17.1, 76.2] <sup>(69)</sup>	67.2 [32.2, 89.8] <sup>(103)</sup>
	Availability of equipment	84.7 [50.7, 96.8] <sup>(70)</sup>	100.0 [100.0, 100.0] <sup>(3)</sup>	100.0 (1)	87.0 [54.8, 97.4] <sup>(74)</sup>	99.3 [93.7, 99.9] <sup>(31)</sup>	100.0 [100.0, 100.0] <sup>(3)</sup>	97.4 [89.3, 99.4] <sup>(69)</sup>	98.3 [94.2, 99.5] <sup>(103)</sup>
	Service readiness	56.7 [32.6, 78.0] <sup>(70)</sup>	2.2 [0.1, 35.4] <sup>(3)</sup>	100.0 (1)	48.8 [23.2, 75.1] <sup>(74)</sup>	59.7 [46.1, 72.0] <sup>(31)</sup>	24.0 [1.7, 85.5] <sup>(3)</sup>	13.0 [5.1, 29.5] <sup>(69)</sup>	35.0 [20.5, 52.9] <sup>(103)</sup>
<b>Implant insertions</b>									
Urban	Availability of commodity	91.1 [75.9, 97.1] <sup>(47)</sup>	- -	100.0 (1)	91.1 [75.9, 97.1] <sup>(48)</sup>	34.5 [17.0, 57.7] <sup>(67)</sup>	0.0 (1)	11.1 [0.6, 71.0] <sup>(4)</sup>	30.1 [12.5, 56.5] <sup>(72)</sup>
	Availability of credentials	86.0 [74.1, 93.0] <sup>(47)</sup>	- -	100.0 (1)	86.0 [74.1, 93.0] <sup>(48)</sup>	98.4 [87.8, 99.8] <sup>(67)</sup>	100.0 (1)	92.3 [89.7, 94.3] <sup>(4)</sup>	97.4 [91.3, 99.3] <sup>(72)</sup>
	Availability of equipment	75.9 [58.7, 87.4] <sup>(47)</sup>	- -	0.0 (1)	75.8 [58.7, 87.4] <sup>(48)</sup>	89.4 [71.1, 96.6] <sup>(67)</sup>	100.0 (1)	18.5 [3.7, 57.4] <sup>(4)</sup>	77.8 [52.7, 91.7] <sup>(72)</sup>
	Service readiness	65.6 [43.1, 82.8] <sup>(47)</sup>	- -	0.0 (1)	65.6 [43.0, 82.7] <sup>(48)</sup>	34.5 [16.9, 57.7] <sup>(67)</sup>	0.0 (1)	11.1 [0.6, 71.0] <sup>(4)</sup>	30.0 [12.4, 56.4] <sup>(72)</sup>
Rural	Availability of commodity	84.4 [58.8, 95.4] <sup>(22)</sup>	- -	- -	84.4 [58.8, 95.4] <sup>(22)</sup>	90.8 [65.1, 98.1] <sup>(13)</sup>	- -	- -	90.8 [65.1, 98.1] <sup>(13)</sup>
	Availability of credentials	90.8 [68.4, 97.8] <sup>(22)</sup>	- -	- -	90.8 [68.4, 97.8] <sup>(22)</sup>	100.0 [0.0, 0.0] <sup>(13)</sup>	- -	- -	100.0 [100.0, 100.0] <sup>(13)</sup>
	Availability of equipment	98.7 [94.1, 99.7] <sup>(22)</sup>	- -	- -	98.7 [94.1, 99.7] <sup>(22)</sup>	99.8 [97.1, 100.0] <sup>(13)</sup>	- -	- -	99.8 [97.1, 100.0] <sup>(13)</sup>

**Table C111: Service readiness\* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – Urban/Rural**

		Public Health Facility	Community Health Workers	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total†
	Proportion of outlets offering service, with‡:	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
	Service readiness	74.5 [44.4, 91.5] <sup>(22)</sup>	- -	- -	74.5 [44.4, 91.5] <sup>(22)</sup>	90.8 [65.1, 98.1] <sup>(13)</sup>	- -	- -	90.8 [65.1, 98.1] <sup>(13)</sup>
<b>IUD insertions</b>									
Urban	Availability of commodity	70.7 [43.5, 88.3] <sup>(52)</sup>	- -	59.3 [54.5, 64.0] <sup>(3)</sup>	70.4 [43.9, 87.8] <sup>(55)</sup>	53.6 [38.1, 68.5] <sup>(92)</sup>	- -	29.2 [1.6, 91.2] <sup>(2)</sup>	53.4 [38.1, 68.1] <sup>(94)</sup>
	Availability of credentials	95.9 [88.6, 98.6] <sup>(52)</sup>	- -	96.4 [51.3, 99.8] <sup>(3)</sup>	95.9 [89.1, 98.5] <sup>(55)</sup>	99.9 [99.6, 100.0] <sup>(92)</sup>	- -	0.0 [0.0, 0.0] <sup>(2)</sup>	99.1 [97.7, 99.7] <sup>(94)</sup>
	Availability of equipment	82.6 [71.0, 90.2] <sup>(51)</sup>	- -	96.4 [51.3, 99.8] <sup>(3)</sup>	82.9 [71.8, 90.2] <sup>(54)</sup>	86.7 [73.5, 93.9] <sup>(92)</sup>	- -	70.8 [8.8, 98.4] <sup>(2)</sup>	86.6 [73.5, 93.8] <sup>(94)</sup>
	Service readiness	55.3 [31.8, 76.6] <sup>(51)</sup>	- -	55.7 [49.1, 62.1] <sup>(3)</sup>	55.3 [32.4, 76.2] <sup>(54)</sup>	48.8 [33.6, 64.2] <sup>(92)</sup>	- -	0.0 [0.0, 0.0] <sup>(2)</sup>	48.4 [33.2, 63.8] <sup>(94)</sup>
Rural	Availability of commodity	56.9 [13.8, 91.6] <sup>(19)</sup>	- -	- -	56.9 [13.8, 91.6] <sup>(19)</sup>	57.1 [38.2, 74.1] <sup>(16)</sup>	- -	- -	57.1 [38.2, 74.1] <sup>(16)</sup>
	Availability of credentials	94.7 [78.2, 98.9] <sup>(19)</sup>	- -	- -	94.7 [78.2, 98.9] <sup>(19)</sup>	99.6 [95.6, 100.0] <sup>(16)</sup>	- -	- -	99.6 [95.6, 100.0] <sup>(16)</sup>
	Availability of equipment	87.9 [63.0, 96.9] <sup>(18)</sup>	- -	- -	87.9 [63.0, 96.9] <sup>(18)</sup>	99.2 [94.4, 99.9] <sup>(16)</sup>	- -	- -	99.2 [94.4, 99.9] <sup>(16)</sup>
	Service readiness	45.1 [7.8, 88.9] <sup>(18)</sup>	- -	- -	45.1 [7.8, 88.9] <sup>(18)</sup>	56.3 [37.7, 73.2] <sup>(16)</sup>	- -	- -	56.3 [37.7, 73.2] <sup>(16)</sup>
<b>Male sterilizations</b>									
Urban	Availability of credentials	100.0 (1)	- -	- -	100.0 (1)	100.0 [100.0, 100.0] <sup>(15)</sup>	- -	- -	100.0 [100.0, 100.0] <sup>(15)</sup>
	Availability of equipment	100.0 (1)	- -	- -	100.0 (1)	80.8 [27.4, 97.9] <sup>(15)</sup>	- -	- -	80.8 [27.4, 97.9] <sup>(15)</sup>
	Service readiness	100.0 (1)	- -	- -	100.0 (1)	80.8 [27.4, 97.9] <sup>(15)</sup>	- -	- -	80.8 [27.4, 97.9] <sup>(15)</sup>
Rural	Availability of credentials	0.0 (1)	- -	- -	0.0 (1)	100.0 [100.0, 100.0] <sup>(2)</sup>	- -	- -	100.0 [100.0, 100.0] <sup>(2)</sup>
	Availability of equipment	0.0 (1)	- -	- -	0.0 (1)	68.0 [2.7, 99.4] <sup>(2)</sup>	- -	- -	68.0 [2.7, 99.4] <sup>(2)</sup>
	Service readiness	0.0 (1)	- -	- -	0.0 (1)	68.0 [2.7, 99.4] <sup>(2)</sup>	- -	- -	68.0 [2.7, 99.4] <sup>(2)</sup>
<b>Female sterilizations</b>									

**Table C111: Service readiness\* to provide provider-dependent contraceptive services, among outlets reportedly offering the procedure, by outlet type – Urban/Rural**

		Public Health Facility	Community Health Workers	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	Private Total†
	Proportion of outlets offering service, with‡:	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
Urban	Availability of credentials	90.1 [42.8, 99.1] <sup>(5)</sup>	- -	100.0 (1)	91.8 [48.0, 99.3] <sup>(6)</sup>	93.0 [75.8, 98.3] <sup>(40)</sup>	- -	- -	93.0 [75.8, 98.3] <sup>(40)</sup>
	Availability of equipment	69.4 [22.1, 94.8] <sup>(5)</sup>	- -	0.0 (1)	57.2 [25.0, 84.3] <sup>(6)</sup>	67.3 [39.2, 86.8] <sup>(40)</sup>	- -	- -	67.3 [39.2, 86.8] <sup>(40)</sup>
	Service readiness	69.4 [22.1, 94.8] <sup>(5)</sup>	- -	0.0 (1)	57.2 [25.0, 84.3] <sup>(6)</sup>	67.3 [39.2, 86.8] <sup>(40)</sup>	- -	- -	67.3 [39.2, 86.8] <sup>(40)</sup>
Rural	Availability of credentials	- -	- -	- -	- -	100.0 [100.0,100.0] <sup>(3)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(3)</sup>
	Availability of equipment	- -	- -	- -	- -	100.0 [100.0,100.0] <sup>(2)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(2)</sup>
	Service readiness	- -	- -	- -	- -	100.0 [100.0,100.0] <sup>(2)</sup>	- -	- -	100.0 [100.0,100.0] <sup>(2)</sup>
<p>* Full service readiness is defined as having available: 1. The commodity (not applicable for male/female sterilization); 2. A provider with credentials meeting the guidelines to perform the service; and 3. A minimum set of sentinel equipment (<a href="http://www.cpc.unc.edu/measure/prh/rh_indicators/specific/long-acting-permanent-methods/percent-of-facilities-with-appropriate">http://www.cpc.unc.edu/measure/prh/rh_indicators/specific/long-acting-permanent-methods/percent-of-facilities-with-appropriate</a>) for providing the service. Observations that are missing information for commodity availability, provider credentials, or equipment are excluded from the 'service readiness' denominator.</p> <p>† In this table, Private Total includes Private For-Profit Health Facilities, Pharmacies and PPMVs. This category excludes General Retailers/Kiosks.</p> <p>‡ The denominator includes outlets that met screening criteria for a full interview but did not complete the interview (were not interviewed or completed a partial interview). The list of family planning products with incomplete survey information are as follows: 42 IUDs, 38 implants, 109 injections, 3 male sterilizations and 11 female tubal ligations. The list of family planning products with incomplete survey information in urban areas are as follows: 31 IUDs, 27 implants, 70 injections, 1 male sterilizations and 10 female tubal ligations. The list of family planning products with incomplete survey information in rural areas are as follows: 11 IUDs, 11 implants, 39 injections, 2 male sterilizations and 1 female tubal ligations.</p>									
Source: FPwatch Outlet Survey, Nigeria, 2015									



## Annexes

### Annex 1: FPwatch Background

FPwatch is a multi-country research project implemented by PSI ([www.psi.org](http://www.psi.org)). Standardized tools and approaches are employed to provide comparable data across countries and over time. Project countries include: Ethiopia, the DRC, India, Nigeria and Myanmar. The project was launched in 2014 with funding from the BMGF for four project countries, and is currently funded through 2016 by the BMGF. Funding for Myanmar was secured through the 3MDG Fund in 2015.

FPwatch is designed to provide timely, relevant and high-quality modern contraceptives and associated services market evidence. The goal of providing this market evidence is to inform and monitor national and global policy, strategy and funding decisions for understanding FP markets. FPwatch is monitoring family planning markets in the context of increased investments in family planning as part of the FP2020 Initiative, a partnership aiming to expand access to family planning information, services and supplies to an additional 120 million women and girls in 69 of the world's poorest countries by 2020.<sup>1</sup>

The project implements a set of research tools designed to:

- 1) **Provide a picture of the total market for distribution of modern family planning methods** including: all providers carrying condoms, oral contraceptives, emergency contraceptives, injectables, contraceptive implants or IUDs, or providing provider-dependent contraceptive services including: injections, implant insertions, IUD insertions or male or female sterilizations; the relative modern contraceptive market share for each provider type; stock outs; and price markups.
- 2) **Monitor the readiness of market components for distribution of modern family planning methods**, including: availability of modern contraceptives and services; and provider qualifications, training and essential equipment for providing services.
- 3) **Monitor the performance of market components for distribution of modern family planning methods**, including: the relative market share for each method and for short-acting relative to long-acting methods; consumer price; quality-assurance indicators for contraceptives.

FPwatch research tools for FP market monitoring include:

#### 1. Outlet surveys

Outlet surveys entail collecting quantitative data from all outlets and providers with the potential to sell or distribute modern contraceptives and/or provide provider-dependent contraceptive services. These include health facilities, community health workers, pharmacies, drug stores, retail outlets, market stalls and mobile providers. Information on male and female condoms is collected from all enumerated outlets including brand, price of most popular condom and volume of all condoms sold. A screening process identifies outlets that provide modern contraceptives above the level of oral contraceptives and/or provide provider-dependent family planning services. Among these eligible outlets, service providers are interviewed and all modern contraceptives are audited. The audit collects information about each modern contraceptive in stock (e.g. brand name, drug active ingredients and strengths, manufacturer, etc.) and retailer reports on consumer price and sale/distribution volumes for each product. A provider interview is conducted among those outlets where services including contraceptive injections, implant and IUD insertions and male and female sterilizations are available. The provider interview on services collects information on price and volume of services, provider qualifications available at the outlet and the availability of a minimum set of equipment needed to provide the service. A representative sample of outlets is

---

<sup>1</sup> FP2020. 2016. *FP2020 Website*. Accessed via: <http://www.familyplanning2020.org/> on January 1, 2016.

identified within target study domains such that findings from the outlet survey provide estimates of contraceptive availability, price and relative market share across the entire market as well as within key market segments.<sup>2</sup>

## 2. Key informant interviews

The outlet survey was complemented by in-depth interviews conducted with key informants at the national and state levels. The interviews provided context for national family planning trends, policies and strategy for interpreting the data.

---

<sup>2</sup> O'Connell KA, Poyer S, Solomon T, et al. 2013. Methods for implementing a medicine outlet survey: lessons from the anti-malarial market. *Malaria Journal*, 12: 52.

## Annex 2: Nigeria Background

Nigeria presents a challenge for health programmers due to its large population of nearly 175 million people, rapid population growth and wide ranging cultural, religious and political contexts. By 2050, Nigeria is projected to have population of 450 million people. At present, nearly half of Nigerians are under the age of 18. This has considerable implications for family planning programs in the next decade as a large portion of the population will be reaching reproductive age. In addition to population growth, significant socioeconomic disparities and access to healthcare exist within the country. Disparities are most apparent between the north and south, but there are differences even between states within the same region. While more than half of the population resides in the north, it is much less densely populated than the south. With communities and households widely spread geographically and women less able to seek care outside of their homes, the north represents a challenging environment for increasing access to health products and services.

The total fertility rate, which remained steady at 5.7 children per woman between 2003 and 2008, has begun to gradually decline and now stands at 5.5.<sup>3</sup> Similarly, CPR among married women has increased slightly, from 13% in 2003 to 15% in 2013 and CPR among all women stands at 17.5%. Unmet need is high, with approximately 20% of women reporting unmet need for family planning methods. Only ten percent of married women use a modern method.<sup>4</sup> Short-term contraceptive methods are most commonly used; 3% of married women use injectables, 2% use male condoms, and 2% use oral contraceptives, while less than 1% of married women use any other modern method.<sup>5</sup> A number of family planning access barriers have been identified including: lack of service availability, fear of social disapproval or lack of social acceptability and fears about the perceived health risk and side effects. Some of these barriers are more apparent in the northern regions of the country with modern CPR ranging from 3-4% in Northern states compared to 15-20% for Southern states. Lack of access to modern family planning methods has been linked to higher rates of maternal and child mortality.<sup>6</sup>

Both the public and private sectors are important providers of family planning commodities in Nigeria, with each providing a different method mix. Of all modern methods, approximately 60% is provided by the private sector. However, this figure is influenced by the large proportion of condoms, which are primarily delivered outside of the public sector such as through social marketing. In contrast, a large proportion of long-acting reversible contraceptives (LARCs) including contraceptive implants and intrauterine devices (IUDs) are provided within the public sector.<sup>7</sup> With frequent stock outs of contraceptive commodities in the public sector, the private sector plays an important role in provision of family planning commodities and services in Nigeria. These facilities include regulated providers, such as registered pharmacies, and unregulated drug shops and retail outlets.<sup>8</sup>

The Government of Nigeria has made recent important advances in increasing access to and uptake of modern contraceptives. As part of its FP2020 commitments of achieving a CPR of 36% by 2018, Nigeria has committed to providing an additional US \$8.35 million annually over the next four years in addition to its current annual commitment of US \$3 million, signifying an increase of nearly 300%. In addition, Nigeria has developed a detailed implementation plan to expand use of modern contraceptives and is effecting policy change and supporting task shifting that will enable community health workers (CHWs) to deliver a range of contraceptives. Nigeria has also scaled up family planning trainings, including training on injectable contraceptives for community health workers, and is distributing contraceptives to the last mile using the review-resupply meeting model.

---

<sup>3</sup> National Population Commission. 2013. Nigeria Demographic and Health Survey 2013: Preliminary Report. Measure DHS, ICF International.

<sup>4</sup> National Population Commission [Nigeria] and ICF International. 2014. Nigeria Demographic and Health Survey 2013. Rockville, Maryland, USA: National Population Commission and ICF International.

<sup>5</sup> UNFPA, 2013: The state of world population 2013.

<sup>6</sup> Department for International Development (DFID). 2011. Scaling up access to contraceptive commodities in Nigeria. DFID, UKaid.

<sup>7</sup> IBID.

<sup>8</sup> ACTwatch Group, SFH/Nigeria and the Independent Evaluation Team. (2012). *ACTwatch Outlet Survey Report 2011 (Round 3). Endline Outlet Survey Report for the Independent Evaluation of Phase 1 of the Affordable Medicines Facility – malaria (AMFm): Nigeria*. Abuja, Nigeria: ACTwatch/PSI/SFH Nigeria.

## Annex 3: Outlet Survey Methods

### Design and Study Population

FPwatch implements cross-sectional outlet surveys in project countries. The study population is defined as all outlets with the potential to sell or distribute modern contraceptives and/or provide associated contraceptive services. In Nigeria, this includes the following outlet types:

The outlet survey is a study of all outlets that distribute modern family planning commodities or offer provider-dependent family planning services. In Nigeria, this includes the following outlet types:

Public health facilities	Government (federal or state) public facilities including teaching hospitals and federal medical centers at the tertiary level; general hospitals at the secondary level; and primary health centers and clinics at the primary level.
Community health workers	Community-based health volunteers including Community Health Extension Workers.
Private not-for-profit health facilities	Non-governmental (NGO) or mission/faith-based health facilities including hospitals and clinics.
Private for-profit health facilities	Private hospitals and clinics.
Pharmacies	Pharmacies are licensed by the Pharmacy Council of Nigeria and are authorized to sell all classes of medicines including prescription-only medicines. Pharmacies are regulated by the National Agency for Food and Drug Administration and Control. Pharmacies are owned by registered pharmacists or owners employing the services of a registered pharmacist.
Drug stores	Proprietary Patent Medicine Vendors (PPMVVs) are small-to-medium sized outlets selling primarily medicines. PPMVVs may be registered by the Directorate of Pharmaceutical Services. However, many are not registered. PPMVVs are legally permitted to sell over-the-counter medicines including oral contraceptives.
General retailers/Kiosks	Supermarkets, mini-markets and kiosks primarily sell fast-moving consumer goods, food and provisions. Kiosks/tables are points of sale located in non-permanent structures that sell fast-moving goods such as food, beverages and household goods. Although retailers may have over-the-counter medicines including oral contraceptives available, national authorities do not regulate the sale of medicines by retailers.

### Inclusion criteria

- One or more modern family planning methods at the level (see below for hierarchy) of oral contraceptives and above reportedly in stock on the day of the survey.
- One or more modern family planning methods at the level of oral contraceptives (see below) or above reportedly in stock within the past 3 months.
- The provision of family planning services including at least one of the following: 1. Insertion of contraceptive implants; 2. Insertion of IUDs; 3. Male sterilizations; or 4. Female sterilizations.

Modern family planning methods include:

1. Cycle Beads, birth control patches and vaginal birth control rings
2. Vaginal foaming tablets
3. Male and female condoms

If an outlet has only one or more of methods 1-3 and no others available today or in the previous three months and are not able to provide any family planning services, they are not eligible for a family planning product audit or provider interview.

4. Oral contraceptives
5. Emergency oral contraceptives
6. Contraceptive injections

7. Contraceptive implants
8. Hormonal and copper-based IUDs
9. Male sterilizations
10. Female sterilizations

If an outlet has at least one of methods/services #4-10 available today or in the previous three months, they are eligible for a family planning product audit and provider interview.

#### Exclusion criteria

1. Outlets that serve the military and/or do not serve the general public.
2. Outlets such as hotels or brothels where condoms are typically available, but other modern family planning methods are not available.
3. Outlets that do not provide informed consent to participate.

#### Sample Size

The outlet survey is powered to meet minimum requirements for the ACTwatch malaria market survey and the FPwatch family planning market survey.

A series of calculations was completed to identify minimum sample size requirements to estimate with precision (+/- 5 percentage points) for 1 key indicator: the proportion of outlets with three or more modern family planning methods available, among outlets with family planning commodities/services available on the day of the survey. This indicator was chosen because it is highly relevant for FP2020 goals for women and girls to have informed choice and access to family planning information and a range of modern contraceptive methods.

The required sample size for each research domain (6 geopolitical zones) was calculated in three steps: 1) determine the required number of family planning outlets; 2) determine the number of clusters for the census to arrive at this number of outlets.

#### Required number of Outlets

The required number of family planning outlets to estimate the key indicator with specified precision is identified using the following formula:

$$n \geq deff * \frac{Z^2(P)(1 - P)}{D^2}$$

Where:

- deff = a design effect of 2 was used to account for cluster sampling.
- Z = Z-score corresponding to level of confidence with which it is desired to be sure that the true population lies within +/- D percentage points. Assuming a 2-sided test with  $\alpha=.05$ ,  $Z=1.96$
- P = estimated proportion of family planning outlets that will have three or more modern family planning methods available. The most conservative estimate (producing the largest sample size) of 50% was used.
- D = maximum tolerable error; to obtain an estimate within +/- D percentage points of the true population value; set at 5 percentage points.

The sample size required was increased to account for up to 10% non-response.

Using these values, the sample size required is approximately 770 outlets per each of the six geo-political domains for a total of 4,620 outlets.

#### Required number of Outlets

The estimated number of enumerated outlets required for the key indicators was determined by the following formula for outlets within each domain:

$$N = n/P_{fp}$$

where  $P_{fp}$  is the proportion of outlets having family planning commodities or services available at the time of the survey among all outlets enumerated. In this equation, the assumptions are as follows:  $N$  = desired sample size of all outlets for monitoring availability,  $n$  is the number of outlets with family planning commodities or services available at the time of the survey.  $P_{fp}$  is the estimated proportion of outlets that will have family planning commodities or services available at the time of the survey.

We expected approximately 85% of outlets screened will have modern family planning commodities or services available based on PMA2020 Nigeria findings. Therefore, we expected to screen 905 outlets in each of the geopolitical zones for a total of 5,430 outlets screened.

#### Required number of Clusters (*localities*)

Information provided by the 2013 ACTwatch Nigeria outlet survey on the average numbers of outlets by type in localities. Based on this information, outlet density for *localities* for each of the six geopolitical zones was expected to be approximately: 15.8 (NC), 37.7 (NE), 23.7 (NW), 23.7 (SE), 30.6 (SS) and 47.9 (SW). Considering sample size requirements to estimate key indicators +/- 10 percentage points, the optimal number of *localities* required to reach desired number of outlets was **210 localities: 58 (NC), 25 (NE), 39 (NW), 39 (SE), 30 (SS) and 19 (SW).**

#### Data Collection

Field teams received training including an orientation to the study and questionnaire, classroom training on completing outlet audits for modern family planning commodities and modules on assessments of service readiness for provision of implants, IUDs and sterilizations, as well as took part in a field exercise. A paper-based structured questionnaire was used with providers in all approached outlets. A series of screening questions was administered at all outlets to determine eligibility for the survey.

Outlets where family planning commodities or services are reportedly available were invited to participate in the survey. Following informed consent services, an audit of all available family planning commodities was conducted. Drug audit information was collected for: spermicidal gels, foams and creams, vaginal birth control rings, birth control patches, oral contraceptives, injectables, implants, IUDs and emergency contraceptives; and included: formulation, package size, brand name, active ingredients and strengths, manufacturer, country of manufacture, reported sale/distribution, retail price and wholesale price. Non-drug product audit information for diaphragms, condoms, and Cycle Beads was collected including: brand name, manufacturer, country of manufacture, reported sale/distribution, retail price and wholesale price. Where provider-dependent methods were available, including IUDs, implants and sterilization, a series of questions was administered to assess basic readiness to perform the service. In addition to the product audit, a series of questions was administered to the senior-most provider regarding provider training and qualifications and presence of essential equipment for FP services. Geo-coordinates were captured at each sampled outlet.

Up to three visits were made to all outlets to complete the screening process, audit and provider interview as needed (e.g., where outlets were closed or providers were not available).

#### Data Entry, Processing, and Analysis

Double data entry was completed using Microsoft Access. All data cleaning and analysis was performed using Stata 13.1 (©StataCorp, College Station, TX). Data were weighted to account for variation in probability of outlet selection (see Annex 4), and standard error calculation reflected clustering of outlets at LGA and locality-levels. Standard indicators were constructed according to definitions applied across FPwatch project countries (see Annex 10).

#### Protection of Human Subjects

The outlet survey protocol was submitted for national ethical review by the National Health Ethics Research Committee (NHREC). The protocol was also submitted to the PSI Research Ethics Board (REB). Provider interviews and product audits were completed only after administration of a standard informed consent form and provider

consent to participate in the study. Providers had the option to end the interview at any point during the study. Standard measures were employed to maintain provider confidentiality and anonymity.

#### Timeframe

Data collection began in August, 2015 following a 10-day fieldworker training and finished by the end of October, 2015.

#### Annex 4: Sampled LGAs and Localities

Region	State	LGA Name	Locality Name	Urban /Rural
NORTH CENTRAL	BENUE	ADO	IKPADARA	RURAL
NORTH CENTRAL	BENUE	AGATU	ATAKPA	RURAL
NORTH CENTRAL	BENUE	GWER EAST	ALIADE	URBAN
NORTH CENTRAL	BENUE	GWER EAST	TSE JIR	RURAL
NORTH CENTRAL	BENUE	KATSINA-ALA	MBAABAA	RURAL
NORTH CENTRAL	BENUE	KWANDE	MBAGBAR	RURAL
NORTH CENTRAL	BENUE	LOGO	AKAA	RURAL
NORTH CENTRAL	BENUE	MAKURDI	MBAAKUVA I	RURAL
NORTH CENTRAL	BENUE	OHIMINI	ONDO (Ohimini)	RURAL
NORTH CENTRAL	BENUE	OJU	IKWOKWU	RURAL
NORTH CENTRAL	BENUE	TARKA	Mbaadi II	RURAL
NORTH CENTRAL	BENUE	USHONGO	MBATAKOR	RURAL
NORTH CENTRAL	FCT ABUJA	AMAC	KUZHIBI-KPANKPAM TESHI	RURAL
NORTH CENTRAL	FCT ABUJA	AMAC	PYAKASA	URBAN
NORTH CENTRAL	FCT ABUJA	AMAC	UTAKO	URBAN
NORTH CENTRAL	FCT ABUJA	Bwari	MPAPE	URBAN
NORTH CENTRAL	FCT ABUJA	KWALI	KWALI	URBAN
NORTH CENTRAL	KOGI	ANKPA	AFORGAMGAM	RURAL
NORTH CENTRAL	KOGI	BASSA	EMI-ASUBA	RURAL
NORTH CENTRAL	KOGI	IBAJI	OFORACHI, ECHA-OJA, ETIOLI, OFUGO, ARUKWAJA, OKO-OFU 1&2	RURAL
NORTH CENTRAL	KOGI	KABBA/BUNU	KABBA	URBAN
NORTH CENTRAL	KOGI	LOKOJA	KAYINKO	RURAL
NORTH CENTRAL	KOGI	LOKOJA	LOKOJA TOWNSHIP	URBAN
NORTH CENTRAL	KOGI	OKEHI	ABOBO	RURAL
NORTH CENTRAL	KOGI	OKENE	OKENE TOWNSHIP	URBAN
NORTH CENTRAL	KOGI	OLAMABORO	OGBODAGA	RURAL
NORTH CENTRAL	KOGI	YAGBA WEST	ODO-ARA	RURAL
NORTH CENTRAL	KWARA	ASA	TURAWA	RURAL
NORTH CENTRAL	KWARA	EDU	GAMALEGI	RURAL
NORTH CENTRAL	KWARA	EKITI	ORA AYEGBAJU	RURAL
NORTH CENTRAL	KWARA	IFELODUN	SHARE	URBAN
NORTH CENTRAL	KWARA	ILORIN EAST	ILORIN KANKATU	URBAN
NORTH CENTRAL	KWARA	ILORIN WEST	Pakata	URBAN
NORTH CENTRAL	KWARA	KAIAMA	KAIAMA	RURAL
NORTH CENTRAL	NASARAWA	DOMA	AKUNYA	RURAL
NORTH CENTRAL	NASARAWA	KARU	TAKALAFIA	RURAL
NORTH CENTRAL	NASARAWA	LAFIA	KANTSAKUWA	RURAL
NORTH CENTRAL	NASARAWA	LAFIA	LAFIA	URBAN
NORTH CENTRAL	NASARAWA	TOTO	ANG. FULANI IGWAPATI	RURAL
NORTH CENTRAL	NASARAWA	WAMBA	WAMBA	RURAL
NORTH CENTRAL	NIGER	AGWARA	ADEHE	RURAL
NORTH CENTRAL	NIGER	BIDA	BIDA	URBAN



NORTH CENTRAL	NIGER	CHANCHAGA	MINNA	URBAN
NORTH CENTRAL	NIGER	KATCHA	EMI-RAFI	RURAL
NORTH CENTRAL	NIGER	LAVUN	RUGGAN-CHIBO	RURAL
NORTH CENTRAL	NIGER	MASHEGU	MAHUTA-MASUCHI	RURAL
NORTH CENTRAL	NIGER	MOKWA	TSafa	RURAL
NORTH CENTRAL	NIGER	PAIKORO	RUGAN--Bodari	RURAL
NORTH CENTRAL	NIGER	RAFI	MERU	RURAL
NORTH CENTRAL	NIGER	RIJAU	RIGITO	RURAL
NORTH CENTRAL	NIGER	SHIRORO	GWADA	RURAL
NORTH CENTRAL	PLATEAU	BOKKOS	TUKYEH	RURAL
NORTH CENTRAL	PLATEAU	JOS NORTH	KABONG	URBAN
NORTH CENTRAL	PLATEAU	JOS SOUTH	RAYFIELD	URBAN
NORTH CENTRAL	PLATEAU	KANKE	KYANGSHI	RURAL
NORTH CENTRAL	PLATEAU	MANGU	BUREH	RURAL
NORTH CENTRAL	PLATEAU	RIYOM	GANAWURI	RURAL
NORTH CENTRAL	PLATEAU	SHENDAM	NIAGLONG	RURAL
NORTH CENTRAL	PLATEAU	SHENDAM	SHENDAM	URBAN
NORTH CENTRAL	PLATEAU	WASE	TIMCHANG VILLAGE - BARKIN RIJIYA	RURAL
NORTH EAST	ADAMAWA	DEMSA	KA ADE	RURAL
NORTH EAST	ADAMAWA	FUFORE	GURIN	RURAL
NORTH EAST	ADAMAWA	GANYE	DAKUNA TIBA	RURAL
NORTH EAST	ADAMAWA	GIREI	VINIKLANG	URBAN
NORTH EAST	ADAMAWA	GIREI	WURO MALA	RURAL
NORTH EAST	ADAMAWA	GUYUK	GUDENYI TUDU	RURAL
NORTH EAST	ADAMAWA	LAMURDE	SABON GARI	RURAL
NORTH EAST	ADAMAWA	MAYO-BELWA	TOLA	RURAL
NORTH EAST	ADAMAWA	NUMAN	GWEDA MALLAM	URBAN
NORTH EAST	ADAMAWA	SONG	MAMBRUSO	RURAL
NORTH EAST	ADAMAWA	YOLA NORTH	KAREWA	URBAN
NORTH EAST	BAUCHI	ALKALERI	BODOL	RURAL
NORTH EAST	BAUCHI	ALKALERI	UNG. SARKIN YAKI DAM	RURAL
NORTH EAST	BAUCHI	BAUCHI	BAUCHI	URBAN
NORTH EAST	BAUCHI	BAUCHI	GASGAL	RURAL
NORTH EAST	BAUCHI	BAUCHI	YELWAN MAKARANTA	RURAL
NORTH EAST	BAUCHI	DARAZO	NAYI NAWA	RURAL
NORTH EAST	BAUCHI	DARAZO	TARA	RURAL
NORTH EAST	BAUCHI	DASS	BUNDOT	RURAL
NORTH EAST	BAUCHI	GAMAWA	GAMAWA	URBAN
NORTH EAST	BAUCHI	GAMAWA	GANGAWA	RURAL
NORTH EAST	BAUCHI	GAMAWA	KAISUWA DOLE	RURAL
NORTH EAST	BAUCHI	NINGI	RAKAJAWA	RURAL
NORTH EAST	BAUCHI	NINGI	SHANDE	RURAL
NORTH EAST	BAUCHI	TAFAWA-BALEWA	DAGRAK	RURAL
NORTH EAST	BAUCHI	TORO	DABABE	RURAL
NORTH EAST	BAUCHI	TORO	MAI GANGA	RURAL
NORTH EAST	BAUCHI	ZAKI	ARIRI	RURAL
NORTH EAST	GOMBE	AKKO	BARAMBU	RURAL

NORTH EAST	GOMBE	AKKO	DOLLI MADAKI	RURAL
NORTH EAST	GOMBE	AKKO	KUMO	URBAN
NORTH EAST	GOMBE	BALANGA	Buwangal	RURAL
NORTH EAST	GOMBE	BILLIRI	LAYAR	RURAL
NORTH EAST	GOMBE	GOMBE	NASARAWO	URBAN
NORTH EAST	GOMBE	KALTUNGO	DINDIBIN	RURAL
NORTH EAST	GOMBE	KWAMI	TAPPI BABA DALA	RURAL
NORTH EAST	TARABA	BALI	SABONGIDA 'A'	RURAL
NORTH EAST	TARABA	DONGA	BIEM	RURAL
NORTH EAST	TARABA	GASHAKA	MAI GANDI	RURAL
NORTH EAST	TARABA	JALINGO	JALINGO	URBAN
NORTH EAST	TARABA	KARIM-LAMIDO	WURO GUGA	RURAL
NORTH EAST	TARABA	LAU	BANKINDANG	RURAL
NORTH EAST	TARABA	SARDAUNA	BONG DADINKOWA	RURAL
NORTH EAST	TARABA	TAKUM	TAKUM	URBAN
NORTH EAST	TARABA	USSA	LISSAM	RURAL
NORTH EAST	TARABA	YORRO	YALI	RURAL
NORTH WEST	JIGAWA	BABURA	GIDAN GAMJI-SHIRINYA	RURAL
NORTH WEST	JIGAWA	BIRNIN KUDU	ZARAINA	RURAL
NORTH WEST	JIGAWA	DUTSE	TAKUR GIDA DUBU	URBAN
NORTH WEST	JIGAWA	KIRIKASAMMA	TUTIYARI	RURAL
NORTH WEST	JIGAWA	KIYAWA	KULLURU	RURAL
NORTH WEST	JIGAWA	MAIGATARI	DANKUMBO	RURAL
NORTH WEST	JIGAWA	MIGA	SANSANI CIKIN GARI	RURAL
NORTH WEST	KADUNA	BIRNIN-GWARI	UNG DANBORNO	RURAL
NORTH WEST	KADUNA	GIWA	GIWA	URBAN
NORTH WEST	KADUNA	IGABI	MARARABAN JOS	RURAL
NORTH WEST	KADUNA	IGABI	TUDUN WADA- RIGACHIKUN	URBAN
NORTH WEST	KADUNA	IKARA	DAN LAWAL	RURAL
NORTH WEST	KADUNA	JEMA 'A	DALLE	RURAL
NORTH WEST	KADUNA	KACHIA	RIJANA	RURAL
NORTH WEST	KADUNA	KADUNA SOUTH	BADIKO	URBAN
NORTH WEST	KADUNA	KUBAU	ANCHAU TAKALAFIYA	URBAN
NORTH WEST	KADUNA	LERE	KWANAN DOYA	RURAL
NORTH WEST	KADUNA	LERE	SAMINAKA	URBAN
NORTH WEST	KANO	ALBASU	MAN GARI	RURAL
NORTH WEST	KANO	BICHI	DARIYA SANAKUR	RURAL
NORTH WEST	KANO	BUNKURE	GORA CIKIN GARI	URBAN
NORTH WEST	KANO	DALA	GOBIRAWA A	URBAN
NORTH WEST	KANO	GAYA	BAROKIJO/SHAGOGO	RURAL
NORTH WEST	KANO	GWALE	LOKON MAKERA	URBAN
NORTH WEST	KANO	KANO MUNICIPAL	DURUMIN ZUNGURA	URBAN
NORTH WEST	KANO	KUMBOTSO	SHEKA UNG. KUDU	URBAN
NORTH WEST	KANO	KUMBOTSO	YAN KUSA FAN DAKA	RURAL
NORTH WEST	KANO	KURA	KURUNSU MAU-RIMI	RURAL
NORTH WEST	KANO	MAKODA	FULANI KOFA/MAKODA	RURAL
NORTH WEST	KANO	MINJIBIR	KUNYA C/GARI	RURAL

NORTH WEST	KANO	NASARAWA	GIGINYU	URBAN
NORTH WEST	KANO	RIMIN GADO	YALWAN DAN ZIYEL	RURAL
NORTH WEST	KANO	ROGO	BELI C/GARI	RURAL
NORTH WEST	KATSINA	BINDAWA	MAZANYA YANHORE	RURAL
NORTH WEST	KATSINA	DANJA	DABAI	RURAL
NORTH WEST	KATSINA	DUTSI	DAURAWA	RURAL
NORTH WEST	KATSINA	FASKARI	REMANYA	RURAL
NORTH WEST	KATSINA	KAITA	LOMI	RURAL
NORTH WEST	KATSINA	KANKARA	KANKARA	URBAN
NORTH WEST	KATSINA	KANKIA	KAFIN SOLI	RURAL
NORTH WEST	KATSINA	KATSINA	FILIN SAMJI	URBAN
NORTH WEST	KATSINA	MUSAWA	FAMMA GORO	RURAL
NORTH WEST	KATSINA	RIMI	ABUKUR	RURAL
NORTH WEST	KEBBI	AUGIE	LITTU GAJE	RURAL
NORTH WEST	KEBBI	BIRNIN KEBBI	BIRNIN KEBBI	URBAN
NORTH WEST	KEBBI	DANDI	YALAWA	RURAL
NORTH WEST	KEBBI	JEGA	KUITANE	RURAL
NORTH WEST	KEBBI	NGASKI	WARA II	RURAL
NORTH WEST	KEBBI	WASAGU/DANKO	TUDUN YAR UKKU	RURAL
NORTH WEST	SOKOTO	SABON BIRNI	SHAMATAWAR ALH. MAMMAN	RURAL
NORTH WEST	SOKOTO	SOKOTO NORTH	SOKOTO	URBAN
NORTH WEST	SOKOTO	TAMBUWAL	SANYINNA	RURAL
NORTH WEST	SOKOTO	TANGAZA	KWANNAWA	RURAL
NORTH WEST	SOKOTO	WURNO	GIDAN JIKAN DAJI, ILLELAR MUAZU	RURAL
NORTH WEST	SOKOTO	YABO	KAURA TSOHON GIDA	RURAL
NORTH WEST	ZAMFARA	BIRNIN-MAGAJI	MODOMAWA	RURAL
NORTH WEST	ZAMFARA	BUKKUYUM	KARARE	RURAL
NORTH WEST	ZAMFARA	GUSAU	SARARA	RURAL
NORTH WEST	ZAMFARA	KAURAN-NAMODA	KAURAN-NAMODA	URBAN
NORTH WEST	ZAMFARA	MARADUN	FARU	RURAL
NORTH WEST	ZAMFARA	MARU	RUWAN DORUWA	RURAL
SOUTH EAST	ABIA	ABA SOUTH	OKPULOR - OKPOJIAKU	RURAL
SOUTH EAST	ABIA	AROCHUKWU	IBOM AROCHUKWU	RURAL
SOUTH EAST	ABIA	BENDE	AMAOKWU ELU	RURAL
SOUTH EAST	ABIA	IKWUANO	ELEMAGA IBERE	RURAL
SOUTH EAST	ABIA	OBINGWA	UMUOCHA	RURAL
SOUTH EAST	ABIA	OSISIOMA NGWA	ABAYI	URBAN
SOUTH EAST	ANAMBRA	AGUATA	UMUGAMA-IHITE-UMUCHU	URBAN
SOUTH EAST	ANAMBRA	ANAOCHA	OKPALAEGBO-ADAZI-NNUKWU	URBAN
SOUTH EAST	ANAMBRA	AYAMELUM	UMERUM	RURAL
SOUTH EAST	ANAMBRA	IDEMILI NORTH	EBENESI-ORAUKWU	URBAN
SOUTH EAST	ANAMBRA	IHALA	UBAHA-ISEKE	RURAL
SOUTH EAST	ANAMBRA	NNEWI NORTH	OKPUNO-EGBU-EKWULU UMUDIM-NNEWI	URBAN
SOUTH EAST	ANAMBRA	NNEWI SOUTH	AFUBE-AMICHI	URBAN

SOUTH EAST	ANAMBRA	OGBARU	ANUMUDU-OKPOKO	URBAN
SOUTH EAST	ANAMBRA	ORUMBA NORTH	UMUEVE-AJALLI	RURAL
SOUTH EAST	ANAMBRA	OYI	OYOLU-PHASE I NKWELLE-EZUNAKA	URBAN
SOUTH EAST	EBONYI	EBONYI	NDIECHI ISHIEKE	RURAL
SOUTH EAST	EBONYI	EZZA NORTH	NDUFU UMUEZEALI ORIUZOR	RURAL
SOUTH EAST	EBONYI	IKWO	ODELIGBO AMAINYIMA OKPUITUMO	RURAL
SOUTH EAST	EBONYI	IVO	NDIBE OKPARIKE IHENTA	RURAL
SOUTH EAST	EBONYI	OHAOZARA	UMUAHAM UMUIGBOKE UGWULANGWU	RURAL
SOUTH EAST	ENUGU	AWGU	EZERE UGWUNGWU	RURAL
SOUTH EAST	ENUGU	ENUGU SOUTH	AWKUNANAW GARIKI	URBAN
SOUTH EAST	ENUGU	EZEAGU	UMUAGBA OWA UMUAGU	URBAN
SOUTH EAST	ENUGU	IGBO-ETITI	AMAKOFIA UKEHE OBINETITI	URBAN
SOUTH EAST	ENUGU	IGBO-EZE SOUTH	UNADU OBAKA AGU	RURAL
SOUTH EAST	ENUGU	NKANU EAST	OVUORIE-UGBAWKA-AMAMFU,ONUORE	URBAN
SOUTH EAST	ENUGU	OJI -RIVER	ISIKWE-ACHI OBINAGU .	URBAN
SOUTH EAST	ENUGU	UDENU	OBOLLO AFOR-UMUEZEJOR	URBAN
SOUTH EAST	ENUGU	UDI	EBE ADUKWU	RURAL
SOUTH EAST	IMO	AHIAZU-MBAISE	UMUAGBAVU	URBAN
SOUTH EAST	IMO	IDEATO NORTH	UMUOPIA	URBAN
SOUTH EAST	IMO	IKEDURU	AMASAA	RURAL
SOUTH EAST	IMO	ISIALA-MBANO	EZIAMA	RURAL
SOUTH EAST	IMO	ISU	EBENANO	URBAN
SOUTH EAST	IMO	NGOR-OKPALA	UMUODAGU NTU	RURAL
SOUTH EAST	IMO	OBOWO	UMUOKPA-UMULOGHO	RURAL
SOUTH EAST	IMO	OKIGWE	OFOATO	RURAL
SOUTH EAST	IMO	ORU EAST	UMUDARA-AKATTA	RURAL
SOUTH EAST	IMO	ORU WEST	UMUEMEOCHA OBI MGBIDI	URBAN
SOUTH EAST	IMO	OWERRI MUNICIPAL	OWERRI	URBAN
SOUTH SOUTH	AKWA IBOM	EASTERN OBOLO	UDUM OKPON	RURAL
SOUTH SOUTH	AKWA IBOM	ETINAN	ETINAN	URBAN
SOUTH SOUTH	AKWA IBOM	IKONO	ITON ODORO	RURAL
SOUTH SOUTH	AKWA IBOM	NSIT IBOM	AFAHA OFFIONG	RURAL
SOUTH SOUTH	AKWA IBOM	UKANAFUN	IKOT AKAI	RURAL
SOUTH SOUTH	AKWA IBOM	URUE -- OFFONG / ORUKO	UKUDA	RURAL
SOUTH SOUTH	AKWA IBOM	UYO	MBIABONG IKOT ESSIEN	RURAL
SOUTH SOUTH	BAYELSA	SAGBAMA	OFONI	URBAN
SOUTH SOUTH	BAYELSA	SAGBAMA	OGOIRI	RURAL
SOUTH SOUTH	BAYELSA	SOUTHERN IJAW	POLOBUBOU	RURAL


SOUTH SOUTH	CROSS RIVER	ABI	IBALEBO-ADADAMA	RURAL
SOUTH SOUTH	CROSS RIVER	AKPABUYO	IKOT EKPE OKON-IKOT ENEYO	RURAL
SOUTH SOUTH	CROSS RIVER	BEKWARRA	ABUALUGU	RURAL
SOUTH SOUTH	CROSS RIVER	ETUNG	MONI BAKA	RURAL
SOUTH SOUTH	DELTA	BURUTU	AYAKOROMO	RURAL
SOUTH SOUTH	DELTA	IKA NORTH EAST	OWA-ALERO	RURAL
SOUTH SOUTH	DELTA	OKPE	EGBORODE	RURAL
SOUTH SOUTH	DELTA	OSHIMILI SOUTH	ASABA	URBAN
SOUTH SOUTH	DELTA	PATANI	PATANI	URBAN
SOUTH SOUTH	DELTA	UGHELLI NORTH	EKREDJEBOR	RURAL
SOUTH SOUTH	DELTA	WARRI SOUTH	IGBUDU 2 OTOVWODO AGBARHA WARRI)	URBAN
SOUTH SOUTH	EDO	ESAN NORTH EAST	UROMI	URBAN
SOUTH SOUTH	EDO	OREDO	BENIN CITY	URBAN
SOUTH SOUTH	EDO	ORHIONMWON	URHONIGBE	URBAN
SOUTH SOUTH	EDO	OVI SOUTH WEST	IKOHA	RURAL
SOUTH SOUTH	EDO	OWAN EAST	UOKHA	RURAL
SOUTH SOUTH	RIVERS	AHOADA WEST	UKPELIEDE	RURAL
SOUTH SOUTH	RIVERS	ASARI TORU	BUGUMA	URBAN
SOUTH SOUTH	RIVERS	IKWERRE	APANI	RURAL
SOUTH SOUTH	RIVERS	OBIO/AKPOR	RUMUROLU	RURAL
SOUTH SOUTH	RIVERS	OYIGBO	OYIGBO URBAN	URBAN
SOUTH SOUTH	RIVERS	PORT-HAROURT	AZUABIE	URBAN
SOUTH SOUTH	RIVERS	TAI	KPOGHOR	RURAL
SOUTH WEST	EKITI	ADO EKITI	ADO-EKITI	URBAN
SOUTH WEST	EKITI	AIYEKIRE(GBONYIN)	ODE EKITI	URBAN
SOUTH WEST	EKITI	EFON	EFON - ALAAYE	URBAN
SOUTH WEST	EKITI	EMURE	OMU-OKE	URBAN
SOUTH WEST	EKITI	IDO-OSI	IFAKI EKITI	URBAN
SOUTH WEST	EKITI	IJERO	OKE ORO EKITI	RURAL
SOUTH WEST	EKITI	IKERE	IKERE EKITI	URBAN
SOUTH WEST	EKITI	IKOLE	IJEBU AGEGE	URBAN
SOUTH WEST	EKITI	OYE	ITAPA EKITI	RURAL
SOUTH WEST	LAGOS	AGEGE	KEKE	URBAN
SOUTH WEST	LAGOS	AGEGE	ORILE	URBAN
SOUTH WEST	LAGOS	AJEROMI IFELODUN	AMUKOKO	URBAN
SOUTH WEST	LAGOS	AJEROMI IFELODUN	AWODI-ORA	URBAN
SOUTH WEST	LAGOS	AJEROMI IFELODUN	TEMIDIRE	URBAN
SOUTH WEST	LAGOS	ALIMOSHO	ABARANJE	URBAN
SOUTH WEST	LAGOS	ALIMOSHO	ABORU	URBAN
SOUTH WEST	LAGOS	ALIMOSHO	ALAGBADO	URBAN
SOUTH WEST	LAGOS	ALIMOSHO	EGBE	URBAN
SOUTH WEST	LAGOS	ALIMOSHO	OKUNOLA	URBAN
SOUTH WEST	LAGOS	AMUWO ODOFIN	AMUWO	URBAN
SOUTH WEST	LAGOS	APAPA	ABETE	URBAN

SOUTH WEST	LAGOS	BADAGRY	OGHOGBO	RURAL
SOUTH WEST	LAGOS	EPE	KETU EJIRIN	RURAL
SOUTH WEST	LAGOS	ETI OSA	TAKWA BAY	URBAN
SOUTH WEST	LAGOS	IFAKO IJAYE	HAMADIYA	URBAN
SOUTH WEST	LAGOS	IFAKO IJAYE	OGBA IJAIYE	URBAN
SOUTH WEST	LAGOS	IKEJA	OPEBI	URBAN
SOUTH WEST	LAGOS	IKORODU	ERUNWEN	URBAN
SOUTH WEST	LAGOS	IKORODU	OWUTU	URBAN
SOUTH WEST	LAGOS	KOSOFE	KETU	URBAN
SOUTH WEST	LAGOS	KOSOFE	MAGODO	URBAN
SOUTH WEST	LAGOS	KOSOFE	OWORONSHOKI	URBAN
SOUTH WEST	LAGOS	LAGOS ISLAND	AGARAWU	URBAN
SOUTH WEST	LAGOS	LAGOS MAINLAND	OYINGBO	URBAN
SOUTH WEST	LAGOS	MUSHIN	ITIRE	URBAN
SOUTH WEST	LAGOS	MUSHIN	MOSHALASI	URBAN
SOUTH WEST	LAGOS	OJO	AJANGBADI	URBAN
SOUTH WEST	LAGOS	OJO	IJANIKIN	URBAN
SOUTH WEST	LAGOS	OSHODI ISOLO	EJIGBO	URBAN
SOUTH WEST	LAGOS	OSHODI ISOLO	ISOLO	URBAN
SOUTH WEST	LAGOS	SHOMOLU	BARIGA	URBAN
SOUTH WEST	LAGOS	SURULERE	IKATE	URBAN
SOUTH WEST	LAGOS	SURULERE	TEJUOSHO	URBAN
SOUTH WEST	OGUN	ABEOKUTA SOUTH	IBARA ABEOKUTA	URBAN
SOUTH WEST	OGUN	ABEOKUTA NORTH	OWU ABEOKUTA	URBAN
SOUTH WEST	OGUN	ADO-ODO/OTA	ADO - ODO	URBAN
SOUTH WEST	OGUN	ADO-ODO/OTA	IJOKO-OTA	URBAN
SOUTH WEST	OGUN	ADO-ODO/OTA	OWODE-OTA	RURAL
SOUTH WEST	OGUN	EGBADO NORTH	ALABATA, ALAGA, ISHAGA, ALABE,	RURAL
SOUTH WEST	OGUN	EWEKORO	OBADA OKO	RURAL
SOUTH WEST	OGUN	IFO	ALAGBOLE	URBAN
SOUTH WEST	OGUN	IFO	OTUN AKUTE	RURAL
SOUTH WEST	OGUN	IJEBU ODE	IJEBU ODE	URBAN
SOUTH WEST	OGUN	IKENNE	IPERU	URBAN
SOUTH WEST	OGUN	ODOGBOLU	OKEORUNDUN	RURAL
SOUTH WEST	ONDO	AKOKO NORTH EAST	IKARE-AKOKO	URBAN
SOUTH WEST	ONDO	AKOKO SOUTH EAST	EPINMI AKOKO	RURAL
SOUTH WEST	ONDO	AKURE SOUTH	AKURE	URBAN
SOUTH WEST	ONDO	ESE ODO	KIRIBO	RURAL
SOUTH WEST	ONDO	IDANRE	TEJUGBOLA	RURAL
SOUTH WEST	ONDO	IFEDORE	IGBARA-OKE	URBAN
SOUTH WEST	ONDO	ILAJE	OJAN	RURAL
SOUTH WEST	ONDO	ILE OLUJI/OKEIGBO	OLORUNTELE	RURAL
SOUTH WEST	ONDO	IRELE	ODE IRELE	URBAN
SOUTH WEST	ONDO	ODIGBO	AJUE	RURAL
SOUTH WEST	ONDO	ONDO WEST	ONDO	URBAN
SOUTH WEST	ONDO	OSE	IFON	URBAN

SOUTH WEST	ONDO	OWO	OLOKO CAMP, BOLORUNDURO	RURAL
SOUTH WEST	OSUN	ATAKUMOSA WEST	IFEWARA	RURAL
SOUTH WEST	OSUN	AYEDADE	GBONGAN	URBAN
SOUTH WEST	OSUN	BOLUWADURO	IRESI	URBAN
SOUTH WEST	OSUN	EGBEDORE	OLORUNSOGO	RURAL
SOUTH WEST	OSUN	IFE CENTRAL	ILE - IFE	URBAN
SOUTH WEST	OSUN	IFE EAST	FADEJI, SOMISEMU, AFEKI. FIDIBOMI	RURAL
SOUTH WEST	OSUN	IFE SOUTH	IFETEDO	URBAN
SOUTH WEST	OSUN	ILESIA WEST	ILESIA	URBAN
SOUTH WEST	OSUN	IREWOLE	IKIRE	URBAN
SOUTH WEST	OSUN	IWO	IWO	URBAN
SOUTH WEST	OSUN	OBOKUN	ESA-OKE	URBAN
SOUTH WEST	OSUN	OLORUNDA	OTA-EFUN	URBAN
SOUTH WEST	OSUN	OSOGBO	OSOGBO	URBAN
SOUTH WEST	OYO	AKINYELE	BAMGBE	URBAN
SOUTH WEST	OYO	ATIBA	ELERINLE	RURAL
SOUTH WEST	OYO	ATIBA	SAAKIN	URBAN
SOUTH WEST	OYO	ATIGBO	TEDE	RURAL
SOUTH WEST	OYO	EGBEDA	ADEGBAYI	URBAN
SOUTH WEST	OYO	IBADAN NORTH	ALARO	URBAN
SOUTH WEST	OYO	IBADAN NORTH EAST	IREFIN	URBAN
SOUTH WEST	OYO	IBADAN NORTH WEST	ELEYELE	URBAN
SOUTH WEST	OYO	IBADAN SOUTH EAST	ODINJO	URBAN
SOUTH WEST	OYO	IBADAN SOUTH WEST	OKE ADO	URBAN
SOUTH WEST	OYO	IBARAPA CENTRAL	GAA EZEKIEL, ABULE ASAKA, ABULE EZEKIEL,	RURAL
SOUTH WEST	OYO	IDO	ALAAFIA ESTATE	URBAN
SOUTH WEST	OYO	KAJOLA	ABA OLUKOTUN ILERO, MAFOHUN, MOLETE II, ABULE BABA AFIS O, ABA- ADEYEMI, OGUN OSUN, MOLETE I,	RURAL
SOUTH WEST	OYO	KAJOLA	OKEHO	URBAN
SOUTH WEST	OYO	OGBOMOSHO NORTH	OGBOMOSHO OWODE- OMOSIN	URBAN
SOUTH WEST	OYO	OLUYOLE	OLUNDE	URBAN
SOUTH WEST	OYO	ONA- ARA	IDI OSE	URBAN
SOUTH WEST	OYO	ORELOPE	BUDO ASO	RURAL
SOUTH WEST	OYO	ORELOPE	IGBOHO	URBAN
SOUTH WEST	OYO	OYO WEST	PAKOYI	URBAN
SOUTH WEST	OYO	SURULERE	ELEBEKEBE	RURAL



Annex 5: Map of Sampled Clusters





## Annex 6: Detailed Sample Description

**Table X1: National Sample Description**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
<b>Number of outlets screened (Figure 1 Box B)</b>	214	12	15	241	333	230	2801	9762	13126	13367
<b>Number of outlets eligible and interviewed (Figure 1 Box D)</b>	159	5	5	169	168	200	1950	35	2353	2522
<b>Number of outlets eligible but not interviewed (interview non-participation)</b>	1	0	0	1	7	5	11	1	24	25
<b>Number of interviewed outlets with at least one modern contraceptive (excluding condoms) on the day of the survey (Figure 1, Box D1)</b>	142	3	3	148	138	197	1730	33	2098	2246
<b>Number of interviewed outlets that provide associated FP services, but do not stock modern contraceptives (excluding condoms) (Figure 1 Box D3)</b>	17	0	2	19	26	2	46	0	74	93

**Table X2: Regional Sample Description**

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
<b>Number of outlets screened (Figure 1 Box B)</b>	214	12	15	241	333	230	2801	9762	13126	13367
North Central	48	3	1	52	51	43	416	1253	1763	1815
North East	25	0	1	26	13	7	127	394	541	567
North West	44	1	1	46	15	4	285	929	1233	1279
South East	21	3	4	28	53	20	329	1094	1496	1524
South South	20	1	1	22	28	21	194	879	1122	1144
South West	56	4	7	67	173	135	1450	5213	6971	7038
<b>Number of outlets eligible and interviewed (Figure 1 Box D)</b>	159	5	5	169	168	200	1950	35	2353	2522
North Central	37	2	1	40	26	42	321	4	393	433
North East	18	0	1	19	6	3	89	0	98	117
North West	32	1	1	34	10	4	221	0	235	269

	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
South East	12	0	0	12	24	16	156	4	200	212
South South	15	0	0	15	8	16	121	0	145	160
South West	45	2	2	49	94	119	1042	27	1282	1331
<b>Number of outlets eligible but not interviewed (interview non-participation)</b>	1	0	0	1	7	5	11	1	24	25
North Central	0	0	0	0	0	0	2	1	3	3
North East	0	0	0	0	0	0	1	0	1	1
North West	0	0	0	0	0	0	0	0	0	0
South East	0	0	0	0	0	0	1	0	1	1
South South	0	0	0	0	1	2	1	0	4	4
South West	1	0	0	1	6	3	6	0	15	16
<b>Number of interviewed outlets with at least one modern contraceptive (excluding condoms) on the day of the survey (Figure 1, Box D1)</b>	142	3	3	148	138	197	1730	33	2098	2246
North Central	34	2	1	37	20	40	274	5	339	376
North East	18	0	1	19	3	2	83	0	88	107
North West	29	0	0	29	5	4	191	0	200	229
South East	11	0	0	11	23	16	141	4	184	195
South South	15	0	0	15	7	17	118	0	142	157
South West	35	1	1	37	80	118	923	24	1145	1182
<b>Number of interviewed outlets that provide associated FP services, but do not stock modern contraceptives (excluding condoms) (Figure 1 Box D3)</b>	17	0	2	19	26	2	46	0	74	93
North Central	3	0	0	3	5	1	7	0	13	16
North East	0	0	0	0	3	1	0	0	4	4
North West	3	0	1	4	5	0	13	0	18	22
South East	1	0	0	1	1	0	4	0	5	6
South South	0	0	0	0	1	0	1	0	2	2

**Table X3: Urban vs Rural Sample Description**

	Public Health Facility	Community Health Workers	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
<b>Number of outlets screened (Figure 1 Box B)</b>	214	12	15	241	333	230	2801	9762	13126	13367
Urban	107	2	11	120	274	214	2231	10548	7829	10668
Rural	107	10	4	121	59	16	570	2578	1933	2699
<b>Number of outlets eligible and interviewed (Figure 1 Box D)</b>	159	5	5	169	168	200	1950	35	2353	2522
Urban	84	1	4	89	131	187	1593	29	1940	2029
Rural	75	4	1	80	37	13	357	6	413	493
<b>Number of outlets eligible but not interviewed (interview non-participation)</b>	1	0	0	1	7	5	11	1	24	25
Urban	0	0	0	0	7	4	10	1	22	22
Rural	1	0	0	1	0	1	1	0	2	3
<b>Number of interviewed outlets with at least one modern contraceptive (excluding condoms) on the day of the survey (Figure 1, Box D1)</b>	142	3	3	148	138	197	1730	33	2098	2246
Urban	76	0	2	78	113	185	1418	25	1744	1822
Rural	66	3	1	70	25	12	312	5	354	424
<b>Number of interviewed outlets that provide associated FP services, but do not stock modern contraceptives (excluding condoms) (Figure 1 Box D3)</b>	17	0	2	19	26	2	46	0	74	93
Urban	8	0	2	10	15	2	36	0	53	63
Rural	9	0	0	19	11	0	10	0	21	30

## Annex 7: Questionnaire

### ACT/FPwatch Integrated Outlet Survey

**NIGERIA 2015**

Section 1: Census Information: <i>Interviewer completes this section for <u>all</u> outlets.</i>		
Outlet ID (Interviewer-State-LGA-Locality-Outlet ID)		
[ ][ ]-[ ][ ][ ]-[ ][ ][ ][ ]-[ ][ ][ ][ ][ ]-[ ][ ][ ][ ]		
C1. Today's date (dd/mm/yyyy)	[ ][ ]-[ ][ ]-[ 2   0   1   5 ]	
C2. Interviewer's name	C2a. Interviewer's code	[ ][ ]
C3. State	C3a. State code	[ ][ ][ ]
C4. Local Government Area (LGA)	C4a. LGA code	[ ][ ][ ][ ]
C5. Locality	C5a. Locality code	[ ][ ][ ][ ][ ][ ]
C6. Village/street		
C7. Name of outlet <i>If no name, record "no name"</i>	C7a. Outlet code	[ ][ ][ ][ ]
C8. Type of Outlet	<div> <div> 01 = University Hospital/Federal Medical Center  02 = General Hospital/Specialist  03 = Primary Health Care Center/Comprehensive Health Center  04 = NGO/Mission Hospital  05 = Private Hospital/Private Clinic  06 = Pharmacy  07 = Proprietary Patent Medicine Vendor  08 = Private Diagnostics Lab (<i>lab only</i>)  09 = NGO/Mission Diagnostics Lab (<i>lab only</i>) </div> <div> 10 = Super/Mini-Market/Provisions Store  11 = Kiosk/Table  12 = Community Health Extension Workers  24 = Role Model Mother  25 = Village Health Worker  15 = Hawker  96 = Other (<i>specify</i>)  [ ][ ][ ][ ] </div> </div>	
C8. Is this area part of the booster sample?	1 = Yes      0=No	[ ]

Hello, my name is \_\_\_\_\_, I work for Society for Family Health on behalf of Population Services International. We are conducting a study on the availability of antimalarial medicines and diagnostic testing services and family planning products and services. The results will be used to improve the availability of appropriate antimalarial treatment and family planning methods in Nigeria. I would like to ask you a few questions to see if you could be part of the survey.

Section 2: Screening & Eligibility for Antimalarials: Interviewer completes this section for <u>all outlets</u> .	
SM1. Do you have any medicines in stock today? 1 = Yes <b>Go to SM3</b> 0 = No	<input type="text"/>
SM2. Are there any medicines that are out of stock today, but that you stocked in the <u>past 3 months</u> ? 1 = Yes <b>Go to SM4</b> 0 = No <b>Go to SM5</b> 8 = Don't know <b>Go to SM5</b>	<input type="text"/>
SM3. Do you have any antimalarial medicines in stock today? 1 = Yes <b>Provide information sheet &amp; gain consent. Record start time in C9.</b> <b>Proceed to <u>Section 4: Antimalarial Audit</u>.</b> 0 = No                    Verify with prompt card. <b>Go to SM4</b>	<input type="text"/>
SM4. Are there any antimalarial medicines that are out of stock today, but that you stocked in the <u>past 3 months</u> ? 1 = Yes <b>Provide information sheet &amp; gain consent. Record start time in C9. Proceed to <u>Section 4: Antimalarial Audit, Question AM16</u>.</b> 0 = No <b>Verify with prompt card. Go to SM5</b> 8 = Don't know <b>Verify with prompt card. Go to SM5</b>	<input type="text"/>
SM5. Are you offering any diagnostic services or selling any diagnostic tests here today?	<input type="text"/>

1 = Yes 0 = No	<b>Go to SM6</b> <b>Verify with prompt card. Proceed to <u>Section 3: Screening &amp; Eligibility for Family Planning</u>.</b>	
SM6. Are any of these services or tests for suspected malaria?  1 = Yes  0 = No	<b>Provide information sheet &amp; gain consent. Record start time in C9.</b> <b>Proceed to <u>Section 5: Diagnostic Audit</u>.</b> <b>Verify with prompt card. Proceed to <u>Section 3: Screening &amp; Eligibility for Family Planning</u>.</b>	<input type="text"/>

***Before proceeding to the full interview ensure you have given the respondent a study information sheet, explained the study and obtained informed consent.***

Section 3: Screening & Eligibility for Family Planning: Interviewer completes this section for <u>all outlets</u> .	
SFP1. Do you have any male or female condoms available at this location today? <b>Verify with prompt cards.</b> 1 = Yes 0 = No      Verify with prompt card. <b>Go to SFP7</b>	<input type="text"/>
SFP2. What brands of male condoms do you have in stock today? A = (specify): <input type="text"/> B = (specify): <input type="text"/> C = (specify): <input type="text"/> D = (specify): <input type="text"/> E = (specify): <input type="text"/> X = No male condoms Z = Refused	
SFP3. What brands of female condoms do you have in stock today? A = (specify): <input type="text"/> B = (specify): <input type="text"/> C = (specify): <input type="text"/> X = No female condoms Z = Refused	
SFP4. What is the most common brand of condom you sell to individual consumers? A = (specify): <input type="text"/> Y = Don't know Z = Refused	
SFP5. What is the price for the most common brand of condoms you sell to individual consumers? <b>If condoms are sold individually, record '1' for package size.</b> This outlet sells a package of <input type="text"/> <input type="text"/> condom(s) for <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> –N– (Nigerian Naira). 98 = Don't know                      9998 = Don't know 99 = Refused                              9999 = Refused	
SFP6. How many condoms <u>of all brands</u> total have you sold to individual consumers at this location in the <u>last 7 days</u> ? <b>If condoms are sold individually, record '1' for package size.</b> This outlet sold <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> individual condoms in the <u>last 7 days</u> . 9998 = Don't know 9999 = Refused	

<p>SFP7. Do you have any of the following family planning products available at this location <u>today</u>? <b><i>Read all options and verify each option with prompt cards.</i></b></p> <ul style="list-style-type: none"> <li>A. Oral contraceptive tablets</li> <li>B. Emergency contraceptive tablets</li> <li>C. Injectable contraceptives</li> <li>D. Contraceptive implants</li> <li>E. Contraceptive IUDs</li> </ul>	<p>1 = Yes (<i>if at least one available</i>)  <b><i>Provide information sheet &amp; gain consent. Record start time in C9. Proceed to <u>Section 8: Family Planning Product Audit.</u></i></b>  0 = No (<i>none available</i>)</p> <p style="text-align: center;">[ ]</p>
<p>SFP8. Are there any of the following family planning products that are out of stock today, but that you stocked in the <u>past 3 months</u> at this location? <b><i>Read all options and verify each option with prompt cards.</i></b></p> <ul style="list-style-type: none"> <li>A. Oral contraceptive tablets</li> <li>B. Emergency contraceptive tablets</li> <li>C. Injectable contraceptives</li> <li>D. Contraceptive implants</li> <li>E. Contraceptive IUDs</li> </ul>	<p>1 = Yes (<i>if at least one available</i>)  <b><i>Provide information sheet &amp; gain consent. Record start time in C9. Proceed to <u>Section 8: Family Planning Product Audit, Question AFP15.</u></i></b>  0 = No</p> <p style="text-align: center;">[ ]</p>
<p>SFP9. Do you provide any of the following family planning services at this location? <b><i>Read all options.</i></b></p> <ul style="list-style-type: none"> <li>A. Insertion/removal of contraceptive implants</li> <li>B. Insertion/removal of contraceptive IUDs</li> <li>C. Female sterilizations</li> <li>D. Male sterilizations</li> </ul>	<p>1 = Yes (<i>if at least one available</i>)  <b><i>Provide information sheet &amp; gain consent. Record start time in C9. Proceed to <u>Section 9 Family Planning Provider Module-All Methods Except Sterilizations</u></i></b>  0 = No  <b><i>Proceed to <u>Section 12: ORS, Zinc &amp; Amoxicillin</u>; Consent not required.</i></b></p> <p style="text-align: center;">[ ]</p>

***If have not done so previously for malaria sections, before proceeding to the full interview for family planning sections ensure you have given the respondent a study information sheet, explained the study and obtained informed consent.***

<b>Section 12: ORS, Zinc &amp; Amoxicillin: Interviewer completes this section for <u>ALL</u> outlets.</b> <b>Read to the provider:</b> I have just a few questions for you about availability of treatments for diarrhea and pneumonia.	
ORS1. Do you have any oral rehydration salts, also known as ORS in stock today? <b>Verify with prompt card</b> 1 = Yes 0 = No	[ ]
ORS2. Do you have any zinc tablets for treatment of diarrhea in children in stock today? <b>Verify with prompt card</b> 1 = Yes 0 = No <b>Go to AB1</b>	[ ]
ORS3. Which strength of zinc tablets for treatment of diarrhea in children do you have in stock today? <b>Read list, circle ALL that apply</b> A = 10mg B = 20mg Z = Other (specify): [ ]	A B Z
ORS4. Do you have any ORS that is packaged together with zinc treatment for diarrhea in children in stock today? <b>Verify with prompt card</b> 1 = Yes 0 = No	[ ]
AB1. Do you have any antibiotics in stock today? 1 = Yes 0 = No	[ ]
AB2. Do you have any amoxicillin dispersible tablets, also known as Amox DT? <b>Show prompt card. Interviewer: ask to see the product and verify that it is dispersible amoxicillin</b> 1 = Yes 0 = No <b>Go to C9 – Result of visit</b>	[ ]
AB3. Which strength of amoxicillin dispersible tablets, also known as Amox DT, do you have in stock today? <b>Read list, circle ALL that apply</b> A = 125mg B = 250mg Z = Other (specify): [ ]	A B Z
<b>Go to <u>C9 – Result of Visit.</u></b>	

C9. Result of visit(s).			
Date (dd/mm/yy)	Visit 1	Visit 2	Visit 3
	[ ][ ]-[ ][ ]-[ 1   5 ]	[ ][ ]-[ ][ ]-[ 1   5 ]	[ ][ ]-[ ][ ]-[ 1   5 ]
Time started (in 24hr clock)	[ ][ ]:[ ][ ]	[ ][ ]:[ ][ ]	[ ][ ]:[ ][ ]
Time completed (in 24hr clock)	[ ][ ]:[ ][ ]	[ ][ ]:[ ][ ]	[ ][ ]:[ ][ ]
Result	[ ][ ]	[ ][ ]	[ ][ ]
	01 = Outlet eligible & survey completed 02 = Outlet ineligible: does not meet any screening criteria 03 = Interview interrupted 04 = Respondent not available/time not convenient 05 = Outlet not open at the time 06 = Outlet closed permanently 96 = Other (specify):[ _____] 99 = Refused		<b>Go to E1</b> <b>Go to E1</b> <b>Go to C11</b> <b>Go to C11</b> <b>Go to C11</b> <b>Go to E1</b> <b>Go to C10</b>
C10. If the provider refused, why? 1 = Client load <b>Ask respondent for a time they would prefer to be interviewed and note in C11</b> 2 = Thinks it's an inspection / nervous about license <b>Go to E1</b> 3 = Not interested <b>Go to E1</b> 6 = Other (specify):[ _____] 9 = Refuses to give reason <b>Go to E1</b>			[ ]
C11. Use this space to record call back details. If it is not possible to complete the interview at another time, Go to E1.			

Section E: Ending the interview	
E1. Name of interviewee:  5 = Not applicable, no respondent; 9 = Refused	[ ]
E2. Physical address or location identifiers of outlet (not PO box) <i>(Give detailed description that will help supervisor to find the outlet)</i>	E3. Telephone number 9999999995 = Not applicable: no respondent or has no telephone 9999999999 = Refused  [ ][ ][ ][ ][ ][ ][ ][ ][ ][ ][ ]
E4. Latitude: [ N ]-[ ][ ][ ][ ][ ][ ][ ][ ]	E5. Longitude: [ E ]-[ ][ ][ ][ ][ ][ ][ ][ ]
E6. Additional observations by interviewer (if any)	

***THANK THE PROVIDER AND END INTERVIEW.***



## I. ANTIMALARIALS

### Section 4: Antimalarial Audit

#### A0. Read to the provider:

Can you please show us the full range of antimalarials that you currently have in stock? Do you currently have any of the following?

**Prompt entire list using antimalarial prompt card; No response to be recorded.**

- **Artemether lumefantrine**, such as *Lonart, Lonart-DS, Amatem, Artemef, Lumartem, Coartem, Lokmal*
- **Artesunate amodiaquine**, such as *Larimal, Comosunate, Dart, Diasuate, Arsuamoon, Malmed*
- **Other artemisinin combination therapies**, such as *P-Alaxin, Artequin, Waip, ACT, Co-Arinate, Duo-Cotecxin*
- **Artemether monotherapies**, such as *Gvither, Sanarteme, Artem*
- **Artesunate monotherapies**, such as *Artesunat, G-Sunate, Askasunate, Malmeter, Eurosunate, Arthlon*
- **Chloroquine**, such as *New 2.2.1, Evans, Palquine, Dana Quimal, Capquin, Vinaquine*
- **SP**, such as *Fansidar, Amalar, Laridox, Maldox, Malareich, Metakelfin, Antimal, Vitadar*
- **Quinine**, such as *Malagold, Alpaquine, Embassy Quine*
- **Amodiaquine**, such as *Amobin, Malaratab, Loquin, Alphaquine*
- **Mefloquine**, such as *Mephaquin, Meflotas, Lariam*
- **Syrups or suspensions**, such as *Vinaquine, Triple Action Maxiquine, Emzor, Lonart, Maldox, Alaxin, Vamirex Triple ACT, Camoquine, Halfan, Palquine, Peace, Labquin, Shekquine, Lokmal*
- **Injectables**, such as *Labquin, Sivoquine, E-mal, Tavquine, Sanarteme, Clotin, Paluther*
- **Granules or powders**, such as *Camosunate, Artesmodia, Artequin, Paediatric, Tamether*

**If the outlet has no antimalarials in stock cross-check screening results then proceed to question A16.**

**Proceed to the antimalarial audit. Different antimalarial audit sheets will be used to record the antimalarial information based on the dosage form of the medicine.**

**Separate the antimalarials into two piles:**

- **The first pile should contain all the antimalarials in the form of tablets, suppositories, or granules. Use the Tablets, Suppositories & Granules Drug Audit Sheet to record these.**
- **The second pile should contain all the antimalarials in any form other than tablets, suppositories or granules. Use the Non-Tablet Drug Audit Sheet to record these.**

**If additional audit sheets are used, add these sheets after the ones provided and staple the questionnaire again. All pages should be in order before you move onto the next outlet.**

**Number each drug by assigning a Product Number (starting from 1 for TSG drugs and again from 1 for NT drugs). Number each audit sheet used in the spaces provided at the bottom of the page.**

#### ADDITIONAL NOTES ON THE SUB-OUTLET CODE

**In all outlets, complete the Sub-Outlet Code (as well as the Product Number) for each drug audited. These codes are listed below.**

SUB-OUTLET CODES	
X	ALL outlets that have only ONE dispensing/distribution point for medicines/diagnostics
A	Outpatient department / dispensary/Main pharmacy (if used by all patients)
B	Adult outpatient department / adult dispensary / adult clinic
C	Child outpatient department / child dispensary / child clinic
D	Antenatal / maternity clinic/MCH
E	ART / HIV/AIDS clinic
G	Private dispensing unit within a public health facility
L	Laboratory ( <i>for RDT audit</i> )
Z	Other ( <i>specify the type in the space for audit comments – TSG 15 or NT 15</i> )

**TABLET, SUPPOSITORY & GRANULE DRUG AUDIT SHEET (TSG)** OUTLET ID: [ ][ ]-[ ][ ][ ][ ]-[ ][ ][ ][ ][ ]-[ ][ ][ ][ ][ ][ ]-[ ][ ][ ][ ][ ][ ]

<b>Sub-outlet code</b>	<b>1. Generic name</b>		<b>2. Strength</b>	<b>2a. Is this base strength?</b>		<b>3. Dosage form/formulation</b>	<b>4. Brand name</b> <i>(Include weight and age information)</i>	
[ ]			[ ][ ][ ].[ ]mg	[ ] 1 = Yes 0 = No 8 = Don't know		1 = Tablet 2 = Suppository 3 = Granule		
<b>Product number</b>			[ ][ ][ ].[ ]mg	If no, specify salt:		[ ]		
[ ][ ]			[ ][ ][ ].[ ]mg	[ ]				
<b>5. Manufacturer</b>		<b>6. Country of manufacture</b>	<b>7. Package size</b> There are a total of [ ][ ][ ][ ] tablets/ suppositories/ granule sachets in each: 1 = Package 2 = Pot/tin	<b>8. Is product a fixed-dose combination (FDC)</b> 1 = Yes 0 = No 8 = Don't know	<b>9. Does product have the Green leaf logo?</b> 1 = Yes 0 = No 8 = Don't know	<b>16a. Does this product contain a scratch area for mobile authentication?</b> 1 = Yes 0 = No go to 10 8 = Don't know go to 10 <b>16b. Record the SMS code</b> 1 = 38353 2 = 38351 3 = 1391 6 = other : [ ]	<b>10. Amount sold/distributed in the last 7 days to individual consumers</b> ( <i>Record # of packages / tins described in Q7 OR record the total # of tablets / suppositories / granule packs sold</i> )  This outlet sold [ ][ ][ ] packages/ tins in the last 7 days  <b>OR</b> This outlet sold [ ][ ][ ] tablets/ suppositories or granule sachets in the last 7 days  <b>Not applicable = 995; Refused = 997; Don't know = 998</b>	
<b>11. Stocked out at any point in the past 3 months?</b>  1 = Yes 0 = No 8 = Don't know		<b>12. Retail selling price</b>  [ ][ ][ ] tablets, suppositories or granule sachets cost an individual customer  [ ][ ][ ][ ][ ][ ] NGN		<b>13. Wholesale purchase price</b>  For the outlet's most recent wholesale purchase  [ ][ ][ ][ ][ ] tablets, suppositories or granule sachets cost  [ ][ ][ ][ ][ ][ ][ ][ ] NGN		<b>14. Why do you stock this medicine [SHOW PRODUCT]?</b> <i>Do not read list. Circle ALL responses given</i>		<b>15. Comments</b>
[ ]		Free = 00000 Refused = 99997 Don't know = 99998		Free = 000000 Refused = 999997 Don't know = 999998		<div>Free supply A</div> <div>Profitable B</div> <div>Recommended by the government C</div> <div>Low price D</div> <div>Customer demand or preference E</div> <div>Positive brand reputation F</div> <div>Often prescribed by doctors G</div> <div>Most effective for treating malaria H</div> <div>Don't know X</div> <div>Other Z</div> <div>Specify [ ]</div>		

## OUTLET ID: [ ][ ]-[ ][ ][ ]-[ ][ ][ ][ ]-[ ][ ][ ][ ][ ]-[ ][ ][ ][ ][ ]

<b>Sub-outlet code</b> <div></div> <b>Product number</b> <div></div>	<b>1. Generic name</b> <div></div> <div></div> <div></div> <div></div>		<b>2. Strength</b> <div></div> mg/[div]mL <div></div> mg/[div]mL <div></div> mg/[div]mL <i>(Note: no mL recorded for powder injection)</i>		<b>2a. Is this base strength?</b> <div></div> 1 = Yes <div></div> 0 = No <div></div> 8 = Don't know <i>If no, specify salt</i> <div></div>		<b>3. Dosage form/formulation</b> 1 = Syrup 2 = Suspension 3=Liquid injection 4 =Powder injection 5 = Drops 6 = Other ( <i>specify</i> ) <div></div>																					
<b>4. Brand name</b> <i>(Include weight and age information)</i>		<b>5. Manufacturer</b>	<b>6. Country of manufacture</b>	<b>7. Package size</b> There are a total of <div></div> mL (or mg for powder injections) in each: 1 = Bottle 2 = Ampoule/vial <div></div>	<b>9. Does this product have the Green leaf logo?</b> 1 = Yes 0 = No 8 = Don't know <div></div>	<b>16a. Does this product contain a scratch area for mobile authentication?</b> 1 = Yes 0 = No <b>go to 10</b> 8 = Don't know <b>go to 10</b> <div></div> <b>16b. Record the SMS code</b> 1 = 38353 2 = 38351 3 = 1391 6 = other : <div></div> <div></div>		<b>10. Amount sold/ distributed in the <u>last 7 days</u> to individual consumers</b> This outlet sold <div></div> <b>bottles, ampoules or vials</b> in the <u>last 7 days</u> <i>Refused = 9997; Don't know = 9998</i>																				
<b>11. Stocked out at any point in the past <u>3 months</u>?</b> 1 = Yes 0 = No 8 = Don't know <div></div>		<b>12. Retail selling price</b> <div></div> <b>bottles ampoules or vials</b> cost an individual customer <div></div> NGN  <i>Free = 00000 Refused = 99997Don't know = 99998</i>	<b>13. Wholesale purchase price</b> For the outlet's most recent wholesale purchase: <div></div> <b>bottles, ampoules or vials</b> cost <div></div> NGN  <i>Free = 000000 Refused = 999997 Don't know = 999998</i>		<b>14. Why do you stock this medicine [SHOW PRODUCT]?</b> <i>Do not read list. <u>Circle ALL</u> responses given</i> <table border="1"> <tr><td>Free supply</td><td>A</td></tr> <tr><td>Profitable</td><td>B</td></tr> <tr><td>Recommended by the government</td><td>C</td></tr> <tr><td>Low price</td><td>D</td></tr> <tr><td>Customer demand or preference</td><td>E</td></tr> <tr><td>Positive brand reputation</td><td>F</td></tr> <tr><td>Often prescribed by doctors</td><td>G</td></tr> <tr><td>Most effective for treating malaria</td><td>H</td></tr> <tr><td>Don't know</td><td>X</td></tr> <tr><td>Other</td><td>Z</td></tr> </table> <i>Specify</i> <div></div>		Free supply	A	Profitable	B	Recommended by the government	C	Low price	D	Customer demand or preference	E	Positive brand reputation	F	Often prescribed by doctors	G	Most effective for treating malaria	H	Don't know	X	Other	Z	<b>15. Comments</b> <div></div>	
Free supply	A																											
Profitable	B																											
Recommended by the government	C																											
Low price	D																											
Customer demand or preference	E																											
Positive brand reputation	F																											
Often prescribed by doctors	G																											
Most effective for treating malaria	H																											
Don't know	X																											
Other	Z																											

**Antimalarials recently in stock**

<p>AM16. Are there any antimalarial medicines that are out of stock <u>today</u>, but that you stocked in the past <b>3 months</b>?</p> <p>1 = Yes                      <b>go to AM17</b>  0 = No                        <b>go to Section 5: Antimalarial Diagnostic Audit</b>  8 = Don't know            <b>go to Section 5: Antimalarial Diagnostic Audit</b></p>	[ ]
<p>AM17. What are the names of the treatments that are out of stock?  <b>Will accept generic or brand names. Record one medicine per line.</b></p> <p>1 = Yes, <i>specify</i></p> <p>[ ] [ ]</p> <p>[ ] [ ]</p> <p>[ ] [ ]</p> <p>[ ] [ ]</p> <p>[ ] [ ]</p> <p>0 = No, provider can't remember</p>	[ ]

***Interviewer: Go to Section 5: Antimalarial Diagnostic Audit.***

**Section 5: Antimalarial Diagnostic Audit**

*This section is about availability of malaria blood testing. Completing the questions may require speaking with more than 1 staff member at the outlet. If the respondent does not know the answer to a question in this section, ask to speak with another staff member who can provide the information.*

D1. Does this outlet/facility have disposable gloves available today for staff to use when seeing customers/patients? 1 = Yes 0 = No 8 = Don't know	[ ]
D2. Does this outlet/facility have a sharps container, also called a sharps disposal box or safety box, available today for staff to use? 1 = Yes 0 = No 8 = Don't know	[ ]
D3. Is malaria microscopic testing available here today? 1 = Yes 0 = No <b>go to D7</b>	[ ]
D4. How many people were tested for <b>malaria</b> at this facility/outlet <b>using microscopy</b> within the past 7 days? <b>997 = Refused; 998 = Don't know</b>	[ ][ ][ ]
D5. What is the <u>total cost</u> for a microscopic test for malaria for an <u>adult</u> : [ ][ ][ ][ ][ ] NGN <b>Free = 00000; NA = 99995; Refused = 99997; Don't know = 99998</b>	
D6. What is the <u>total cost</u> for a microscopic test for malaria for a <u>child under five</u> : [ ][ ][ ][ ][ ] NGN <b>Free = 00000; NA = 99995; Refused = 99997; Don't know = 99998</b>	
D7. Malaria rapid diagnostic tests, also called RDTs, are small, individually wrapped blood tests that are able to quickly diagnose whether a person has malaria. <b>Show RDT images in prompt card</b> Are malaria RDTs available here today? 1 = Yes 0 = No <b>go to D9</b> 8 = Don't know <b>ask to speak with a respondent who has this information</b>	[ ]
D8. Please show us the full range of RDTs that you currently have in stock. Do you currently have any of the following? <b>Read entire list; No response to be recorded.</b> <ul style="list-style-type: none"> <li>• SD Bioline, Wondfo One Step, Nova test, AStel P.f</li> <li>• First Response, ParaCheck, Maleriscan, CTK on site rapid test</li> </ul>	

**Proceed to the RDT audit.**

**If additional audit sheets are used, add these sheets after the ones provided and staple the questionnaire again. All pages should be in order before you move onto the next outlet.**

**Number each RDT by assigning a Product Number.**

**Number each audit sheet used in the spaces provided at the bottom of the page.**

**Complete the Sub-outlet Code as well as the Product Number for each RDT audited.**

**Sub-outlet codes are listed on page 6.**

**RAPID DIAGNOSTIC TEST AUDIT SHEET (RDT)** OUTLET ID: [ ]-[ ]-[ ]-[ ]-[ ]-[ ]-[ ]-[ ]-[ ]-[ ]

<b>Sub-outlet code</b> <div> <div></div> </div>  <b>Product number</b> <div> <div></div> </div>	<b>1. Brand name</b>	<b>2. Antigen test</b> <i>(circle ALL that apply)</i> <div> <div>HRP2</div> <div>A</div> </div> <div> <div>pLDH</div> <div>B</div> </div> <div> <div>Aldolase</div> <div>C</div> </div> <div> <div>Not indicated</div> <div>Z</div> </div>	<b>3. Parasite species</b> <i>(circle ALL that apply)</i> <div> <div>Pf</div> <div>A</div> </div> <div> <div>Pv</div> <div>B</div> </div> <div> <div>Po</div> <div>C</div> </div> <div> <div>pm</div> <div>D</div> </div> <div> <div>pan</div> <div>E</div> </div> <div> <div>vom/Pvom</div> <div>F</div> </div> <div> <div>Other</div> <div>G</div> </div> <div> <b>Specify</b>  <div></div> </div> <div> <div>Not indicated</div> <div>Z</div> </div>	<b>4. Manufacturer</b>	<b>5. Country of Manufacture</b>	<b>6a. Product catalogue number</b>	<b>6b. Lot Number</b>	<b>7. Is this a self test kit, with each test kit co-packaged with its own buffer, pipette and lancet?</b>  <div> <div>1 = Yes</div> <div>0 = No</div> <div>8 = Don't know</div> </div> <div> <div></div> </div>
<b>13. Number of tests sold/ distributed /used in the last 7 days to individual consumers</b> <i>(Record total # of tests)</i> This outlet sold or distributed  <div> <div></div> </div> <b>tests in the last 7 days</b>  <i>Refused = 9997; Don't know=9998</i>	<b>14. Has this test been stocked out at any point in the past 3 months?</b>  <div> <div>1 = Yes</div> <div>0 = No</div> <div>8 = Don't know</div> </div> <div> <div></div> </div>	<b>15a. Do you or other staff use this brand of RDT to test clients here at this facility/outlet?</b>  <div> <div>1 = Yes</div> <div>0 = No</div> <div>8 = Don't know</div> </div> <div> <div></div> </div> <b>15b. If yes, what is the total cost for an adult to have a test conducted with this RDT, including RDT cost and service fee?</b>  <div> <div></div> </div> NGN  <b>15c. If yes, what is the total cost for a child under the age of five to have a test conducted with this RDT, including RDT cost and service fee?</b>  <div> <div></div> </div> NGN	<b>16a. Does this facility/outlet provide this brand of RDT for clients to take away for testing somewhere else?</b>  <div> <div>1 = Yes</div> <div>0 = No</div> <div>8 = Don't know</div> </div> <div> <div></div> </div> <b>16b. If yes, what is cost of this RDT for an adult?</b>  <div> <div></div> </div> NGN  <b>16c. If yes, what is the cost of this RDT for a child under the age of five?</b>  <div> <div></div> </div> NGN	<b>17. Wholesale purchase price</b> For the outlet's most recent wholesale purchase:  <div> <div></div> </div> tests  cost  <div> <div></div> </div> NGN  <i>Free = 000000</i> <i>NA = 999995</i> <i>Refused = 999997</i> <i>Don't know=999998</i>	<b>18. Why do you stock this RDT [SHOW RDT]?</b> <i>Do not read list. Circle ALL responses given</i>  <div> <div>Free supply</div> <div>A</div> </div> <div> <div>Profitable</div> <div>B</div> </div> <div> <div>Recommended by the government</div> <div>C</div> </div> <div> <div>Low price</div> <div>D</div> </div> <div> <div>Customer demand or preference</div> <div>E</div> </div> <div> <div>Positive brand reputation</div> <div>F</div> </div> <div> <div>Don't know</div> <div>X</div> </div> <div> <div>Other</div> <div>Z</div> </div> <div> <b>specify</b>  <div></div> </div>	<b>19. Comment</b>		
<i>Free = 00000; NA = 99995; Refused = 99997; Don't know=99998</i>								

**RDT stock outs**

<p>D9. Are there any malaria RDTs that are out of stock today, but that you stocked in the past <b>3 months</b>?</p> <p>1 = Yes  0 = No                    <b>go to D11</b>  8 = Don't know        <b>go to D11</b></p>	<div style="border: 1px solid black; width: 30px; height: 20px; margin: 0 auto;"></div>
<p>D10. What are the brand names of the malaria RDTs that are out of stock?  <b>Record one brand per line.</b></p> <p>1 = Yes, <i>specify</i></p> <div style="border: 1px solid black; height: 15px; margin-bottom: 5px;"></div> <div style="border: 1px solid black; height: 15px; margin-bottom: 5px;"></div> <div style="border: 1px solid black; height: 15px; margin-bottom: 5px;"></div> <p>0 = No, provider can't remember</p>	<div style="border: 1px solid black; width: 30px; height: 20px; margin: 0 auto;"></div>
<p>D11. Does this facility/outlet <b>provide medicines or prescription</b> for medicines?</p> <p>1 = Yes                    <b>go to Section 5: Provider Module</b></p> <p>0 = No                    <b>check that S1 is no and S2 is no (the outlet has no medicines/had no medicines recently) and that C7 is 14 or 15. Go to <u>Section 3: Screening &amp; Eligibility for Family Planning</u>.</b></p>	<div style="border: 1px solid black; width: 30px; height: 20px; margin: 0 auto;"></div>

***Interviewer: Go to Section 6: Antimalarial Provider Module.***

**Section 6: Antimalarial Provider Module**

***This section is for the senior-most staff member who is responsible for providing malaria treatment, prescriptions or medicines to clients/patients.***

PM1. Do your responsibilities at this outlet/facility include: providing prescriptions, treatment, <u>or</u> medicines to clients?  1 = Yes 0 = No <b><i>ask to speak with the senior-most person at the outlet with 1 or more of these responsibilities.</i></b>	[ ]
PM2. For how many years have you worked in this outlet/facility? <b>If less than 1 year, enter 01</b>	[ ][ ]
PM3. What age are you today? <b>Write age in years</b> 97 = Refused 98 = Don't know	[ ][ ]
PM4. <b>Don't read:</b> Is respondent male or female?  1 = Male 2 = Female	[ ][ ]
PM5. What is the highest level of education you completed?  1 = No formal education 2 = Some primary school 3 = Completed primary school 4 = Some secondary school 5 = Completed secondary school 6 = Some university/college 7 = Completed a university/college degree/diploma	[ ]
PM6. Have you received any training in the last 12 months that included a component on malaria diagnosis, including malaria rapid diagnostic tests or microscopy? <b>Include pre-service training and stand-alone workshops.</b>  1 = Yes 0 = No 8 = Don't know	[ ]
PM7. Have you received any training in the last 12 months on the national treatment guidelines for malaria? <b>Include pre-service training and stand-alone workshops.</b>  1 = Yes 0 = No 8 = Don't know	[ ]
PM8. Do you have any of the following <b>health qualifications</b> ? <b><u>Read list.</u> Record 1 for yes, 0 for no</b>	
I. Dispenser (diploma in Pharmacy)	[ ]
II. Pharmacist (Degree in Pharmacy)	[ ]
III. Medical doctor	[ ]
IV. Clinical Officer	[ ]
V. Nurse / Nursing Officer	[ ]
VI. Midwife	[ ]
VII. Laboratory technician / Lab assistant	[ ]
VIII. Pharmaceutical technologist	[ ]
IX. Pharmacy technician	[ ]
X. Public Health Technician/Officer	[ ]
XI. Health Assistant, Medical Assistant / Nursing Assistant / Nursing Aid	[ ]
XII. Community Health Worker	[ ]



PM9. <b>Not</b> including yourself, do any other people working in this outlet or facility have the following health qualifications? <u>Read list.</u> <i>Record 1 for yes, 0 for no, 8 for don't know</i>		
I.	Dispenser (Diploma in Pharmacy)	<input type="text"/>
II.	Pharmacist (Degree in Pharmacy)	<input type="text"/>
III.	Medical doctor	<input type="text"/>
IV.	Clinical Officer	<input type="text"/>
V.	Nurse / Nursing Officer	<input type="text"/>
VI.	Midwife	<input type="text"/>
VII.	Laboratory technician / Lab assistant	<input type="text"/>
VIII.	Pharmaceutical technologist	<input type="text"/>
IX.	Pharmacy technician	<input type="text"/>
X.	Public Health Technician/Officer	<input type="text"/>
XI.	Health Assistant, Medical Assistant / Nursing Assistant / Nursing Aid	<input type="text"/>
XII.	Community Health Worker	<input type="text"/>

**Interviewer:** For the following questions record the antimalarial brand name or generic name, and dosage form, in the spaces provided.

Ask the provider to show you the medicine if it is in stock to verify the name and dosage form.

<p>PM10. In your opinion, for treating uncomplicated malaria in <u>adults</u>, what is the <u>most effective</u> antimalarial medicine?</p> <p><b>Ask the provider to show you the medicine if it is in stock.</b></p>		
<p><b>Generic or brand name</b></p>          <p>[ _____ ]</p> <p><b>Don't know = 98</b></p>	<p><b>Dosage form/formulation</b></p> <p>01 = Tablet                      04 = Syrup                      07 = Drops</p> <p>02 = Suppository              05 = Suspension              95 = None specified</p> <p>03 = Granule                    06 = IM/IV Injection              98 = Don't know</p> <p style="text-align: center;">(liquid or powder)</p>	
	<p style="text-align: center;">[    ] [    ]</p>	

PM11. In your opinion, for treating uncomplicated malaria in children under five, what is the most effective antimalarial medicine?

**Ask the provider to show you the medicine if it is in stock.**

Generic or brand name	Dosage form/formulation
[ ]	01 = Tablet                  04 = Syrup                  07 = Drops 02 = Suppository        05 = Suspension        95 = None specified 03 = Granule              06 = IM/IV Injection    98 = Don't know (liquid or powder)
	[ ] [ ]

**Don't know = 98**

PM12. What antimalarial medicine for treating uncomplicated malaria in adults do you most often recommend to customers?*Ask the provider to show you the medicine if it is in stock.*

<b>Generic or brand name</b>	<b>Dosage form/formulation</b>		
[ ]	01 = Tablet	04 = Syrup	07 = Drops
	02 = Suppository	05 = Suspension	95 = None specified
	03 = Granule	06 = IM/IV Injection (liquid or powder)	98 = Don't know
[ ]	[ ][ ]		
<b>Don't know = 98</b>			

PM13. What antimalarial medicine for treating uncomplicated malaria in children under five do you most often recommend to customers?*Ask the provider to show you the medicine if it is in stock.*

<b>Generic or brand name</b>	<b>Dosage form/formulation</b>		
[ ]	01 = Tablet	04 = Syrup	07 = Drops
	02 = Suppository	05 = Suspension	95 = None specified
	03 = Granule	06 = IM/IV Injection (liquid or powder)	98 = Don't know
[ ]	[ ][ ]		
<b>Don't know = 98</b>			

PM14. In your opinion, for treating severe malaria in children under five, what is the most effective antimalarial medicine?*Ask the provider to show you the medicine if it is in stock.*

<b>Generic or brand name</b>	<b>Dosage form/formulation</b>		
[ ]	01 = Tablet	04 = Syrup	07 = Drops
	02 = Suppository	05 = Suspension	95 = None specified
	03 = Granule	06 = IM/IV Injection (liquid or powder)	98 = Don't know
[ ]	[ ][ ]		
<b>Don't know = 98</b>			

PM15. What antimalarial medicine for treating severe malaria in children under five do you most often recommend to customers?*Ask the provider to show you the medicine if it is in stock.*

<b>Generic or brand name</b>	<b>Dosage form/formulation</b>		
[ ]	01 = Tablet	04 = Syrup	07 = Drops
	02 = Suppository	05 = Suspension	95 = None specified
	03 = Granule	06 = IM/IV Injection (liquid or powder)	98 = Don't know
[ ]	[ ][ ]		
<b>Don't know = 98</b>			

PM16. Please name the first line medicine recommended by the government to treat uncomplicated malaria.

**Do not read list. Only one response allowed.**

01 = Artemether Lumefantrine (*Lonart, Artefan, Lumartem, Coartem*) ..... **Go to PM17**

02 = ACT..... **Go to PM17**

03 = ACTm..... **Go to PM17**

04 = Artesunate Amodiaquine (*DUAC, Coarsucam, Winthrop*)

05 = Dihydroartemisinin Piperaquine (*Duo-cotecxin, P-alaxin*)

06 = Amodiaquine

07 = Artemether(*Artenam, Paluther, Artesiane, Larither*)

08 = Artemisinin

09 = Artesunate (*Artesun, Larinate, Plasmotrim*)

10 = Chloroquine (*Sugarquin*)

11 = Quinine

12 = Sulfadoxine Pyrimethamine (*Fansidar, SP, Orodar, Ekelfin, Metakelfin*)

96 = Other specify: [ ]

98 = Don't know

**Go to PM19**

[ ][ ]

PM17. Please explain the government recommended treatment regimen for this drug for an adult (60kg)

**What is the dosage formulation?**

01 = Tablet

04 = Syrup

07 = Drop

02 = Suppository

05 = Suspension

95 = None specified

03 = Granule

06 = Injection (IV/IM)

96 = Not applicable

98 = Don't know

[ ][ ]

**If provider responded not tablet then skip to PM18**

**Read the following 3 questions to the provider**

I. How many tablets should they take at a time?

[ ][ ].[ ][ ]

II. How many times per day?

[ ][ ]

III. Over how many days?

[ ][ ]

**If respondent has the medicine available use the package to complete the table below.**

**If the medicine is not available ask respondent to identify from prompt card.**

**If identification not possible, ask respondent to recall medicine details.**

**Don't know = 98**

	Generic name	Strength in mg	Brand name
[ ][ ]	_____	[ ][ ][ ].[ ]mg	
[ ][ ]	_____	[ ][ ][ ].[ ]mg	
[ ][ ]	_____	[ ][ ][ ].[ ]mg	
	[ ][ ]	<b>Don't know=999.8</b>	
<b>Manufacturer</b>		Is this drug a <b>fixed-dose combination</b>	
		1 = Yes 0 = No 8 = Don't know	
<b>Don't know = 98</b>			

PM18. Please explain the government recommended treatment regimen for this drug for a 2-year old child (10kg) **Read the following 3 questions to the provider**

**What is the dosage formulation?**

01 = Tablet	04 = Syrup	07 = Drop
02 = Suppository	05 = Suspension	95 = None specified
03 = Granule	06 = Injection (IV/IM)	96 = Not applicable
		98 = Don't know

[ ][ ]

**If provider responded not tablet then skip to PM19**  
**Read the following 3 questions to the provider**

- How many tablets should they take at a time?
- How many times per day?
- Over how many days?

[ ][ ].[ ][ ]

[ ][ ]

[ ][ ]

**If respondent has the medicine available use the package to complete the table below.**  
**If the medicine is not available ask respondent to identify from prompt card.**  
**If identification not possible, ask respondent to recall medicine details.**

**Don't know = 98**

	Generic name	Strength in mg	Brand name
[ ][ ]	_____	[ ][ ][ ].[ ][ ]mg	
[ ][ ]	_____	[ ][ ][ ].[ ][ ]mg	
[ ][ ]	_____	[ ][ ][ ].[ ][ ]mg	
	[ ][ ]	<b>Don't know=999.8</b>	
<b>Manufacturer</b>		Is this drug a <b>fixed-dose combination</b>	
		1 = Yes 0 = No 8 = Don't know	
<b>Don't know = 98</b>		[ ]	

PM19. Please name the medicine recommended by the government to treat severe malaria.

**Do not read list. Only one response allowed.**

- 01 = Artesunate (Artesun, Larinate, Plasmodium) ..... **Go to PM20**  
 02 = Artemether (Artemam, Paluther, Artesiane, Larither) ..... **Go to PM20**  
 03 = Quinine..... **Go to PM20**  
 04 = ACT/ACTm  
 05 = Artemether Lumefantrine (Lonart, Artefan, Lumartem, Coartem)  
 06 = Artesunate Amodiaquine (DUAC, Coarsucam, Winthrop)  
 07 = Dihydroartemisinin Piperaquine (Duo-cotecxin, P-alaxin)  
 08 = Chloroquine (Sugarcin)  
 09 = Sulfadoxine Pyrimethamine (Fansidar, SP, Orodar, Ekelfin, Metakelfin)  
 96 = Other (specify): [ \_\_\_\_\_ ]  
 98 = Don't know
- Go to PM21**

[ ][ ]

PM20. What is the drug formulation for the recommended medicine by the government to treat severe malaria? **Do not read dosage form options**

- |                  |   |                     |
|------------------|---|---------------------|
| 01 = Tablet      | 04 = Syrup                              | 07 = Drops          |
| 02 = Suppository | 05 = Suspension                         | 95 = None specified |
| 03 = Granule     | 06 = IM/IV Injection (Liquid or powder) | 98 = Don't know     |

[ ][ ]

<p>PM21. Malaria rapid diagnostic tests, also called RDTs, are small, individually wrapped blood tests that are able to quickly diagnose whether a person has malaria. <b>Show RDT images in prompt card</b></p> <p>Have you ever seen or heard of malaria RDTs?</p> <p>1 = Yes <b>Go to PM22</b>  0 = No <b>Go to PM29</b>  8 = Don't know <b>Go to PM29</b></p>	<div style="border: 1px solid black; width: 40px; height: 40px; margin: 0 auto;"></div>																
<p>PM22. Have you ever tested a client for malaria using an RDT?</p> <p>1 = Yes  0 = No  8 = Don't know</p>	<div style="border: 1px solid black; width: 40px; height: 40px; margin: 0 auto;"></div>																
<p>PM23. Would you ever recommend a patient/customer take an antimalarial if a blood test using a rapid diagnostic test produced a negative test result for malaria?  <b>Read list. Record only one response.</b></p> <p>1 = Yes, Sometimes  2 = Yes, Always  3 = No, Never <b>Go to PM29</b>  8 = Don't know <b>Go to PM29</b></p>	<div style="border: 1px solid black; width: 40px; height: 40px; margin: 0 auto;"></div>																
<p>PM24. Under what circumstances would you recommend a patient/customer take an antimalarial following a negative RDT test for malaria?  <b>Do not read list. Prompt "anything else" until the respondent is finished.</b>  <b>Circle ALL responses given</b></p> <table border="0" style="width: 100%;"> <tr> <td style="width: 80%; text-align: right;">When they have signs/symptoms of malaria</td> <td style="width: 20%; text-align: center;">A</td> </tr> <tr> <td style="text-align: right;">When they ask for antimalarial treatment</td> <td style="text-align: center;">B</td> </tr> <tr> <td style="text-align: right;">When they are a child</td> <td style="text-align: center;">C</td> </tr> <tr> <td style="text-align: right;">When they are an adult</td> <td style="text-align: center;">D</td> </tr> <tr> <td style="text-align: right;">When they are a pregnant woman</td> <td style="text-align: center;">E</td> </tr> <tr> <td style="text-align: right;">When I do not trust/believe the test</td> <td style="text-align: center;">F</td> </tr> <tr> <td style="text-align: right;">When I know the patient/customer</td> <td style="text-align: center;">G</td> </tr> <tr> <td style="text-align: right;">Other (specify) [_____]</td> <td style="text-align: center;">X</td> </tr> </table>	When they have signs/symptoms of malaria	A	When they ask for antimalarial treatment	B	When they are a child	C	When they are an adult	D	When they are a pregnant woman	E	When I do not trust/believe the test	F	When I know the patient/customer	G	Other (specify) [_____]	X	
When they have signs/symptoms of malaria	A																
When they ask for antimalarial treatment	B																
When they are a child	C																
When they are an adult	D																
When they are a pregnant woman	E																
When I do not trust/believe the test	F																
When I know the patient/customer	G																
Other (specify) [_____]	X																

PM29. What are the danger signs of <u>severe</u> illness in a child under 5? <b><i>Do not read list. Prompt "anything else" until the respondent is finished.</i></b> <b><i>Circle ALL responses given</i></b>		
Unable to drink /unable to breastfeed		A
Vomits everything		B
Convulsions		C
Lethargic or unconscious		D
Don't know		Z
Other (specify) [_____]		X
PM30. What would you do if a 2-year old child was brought to this outlet with the danger signs of <u>severe</u> illness? <b><i>Do not read list. Only one response allowed.</i></b>  01 = Seek advice/help from someone in this facility 02 = Treat the child in this facility 03 = Refer to a health facility (clinic, hospital) with or without treating here 04 = Refer to a non health facility outlet (not a clinic or hospital) with or without treating here 05 = Send them away/home without medicine 06 = Send them away/home with medicine 96 = Other (specify): [_____] 98 = Don't know		[ ][ ]

***Interviewer: Go to Section 7: Antimalarial Audit Tracking Sheet.***

**Section 7: Antimalarial Audit Tracking Sheet**

<p>TM1. Were there any antimalarial TABLETS/SUPPOSITORIES/GRANULES <u>in stock</u> at this outlet?</p> <p>1 = Yes 0 = No <b>go to T4</b> 8 = Don't know <b>go to T4</b></p>	[ ]
<p>TM2. Total number of TABLET/SUPPOSITORY/GRANULE <u>audit sheets</u> completed</p>	[ ][ ]
<p>TM3. Did you complete audit sheet information for <u>all available</u> TABLETS/SUPPOSITORIES/GRANULES?</p> <p>1 = Yes, audit complete 0 = No, audit not complete</p>	[ ]
<p>TM4. Were there any antimalarial NON TABLETS (Syrups, suspensions, Injectables) <u>in stock</u> at this outlet?</p> <p>1 = Yes 0 = No <b>go to T7</b> 8 = Don't know <b>go to T7</b></p>	[ ]
<p>TM5. Total number of NON-TABLET <u>audit sheets</u> completed</p>	[ ][ ]
<p>TM6. Did you complete audit sheet information for <u>all available</u> NON-TABLETS?</p> <p>1 = Yes, audit complete 0 = No, audit not complete</p>	[ ]
<p>TM7. Were there any RDTs <u>in stock</u> at this outlet?</p> <p>1 = Yes 0 = No <b>go to T10</b> 8 = Don't know <b>go to T10</b></p>	[ ]
<p>TM8. Total number of RDT <u>audit sheets</u> completed</p>	[ ][ ]
<p>TM9. Did you complete audit sheet information for <u>all available</u> RDT?</p> <p>1 = Yes, audit complete 0 = No, audit not complete</p>	[ ]
<p>T10. COMMENTS: Reason for incomplete audit sheets (if response is no to T3, T6, or T9):</p>	

***Interviewer: Very important! Make sure to Go to Section 3: Screening & Eligibility for Family Planning.***

## Section 8: Family Planning Product Audit

**Before Going to the full interview ensure you have given the respondent a study information sheet, explained the study and obtained informed consent.**

### A0. Read to the provider:

Can you please show us the full range of family planning products that you currently have in stock? Do you currently have any of the following?

**Prompt entire list using family planning prompt card; No response to be recorded.**

- Rapid pregnancy test kits
- Birth control patches
- Vaginal birth control rings
- CycleBeads
- Diaphragms
- Vaginal foaming tablets
- Male condoms such as X
- Female condoms such as X
- Oral contraceptive tablets such as X
- Emergency contraceptive tablets such as X
- Injectable contraceptives such as X
- Contraceptive implants such as X
- Contraceptive IUDs such as X
- Early term medical abortion tablets such as X; *\*These may be located in a different department of the outlet/facility*

**If the outlet has no family planning products in stock check screening results then Go to question A15.**

*Different product audit sheets will be used to record the product information based on the form and brand of product.*

**Separate the family planning products into five piles:**

- *The first pile should contain one of each brand of all non-drug family products available at the outlet including: male and/or female condoms. If rapid pregnancy test kits, CycleBeads and/or diaphragms are available, include in this pile. Use the FP Non-Drug Audit Sheet to record.*
- *The second pile should contain one of each brand of all oral contraceptive tablets available at the outlet including: oral contraceptives and/or emergency contraceptives. If birth control patches, misoprostol and/or vaginal foaming tablets are available, include in this pile. Use the FP Tablet Audit Sheet to record.*
- *The third pile should contain one of each brand of all injectable contraceptives available at the outlet. Use the FP Injection Audit Sheet to record.*
- *The fourth pile should contain one of each brand of all contraceptive implants and IUDs available at the outlet. If vaginal birth control rings are available, include in this pile. Use the FP Insertion Audit Sheet to record.*

*If additional audit sheets are used, add these sheets after the ones provided and staple the questionnaire again. All pages should be in order before you move onto the next outlet.*

**Number each family planning product by assigning a Product Number (starting from 1 for FP Non-Drugs, again from 1 for Tablets and so on).**

**Number each audit sheet used in the spaces provided at the bottom of the page.**

A0. Does outlet collect facility-level records of family planning products sold and/or services provided?

1 = outlet keeps records

0 = outlet does not keep records

[ ]

*If records are available and permitted to view, ask respondent to cross-check answers given for “amount sold/distributed” for all products and services. If figures for audit sheets given by the respondent and the records are not the same, ask the respondent the reasons for discrepancies and make a comment in “comments” section for each brand/product. If discrepancies exist, record the figure given by the respondent after viewing the records.*



<b>Product number</b>  [ ][ ]	<b>1. Non-drug type</b> 1 = Male condom 2 = Female condom 3 = CycleBeads 4 = Diaphragm 5 = Rapid pregnancy test kit  [ ]	<b>2. Brand name</b>  	<b>3. Manufacturer</b>  	<b>4. Country of manufacture</b>  	<b>5. Package size</b> <i>(Record '1' if products individually sold)</i>  There are a total of  [ ][ ]  <b>individual non-drug products</b> in each package.	
				[ ][ ][ ]		
<b>6. Amount sold/distributed in the last 1 month to individual consumers</b> <i>(Record # of packages described in Q5)</i>  This outlet sold/distributed  [ ][ ][ ][ ]  <b>packages</b> in the <u>last 1 month</u> .  <i>Refused = 9997</i> <i>Don't know = 9998</i>		<b>7. Stocked out at any point in the past 3 months?</b>  1 = Yes 0 = No 8 = Don't know  [ ]	<b>8. Retail selling price</b> <i>(Record # of packages or non-drug products described in Q5)</i>  [ ][ ]  <b>packages</b> cost an individual customer  [ ][ ][ ][ ][ ] NGN  <i>Free = 00000</i> <i>Refused = 99997</i> <i>Don't know = 99998</i>	<b>9. Wholesale purchase price</b> For the outlet's most recent wholesale purchase. <i>(Record # of packages or non-drug products described in Q5)</i>  [ ][ ][ ][ ][ ]  <b>packages</b> cost  [ ][ ][ ][ ][ ][ ][ ]NGN  <i>Free = 000000</i> <i>Refused = 999997</i> <i>Don't know = 999998</i>	<b>10. Comments</b>  	
<b>6a. Source of information</b>  0 = Provider recall 1 = Outlet records  [ ]						

Product number [ ][ ]	1. Tablet type	1a. Tablet type-use (Ask provider) Do you ever use this product for emergency contraception?	2. Brand name	[ ][ ] [ ][ ] [ ][ ] [ ][ ]	3. Generic name	3a. Strength
	1 = contraceptive tablets 2 = birth control patch 3 = vaginal foaming tablets 4 = misoprostol tablets [ ]	1 = Yes 0 = No 8 = Don't know 9 = Not applicable [ ]			A.	[ ][ ][ ][ ] mg/tab
			B.		[ ][ ][ ][ ] mg/tab	
			C.		[ ][ ][ ][ ] mg/tab	
4. Manufacturer		5. Country of Manufacture	6. Package size (For contraceptive tablets, 1 package = 1 blister package of X tablets)  There are a total of [ ][ ] tablets in each package.		7. Amount sold/distributed in the last 1 month to individual consumers (Record # of packages described in Q6)  This outlet sold/distributed [ ][ ][ ][ ] packages in the <u>last 1 month</u> .  Refused = 9997 Don't know = 9998	
					7a. Source of information  0 = Provider recall 1 = Outlet records [ ]	
8. Stocked out at any point in the past 3 months?  1 = Yes 0 = No 8 = Don't know [ ]	9. Retail selling price (Record # of packages described in Q6) [ ][ ] packages cost an individual customer [ ][ ][ ][ ][ ] NGN  Free = 0000 Refused = 9997 Don't know = 9998		10. Wholesale purchase price For the outlet's most recent wholesale purchase (Record # of packages described in Q6) [ ][ ][ ][ ][ ] packages cost [ ][ ][ ][ ][ ][ ][ ] NGN  Free = 000000 Refused = 999997 Don't know = 999998		11. Comments	

**FP INJECTION AUDIT SHEET (INJ): INCLUDES INJECTABLES**

OUTLET ID: [ ][ ]-[ ][ ]-[ ][ ][ ][ ]-[ ][ ][ ][ ]-[ ][ ][ ][ ][ ]

Product number  [ ][ ]	1. Brand name		[ ][ ]	2. Generic name		2a. Strength		3. Manufacturer		4. Country of Manufacture		
				A.  [ ][ ]		[ ][ ][ ][ ] mg / [ ][ ].[ ][ ] mL						
			[ ][ ]	B.  [ ][ ]		[ ][ ][ ][ ] mg / [ ][ ].[ ][ ] mL				[ ][ ][ ][ ]		
5. Package size			6. Package contents		7. Amount sold/distributed in the last 1 month to individual consumers (Record # of vials described in Q5)		8. Stocked out at any point in the past 3 months?		9. Do you, or other staff, perform injection services for this brand of injectable at this outlet/facility?		10. How many injection procedures have been conducted at this outlet/facility in the last 1 month?	
There are a total of  [ ][ ][ ][ ].[ ][ ]  mL in each vial.			Does package with vial contain disposable needle for injection?  1 = Yes 0 = No  [ ]		This outlet sold/distributed  [ ][ ][ ][ ][ ]  vials in the last 1 month.  Refused = 9997 Don't know = 9998		1 = Yes 0 = No 8 = Don't know  [ ]		1 = Yes 0 = No → Go to Q11 8 = Don't know → Go to Q11  [ ]		[ ][ ][ ][ ][ ]  Refused = 9997 Don't know = 9998	
					7a. Source of information  0 = Provider recall 1 = Outlet records  [ ]				9a. If yes, what is the total cost to have an injection, including product cost and service fee?  [ ][ ][ ][ ][ ][ ] NGN  Free = 00000 Refused = 99997 Don't know = 99998		10a. Source of information  0 = Provider recall 1 = Outlet records  [ ]	
11. Does this outlet/facility provide this brand of injectable for clients to take away for injection procedures somewhere else?						12. Wholesale purchase price (Record # of vials described in Q5)				13. Comments		
1 = Yes 0 = No → Go to Q12 8 = Don't know → Go to Q12  [ ]						For the outlet's most recent wholesale purchase  [ ][ ][ ][ ][ ]  vials cost  [ ][ ][ ][ ][ ][ ][ ][ ] NGN  Free = 000000 Refused = 999997 Don't know = 999998						
11b. If yes, what is cost of 1 vial for an individual customer?  [ ][ ][ ][ ][ ] NGN  Free = 0000 Refused = 9997 Don't know = 9998												

**FP INSERTION AUDIT SHEET (INS): INCLUDES IMPLANTS, RINGS, IUDS**

OUTLET ID: [ ][ ]-[ ][ ][ ][ ]-[ ][ ][ ][ ]-[ ][ ][ ][ ][ ]-[ ][ ][ ][ ][ ]

Product number  [ ][ ]	1. Brand name	2. Type 1 = Contraceptive implant 2 = Vaginal birth control ring 3 = Hormonal-based IUD 4 = Copper-based IUD  [ ]	[ ][ ]	3. Generic name A.  B.  [ ][ ]	3a. Strength (Do not record for copper IUD)  [ ][ ][ ] . [ ] mg  [ ][ ][ ] . [ ] mg  For <u>implants only</u> , strengths for  [ ] number of rods	4. Manufacturer	5. Country of Manufacture  [ ][ ][ ]				
6. Package size  In each package, there are a total of  [ ][ ] number of  1 = Rod(s) 2 = IUD(s) → Go to Q8 3 = Ring(s) → Go to Q8  [ ]		7. Package contents Does package come with disposable applicator?  1 = Yes 0 = No  [ ]  7a. Package contents Does package come with disposable trocar?  1 = Yes 0 = No  [ ]		8. Amount sold/distributed in the last 1 month to individual consumers (Record # of packages described in Q6)  This outlet sold/distributed  [ ][ ][ ] packages in the <u>last 1 month</u> .  Refused = 997 Don't know = 998  8a. Source of information  0 = Provider recall 1 = Outlet records  [ ]		9. Stocked out at any point in the past <u>3 months</u> ?  1 = Yes 0 = No 8 = Don't know  [ ]		10. Do you, or other staff, perform insertion services for this brand at this outlet/facility?  1 = Yes 0 = No → Go to Q12 8 = Don't know → Go to Q12  [ ]  10a. If yes, what is the <u>total cost</u> to have this brand inserted, including product cost and service fee?  [ ][ ][ ][ ][ ][ ] NGN  Free = 00000 Refused = 99997 Don't know = 99998		11. How many injection procedures have been conducted at this outlet/facility in the <u>last 1 month</u> ?  [ ][ ][ ][ ]  Refused = 9997 Don't know = 9998  11a. Source of information  0 = Provider recall 1 = Outlet records  [ ]	
12. Does this outlet/facility provide this brand of implant/IUD for clients <u>to take away</u> for injection procedures <u>somewhere else</u> ?  1 = Yes 0 = No → Go to Q13 8 = Don't know → Go to Q13  [ ]  12a. If yes, what is cost of <u>1 implant/IUD</u> for an individual customer?  [ ][ ][ ][ ][ ] NGN  Free = 0000 Refused = 9997 Don't know = 9998				13. Wholesale purchase price (Record # of packages described in Q6)  For the outlet's most recent wholesale purchase  [ ][ ][ ][ ][ ] packages cost  [ ][ ][ ][ ][ ][ ][ ] NGN  Free = 000000 Refused = 999997 Don't know = 999998				14. Comments			

<p>AFP15. Are there any family planning products that are out of stock today, but that you stocked in the past 3 months?</p> <p>1 = Yes          0 = No      <b><i>Go to <u>Section 9: Family Planning Provider Module—All Methods Except Sterilizations</u></i></b>          8 = Don't know    <b><i>Go to <u>Section 9: Family Planning Provider Module—All Methods Except Sterilizations</u></i></b></p>	<p>[ ]</p>										
<p>AFP16. Do you know the names of the products that are out of stock?          Will accept generic or brand names. Record one product per line.</p> <p>1 = Yes, specify</p> <table border="0"> <tr> <td>[ ]</td> <td>[ ]</td> </tr> <tr> <td>[ ]</td> <td>[ ]</td> </tr> <tr> <td>[ ]</td> <td>[ ]</td> </tr> <tr> <td>[ ]</td> <td>[ ]</td> </tr> <tr> <td>[ ]</td> <td>[ ]</td> </tr> </table> <p>0 = No</p>	[ ]	[ ]	[ ]	[ ]	[ ]	[ ]	[ ]	[ ]	[ ]	[ ]	<p>[ ]</p>
[ ]	[ ]										
[ ]	[ ]										
[ ]	[ ]										
[ ]	[ ]										
[ ]	[ ]										

***Interviewer: Go to Section 9: Family Planning Provider Module—All Methods Except Sterilizations.***

## Section 9: Family Planning Provider Module—All Methods Except Sterilizations

*This section is about provider training, credentials and equipment for all methods except sterilizations. Completing the questions may require speaking with more than 1 staff member at the outlet. If the respondent does not know the answer to a question in this section, ask to speak with another staff member who can provide the information.*

FP1. How many days per week are family planning products provided at this outlet/facility?	<input type="text"/>
FP2. Do you provide counseling on which type of family planning methods to choose at this outlet/facility?  1 = Yes <b>Ask to speak with the senior-most staff member present at the outlet providing counseling services for family planning.</b> 0 = No <b>Go to FP6</b>	<input type="text"/>
FP3. Does this outlet have any job aids for counseling customers on which type of family planning method to choose? <i>(Ask to the respondent to see job aids)</i>  1 = Yes, observed 2 = Yes, not observed 0 = No 8 = Don't know	<input type="text"/>
FP4. Have you or any other current staff member at this outlet/facility received any training in the last 12 months on counseling customers on which type of family planning methods to use? <i>Including pre-service training and stand-alone workshops.</i>  1 = Yes 0 = No <b>Go to FP6</b> 8 = Don't know <b>Go to FP6</b>	<input type="text"/>
FP5. From which organization(s) did you, or staff from this outlet/facility, receive training on counseling customers on which types of family planning methods to use?  A = <input type="text"/> B = <input type="text"/> C = <input type="text"/> X = Don't know Z = Refused	A B C X Z
FP6. Does this outlet/facility provide any of the following services? <b>Read each procedure from the following list and record response.</b>  <div style="text-align: right;">           P6a. Contraceptive injections            P6b. Contraceptive implant insertion procedures            P6c. IUD insertion procedures         </div>	1 = Yes 0 = No 8 = Don't know  <input type="text"/> <input type="text"/> <input type="text"/>  <b>If 'no' or 'don't know' for all, → Go to FP26</b>
FP7. Are you the senior-most staff member available today that can perform any of the following services: contraceptive injections, contraceptive implant procedures and/or IUD insertion procedures?  1 = Yes <b>Go to FP9</b> 0 = No 8 = Don't know	<input type="text"/>
FP8. Is the senior-most staff member available today to speak with?  1 = Yes <b>Speak with the senior-most staff member</b> 0 = No <b>Continue speaking with current respondent</b> 8 = Don't know <b>Continue speaking with current respondent</b>	<input type="text"/>

<p>FP9. Do your own responsibilities at this outlet/facility include providing any of the following?  <b>Read each procedure from the following and record response:</b></p> <p style="text-align: right;">P9a. Contraceptive injections</p> <p style="text-align: right;">P9b. Contraceptive implant insertion procedures</p> <p style="text-align: right;">P9c. IUD insertion procedures</p>	<p>1 = Yes 0 = No</p> <p><input type="checkbox"/></p> <p><input type="checkbox"/></p> <p><input type="checkbox"/></p>
<p>FP10. Have you received any training in the last 2 years that included a component on performing contraceptive injections, contraceptive implant insertions and/or IUD insertions? <b>Include pre-service training and stand-alone workshops. Ask for and record each method.</b></p> <p style="text-align: right;">P10a. Injectable contraceptives</p> <p style="text-align: right;">P10b. Contraceptive implant insertions</p> <p style="text-align: right;">P10c. IUD insertion</p>	<p>1 = Yes 0 = No</p> <p><input type="checkbox"/></p> <p><input type="checkbox"/></p> <p><input type="checkbox"/></p>
<p>FP11. <b>Not including yourself</b>, has any other current staff member at this outlet/facility received any training in the last 2 years that included a component on performing contraceptive injections, contraceptive implant insertions and/or IUD insertions? <b>Include pre-service training and stand-alone workshops. Ask for and record each method.</b></p> <p style="text-align: right;">P11a. Contraceptive injections</p> <p style="text-align: right;">P11b. Contraceptive implant insertions</p> <p style="text-align: right;">P11c. IUD insertion</p>	<p>1 = Yes 0 = No 8 = Don't know</p> <p><input type="checkbox"/></p> <p><input type="checkbox"/></p> <p><input type="checkbox"/></p>
<p>FP12. From which organization(s) did you or staff from this facility/outlet receive training on performing contraceptive implant insertions, IUD insertions, and/or male or female sterilizations?</p> <p>A = <input type="text"/></p> <p>B = <input type="text"/></p> <p>C = <input type="text"/></p> <p>X = Don't know</p> <p>Y = None/not applicable</p> <p>Z = Refused</p>	<p>A</p> <p>B</p> <p>C</p> <p>X</p> <p>Z</p>
<p>FP13. <b>Check question P6 (Don't ask respondent):</b>  Does this outlet/facility provide any of the following services?</p> <p style="text-align: right;">P13a. Contraceptive implant insertion procedures</p> <p style="text-align: right;">P13b. IUD insertion procedures</p> <p><b>If 'no' or 'don't know' for all → Go to FP26</b></p>	<p>1 = Yes 0 = No 8 = Don't know</p> <p><input type="checkbox"/></p> <p><input type="checkbox"/></p>
<p>FP14. How many days per week are contraceptive implant insertion procedures available at this outlet/facility?  <b>If none or never, record '0' and → Go to P17</b></p>	<p><input type="text"/></p>
<p>FP15. If a woman came in today, could she receive a contraceptive implant insertion procedure at this outlet/facility?</p> <p>1 = Yes      <b>Go to FP17</b>  0 = No  8 = Don't know</p>	<p><input type="text"/></p>
<p>FP16. If a woman could not receive a contraceptive implant insertion procedure today, why would a woman be unable to receive this procedure today at this outlet/facility? <b>Record all that apply.</b></p> <p>A = Service not offered today  B = Trained provider not available today  C = Product not available today  D = Equipment not available/non-functional today  E = Individual did not meet requirements to receive procedure  Z = Other</p> <p><b>If other, specify:</b> <input type="text"/></p>	<p>A</p> <p>B</p> <p>C</p> <p>D</p> <p>E</p> <p>Z</p>

FP17. How many days per week are IUD insertion procedures available at this outlet/facility? <b>If none or never, record '0' and → Go to FP20</b>	<input type="text"/>
FP18. If a woman came in today, could she receive an IUD insertion procedure at this outlet/facility?  1 = Yes <b>Go to FP20</b> 0 = No 8 = Don't know	<input type="text"/>
FP19. If a woman could not receive an IUD insertion procedure today, why would a woman be unable to receive this procedure today at this outlet/facility? <b>Record all that apply.</b>  A = Service not offered today B = Trained provider not available today C = Product not available today D = Equipment not available/non-functional today E = Individual did not meet requirements to receive procedure Z = Other <b>If other, specify:</b> <input type="text"/>	A B C D E Z
FP20. <b>Check Question FP6 (Don't ask respondent):</b> Does outlet ever provide contraceptive implant procedures?  1 = Yes 0 = No <b>Go to FP23</b>	<input type="text"/>
FP21. Does outlet/facility have a room for providing contraceptive implant procedures? <b>Ask to observe room.</b>  1 = Observed 2 = Reported, not seen 0 = Not available	<input type="text"/>
FP22. Does outlet/facility have the following equipment for providing contraceptive implant procedures? <b>Read list and ask to observe equipment. When asking to locate each piece of equipment, verify each option with prompt cards.</b>  <div style="text-align: right;">i. Trocar (non-disposable) ii. Iodine iii. Scalpel with blade (for removal) iv. Straight mosquito forceps (for removal)</div>	1 = Observed 2 = Reported, not seen 0 = Not available  <div style="text-align: right;"><input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/></div>
FP23. <b>Check Question FP6 (Don't ask respondent):</b> Does outlet ever provide IUD insertion procedures?  1 = Yes 0 = No <b>Go to FP26</b>	<input type="text"/>
FP24. Does outlet/facility have a room for providing IUD insertion procedures? <b>Ask to observe room.</b>  1 = Observed 2 = Reported, not seen 0 = Not available	<input type="text"/>
FP25. Does outlet/facility have the following equipment for providing IUD insertion procedures? <b>Read list and ask to observe equipment. When asking to locate each piece of equipment, verify each option with prompt cards.</b>  <div style="text-align: right;">i. Examination table ii. Tenaculum iii. Uterine sound iv. Iodine v. IUD string retriever (for removal)</div>	1 = Observed 2 = Reported, not seen 0 = Not available  <div style="text-align: right;"><input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/></div>
FP26. For how many years have you worked in this outlet/facility? If less than 1 year, enter 01	<input type="text"/> <input type="text"/>



<p>FP27. What age are you today?</p> <p>Write age in years</p> <p>97= Refused</p> <p>98 = Don't know</p>	<div></div>
<p>FP28. Don't read: Is respondent male or female?</p> <p>1 = Male</p> <p>2 = Female</p>	<div></div>
<p>FP29. What is the highest level of education you completed?</p> <p>8 = No formal education</p> <p>9 = Some primary school</p> <p>10 = Completed primary school</p> <p>11 = Some secondary school</p> <p>12 = Completed secondary school</p> <p>13 = Some university/college</p> <p>14 = Completed a university/college degree</p>	<div></div>
<p>FP30. Have you or any other current staff member at this outlet/facility received any training in the last 12 months on the national guidelines for family planning? Include pre-service training and stand-alone workshops.</p> <p>1 = Yes</p> <p>0 = No</p> <p>8 = Don't know</p>	<div></div>
<p>FP31. Do you have any of the following <b>health qualifications</b>?</p> <p><b><u>Read list.</u></b></p> <p><b><i>Record 1 for yes, 0 for no</i></b></p>	
I. Dispenser (diploma in Pharmacy)	<div></div>
II. Pharmacist (Degree in Pharmacy)	<div></div>
III. Medical doctor	<div></div>
IV. Clinical Officer	<div></div>
V. Nurse / Nursing Officer	<div></div>
VI. Midwife	<div></div>
VII. Laboratory technician / Lab assistant	<div></div>
VIII. Pharmaceutical technologist	<div></div>
IX. Pharmacy technician	<div></div>
X. Public Health Technician/Officer	<div></div>
XI. Health Assistant, Medical Assistant / Nursing Assistant / Nursing Aid	<div></div>
XII. Community Medicine Distributor/Village Health Team	<div></div>

FP32. <b>Not including yourself</b> , do any other people working in this outlet/facility have the following <b>health qualifications?</b> <i>Read list.</i> <b>Record 1 for yes, 0 for no, 8 for don't know</b>		
I.	Dispenser (diploma in Pharmacy)	<input type="text"/>
II.	Pharmacist (Degree in Pharmacy)	<input type="text"/>
	III. Medical doctor	<input type="text"/>
	IV. Clinical Officer	<input type="text"/>
	V. Nurse / Nursing Officer	<input type="text"/>
	VI. Midwife	<input type="text"/>
	VII. Laboratory technician / Lab assistant	<input type="text"/>
	VIII. Pharmaceutical technologist	<input type="text"/>
	IX. Pharmacy technician	<input type="text"/>
	X. Public Health Technician/Officer	<input type="text"/>
	XI. Health Assistant, Medical Assistant / Nursing Assistant / Nursing Aid	<input type="text"/>
	XII. Community Medicine Distributor/Village Health Team	<input type="text"/>

## **Interviewer: Go to Section 10: Family Planning Provider Module—Sterilizations.**

<b>Section 10: Family Planning Provider Module—Sterilizations</b> <i>This section is about provider training, credentials and equipment for outlets that provide male and/or female sterilizations. This may require speaking with staff from a different department or location in the facility from Section 9. Completing the questions may require speaking with more than 1 staff member at the outlet. If the respondent does not know the answer to a question in this section, ask to speak with another staff member who can provide the information.</i>
--

PS1. Does this outlet/facility provide any of the following services? <b>Read each procedure from the following list and record response.</b>	1 = Yes 0 = No 8 = Don't know
PS1a. Male sterilization procedures PS1b. Female Sterilization procedures	<input type="text"/> <input type="text"/>  <b>If 'no' or 'don't know' for both → Go to Section 11: Family Planning Audit Tracker Sheet</b>
PS2. Are you the senior-most staff member available today that can perform any of the following services: male sterilization and/or female sterilization procedures?  1 = Yes <b>Go to PS4</b> 0 = No 8 = Don't know	<input type="text"/>
PS3. Is the senior-most staff member available today to speak with?  1 = Yes <b>Speak with the senior-most staff member</b> 0 = No <b>Continue speaking with current respondent</b> 8 = Don't know <b>Continue speaking with current respondent</b>	<input type="text"/>
PS4. Have you received any training in the last 2 years that included a component on performing male or female sterilizations? <b>Include pre-service training and stand-alone workshops. Ask for and record each method.</b>	1 = Yes 0 = No

PS4a. Male sterilization	<input type="text"/>
PS4b. Female sterilization	<input type="text"/>
PS5. <b>Not including yourself</b> , has any other current staff member at this outlet/facility received any training in the last 2 years that included a component on performing male or female sterilizations? <i>Include pre-service training and stand-alone workshops. Ask for and record each method.</i>	1 = Yes 0 = No 8 = Don't know
PS5a. Male sterilization	<input type="text"/>
PS5b. Female sterilization	<input type="text"/>
PS6. From which organization(s) did you or staff from this facility/outlet receive training on performing male or female sterilizations?  A = <input type="text"/> B = <input type="text"/> C = <input type="text"/> X = Don't know Z = Refused	A B C X Z
PS7. For how many years have you worked in this outlet/facility? <b>If less than 1 year, enter 01</b>	<input type="text"/> <input type="text"/>
PS8. What age are you today?  <i>Write age in years</i> 97 = Refused 98 = Don't know	<input type="text"/> <input type="text"/>
PS9. <b>Don't read:</b> Is respondent male or female?  1 = Male 2 = Female	<input type="text"/>
PS10. What is the highest level of education you completed?  15 = No formal education 16 = Some primary school 17 = Completed primary school 18 = Some secondary school 19 = Completed secondary school 20 = Some university/college 21 = Completed a university/college degree	<input type="text"/>
P11. Do you have any of the following <b>health qualifications</b> ? <u>Read list.</u> <b>Record 1 for yes, 0 for no</b>	
I. Medical Doctor	<input type="text"/>
II. Clinical Officer	<input type="text"/>
III. Nurse / Nursing Officer	<input type="text"/>
P12. <b>Not including yourself</b> , do any other people working in this outlet/facility have the following <b>health qualifications</b> ? <u>Read list.</u> <b>Record 1 for yes, 0 for no, 8 for don't know</b>	
I. Medical Doctor	<input type="text"/>
II. Clinical Officer	<input type="text"/>
III. Nurse / Nursing Officer	<input type="text"/>
PS13. How many days per week are male sterilization procedures available at this outlet/facility?	<input type="text"/>
PS14. If a man came in today, could he receive a male sterilization procedure at this outlet/facility?  1 = Yes <b>Go to PS16</b> 0 = No 8 = Don't know	<input type="text"/>

PS15. If a man could not receive a male sterilization procedure today, why would a man be unable to receive this procedure today at this outlet/facility? <b>Record all that apply.</b>  A = Service not offered today B = Trained provider not available today C = Equipment not available/non-functional today D = Individual did not meet requirements to receive procedure Z = Other If other, specify: [ ]		A B C D Z
PS16. What would be the total cost for a male sterilization procedure at this outlet/facility?  [ ] [ ] [ ] [ ] [ ] [ ] [ ] NGN  Free = 000000; Refused = 999997; Don't know=999998		
PS17. How many male sterilization procedures have you performed at this outlet/facility in the previous <u>1 month</u> ?  [ ] [ ] [ ] male sterilizations  Refused = 997; Don't know=998	PS17a. Source of information  0 = Provider recall 1 = Outlet records  [ ]	
PS18. How many days per week are female sterilization procedures available at this outlet/facility?	[ ]	
PS19. If a woman came in today, could she receive a female sterilization procedure at this outlet/facility?  1 = Yes <b>Go to PS21</b> 0 = No 8 = Don't know	[ ]	
PS20. If a woman could not receive a female sterilization procedure today, why would a woman be unable to receive this procedure today at this outlet/facility? <b>Record all that apply.</b>  A = Service not offered today B = Trained provider not available today C = Equipment not available/non-functional today D = Individual did not meet requirements to receive procedure Z = Other If other, specify: [ ]		A B C D Z
PS21. What would be the total cost for a female sterilization procedure at this outlet/facility?  [ ] [ ] [ ] [ ] [ ] [ ] [ ] NGN  Free = 000000; Refused = 999997; Don't know=999998		
PS22. How many female sterilization procedures have you performed at this outlet/facility in the previous <u>1 month</u> ?  [ ] [ ] [ ] female sterilizations  Refused = 997; Don't know=998	PS22a. Source of information  0 = Provider recall 1 = Outlet records  [ ]	
PS23. What types of female sterilization procedures are performed at this outlet/facility? <b>Read list and record all responses.</b>  A = Minilaparotomy B = Laparoscopy C = Transcervical Z = Other If other, specify: [ ]		A B C Z
PS24. Does outlet/facility have a room for providing female sterilization procedures? <b>Ask to observe room.</b>  1 = Observed 2 = Reported, not seen 0 = Not available		[ ]

<p>PS25. Does outlet/facility have the following equipment for providing female sterilization procedures? <b><u>Read list and ask to observe equipment.</u></b> <i>When asking to locate each piece of equipment, verify each option with prompt cards.</i></p> <table border="0"> <tr> <td style="width: 50%;"></td> <td style="width: 50%;">i. Surgical/examination table</td> <td style="width: 10%; text-align: center;">[ ]</td> </tr> <tr> <td></td> <td>ii. Lidocaine</td> <td style="text-align: center;">[ ]</td> </tr> <tr> <td></td> <td>iii. Sterile needle with syringe</td> <td style="text-align: center;">[ ]</td> </tr> <tr> <td></td> <td>iv. Scalpel with blade</td> <td style="text-align: center;">[ ]</td> </tr> <tr> <td></td> <td>v. Uterine elevator</td> <td style="text-align: center;">[ ]</td> </tr> <tr> <td></td> <td>vi. Tubal hook</td> <td style="text-align: center;">[ ]</td> </tr> </table>		i. Surgical/examination table	[ ]		ii. Lidocaine	[ ]		iii. Sterile needle with syringe	[ ]		iv. Scalpel with blade	[ ]		v. Uterine elevator	[ ]		vi. Tubal hook	[ ]	<p>1 = Observed 2 = Reported, not seen 0 = Not available</p>
	i. Surgical/examination table	[ ]																	
	ii. Lidocaine	[ ]																	
	iii. Sterile needle with syringe	[ ]																	
	iv. Scalpel with blade	[ ]																	
	v. Uterine elevator	[ ]																	
	vi. Tubal hook	[ ]																	
<p>PS26. What types of male sterilization procedures are performed at this outlet/facility? <b><u>Read list and record all responses.</u></b></p> <p>A = Scalpel vasectomy B = No-scalpel vasectomy Z = Other <b><i>If other, specify:</i></b> [ ]</p>	<p>A B Z</p>																		
<p>PS27. Does outlet/facility have a room for providing male sterilization procedures? <b><u>Ask to observe room.</u></b></p> <p>1 = Observed 2 = Reported, not seen 0 = Not available</p>	<p style="text-align: center;">[ ]</p>																		
<p>PS28. Does outlet/facility have the following equipment for providing male sterilization procedures? <b><u>Read list and ask to observe equipment.</u></b> <i>When asking to locate each piece of equipment, verify each option with prompt cards.</i></p> <table border="0"> <tr> <td style="width: 50%;"></td> <td style="width: 50%;">i. Surgical/examination table</td> <td style="width: 10%; text-align: center;">[ ]</td> </tr> <tr> <td></td> <td>ii. Lidocaine</td> <td style="text-align: center;">[ ]</td> </tr> <tr> <td></td> <td>iii. Sterile needle with syringe</td> <td style="text-align: center;">[ ]</td> </tr> <tr> <td></td> <td>iv. Scalpel with blade</td> <td style="text-align: center;">[ ]</td> </tr> <tr> <td></td> <td>v. Ringed/sponge forceps</td> <td style="text-align: center;">[ ]</td> </tr> <tr> <td></td> <td>vi. Dissecting forceps</td> <td style="text-align: center;">[ ]</td> </tr> </table>		i. Surgical/examination table	[ ]		ii. Lidocaine	[ ]		iii. Sterile needle with syringe	[ ]		iv. Scalpel with blade	[ ]		v. Ringed/sponge forceps	[ ]		vi. Dissecting forceps	[ ]	<p>1 = Observed 2 = Reported, not seen 0 = Not available</p>
	i. Surgical/examination table	[ ]																	
	ii. Lidocaine	[ ]																	
	iii. Sterile needle with syringe	[ ]																	
	iv. Scalpel with blade	[ ]																	
	v. Ringed/sponge forceps	[ ]																	
	vi. Dissecting forceps	[ ]																	

**Interviewer: Go to Section 11: Family Planning Audit Tracker Sheet.**

Section 11: Family Planning Audit Tracking Sheet	
<p>FPT1. Were there any family planning non-drugs including condoms, CycleBeads, diaphragms and/or rapid pregnancy test kits <u>in stock</u> at this outlet?</p> <p>1 = Yes 0 = No → <b>Go to T4</b> 8 = Don't know → <b>Go to T4</b></p>	[ ]
FPT2. Total number of FP Non-Drug <u>audit sheets</u> completed?	[ ][ ]
<p>FPT3. Did you complete audit sheet information for <u>all available</u> family planning non-drugs including condoms, CycleBeads, diaphragms and/or rapid pregnancy test kits?</p> <p>1 = Yes, audit complete 0 = No, audit not complete</p>	[ ]
<p>FPT4. Were there any family planning tablets including oral contraceptives, emergency contraceptives, vaginal foaming tablets and/or birth control patches <u>in stock</u> at this outlet?</p> <p>1 = Yes 0 = No → <b>Go to T7</b> 8 = Don't know → <b>Go to T7</b></p>	[ ]
FPT5. Total number of FP Tablet <u>audit sheets</u> completed?	[ ][ ]
<p>FPT6. Did you complete audit sheet information for <u>all available</u> family planning tablets including oral contraceptives, emergency contraceptives, vaginal foaming tablets and/or birth control patches?</p> <p>1 = Yes, audit complete 0 = No, audit not complete</p>	[ ]
<p>FPT7. Were there any family planning injections including injectable contraceptives <u>in stock</u> at this outlet?</p> <p>1 = Yes 0 = No → <b>Go to T10</b> 8 = Don't know → <b>Go to T10</b></p>	[ ]
FPT8. Total number of FP Injection <u>audit sheets</u> completed?	[ ][ ]
<p>FPT9. Did you complete audit sheet information for <u>all available</u> family planning injections including injectable contraceptives?</p> <p>1 = Yes, audit complete 0 = No, audit not complete</p>	[ ]
<p>FPT10. Were there any family planning insertions including contraceptive implants, IUDs and/or vaginal birth control rings <u>in stock</u> at this outlet?</p> <p>1 = Yes 0 = No → <b>Go to T13</b> 8 = Don't know → <b>Go to T13</b></p>	[ ]
FPT11. Total number of FP Insertion <u>audit sheets</u> completed?	[ ][ ]
<p>FPT12. Did you complete audit sheet information for <u>all available</u> family planning insertions including contraceptive implants, IUDs and/or vaginal birth control rings?</p> <p>1 = Yes, audit complete 0 = No, audit not complete</p>	[ ]
<p>FPT13. COMMENTS: Reason for incomplete audit sheets (if response is no to FPT3, FPT6, FPT9, or FPT12):</p>	

**GO TO Section 12: ORS and Zinc—Make sure to complete!**



## Annex 8: Detailed Brand Listing with Quality Assurance Indications

Contraceptive Commodity	Brand	Formulation	Manufacturer (Country of Manufacturer)	WHO Prequalified List*	SRA List†
Tablets	Combination 3	Levonorgestrel	Delpharm Lille Sas (France)		Yes
	Copill	Levonorgestrel	West Coast Pharmaceutical Works Ltd (India)		
	Curesinor	Levonorgestrel	Unicare Pharmaceutical Ltd (Nigeria)		
	Dianette	Ethinylestradiol	Bayer Schering Pharma Ag (Ireland)		Yes
	Evadir 2	Levonorgestrel	Precise Biopharma Pvt Ltd (India)		
	Exluton	Lynestrenol	Nv Organon Oss (Netherlands / Holland)		Yes
	Glostinor 2	Levonorgestrel	Global Healthcare Limited (India)		
	Levofem	Levonorgestrel	Pt Harsen Lab (Indonesia)		
	Microgynon	Levonorgestrel	Bayer Schering Pharma Ag (Germany)	Yes	
	Microgynon 30	Levonorgestrel	Bayer Schering Pharma Ag (Germany)	Yes	
	Microgynon Ed Fe	Levonorgestrel	Bayer Schering Pharma Ag (Germany)	Yes	
	Microlut	Levonorgestrel	Bayer Schering Pharma Ag (Germany)		Yes
	Nerostinor	Levonorgestrel	Pharbaco Central Pharmaceutical J.S.C No.1 (Vietnam)		
	Nicpostinew	Levonorgestrel	Nic Pharma Co Ltd (Vietnam)		
	Norlevo	Levonorgestrel	Delpharm Lille Sas (France)		Yes
	Ovrette	Norgestrel	Wyeth Laboratories Inc (Vietnam)		
	Pillanor 2	Levonorgestrel	Acme Formulation Pvt Ltd (India)		
	Poster Tablets	Levonorgestrel	Shuangwei Pharm Co Ltd (China)		
	Postiga 4	Levonorgestrel	JiangYesi Yesier Kang Tai Pharm Co. Ltd (China)		
	Postinor 1	Levonorgestrel	Gedeon Richter Plc (Hungary)	Yes	
	Postinor 2	Levonorgestrel	Gedeon Richter Plc (Hungary)	Yes	
	Postpill	Levonorgestrel	Jagsonpal Pharmaceutical Ltd (India)		
	Pregnon	Levonorgestrel	Famy Care Ltd (India)		
	Rogotinor	Levonorgestrel	Shanghai Pharmaceutical (Group) Co Ltd (China)		
	Sendinor 2	Levonorgestrel	Unicare Remedies Pvt Ltd (India)		
	Arthrotec 75	Misoprostal	Npil Pharmaceutical (Uk) Ltd (United Kingdom)		
	Cytotec	Misoprostal	Pfizer S.A. (Spain)		Yes
	Eprostol 200	Misoprostal	Zolon Healthcare Limited (South Korea)		
	Manstogan	Misoprostal	Manstogan (994)		
	Misoclear	Misoprostal	Acme Formulation Pvt Ltd (India)	Yes	



	Misofem	Misoprostal	Naari Ag (India)		
	Misoprostol 200	Misoprostal	West Coast Pharmaceutical Works Ltd (India)		
	Misotec	Misoprostal	Nisenton Pharmaceuticals (India)		
	Tyonex Misoprostol	Misoprostal	Divine Essential Formulations (Nigeria)		
	Vanprazol 200	Misoprostal	Cipla Ltd (India)		
<b>Injectables</b>	Depo Provera	Medroxyprogesterone Acetate	Pfizer Pharmacia & Upjohn Co (United States)	Yes	
	Norigynon	Norethisterone + Estradiol Valerate	Bayer Schering Pharma Ag (Germany)		Yes
	Noristerat	Norethisterone	Bayer Schering Pharma Ag (Germany)		Yes
	Sayana Press	Medroxyprogesterone Acetate	Pfizer (Belgium)	Yes	
<b>IUDs and Implants</b>	Copper T Model Tcu 380A	Copper / Cu 380A	Finishing Enterprises Inc (United States)		
	Eves	Copper / Cu 380A	Corporate Channels India Private Limited (India)	Yes	
	Implanon	Etonogestrel	Nv Organon Oss (Netherlands / Holland)		Yes
	Jadelle	Levonorgestrel	Bayer Schering Pharma Oy (Finland)		Yes
	Lng Ius	Levonorgestrel	Bayer Schering Pharma Ag (Finland)		
	Lydia	Copper / Cu 380A	Pregna International Ltd (India)	Yes	
	Optima	Copper / Cu 380A	Injeflex Ind Com Ltd (Brazil)	Yes	
	Pregna	Copper / Cu 380A	Pregna International Ltd (India)	Yes	
	Smb Copper T380A	Copper / Cu 380A	Smb Corporation India (India)	Yes	

## Annex 9. Sampling Weights

Sampling weights were applied for analysis of the Nigeria 2015 outlet survey data to account for variations in probability of selection as a result of the sampling design:

- 1) **Stratification:** Disproportionate allocation stratification was used to ensure adequate sample size within the regional domains to allow for domain-specific estimates. A representative sample was selected within each domain.
- 2) **Multi-stage cluster sampling:** A representative sample of localities (administrative units with population of approximately 10,000-15,000) was selected in each geopolitical zone using multi-stage cluster sampling. Using a list of all localities within each geopolitical zone, i.e. North Central, North East, North West, South East, South South and South West regions, localities were selected with probability proportional to size (PPS). Within each selected *locality*, a census of all outlets with the potential to sell or distribute modern contraceptives and/or provide associated contraceptive procedures was conducted.

For North Central, North East, North West, South East, South South and South West regions, weights were calculated for both *LGA* probability of selection and *locality* probability of selection. Final weights were calculated by multiplying the corresponding *LGA* weight by a given *locality* weight:

The sampling weights applied during analysis are the inverse of the probability of selection. For North Central, North East, North West, South East, South South and South West:

$$W_i = \frac{1}{a \times \frac{D_\alpha}{\sum D_\alpha} \times b \times \frac{M_\alpha}{\sum M_\alpha}}$$

Where:

1<sup>st</sup> Stage of selection:

- $D_\alpha$  = estimated *LGA* population size
- $\sum D_\alpha$  = sum of estimated *LGA* population sizes
- $a$  = number of *LGA* selected

2<sup>nd</sup> Stage of selection:

- $M_\alpha$  = estimated *locality* population size
- $\sum M_\alpha$  = sum of estimated *locality* population sizes in the stratum (region)
- $b$  = number of *locality* selected within the district

Sampling weights are calculated at the cluster level and are applied to all outlets within a given cluster, regardless of outlet type.

A sampling frame with population sizes was used for selecting the sample because accurate estimates on the total number of outlets per geographic/administrative unit that may be eligible for a medicine outlet survey do not exist. The major assumption in using population figures for sampling and weighting is that distribution of outlets and/or distribution of medicines moving through outlets in a given cluster is correlated with population size.

## Annex 10: FPwatch Indicator List

### Indicator 1: Modern contraceptive method market composition

Table 1 reports the distribution of outlet types among outlets: 1. With at least one modern contraceptive method available on the day of the survey. Outlet types will be broad-based (public vs. private) as well as for major outlet types by country. Market composition is reported for provincial (Kinshasa, Katanga) as well as for urban/rural estimates.

Numerator	By outlet type, the number of outlets with any modern contraceptive method in stock at the time of the survey visit, as confirmed by presence of at least 1 brand/generic of 1 modern contraceptive method in the FP commodity audit section or condoms module or contraceptive procedure recorded in the FP provider section.
Denominator	Total number of outlets with any modern contraceptive method in stock or available at the time of the survey visit, as confirmed by presence of at least 1 brand/generic of 1 modern contraceptive method (male/female condoms, oral contraceptives, emergency contraceptives, injectables implants, IUDs) recorded in the contraceptive method audit section or condoms section or type of contraceptive procedure in the FP provider section.
Calculation	Numerator for each outlet type divided by the denominator.
Handling missing values	All outlets with at least 1 modern contraceptive method recorded in the contraceptive audit section or reporting availability of condoms in screening section or reporting availability of at least 1 contraceptive procedure will contribute to the indicator. This includes outlets where the interview was not fully completed (partial interview).
Notes and considerations	None.

## Indicator 2: Availability of at least 1 method of modern contraception

Table 2 reports the proportion of all outlets screened that had any modern contraceptive method (male/female condoms, oral contraceptives, emergency contraceptives, injectables, implants, IUDs, cycle beads) in stock or offering male/female sterilization procedures at the time of the survey visit. Modern contraceptive method availability is reported for provincial (Kinshasa, Katanga) as well as for urban/rural estimates. Availability is reported among all outlets as well as among: individual outlet types and comparing all public outlets to all private for profit and not-for-profit outlets.

Numerator	1. Number of outlets with any modern contraceptive commodity in stock at the time of the survey visit, as confirmed by presence of at least 1 brand/generic of 1 modern contraceptive commodity recorded in the contraceptive commodity audit section, offering male/female sterilization procedures as indicated in the service provider interview, or reporting availability of condoms in condoms module.
Denominator	Number of outlets screened.
Calculation	Numerator divided by denominator.
Handling missing values	All screened outlets will contribute to the denominator. This includes outlets with commodities/procedures available but: 1) were not interviewed; or 2) the interview was partially completed.
Notes and considerations	Given partial or non-completion of interviews among eligible outlets and the inclusion of these outlets in the denominator, these availability indicators can be considered conservative estimates of modern contraceptive method availability. Outlets that only offer procedures for injectables, implants and/or IUDs but do not have the commodity in stock, will not be counted as having the method available.

### Indicator 3: Availability of selected modern contraceptive methods

Table 3 reports the proportion of modern contraceptive commodity-stocking or procedure-providing (no contraceptive commodities available but providing injections, implant/IUD insertions and/or male/female sterilizations) outlets with specific modern contraceptive commodities in stock at the time of the survey visit. Modern contraceptive method availability is reported for provincial (Kinshasa, Katanga) as well as for urban/rural estimates. Availability is reported among all outlets as well as among: individual outlet types and comparing all public outlets to all private for profit and not-for-profit outlets.

Numerator	Number of outlets with <i>X</i> modern contraceptive commodity/procedure type in stock/available at the time of the survey visit, as confirmed by presence of at least 1 brand/generic of <i>X</i> modern contraceptive commodity for the commodity type recorded in the FP audit section. For condoms, this includes outlets with condoms only as indicated in the condoms module. For procedures, this includes outlets indicating availability of <i>X</i> service in the provider section.
Denominator	Number of outlets with any modern contraceptive commodity in stock or providing any contraceptive procedure at the time of the survey visit, as confirmed by presence of at least 1 brand/generic of 1 modern contraceptive commodity recorded in the FP method audit section, reporting availability of condoms in condoms module or reporting availability of at least one modern contraceptive procedure.
Calculation	Numerator for each modern contraceptive commodity/service type divided by the denominator.
Handling missing values	All outlets with any modern contraceptive method available will contribute to the denominator. This includes outlets with commodities/procedures available but the interview was partially completed.
Notes and considerations	Given partial completion of interviews among outlets potentially providing modern contraceptive methods and the inclusion of these outlets in the denominator, these availability indicators can be considered conservative estimates of modern contraceptive method availability.

#### Indicator 4: Availability of range/diversity of modern contraceptive methods

Table 4 reports the proportion of modern contraceptive commodity-stocking and procedure-providing outlets with 3 or more modern FP methods (commodity and/or service) in stock or available at the time of the survey visit, 3 or more methods with at least one method a LARC and 5 or more methods. Modern contraceptive method availability is reported for provincial (Kinshasa, Katanga) as well as for urban/rural estimates. Availability is reported among all outlets as well as among: individual outlet types and comparing all public outlets to all private for profit and not-for-profit outlets.

Numerator	<p>1. Number of outlets with 3 or more modern contraceptive methods available at the time of the survey visit, as confirmed by presence of at least 1 brand/generic for any 3 or more combinations of modern contraceptive commodities (male condoms, female condoms, oral contraceptives, emergency contraceptives, injectables, implants, IUDs) recorded in the contraceptive method audit section, and/or condoms module and/or types of contraceptive procedures (male/female sterilizations) recorded in the FP provider section.</p> <p>2. Number of outlets with 3 or more modern FP methods, including at least 1 LARC (implants, IUDs), available at the time of the survey visit, as confirmed by presence of at least 1 brand/generic for any 3 or more combinations, including at least 1 LARC, of modern contraceptive commodities (male condoms, female condoms, oral contraceptives, emergency contraceptives, injectables, implants, IUDs) recorded in the contraceptive audit section and/or condoms module and/or types of contraceptive procedures (male or female sterilizations) recorded in the FP provider section.</p> <p>3. Number of outlets with 5 or more modern contraceptive methods available at the time of the survey visit, as confirmed by presence of at least 1 brand/generic for any 5 or more combinations of modern contraceptive commodities (male condoms, female condoms, oral contraceptives, emergency contraceptives, injectables, implants, IUDs) recorded in the contraceptive method audit section, and/or condoms module and/or types of contraceptive procedures (male/female sterilizations) recorded in the FP provider section.</p>
Denominator	<p>1. Number of outlets with any modern contraceptive commodity in stock or providing any contraceptive procedure at the time of the survey visit, as confirmed by presence of at least 1 brand/generic of 1 modern contraceptive commodity recorded in the contraceptive method audit section, reporting availability of condoms in condoms module or reporting availability of at least one contraceptive procedure.</p>
Calculation	Numerator divided by denominator.
Handling missing values	All outlets with any modern contraceptive method available will contribute to the denominator. This includes outlets with commodities/procedures available but the interview was partially completed.
Notes and considerations	Given partial completion of interviews among outlets potentially providing modern contraceptive methods and the inclusion of these outlets in the denominator, these availability indicators can be considered conservative estimates of modern contraceptive method availability.

### Indicator 5: Stock outs

Table 5 reports the proportion of outlets reporting a current stock out of a method (oral contraceptives, emergency contraceptives, injectables, implants, IUDs) that the outlet has reportedly had in stock in the previous 3 months. Stock outs are reported among all outlets as well as among: individual outlet types and comparing all public outlets to all private for profit and not-for-profit outlets.

Numerator	Number of outlets reporting a stock out of a method, as confirmed by report of a current stock out in the FP provider section, and the outlet does not have the method currently available, as confirmed in the contraceptive method audit section.
Denominator	Number of outlets reportedly offering the method at any point in the previous 3 months.
Calculation	Numerator for each modern FP commodity type divided by the denominator.
Handling missing values	All outlets reportedly offering the method will contribute to the denominator. This includes outlets with products available but the interview was partially completed.
Notes and considerations	This indicator only applies to outlets that reportedly offered the method in the previous three months. Those outlets that did not offer the method in the previous three months but might be expected to carry the product will not appear in this indicator. Instead, they will be seen in the converse (non-availability) of the availability of methods indicator.

#### Indicator 6: Price of modern contraceptive methods

Table 6 provides the median retail price, by method, combining all brands of X method. The IQR is provided as a measure of dispersion. Commodities with a service component (injections, implant and IUD insertions) may include a procedure price in addition to the commodity cost. Methods without a commodity (male/female sterilizations) will be reported on the price of procedure only. Median price is reported for provincial (Kinshasa, Katanga) as well as for urban/rural estimates and among all outlets as well as among: individual outlet types and comparing all public outlets to all private for profit and not-for-profit outlets.

Calculation	Median retail price for each modern contraceptive method price in US dollars with IQR.
Handling missing values	Contraceptive brands/generics with missing price information are excluded from the median price calculation.
Notes and considerations	For methods with an associated procedure (injection, implant and IUD insertion, male/female sterilization), cost will be determined for commodity (if there is commodity) and may include a service charge. Price in US dollars is calculated based on exchange rates available from <a href="http://www.oanda.com">www.oanda.com</a> using the historical exchange rates tool. The average exchange rate over the entire data collection period is used for converting local currency captured during data collection to US dollars.



#### Indicator 7: Price of modern contraceptive methods in CYP

Table 7 provides the median retail price of 1 CYP by method, combining all brands/generics of X method. The IQR is provided as a measure of dispersion. Commodities with a service component (injections, implant and IUD insertions) may include a procedure price in addition to the commodity cost. Methods without a commodity (male/female sterilizations) will be reported on the price of procedure only. Median price is reported for provincial (Kinshasa, Katanga) as well as for urban/rural estimates and among all outlets as well as among individual outlet types and comparing all public outlets to all private for profit and not-for-profit outlets.

Calculation	Median retail price for 1 CYP of each modern contraceptive method price in US dollars with IQR.
Handling missing values	Contraceptive brands/generics with missing price information are excluded from the median price calculation.
Notes and considerations	<p>Price per CYP will be determined by multiplying retail price by the CYP conversion factor. CYP conversion factors are used from <a href="http://www.cpc.unc.edu/measure/prh/rh_indicators/specific/fp/cyp">http://www.cpc.unc.edu/measure/prh/rh_indicators/specific/fp/cyp</a>. See Annex 11 for description of CYP calculation.</p> <p>For methods with an associated procedure (injection, implant and IUD insertion, male/female sterilization), cost will be determined for commodity (if there is commodity) and may include a service charge. Price in US dollars is calculated based on exchange rates available from <a href="http://www.oanda.com">www.oanda.com</a> using the historical exchange rates tool. The average exchange rate over the entire data collection period is used for converting local currency captured during data collection to US dollars.</p>

#### Indicator 8: Median markup percentage of modern contraceptives

Table 8 provides the median percentage markup (mean of retail price minus wholesale price) by selected methods combining the price for all brands/generics of a given method. The IQR is provided as a measure of dispersion. Median markups are reported for provincial (Kinshasa, Katanga) as well as for urban/rural estimates and among all outlets as well as among individual outlet types and comparing all public outlets to all private for profit and not-for-profit outlets.

Calculation	Median with IQR of: [(Retail price – wholesale price)/wholesale price] x 100
Handling missing values	Brands/generics with missing retail or wholesale price information will be excluded.
Notes and considerations	Given missing information among eligible outlets, potential variation for cost of methods within an outlet and the difficulties in disaggregating service/procedure cost from commodity cost this indicator should be interpreted with caution.

#### Indicator 9: Modern contraceptive method market share

Modern contraceptive method market share is the volume in CYP reportedly sold or distributed in the previous month for a selected contraceptive method as a percentage of the total CYP sold or distributed in the previous month across all method types. Expressed as a percentage, market share is the amount of a specific contraceptive method sold/distributed by a specific outlet type relative to the entire contraceptive market (total volume in CYP across all method types). Totals are reported per modern contraceptive method type. Across modern contraceptive method types, percentages in the entire table sum to 100% (the total market). Method market shares are reported for provincial (Kinshasa, Katanga) as well as for urban/rural estimates.

Numerator	Total number of CYPs sold/distributed for X method and Y outlet.
Denominator	Total number of CYP sold/distributed for all methods.
Calculation	Numerator divided by denominator.
Handling missing values	CYPs sold/distributed are calculated among audited modern contraceptive methods with complete and consistent information. Modern contraceptive methods with incomplete or inconsistent information among key variables that define CYP sold/distributed (package size, amount sold/distributed) are excluded from the calculation.
Notes and considerations	See description of CYP calculation in Annex 11.

#### Indicator 10: Modern contraceptive market share within outlet types

Outlet market share is the volume in CYP reportedly sold or distributed in the previous month for a selected method type as a percentage of the total CYP sold or distributed in the previous month across within a given outlet type. Expressed as a percentage, market share is the volume in CYP sold/distributed for a given method relative to the total volume in CYP for that a given outlet type. Outlet types will be broad-based (public vs. private vs. not-for-profit) as well as for major outlet types by country. Within outlet categories, percentages sum to 100% (the total market). Outlet market shares are reported for provincial (Kinshasa, Katanga) as well as for urban/rural estimates.

Numerator	Total number of CYPs sold/distributed for X method in Y outlet.
Denominator	Total number of CYP sold/distributed in Y outlet category.
Calculation	Numerator divided by denominator.
Handling missing values	CYPs sold/distributed are calculated among audited modern contraceptive methods with complete and consistent information. Modern contraceptive methods with incomplete or inconsistent information among key variables that define CYP sold/distributed (package size, amount sold/distributed) are excluded from the calculation.
Notes and considerations	See description of CYP calculation in Annex 11.

Indicator 11: Availability of provider skills and certification for contraceptive procedures

Table 11 provides the proportion of outlets with a trained provider available for key modern contraceptive procedures (injection, implant and IUD insertion, male/female sterilization) among: 1. All screened outlets; and 2. Outlets recorded as providing the method, regardless of legality. Proportions are reported for selected outlet types and for provincial as well as for urban/rural estimates.

Numerator	Number of outlets with at least 1 provider having credentials to legally provide X contraceptive procedure (injection, implant and IUD insertion, male/female sterilization).
Denominator	1. All screened outlets; and 2. Outlets reportedly providing X provider-dependent method.
Calculation	Numerator divided by denominator 1 and denominator 2, for each method type.
Handling missing values	Methods with missing certification/training information will be excluded.
Notes and considerations	Necessary certifications for provider-dependent FP methods found in DRC National Family Planning Guidelines: Normes De La Zone De Sante Relatives Aux Interventions Integrees De Sante De La Mere, Du Nouveau-Ne Et De L'enfant En Republique Democratique Du Congo. Volume 6: Les Interventions De Planification Familiale. Secretariat General de La Ministere De La Sante Publique Edition 2012.

## Indicator 12: Availability of necessary equipment for contraceptive procedures

Table 12 provides the proportion of outlets with a minimum set of necessary equipment available for contraceptive procedures (injection, implant and IUD insertion, male/female sterilization) among: 1. All screened outlets; and 2. Outlets recorded as providing the method, regardless of legality. Proportions are reported for selected outlet types and for provincial as well as for urban/rural estimates.

Numerator	Number of outlets reporting availability of all equipment (see list of equipment for each method below) necessary to provide X contraceptive procedure (injection, implant and IUD insertion, male/female sterilization).
Denominator	1. All screened outlets; and 2. Outlets reportedly providing X provider-dependent method.
Calculation	Numerator divided by denominator 1 and denominator 2, for each method type.
Handling missing values	Methods with missing information on availability of key equipment will be excluded.
Notes and considerations	<p><i>Contraceptive injection procedure: <b>Equipment:</b> Sterile needle with syringe</i></p> <p><i>Contraceptive implant procedure: <b>Equipment:</b> 1. Trocar; 2. Iodine;</i></p> <p><b>Equipment for Removal:</b> 1. Scalpel with Blade (removal); 2. Straight Mosquito Forceps (removal)</p> <p><i>IUD insertion procedure: <b>Equipment:</b> 1. Room; 2. Examination Table; 3. Iodine; 4. Tenaculum; 5. Speculum; 6. Uterine Sound</i></p> <p><i>Female sterilization procedure: <b>Equipment:</b> 1. Room; 2. Examination Table; 3. Blood Pressure Apparatus; 4. Lidocaine; 5. Sterile Needle with Syringe; 6. Scalpel with Blade; 7. Uterine elevator; 8. Tubal Hook</i></p> <p><i>Male sterilization procedure: <b>Equipment:</b> 1. Room; 2. Examination Table; 3. Lidocaine; 4. Sterile Needle with Syringe; 5. Scalpel with Blade; 6. Ringed clamp/forceps; 7. Dissecting forceps</i></p> <p>Necessary equipment list taken from Measure Evaluation's Family Planning and Reproductive Health Indicators Database:  <a href="http://www.cpc.unc.edu/measure/prh/rh_indicators">http://www.cpc.unc.edu/measure/prh/rh_indicators</a>.</p>

Indicator 13: Full service readiness to provide contraceptive procedures

Table 13 provides the proportion of outlets with full service readiness for contraceptive procedures defined as: 1. Having at least one brand/generic of a selected contraceptive commodity available on the day of the survey (for injections, implants, IUDs); 2. Having at least one provider trained/certified for a selected method available at the outlet (for injections, implants, IUDs, sterilizations); and 3. Having a minimum, necessary set of equipment for providing a selected method available at the outlet. Outlets meeting each of these three criteria will be classified as “service ready.” Proportions are reported for selected outlet types and for provincial as well as for urban/rural estimates.

Numerator	Number of outlets reporting availability of commodity and provider credentials and all necessary equipment for a selected method.
Denominator	1. All screened outlets; and 2. Outlets reportedly providing X contraceptive procedure.
Calculation	Numerator divided by denominator 1 and denominator 2, for each method type.
Handling missing values	Methods with missing information on availability of commodities, provider credentials or key equipment will be excluded.
Notes and considerations	None.

## Annex 11. Couple-Years of Protection (CYP)

### Definition

Couple-years of protection (CYP) is the estimated protection provided by modern contraceptive methods during a one-year period, based upon the volume of all contraceptives sold or distributed free of charge to clients during that period. The CYP is calculated by multiplying the quantity of each method sold or distributed to clients by a conversion factor, to yield an estimate of the duration of contraceptive protection per unit of the method. The CYP for each method are then summed over all methods to obtain a total CYP figure. CYP conversion factors are based on how a method is used, failure rates, wastage, and how many units of the method are typically needed to provide one year of contraceptive protection for a couple. The calculation takes into account that some methods, like condoms and oral contraceptives, for example, may be used incorrectly and then discarded, or that IUDs and implants may be removed before their life span is realized.

FPwatch uses the CYP as a standard unit for price and sale/distribution analyses. Updated (2011) conversion factors, endorsed by USAID, are used in analysis. Updated conversion factors are listed below and can also be accessed from [http://www.cpc.unc.edu/measure/prh/rh\\_indicators/specific/fp/cyp](http://www.cpc.unc.edu/measure/prh/rh_indicators/specific/fp/cyp).

Table X4: CYP Conversion Factors	
Contraceptive method	Dose/unit used for calculating 1 CYP
Oral contraceptives	15 cycles per CYP
Condoms (male and female)	120 condoms per CYP
Monthly vaginal ring/patch	15 rings/patches per CYP
Vaginal foaming tablets	120 tablets per CYP
Depo-provera injectable	4 doses (ml) per CYP
Noristerat injectable	6 doses per CYP
Cyclofem monthly injectable	13 doses per CYP
Copper-T 38-A IUD	4.6 CYP per IUD inserted
Levonorgestrel intrauterine system (LNG-IUS)	3.3 CYP per LNG-IUS inserted
3-year implant (e.g., Implanon)	2.5 CYP per implant
4-year implant (e.g., Sino-Implant)	3.2 CYP per implant
5-year implant (e.g., Jadelle)	3.8 CYP per implant
Emergency contraceptives	20 doses per CYP
Standard days method (e.g., CycleBeads)	1.5 CYP per trained adopter
Sterilization (male and female)	Global: 10 CYP India, Bangladesh, Nepal: 13 CYP Other Asian Countries: 10.3 CYP Africa: 9.3 CYP

While it is recognized that the use of CYP may over-simplify and ignore many of the complexities of consumption and use, this analytical approach was selected because it standardizes dosing across method types and across countries (which may sometimes vary), thus permitting comparisons on both prices and volumes calculated on the basis of a CYP.

### Additional considerations:

- CYP primarily reflects distribution and not actual use or impact. FPwatch calculates CYP according to contraceptive commodities sold/distributed rather than procedures performed.
- For provider-dependent contraceptive procedures, commodities sold/distributed does not necessarily imply that these commodities have been injected or inserted. We have chosen to count CYP for commodities



sold/distributed across all methods, assuming that contraceptive procedures on sold contraceptives requiring a procedure are performed.

### Calculation

Price and volume data were entered according to how an outlet reported selling the contraceptive commodity. For example, if they sold oral contraceptives in packages of three blisters, they reported sales for a package of three blisters. If they sold blisters individually, there was an option to report sales by blister rather than package of three. During analysis, price and volume data were divided by how the units were sold. For example, if oral contraceptives are sold in a package of three blisters, volume and price is manipulated to give volume and price for each one unit. The units considered are those listed for CYP conversion rates. No product was sold by less than the CYP unit (e.g., by single oral contraceptive tablet vs. a blister (cycle)).

Price per CYP was determined by multiplying the given price by the CYP conversion factor (if short-acting method because all < 1 year) and dividing by the CYP conversion factor (if long-acting method because all > 1 year). Volume of CYP was determined by dividing the number of units sold by the CYP conversion factor (if short-acting method) and multiplying by the CYP conversion factor (if long-acting method). Some prices/volumes are given for an entire method that may use multiple conversion factors. For example, the volume of implants was reported by combining all 3-, 4- and 5-year implants using each of their appropriate CYP conversion factors.

## Annex 12: Contraceptive Method Volume

**Table X5: Reported Contraceptive Method Volumes — National, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type <sup>*,†</sup>	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
<b>1. Male condoms</b>	36770.1 (0.0, 74856.9)	20.9 -	3.4 -	36794.5 (0.0, 74878.9)	7566.1 -	10352.0 -	151450.0 (77124.1, 225776.0)	17689.8 (0.0, 37138.5)	187057.9 (99047.7, 275068.2)	223852.4 (130453.3, 317251.5)
<b>2. Female condoms</b>	1835.1 (0.0, 3971.4)	0.0 -	0.0 -	1835.1 (0.0, 3971.4)	98.7 -	4.8 -	298.7 -	0.9 -	403.2 -	2238.3 (89.4, 4387.1)
<b>3. Cyclebeads</b>	446.0 -	0.0 -	0.0 -	446.0 -	576.4 -	8.5 -	212.3 (0.0, 517.1)	0.0 -	797.3 (0.0, 2092.9)	1243.3 -
<b>4. Oral contraceptives</b>	8199.2 (4123.6, 12274.9)	0.0 -	12.4 -	8211.6 (4137.9, 12285.3)	5681.2 (0.0, 14613.2)	2651.2 (358.5, 4944.0)	48417.4 (26003.0, 70831.9)	205.3 (0.0, 435.8)	56955.1 (26611.3, 87298.8)	65166.7 (34806.6, 95526.7)
IQA oral contraceptives	8199.2 (4123.6, 12274.9)	0.0 -	12.4 -	8211.6 (4137.9, 12285.3)	5677.8 (0.0, 14609.8)	2647.8 (359.2, 4936.3)	48137.2 (25946.9, 70327.5)	205.3 (0.0, 435.8)	56668.1 (26585.8, 86750.3)	64879.7 (34774.9, 94984.4)
Combined oral contraceptives	4991.4 (2064.8, 7918.0)	0.0 -	0.1 -	4991.5 (2064.9, 7918.2)	5670.7 (0.0, 14602.7)	2651.2 (358.5, 4944.0)	48227.4 (25841.2, 70613.5)	205.3 (0.0, 435.8)	56754.5 (26431.9, 87077.1)	61746.0 (31624.7, 91867.4)
Progestin-only pills	3207.8 (1750.3, 4665.4)	0.0 -	12.3 -	3220.1 (1765.0, 4675.2)	10.5 (0.0, 21.1)	0.0 -	190.1 (0.0, 452.2)	0.0 -	200.6 (0.0, 462.9)	3420.6 (1882.8, 4958.5)
<b>5. Emergency contraceptives</b>	8.8 (0.0, 26.9)	0.0 -	0.0 -	8.8 (0.0, 26.9)	11.4 (0.0, 24.5)	4960.3 (288.7, 9631.8)	20032.1 (1739.4, 38324.8)	41.9 (0.0, 102.0)	25045.7 (3767.0, 46324.3)	25054.5 (3775.8, 46333.2)
IQA emergency contraceptives	8.8 (0.0, 26.9)	0.0 -	0.0 -	8.8 (0.0, 26.9)	0.0 -	2363.9 (215.8, 4512.1)	12956.4 (0.0, 26508.8)	23.1 (0.0, 61.2)	15343.5 (409.6, 30277.3)	15352.3 (418.5, 30286.1)
<b>6. Contraceptive injectables</b>	44500.3 (18504.2, 70496.4)	816.7 -	156.6 -	45473.6 (19543.0, 71404.2)	11791.5 (0.0, 25308.2)	6074.3 (1874.0, 10274.5)	23690.3 (9930.4, 37450.3)	1.8 (0.0, 5.3)	41557.8 (20784.5, 62331.2)	87031.4 (53115.1, 120947.7)
Depo-provera injectables	30802.7 (11670.0, 49935.4)	54.1 (54.1, 54.1)	110.4 (110.4, 110.4)	30967.2 (11837.0, 50097.4)	6744.3 (196.5, 13292.0)	2969.7 (545.3, 5394.0)	14329.5 (5374.3, 23284.8)	0.0 -	24043.5 (12313.0, 35774.0)	55010.7 (32519.4, 77501.9)
Noristerat injectables	13697.6 (5073.3, 22321.8)	762.6 (762.6, 762.6)	46.3 -	14506.4 (5862.1, 23150.7)	5047.2 (0.0, 12168.5)	3104.6 (1112.1, 5097.1)	9360.8 (4041.5, 14680.1)	1.8 (0.0, 5.3)	17514.4 (7928.6, 27100.2)	32020.8 (18448.0, 45593.5)
Sayana Press injectables	0.0 -	0.0 -	0.0 -	0.0 -	23.5 (0.0, 58.8)	28.6 (0.0, 73.2)	994.1 (0.0, 2697.5)	0.0 -	1046.2 (0.0, 2752.2)	1046.2 (0.0, 2752.2)
<b>7. Implants</b>	131807.4 (36054.2, 227560.6)	0.0 -	34.0 -	131841.5 (36082.6, 227600.3)	276907.4 (0.0, 693839.2)	0.0 -	167.6 (0.0, 509.0)	0.0 -	277075.1 (0.0, 691314.3)	408916.5 (6101.2, 811731.8)
Implanon implants	47463.2 (12097.7, 82828.8)	0.0 -	16.5 -	47479.7 (12107.9, 82851.6)	168669.7 (0.0, 417573.9)	0.0 -	167.6 (0.0, 509.0)	0.0 -	168837.3 (0.0, 415433.5)	216317.1 (0.0, 459321.4)
Jadelle implants	84344.2 (7857.6, 160830.7)	0.0 -	17.6 -	84361.7 (7874.6, 160848.8)	108237.7 (0.0, 295323.9)	0.0 -	0.0 -	0.0 -	108237.7 (0.0, 294834.1)	192599.5 (7524.6, 377674.3)

**Table X5: Reported Contraceptive Method Volumes — National, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type <sup>*,†</sup>	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
<b>8. IUDs</b>	24793.9 (0.0, 61438.9)	0.0 -	154.3 -	24948.2 (0.0, 61621.0)	119547.9 (0.0, 318411.9)	322.0 (0.0, 748.9)	1546.5 (0.0, 3734.5)	0.0 -	121416.3 (0.0, 318162.3)	146364.5 (0.0, 348353.8)
<b>9. Male sterilization</b>	0.0 -	0.0 -	0.0 -	0.0 -	565.5 -	0.0 -	0.0 -	0.0 -	565.5 -	565.5 -
<b>10. Female sterilization</b>	1102.8 -	0.0 -	0.0 -	1102.8 -	2516.5 -	0.0 -	0.0 -	0.0 -	2516.5 -	3619.3 -
<b>Total Volume</b>	249463.7 (102927.1, 396000.3)	837.6 (0.0, 3826.0)	360.8 -	250662.0 (104179.8, 397144.3)	425262.6 (0.0, 966273.1)	24373.1 (7536.8, 41209.4)	245815.0 (134245.0, 357385.1)	17939.7 (0.0, 37394.7)	713390.3 (68493.3, 1358287.3)	964052.4 (324792.2, 1603312.5)

\* A total of 964,052 CYP (weighted) were reportedly distributed in the previous 1 month. This is based on the number of commodities reportedly sold for categories 1-8 (not number of services performed for categories 6-8) and number of sterilizations reportedly performed for categories 9-10.

† A total of 4,295 FP products were audited (3,007 contraceptive tablets, 1,004 injection products). In addition, 1,923 outlets were audited for male condoms, 223 for female condoms, 72 for Cyclebeads, 37 outlets for female sterilization services and 15 outlets for male sterilization services. A total of 2 injection products and 4 tablet products were excluded from market share analysis due to inconsistent or missing generic names. 56 emergency contraceptive products, 129 oral contraceptives, 205 male condoms, 17 female condoms and 10 Cyclebeads were excluded from analysis for missing volume information. 2 male sterilizations and 4 female sterilizations were excluded for similar missing volume information as well. A total of 49 products were excluded due to outlier volumes and prices.

**Table X6: Reported Contraceptive Method Volumes — Geopolitical Zones, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type <sup>*,†</sup>	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
<b>1. Male condoms</b>										
North Central	6227.4 (0.0, 13128.0)	20.9 -	0.0 -	6248.3 (0.0, 13130.5)	1305.7 (0.0, 3367.6)	2295.8 (0.0, 5509.9)	29303.7 (12345.3, 46262.1)	9014.7 (0.0, 30679.2)	41919.9 (6060.5, 77779.2)	48168.1 (6459.0, 89877.2)
North East	912.9 (0.0, 2486.7)	0.0 -	2.4 -	915.3 (0.0, 2488.4)	0.9 -	196.9 (0.0, 1966.5)	5213.8 (3280.7, 7146.9)	157.5 (0.0, 1771.9)	5569.1 (3022.3, 8115.9)	6484.4 (2781.2, 10187.6)
North West	1783.2 (68.8, 3497.6)	0.0 -	0.0 -	1783.2 (68.8, 3497.6)	381.6 -	97.7 -	5056.6 (0.0, 11070.4)	3.5 (0.0, 48.3)	5539.4 (0.0, 12594.2)	7322.7 (0.0, 14743.3)
South East	322.2 (0.0, 1338.7)	0.0 -	0.0 -	322.2 (0.0, 1338.7)	386.0 (0.0, 868.1)	1052.5 (0.0, 2456.6)	18454.9 (0.0, 41449.8)	1822.9 (0.0, 4105.8)	21716.3 (0.0, 46231.4)	22038.5 (0.0, 46727.9)
South South	26479.6 (0.0, 84428.2)	0.0 -	0.0 -	26479.6 (0.0, 84428.2)	3904.2 (0.0, 15292.9)	1930.1 (0.0, 5961.9)	48760.8 (0.0, 124445.8)	294.6 (0.0, 1240.3)	54889.6 (0.0, 139883.8)	81369.2 (0.0, 172005.0)
South West	1044.9 (0.0, 2394.4)	0.0 -	1.1 -	1046.0 (0.0, 2397.3)	1587.8 (0.0, 3660.3)	4779.0 (0.0, 12941.5)	44660.3 (0.0, 91411.3)	6396.6 (0.0, 19578.5)	57423.6 (2481.2, 112366.0)	58469.6 (3211.7, 113727.5)

**Table X6: Reported Contraceptive Method Volumes — Geopolitical Zones, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type*†:	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
<b>2. Female condoms</b>										
North Central	25.7 (0.0, 66.1)	0.0 -	0.0 -	25.7 (0.0, 66.1)	0.0 -	3.1 -	13.8 (0.0, 57.3)	0.0 -	16.9 (0.0, 63.3)	42.6 (0.0, 92.2)
North East	51.0 (0.0, 207.3)	0.0 -	0.0 -	51.0 (0.0, 207.3)	0.0 -	0.0 -	0.4 -	0.0 -	0.4 -	51.5 (0.0, 209.2)
North West	444.2 (0.0, 1545.3)	0.0 -	0.0 -	444.2 (0.0, 1545.3)	0.0 -	0.0 -	54.1 (0.0, 206.7)	0.0 -	54.1 (0.0, 206.7)	498.4 (0.0, 1575.9)
South East	126.0 (0.0, 555.6)	0.0 -	0.0 -	126.0 (0.0, 555.6)	21.0 (0.0, 89.6)	0.7 (0.0, 9.7)	130.2 (0.0, 470.3)	0.0 -	151.9 (0.0, 479.5)	277.9 (0.0, 892.3)
South South	991.9 (0.0, 3929.9)	0.0 -	0.0 -	991.9 (0.0, 3929.9)	63.3 -	0.0 -	18.2 (0.0, 63.4)	0.0 -	81.5 (0.0, 296.3)	1073.4 (0.0, 3439.1)
South West	196.2 (0.0, 570.0)	0.0 -	0.0 -	196.2 (0.0, 570.0)	14.4 (0.0, 57.7)	1.1 (0.0, 3.3)	81.9 (0.0, 233.8)	0.9 -	98.3 (0.0, 255.9)	294.6 (0.0, 708.5)
<b>3. Cyclebeads</b>										
North Central	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	7.6 (0.0, 31.6)	0.0 -	7.6 (0.0, 31.6)	7.6 (0.0, 28.5)
North East	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
North West	414 (0.0, 2183.8)	0.0 -	0.0 -	414 (0.0, 2183.8)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	414 (0.0, 1723.0)
South East	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
South South	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	134.1 (0.0, 559.1)	0.0 -	134.1 (0.0, 559.1)	134.1 (0.0, 504.9)
South West	32.0 -	0.0 -	0.0 -	32.0 -	576.4 -	8.5 -	70.6 (0.0, 184.7)	0.0 -	655.6 (0.0, 2499.6)	687.7 (0.0, 2631.3)
<b>4. Oral contraceptives</b>										
North Central	1412.3 (0.0, 3294.2)	0.0 -	11.4 -	1423.7 (0.0, 3299.0)	969.5 (0.0, 2610.0)	425.1 (97.4, 752.8)	11777.9 (54.6, 23501.2)	9.6 (0.0, 33.1)	13182.2 (1165.1, 25199.3)	14605.9 (1957.3, 27254.5)
North East	640.2 (0.0, 1314.7)	0.0 -	1.0 -	641.2 (0.0, 1318.4)	3.1 (0.0, 10.6)	25.6 (0.0, 348.5)	1994.4 (0.0, 5056.1)	0.0 -	2023.1 (0.0, 5056.5)	2664.3 (0.0, 5776.7)
North West	2525.5 (0.0, 5075.7)	0.0 -	0.0 -	2525.5 (0.0, 5075.7)	3.1 (0.0, 13.1)	45.3 (0.0, 616.8)	6128 (1328.2, 10927.8)	0.0 -	6176.4 (1338.2, 11014.5)	8701.9 (2906.1, 14497.7)
South East	367.2 (0.0, 749.2)	0.0 -	0.0 -	367.2 (0.0, 749.2)	67.5 (11.3, 123.8)	170.3 (0.0, 453.5)	4951.8 (0.0, 11865.5)	87.0 (0.0, 326.4)	5276.6 (0.0, 12648.6)	5643.8 (0.0, 13187.7)
South South	2596.6	0.0	0.0	2596.6	4442.3	522.2	10691.2	0.0	15655.7	18252.3

Table X6: Reported Contraceptive Method Volumes — Geopolitical Zones, 2016										
CYP sold or distributed in previous 1 month by outlet type and contraceptive method type*†:	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
	(0.0, 6617.3)	-	-	(0.0, 6617.3)	(0.0, 16310.8)	(0.0, 1282.3)	(0.0, 31198.2)	-	(0.0, 47695.1)	(0.0, 49764.3)
South West	657.4 (0.0, 1548.1)	0.0 -	0.0 -	657.4 (0.0, 1548.1)	195.6 (0.0, 402.1)	1462.6 (0.0, 4176.2)	12874.2 (670.5, 25077.9)	108.6 (0.0, 293.5)	14641.0 (850.0, 28432.1)	15298.5 (1358.6, 29238.3)
<i>IQA oral contraceptives</i> <sup>¶</sup>										
North Central	1412.3 (0.0, 3294.2)	0.0 -	11.4 -	1423.7 (0.0, 3299.0)	969.5 (0.0, 2610.0)	425.1 (97.4, 752.8)	11750.6 (71.8, 23429.4)	9.6 (0.0, 33.1)	13154.9 (1182.0, 25127.7)	14578.6 (1969.9, 27187.2)
North East	640.2 (0.0, 1314.7)	0.0 -	1.0 -	641.2 (0.0, 1318.4)	3.1 (0.0, 10.6)	25.6 (0.0, 349.5)	1989.4 (0.0, 5035.4)	0.0 -	2018 (0.0, 5035.8)	2659.3 (0.0, 5756.3)
North West	2525.5 (0.0, 5075.7)	0.0 -	0.0 -	2525.5 (0.0, 5075.7)	3.1 (0.0, 13.1)	45.3 (0.0, 616.8)	6128 (1328.2, 10927.8)	0.0 -	6176.4 (1338.2, 11014.5)	8701.9 (2906.1, 14497.7)
South East	367.2 (0.0, 749.2)	0.0 -	0.0 -	367.2 (0.0, 749.2)	67.5 (11.3, 123.8)	170.3 (0.0, 453.5)	4951.8 (0.0, 11865.5)	87.0 (0.0, 326.4)	5276.6 (0.0, 12648.6)	5643.8 (0.0, 13187.7)
South South	2596.6 (0.0, 6617.3)	0.0 -	0.0 -	2596.6 (0.0, 6617.3)	4442.3 (0.0, 16310.8)	522.2 (0.0, 1282.3)	10539.0 (0.0, 30657.6)	0.0 -	15503.5 (0.0, 47153.8)	18100.0 (0.0, 49227.9)
South West	657.4 (0.0, 1548.1)	0.0 -	0.0 -	657.4 (0.0, 1548.1)	192.3 (0.0, 397.3)	1459.3 (0.0, 4167.5)	12778.5 (525.9, 25031.1)	108.6 (0.0, 293.5)	14538.7 (709.7, 28367.6)	15196.1 (1225.6, 29166.6)
<i>Combined oral contraceptives</i>										
North Central	863.8 (0.0, 2013.8)	0.0 -	0.0 -	863.8 (0.0, 2013.8)	969.5 (0.0, 2610.0)	425.1 (97.4, 752.8)	11772.0 (47.0, 23497.1)	9.6 (0.0, 33.1)	13176.3 (1159.2, 25193.4)	14040.1 (1592.3, 26487.9)
North East	473.7 (0.0, 977.7)	0.0 -	0.1 -	473.9 (0.0, 978.1)	2.4 (0.0, 7.5)	25.6 (0.0, 348.5)	1994.4 (0.0, 5056.1)	0.0 -	2022.4 (0.0, 5056.6)	2496.3 (0.0, 5746.0)
North West	1635 (0.0, 3560.9)	0.0 -	0.0 -	1635 (0.0, 3560.9)	3.1 (0.0, 13.1)	45.3 (0.0, 616.8)	5945.8 (1337.8, 10553.9)	0.0 -	5994.3 (1348.6, 10639.9)	7629.3 (2627.5, 12631.1)
South East	140.3 (0.0, 302.3)	0.0 -	0.0 -	140.3 (0.0, 302.3)	60.1 (0.0, 122.5)	170.3 (0.0, 453.5)	4949.8 (0.0, 11858.3)	87.0 (0.0, 326.4)	5267.2 (0.0, 12642.1)	5407.5 (0.0, 12823.9)
South South	1742.9 (0.0, 4734.0)	0.0 -	0.0 -	1742.9 (0.0, 4734.0)	4442.3 (0.0, 16310.8)	522.2 (0.0, 1282.3)	10691.2 (0.0, 31198.2)	0.0 -	15655.7 (0.0, 47695.1)	17398.6 (0.0, 48824.0)
South West	135.8 (0.0, 413.8)	0.0 -	0.0 -	135.8 (0.0, 413.8)	193.3 (0.0, 396.5)	1462.6 (0.0, 4176.2)	12874.1 (670.4, 25077.9)	108.6 (0.0, 293.5)	14638.6 (849.7, 28427.5)	14774.4 (880.1, 28668.8)
<i>Progestin-only pills</i>										
North Central	548.6 (0.0, 1317.8)	0.0 -	11.4 -	560.0 (0.0, 1322.0)	0.0 -	0.0 -	5.9 (0.0, 18.9)	0.0 -	5.9 (0.0, 18.9)	565.8 (0.0, 1325.0)
North East	166.5 (0.0, 441.2)	0.0 -	0.9 -	167.4 (0.0, 444.4)	0.7 (0.0, 3.7)	0.0 -	0.0 -	0.0 -	0.7 (0.0, 2.9)	168.1 (0.0, 446.9)
North West	890.5 (135.1, 1645.9)	0.0 -	0.0 -	890.5 (135.1, 1645.9)	0.0 -	0.0 -	182.1 (0.0, 495.4)	0.0 -	182.1 (0.0, 495.4)	1072.7 (169.1, 1976.2)

**Table X6: Reported Contraceptive Method Volumes — Geopolitical Zones, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type*†:	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
South East	226.9 (0.0, 499.7)	0.0 -	0.0 -	226.9 (0.0, 499.7)	7.4 (0.0, 20.9)	0.0 -	2.0 (0.0, 7.4)	0.0 -	9.4 (0.0, 21.9)	236.3 (0.0, 515.9)
South South	853.7 (0.0, 2171.8)	0.0 -	0.0 -	853.7 (0.0, 2171.8)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	853.7 (0.0, 2126.8)
South West	521.6 (0.0, 1200.2)	0.0 -	0.0 -	521.6 (0.0, 1200.2)	2.3 (0.0, 6.2)	0.0 -	0.1 (0.0, 0.2)	0.0 -	2.4 (0.0, 6.2)	524.1 (0.0, 1202.6)
<b>5. Emergency contraceptives</b>										
North Central	0.0 -	0.0 -	0.0 -	0.0 -	8.9 (0.0, 23.2)	450.3 (0.0, 1129.3)	7219.7 (0.0, 20281.9)	0.0 -	7678.9 (0.0, 20573.1)	7678.9 (0.0, 20573.1)
North East	8.8 (0.0, 36.9)	0.0 -	0.0 -	8.8 (0.0, 36.9)	0.0 -	50.8 (0.0, 669.9)	397 (0.0, 1148.8)	0.0 -	447.8 (0.0, 1192.5)	456.6 (0.0, 1203.8)
North West	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	15.4 (0.0, 210.4)	194.5 (0.0, 584.3)	0.0 -	210 (0.0, 637.1)	210 (0.0, 637.1)
South East	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	141.0 (0.0, 335.0)	632.5 (80.6, 1184.4)	18.2 (0.0, 68.3)	791.7 (264.5, 1318.9)	791.7 (264.5, 1318.9)
South South	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	1816.2 (0.0, 6905.1)	8444.7 (0.0, 26687.2)	0.0 -	10260.9 (0.0, 32663.1)	10260.9 (0.0, 32663.1)
South West	0.0 -	0.0 -	0.0 -	0.0 -	2.5 (0.0, 8.9)	2486.5 (0.0, 6419.8)	3143.7 (551.5, 5735.8)	23.7 (0.0, 83.3)	5656.4 (260.5, 11052.3)	5656.4 (260.5, 11052.3)
<i>IQA Emergency contraceptives</i>										
North Central	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	324.6 (0.0, 827.9)	1611.2 (0.0, 3916.8)	0.0 -	1935.7 (0.0, 4294.7)	1935.7 (0.0, 4294.7)
North East	8.8 (0.0, 36.9)	0.0 -	0.0 -	8.8 (0.0, 36.9)	0.0 -	39.0 (0.0, 516.5)	380.1 (0.0, 1101.5)	0.0 -	419.1 (0.0, 1130.6)	427.9 (0.0, 1140.2)
North West	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	15.4 (0.0, 210.4)	131.2 (0.0, 417.7)	0.0 -	146.7 (0.0, 470.6)	146.7 (0.0, 470.6)
South East	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	123.8 (0.0, 315.7)	543.3 (43.2, 1043.4)	18.2 (0.0, 68.3)	685.3 (205.1, 1165.5)	685.3 (205.1, 1165.5)
South South	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	817.1 (0.0, 2757.7)	7780.5 (0.0, 24406.4)	0.0 -	8597.6 (0.0, 26837.2)	8597.6 (0.0, 26837.2)
South West	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	1044.1 (0.0, 3090.7)	2510.1 (0.0, 5195.2)	4.9 (0.0, 17.1)	3559.1 (0.0, 7142.3)	3559.1 (0.0, 7142.3)
<b>6. Contraceptive injectables</b>										
North Central	7721.6 (3395.5, 12047.7)	816.7 (0.0, 3855.5)	137.5 -	8675.8 (4977.9, 12373.6)	2123.4 (0.0, 5357.0)	1856.5 (0.0, 3728.2)	3044.5 (1402.8, 4686.2)	0.0 -	7024.3 (3048.6, 11000.1)	15700.1 (10138.6, 21261.5)

Table X6: Reported Contraceptive Method Volumes — Geopolitical Zones, 2016										
CYP sold or distributed in previous 1 month by outlet type and contraceptive method type*†:	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
North East	4774.1	0.0	9.1	4783.2	0.0	51.8	929.1	0.0	980.9	5764.1
	(0.0, 11359.5)	-	-	(0.0, 11388.8)	-	(0.0, 691.3)	(121.6, 1736.6)	-	(49.5, 1912.2)	(0.0, 12429.2)
North West	14000.6	0.0	0.0	14000.6	699.9	57.3	17115.4	0.0	17872.5	31873.1
	(0.0, 32445.4)	-	-	(0.0, 32445.4)	(0.0, 2662.6)	(0.0, 760.5)	(950.1, 33280.7)	-	(287.4, 35457.6)	(5336.2, 58409.9)
South East	1781.3	0.0	0.0	1781.3	737.2	88.7	1023.6	0.0	1849.4	3630.8
	(0.0, 4039.4)	-	-	(0.0, 4039.4)	(168.4, 1306.0)	(0.0, 288.6)	(0.0, 3214.1)	-	(0.0, 3966.2)	(673.6, 6588.0)
South South	12704.3	0.0	0.0	12704.3	7479.0	968.7	681.8	0.0	9129.5	21833.8
	(0.0, 39666.7)	-	-	(0.0, 39666.7)	(0.0, 25164.3)	(0.0, 2726.3)	(0.0, 1792.9)	-	(0.0, 25791.8)	(0.0, 51542.9)
South West	3518.3	0.0	10.1	3528.4	752.1	3051.3	896.0	1.8	4701.2	8229.6
	(10.6, 7026.0)	-	(0.0, 52.5)	(16.5, 7040.3)	(0.0, 1743.0)	(0.0, 7597.4)	(0.0, 2292.9)	(0.0, 6.2)	(0.0, 11098.9)	(0.0, 17543.0)
<i>Depo-provera injectables</i>										
North Central	4445.3	54.1	99.6	4599.0	1671.2	680.8	1723.2	0.0	4075.2	8674.2
	(1646.8, 7243.9)	(0.0, 285.4)	-	(1839.5, 7358.5)	(0.0, 4257.7)	(0.0, 1635.2)	(863.6, 2582.9)	-	(1729.0, 6421.4)	(5316.9, 12031.5)
North East	3156.9	0.0	5.8	3162.7	0.0	0.7	423.8	0.0	424.4	3587.1
	(0.0, 7887.6)	-	-	(0.0, 7907.0)	-	(0.0, 9.0)	(0.0, 872.1)	-	(0.0, 872.1)	(0.0, 8195.1)
North West	11760.0	0.0	0.0	11760.0	279.0	26.2	9972.8	0.0	10278.0	22038.1
	(0.0, 28599.3)	-	-	(0.0, 28599.3)	(0.0, 956.5)	(0.0, 356.9)	(0.0, 20382.3)	-	(0.0, 21207.2)	(2144.6, 41931.6)
South East	1393.5	0.0	0.0	1393.5	672.2	82.1	990.6	0.0	1744.9	3138.4
	(0.0, 2846.2)	-	-	(0.0, 2846.2)	(62.0, 1282.4)	(0.0, 283.3)	(0.0, 3187.0)	-	(0.0, 3889.4)	(737.0, 5539.7)
South South	8074.6	0.0	0.0	8074.6	3608.9	322.7	613.9	0.0	4545.5	12620.1
	(0.0, 24511.9)	-	-	(0.0, 24511.9)	(0.0, 11838.8)	(0.0, 938.1)	(0.0, 1717.2)	-	(0.0, 12310.2)	(0.0, 29796.2)
South West	1972.3	0.0	5.0	1977.4	512.8	1857.3	605.3	0.0	2975.4	4952.8
	(0.0, 4594.3)	-	(0.0, 26.3)	(0.0, 4600.6)	(0.0, 1181.2)	(0.0, 4610.8)	(0.0, 1500.5)	-	(0.0, 6862.9)	(0.0, 10960.3)
<i>Noristerat injectables</i>										
North Central	3276.3	762.6	37.9	4076.7	452.2	1175.7	1321.3	0.0	2949.1	7025.9
	(1073.3, 5479.2)	(0.0, 3905.9)	-	(1769.2, 6384.3)	(0.0, 1142.7)	(0.0, 2459.6)	(395.3, 2247.2)	-	(1217.2, 4681.0)	(3991.9, 10059.8)
North East	1617.3	0.0	3.3	1620.6	0.0	51.1	505.3	0.0	556.4	2177.0
	(0.0, 3550.7)	-	-	(0.0, 3559.9)	-	(0.0, 699.0)	(0.0, 1101.0)	-	(0.0, 1209.6)	(34.1, 4319.9)
North West	2240.5	0.0	0.0	2240.5	420.8	31.1	7142.6	0.0	7594.5	9835.0
	(0.0, 5502.9)	-	-	(0.0, 5502.9)	(0.0, 1710.5)	(0.0, 403.6)	(889.0, 13396.2)	-	(543.1, 14645.9)	(385.7, 19284.3)
South East	387.9	0.0	0.0	387.9	64.9	6.6	33.0	0.0	104.6	492.4
	(0.0, 1337.6)	-	-	(0.0, 1337.6)	(0.0, 166.7)	(0.0, 27.5)	(0.0, 123.8)	-	(0.0, 248.2)	(0.0, 1540.1)
South South	4629.7	0.0	0.0	4629.7	3870.0	646.0	67.9	0.0	4584.0	9213.7
	(0.0, 15186.6)	-	-	(0.0, 15186.6)	(0.0, 13342.8)	(0.0, 1794.9)	(0.0, 187.2)	-	(0.0, 13535.3)	(0.0, 22134.3)
South West	1546.0	0.0	5.0	1551.0	239.3	1194.1	290.7	1.8	1725.8	3276.8
	(413.3, 2678.7)	-	(0.0, 26.3)	(414.7, 2687.4)	(0.0, 597.9)	(0.0, 3006.5)	(0.0, 872.4)	(0.0, 6.2)	(0.0, 4284.9)	(0.0, 6658.1)

**Table X6: Reported Contraceptive Method Volumes — Geopolitical Zones, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type*†:	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
<i>Sayana Press injectables</i>										
North Central	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	19.5 (0.0, 67.0)	0.0 -	0.0 -	19.5 (0.0, 67.0)	19.5 (0.0, 67.0)
North East	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
North West	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
South East	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	827.4 (0.0, 3105.0)	0.0 -	827.4 (0.0, 3105.0)	827.4 (0.0, 3105.0)
South South	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	142.7 (0.0, 508.1)	0.0 -	142.7 (0.0, 508.1)	142.7 (0.0, 508.1)
South West	0.0 -	0.0 -	0.0 -	0.0 -	23.5 (0.0, 67.5)	9.0 (0.0, 31.8)	24.0 (0.0, 80.4)	0.0 -	56.6 (0.0, 178.8)	56.6 (0.0, 178.8)
<b>7. Implants</b>										
North Central	27461.5 (0.0, 80808.9)	0.0 -	0.0 -	27461.5 (0.0, 80808.9)	67410.1 (0.0, 231169.3)	0.0 -	0.0 -	0.0 -	67410.1 (0.0, 231169.3)	94871.6 (0.0, 256341.9)
North East	4394.7 (0.0, 16435.9)	0.0 -	34.0 -	4428.7 (0.0, 16577.8)	13.2 (0.0, 69.8)	0.0 -	0.0 -	0.0 -	13.2 (0.0, 55.1)	4441.9 (0.0, 16632.9)
North West	34179.8 (0.0, 84805.3)	0.0 -	0.0 -	34179.8 (0.0, 84805.3)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	34179.8 (0.0, 84805.3)
South East	2374.0 (0.0, 8909.2)	0.0 -	0.0 -	2374.0 (0.0, 8909.2)	3545.1 (0.0, 9632.9)	0.0 -	0.0 -	0.0 -	3545.1 (0.0, 9632.9)	5919.1 (0.0, 18388.8)
South South	54720.1 (0.0, 151921.5)	0.0 -	0.0 -	54720.1 (0.0, 151921.5)	205497.8 (0.0, 734662.9)	0.0 -	167.6 (0.0, 596.7)	0.0 -	205665.4 (0.0, 697031.8)	260385.5 (0.0, 733934.3)
South West	8677.3 (0.0, 24149.1)	0.0 -	0.0 -	8677.3 (0.0, 24149.1)	441.3 (0.0, 1334.8)	0.0 -	0.0 -	0.0 -	441.3 (0.0, 1334.8)	9118.6 (0.0, 24702.1)
<i>Implanon implants</i>										
North Central	15018.2 (0.0, 40830.7)	0.0 -	0.0 -	15018.2 (0.0, 40830.7)	67410.1 (0.0, 231169.3)	0.0 -	0.0 -	0.0 -	67410.1 (0.0, 231169.3)	82428.2 (0.0, 242252.7)
North East	3745.7 (0.0, 14071.5)	0.0 -	16.5 -	3762.2 (0.0, 14140.3)	13.2 (0.0, 69.8)	0.0 -	0.0 -	0.0 -	13.2 (0.0, 55.1)	3775.4 (0.0, 14195.3)
North West	13429.7 (0.0, 34059.0)	0.0 -	0.0 -	13429.7 (0.0, 34059.0)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	13429.7 (0.0, 34059.0)
South East	818.6 (0.0, 3072.1)	0.0 -	0.0 -	818.6 (0.0, 3072.1)	496.7 (0.0, 1355.5)	0.0 -	0.0 -	0.0 -	496.7 (0.0, 1355.5)	1315.4 (0.0, 4044.7)
South South	9965.6 (0.0, 37246.1)	0.0 -	0.0 -	9965.6 (0.0, 37246.1)	100735.5 (0.0, 379282.2)	0.0 -	167.6 (0.0, 596.7)	0.0 -	100903.1 (0.0, 358711.1)	110868.7 (0.0, 364824.0)



**Table X6: Reported Contraceptive Method Volumes — Geopolitical Zones, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type*†:	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
South West	4485.4 (0.0, 11750.2)	0.0 -	0.0 -	4485.4 (0.0, 11750.2)	14.2 (0.0, 50.0)	0.0 -	0.0 -	0.0 -	14.2 (0.0, 50.0)	4499.6 (0.0, 11753.8)
<i>Jadelle implants</i>										
North Central	12443.3 (0.0, 40793.1)	0.0 -	0.0 -	12443.3 (0.0, 40793.1)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	12443.3 (0.0, 40793.1)
North East	649.0 (0.0, 2377.9)	0.0 -	17.6 -	666.5 (0.0, 2450.6)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	666.5 (0.0, 2450.6)
North West	20750.1 (0.0, 51228.2)	0.0 -	0.0 -	20750.1 (0.0, 51228.2)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	20750.1 (0.0, 51228.2)
South East	1555.4 (0.0, 5837.1)	0.0 -	0.0 -	1555.4 (0.0, 5837.1)	3048.4 (0.0, 8771.9)	0.0 -	0.0 -	0.0 -	3048.4 (0.0, 8771.9)	4603.7 (0.0, 14483.1)
South South	44754.4 (0.0, 136484.6)	0.0 -	0.0 -	44754.4 (0.0, 136484.6)	104762.3 (0.0, 356371.8)	0.0 -	0.0 -	0.0 -	104762.3 (0.0, 339227.6)	149516.8 (0.0, 377641.8)
South West	4192.0 (0.0, 12572.9)	0.0 -	0.0 -	4192.0 (0.0, 12572.9)	427.0 (0.0, 1328.4)	0.0 -	0.0 -	0.0 -	427.0 (0.0, 1328.4)	4619.0 (0.0, 13021.2)
<b>8. IUDs</b>										
North Central	565.6 (0.0, 1531.7)	0.0 -	0.0 -	565.6 (0.0, 1531.7)	99110.4 (0.0, 333655.3)	71.8 (0.0, 246.1)	1003.1 (0.0, 3440.6)	0.0 -	100185.3 (0.0, 334309.2)	100750.9 (0.0, 334655.0)
North East	1122.6 (0.0, 4039.4)	0.0 -	15.2 -	1137.8 (0.0, 4102.0)	41.1 (0.0, 163.6)	0.0 -	0.0 -	0.0 -	41.1 (0.0, 137.0)	1178.9 (0.0, 4131.9)
North West	1697.3 (0.0, 4687.6)	0.0 -	0.0 -	1697.3 (0.0, 4687.6)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	1697.3 (0.0, 4687.6)
South East	0.0 -	0.0 -	0.0 -	0.0 -	4198.3 (0.0, 11217.8)	182.5 (0.0, 758.5)	336.1 (0.0, 1261.5)	0.0 -	4717.0 (0.0, 11522.7)	4717.0 (0.0, 11522.7)
South South	17778.3 (0.0, 66937.6)	0.0 -	0.0 -	17778.3 (0.0, 66937.6)	5078.1 (0.0, 18870.2)	0.0 -	0.0 -	0.0 -	5078.1 (0.0, 17856.9)	22856.3 (0.0, 81148.4)
South West	3630.1 (0.0, 8802.6)	0.0 -	139.1 (0.0, 724.6)	3769.2 (0.0, 9226.5)	11120.0 (0.0, 31856.0)	67.7 (0.0, 225.7)	207.2 (0.0, 728.4)	0.0 -	11394.9 (0.0, 32640.5)	15164.1 (0.0, 40010.8)
<b>9. Male sterilizations</b>										
North Central	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
North East	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
North West	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
South East	0.0 -	0.0 -	0.0 -	0.0 -	480.1 (0.0, 1995.1)	0.0 -	0.0 -	0.0 -	480.1 (0.0, 1995.1)	480.1 (0.0, 1995.1)

**Table X6: Reported Contraceptive Method Volumes — Geopolitical Zones, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type*†:	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
South South	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
South West	0.0 -	0.0 -	0.0 -	0.0 -	85.4 -	0.0 -	0.0 -	0.0 -	85.4 -	85.4 -
<b>10. Female sterilizations</b>										
North Central	454.3 -	0.0 -	0.0 -	454.3 -	79.9 (0.0, 421.5)	0.0 -	0.0 -	0.0 -	79.9 (0.0, 421.5)	534.3 (0.0, 2329.4)
North East	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
North West	648.5 (0.0, 2859.5)	0.0 -	0.0 -	648.5 (0.0, 2859.5)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	648.5 (0.0, 2859.5)
South East	0.0 -	0.0 -	0.0 -	0.0 -	690.4 (0.0, 2869.0)	0.0 -	0.0 -	0.0 -	690.4 (0.0, 2869.0)	690.4 (0.0, 2869.0)
South South	0.0 -	0.0 -	0.0 -	0.0 -	16.3 (0.0, 86.1)	0.0 -	0.0 -	0.0 -	16.3 (0.0, 86.1)	16.3 (0.0, 86.1)
South West	0.0 -	0.0 -	0.0 -	0.0 -	1729.8 (0.0, 6281.8)	0.0 -	0.0 -	0.0 -	1729.8 (0.0, 6281.8)	1729.8 (0.0, 6281.8)
<b>Total Volume</b>										
North Central	43868.5 (0.0, 96050.4)	837.6 (0.0, 3826.0)	148.9 -	44854.9 (0.0, 96713.4)	171007.8 (0.0, 570892.3)	5102.5 (0.0, 10459.7)	52370.3 (12399.0, 92341.7)	9024.4 (0.0, 30683.6)	237505.0 (0.0, 693225.9)	282359.9 (0.0, 735282.3)
North East	11904.4 (0.0, 32662.9)	0.0 -	61.7 -	11966.1 (0.0, 32912.3)	58.2 (0.0, 188.2)	325.1 (0.0, 3676.1)	8534.7 (6932.2, 10137.2)	157.5 (0.0, 1771.9)	9075.6 (6752.0, 11399.2)	21041.7 (1768.1, 40315.3)
North West	55693.1 (0.0, 116564.5)	0.0 -	0.0 -	55693.1 (0.0, 116564.5)	1084.6 (0.0, 5317.4)	215.7 (0.0, 2919.4)	28548.6 (2918.9, 54178.2)	3.5 (0.0, 18.7)	29852.5 (1763.2, 57941.8)	85545.5 (3499.4, 167591.7)
South East	4970.6 (0.0, 14918.1)	0.0 -	0.0 -	4970.6 (0.0, 14918.1)	10125.7 (0.0, 21854.7)	1635.7 (0.0, 3659.0)	25529.0 (0.0, 51574.0)	1928.1 (0.0, 4297.7)	39218.6 (5261.2, 73176.0)	44189.3 (3323.6, 85054.9)
South South	115270.7 (0.0, 313797.0)	0.0 -	0.0 -	115270.7 (0.0, 313797.0)	226480.8 (0.0, 792714.3)	5237.2 (0.0, 13226.9)	68898.4 (0.0, 182894.0)	294.6 (0.0, 1240.3)	300911.1 (0.0, 945730.7)	416181.8 (0.0, 1044472.9)
South West	17756.4 (0.0, 40743.5)	0.0 -	150.2 -	17906.7 (0.0, 41045.2)	16505.3 (0.0, 39206.5)	11856.8 (0.0, 30587.0)	61933.9 (1953.0, 121914.8)	6531.6 (0.0, 19956.9)	96827.5 (0.0, 197479.7)	114734.2 (0.0, 238445.9)

\* A total of 282359, 21041, 85545, 44189, 416181 and 114734 CYP (weighted) were reportedly distributed in the previous 1 month in the NC, NE, NW, SE, SS and SW regions, respectively. This is based on the number of commodities reportedly sold for categories 1-8 (not number of services performed for categories 6-8) and number of sterilizations reportedly performed for categories 9-10. See Annex 11 for a description of CYP calculation and Annex 12 for CYP numbers by outlet type and method category.

† A total of 2 injection products (NC region) and 4 tablet products (SW region), were excluded from analysis due to inconsistent or missing generic names. In addition, a total of 56 emergency contraceptive products (6, 2, 1, 11 & 36 in NC, NW, SE, SS & SW regions, respectively), 129 oral contraceptives (10, 6, 6, 8 & 99 in NC, NW, SE, SS & SW regions, respectively), 205 male condoms (21, 4, 12, 14, 11 & 143 in NC, NE, NW, SE, SS & SW regions, respectively), 17 female condoms (2, 1, 1, 1 & 11 in NC, NE, NW, SE, SS & SW regions, respectively) and 10 Cyclebeads (8 in SE and 2 in SW) were excluded from analysis for missing volume information. 2 male sterilizations and 4 female sterilizations were excluded for missing volume information as well. A total of 179 products were excluded due to outlier volumes and prices (45, 1, 30, 14, 1 & 88 in NC, NE, NW, SE, SS & SW regions respectively).

**Table X6: Reported Contraceptive Method Volumes — Geopolitical Zones, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type*†:	Public Health Facility	Community Health Worker	Private Not-For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)

Source: FPwatch Outlet Survey, Nigeria, 2015

**Table X7: Reported Contraceptive Method Volumes — Urban/Rural, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type*†:	Public Health Facility	Community Health Worker	Private Not- For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
<b>1. Male condoms</b>										
Urban	1946.3 (177.6, 3715.0)	20.9 -	3.4 -	1970.6 (202.0, 3739.3)	1414.2 -	8077.9 -	62929.1 (18204.9, 107653.4)	8167.8 -	80589.1 (26795.5, 134382.7)	82559.8 (28400.5, 136719.0)
Rural	34823.8 (0.0, 73380.1)	0.0 -	0.0 -	34823.8 (0.0, 73318.4)	6151.9 (0.0, 14581.1)	2274.0 -	88520.9 (33683.5, 143358.3)	9522.0 -	106468.8 (39996.0, 172941.7)	141292.7 (66038.6, 216546.7)
<b>2. Female condoms</b>										
Urban	349.1 (349.1,349.1)	0.0 -	0.0 -	349.1 (349.1,349.1)	18.0 -	4.4 -	225.7 -	0.9 -	248.9 -	598.0 (30.0, 1166.1)
Rural	1485.9 (0.0, 3630.7)	0.0 -	0.0 -	1485.9 (0.0, 3630.7)	80.8 -	0.5 -	73.0 (0.0, 160.6)	0.0 -	154.3 (0.0, 346.6)	1640.2 (0.0, 3704.1)
<b>3. Cyclebeads</b>										
Urban	32.0 -	0.0 -	0.0 -	32.0 -	576.4 -	8.5 -	212.3 -	0.0 -	797.3 -	829.3 -
Rural	414.0 (0.0, 1723.0)	0.0 -	0.0 -	414.0 (0.0, 1723.0)	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	414.0 -
<b>4. Oral contraceptives</b>										
Urban	1654.1 (594.4, 2713.8)	0.0 -	1.0 -	1655.1 (595.4, 2714.7)	265.6 (80.2, 451.0)	2471.2 (171.0, 4771.3)	16340.7 (4617.8, 28063.5)	118.3 (0.0, 267.2)	19195.7 (5889.9, 32501.4)	20850.8 (7179.4, 34522.1)
Rural	6545.2 (2587.0, 10503.3)	0.0 -	11.4 -	6556.5 (2615.1, 10497.9)	5415.6 (0.0, 14519.0)	180.1 -	32076.8 (13835.7, 50317.8)	87.0 (0.0, 263.4)	37759.4 (12170.2, 63348.6)	44315.9 (18660.2, 69971.6)

**Table X7: Reported Contraceptive Method Volumes — Urban/Rural, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type*†:	Public Health Facility	Community Health Worker	Private Not- For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
<i>Combined Oral Contraceptives</i>										
Urban	853.8 (340.8, 1366.7)	0.0 -	0.1 -	853.9 (341.0, 1366.8)	260.0 (76.2, 443.7)	2471.2 (171.0, 4771.3)	16284.1 (4572.5, 27995.6)	118.3 (0.0, 267.2)	19133.4 (5839.5, 32427.3)	19987.3 (6556.6, 33418.1)
Rural	4137.6 (1245.9, 7029.3)	0.0 -	0.0 -	4137.6 (1257.6, 7017.7)	5410.7 (0.0, 14514.2)	180.1 -	31943.3 (13710.3, 50176.3)	87.0 (0.0, 263.4)	37621.1 (12037.5, 63204.6)	41758.7 (16313.9, 67203.5)
<i>Progestin Only Pills</i>										
Urban	800.3 (232.9, 1367.7)	0.0 -	0.9 -	801.2 (233.8, 1368.5)	5.6 (0.0, 12.0)	0.0 -	56.6 (0.0, 124.9)	0.0 -	62.3 (0.0, 130.7)	863.4 (272.6, 1454.3)
Rural	2407.5 (1060.6, 3754.5)	0.0 -	11.4 -	2418.9 (1075.7, 3762.1)	4.9 (0.0, 15.0)	0.0 -	133.5 (0.0, 342.0)	0.0 -	138.3 (0.0, 346.7)	2557.2 (1102.8, 4011.7)
<b>5. Emergency contraceptives</b>										
Urban	0.0	0.0	0.0	0.0	11.4	4729.3	4100.9	23.7	8865.3	8865.3
	-	-	-	-	(0.0, 24.5)	(0.0, 9479.1)	(1551.5, 6650.4)	(0.0, 71.3)	(1814.4, 15916.2)	(1814.4, 15916.2)
Rural	8.8 (0.0, 27.0)	0.0 -	0.0 -	8.8 (0.0, 27.0)	0.0 -	231.0 -	15931.2 (0.0, 32955.1)	18.2 (0.0, 55.1)	16180.4 (0.0, 33147.1)	16189.2 (0.0, 33155.7)
<b>6. Contraceptive Injectables</b>										
Urban	9354.8 (2902.4, 15807.3)	0.0 -	19.2 -	9374.0 (2919.6, 15828.4)	1905.7 (698.8, 3112.7)	4838.4 (846.1, 8830.7)	8678.8 (1287.6, 16070.1)	1.8 (0.0, 5.3)	15424.7 (5528.2, 25321.1)	24798.7 (10692.6, 38904.7)
Rural	35145.4 (9502.8, 60788.1)	816.7 -	137.5 -	36099.6 (10616.1, 61583.1)	9885.8 (0.0, 23251.5)	1235.9 -	15011.5 (6238.4, 23784.6)	0.0 -	26133.2 (10151.1, 42115.2)	62232.8 (33242.2, 91223.3)
<i>Depo-provera injectables</i>										
Urban	6858.5 (1268.4, 12448.6)	0.0 -	10.8 -	6869.3 (1278.9, 12459.7)	1349.1 (511.7, 2186.5)	2685.8 (259.3, 5112.2)	5176.4 (121.0, 10231.8)	0.0 -	9211.3 (2730.1, 15692.4)	16080.6 (6517.4, 25643.8)
Rural	23944.2 (4936.5, 42951.9)	54.1 -	99.6 -	24097.9 (5163.5, 43032.3)	5395.2 (0.0, 11819.4)	283.9 -	9153.2 (3607.8, 14698.5)	0.0 -	14832.2 (6550.6, 23113.9)	38930.1 (19229.8, 58630.4)
<i>Noristerat injectables</i>										
Urban	2496.3 (858.8, 4133.9)	0.0 -	8.3 -	2504.7 (864.4, 4145.0)	556.7 (123.9, 989.4)	2152.6 (530.9, 3774.3)	3502.4 (827.5, 6177.4)	1.8 (0.0, 5.3)	6213.4 (2516.2, 9910.7)	8718.1 (3520.4, 13915.8)
Rural	11201.2 (2906.8, 19495.7)	762.6 -	37.9 -	12001.7 (3722.5, 20281.0)	4490.6 (0.0, 11618.2)	952.0 -	5858.4 (2350.0, 9366.7)	0.0 -	11300.9 (3277.8, 19324.0)	23302.7 (11820.9, 34784.4)
<i>Sayana Press Injectables</i>										
Urban	0.0	0.0	0.0	0.0	23.5	28.6	166.7	0.0	218.9	218.9

**Table X7: Reported Contraceptive Method Volumes — Urban/Rural, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type*†:	Public Health Facility	Community Health Worker	Private Not- For-Profit	Public Total	Private For-Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
	-	-	-	-	(0.0, 59.2)	(0.0, 73.2)	(0.0, 461.9)	-	(0.0, 528.9)	(0.0, 528.9)
Rural	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	827.4 (0.0, 2507.7)	0.0 -	827.4 (0.0, 2505.1)	827.4 (0.0, 2505.1)
<b>7. Implants</b>										
Urban	62052.5 (481.7, 123623.3)	0.0 -	34.0 -	62086.6 (515.9, 123657.3)	3614.1 (0.0, 8207.3)	0.0 -	167.6 (0.0, 510.1)	0.0 -	3781.7 (0.0, 8310.4)	65868.3 (3923.0, 127813.6)
Rural	69754.9 (0.0, 140206.6)	0.0 -	0.0 -	69754.9 (0.0, 139920.9)	273293.4 (0.0, 693694.4)	0.0 -	0.0 -	0.0 -	273293.4 (0.0, 687580.9)	343048.3 (0.0, 744096.9)
<i>Implanon implants</i>										
Urban	28325.7 (49.8, 56601.6)	0.0 -	16.5 -	28342.2 (66.4, 56618.1)	539.8 (0.0, 1153.3)	0.0 -	167.6 (0.0, 510.1)	0.0 -	707.5 (13.6, 1401.3)	29049.7 (830.7, 57268.6)
Rural	19137.5 (0.0, 41631.3)	0.0 -	0.0 -	19137.5 (0.0, 41540.1)	168129.9 (0.0, 422573.8)	0.0 -	0.0 -	0.0 -	168129.9 (0.0, 414784.8)	187267.4 (0.0, 430948.6)
<i>Jadelle implants</i>										
Urban	33726.8 (327.9, 67125.7)	0.0 -	17.6 -	33744.3 (345.5, 67143.2)	3074.2 (0.0, 7409.6)	0.0 -	0.0 -	0.0 -	3074.2 (0.0, 7338.6)	36818.6 (2841.6, 70795.6)
Rural	50617.4 (0.0, 117818.5)	0.0 -	0.0 -	50617.4 (0.0, 117546.0)	105163.5 (0.0, 290109.7)	0.0 -	0.0 -	0.0 -	105163.5 (0.0, 291741.1)	155780.9 (0.0, 337697.6)
<b>8. IUD</b>										
Urban	4446.4 (197.4, 8695.4)	0.0 -	154.3 -	4600.7 (131.3, 9070.0)	15657.8 (0.0, 33497.7)	322.0 (0.0, 748.9)	1546.5 (0.0, 3741.6)	0.0 -	17526.3 (0.0, 35509.0)	22127.0 (1207.4, 43046.5)
Rural	20347.5 (0.0, 56985.7)	0.0 -	0.0 -	20347.5 (0.0, 56837.1)	103890.0 (0.0, 306184.1)	0.0 -	0.0 -	0.0 -	103890.0 (0.0, 300136.8)	124237.5 (0.0, 325279.3)
<b>9. Male Sterilizations</b>										
Urban	0.0 -	0.0 -	0.0 -	0.0 -	85.4 -	0.0 -	0.0 -	0.0 -	85.4 -	85.4 -
Rural	0.0 -	0.0 -	0.0 -	0.0 -	480.1 (0.0, 6528.8)	0.0 -	0.0 -	0.0 -	480.1 (0.0, 6528.8)	480.1 (0.0, 6528.8)
<b>10. Female Sterilizations</b>										
Urban	1102.8 -	0.0 -	0.0 -	1102.8 -	1826.0 -	0.0 -	0.0 -	0.0 -	1826.0 -	2928.8 -
Rural	0.0 -	0.0 -	0.0 -	0.0 -	690.4 -	0.0 -	0.0 -	0.0 -	690.4 -	690.4 -
<b>Total Volume</b>	0.0	0.0	0.0	0.0	690.4	0.0	0.0	0.0	690.4	690.4
Urban	80938.1	20.9	211.9	81170.9	25374.6	20451.6	94201.6	8312.5	148340.3	229511.3

**Table X7: Reported Contraceptive Method Volumes — Urban/Rural, 2016**

CYP sold or distributed in previous 1 month by outlet type and contraceptive method type*†:	Public Health Facility	Community Health Worker	Private Not- For- Profit	Public Total	Private For- Profit Health Facility	Pharmacy	PPMV	General Retailer	Private Total	Total
	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)	Vol CYP (95% CI)
	(11066.1, 150810.2)	-	-	(11237.6, 151104.3)	(3636.0, 47113.2)	(3668.6, 37234.7)	(34418.5, 153984.8)	-	(52958.8, 243721.8)	(91091.4, 367931.1)
Rural	168525.6 (37176.1, 299875.1)	816.7 (0.0, 9300.6)	148.9 -	169491.1 (38134.6, 300847.6)	399887.9 (0.0, 947436.1)	3921.5 -	151613.4 (65047.2, 238179.6)	9627.2 -	565050.0 (0.0, 1189678.1)	734541.1 (117200.6, 1351881.6)
<p>* A total 734,541 and 229,511 CYP (weighted) were reportedly distributed in the previous 1 month in rural and urban areas, respectively. This is based on the number of commodities reportedly sold for categories 1-8 (not number of services performed for categories 6-8) and number of sterilizations reportedly performed for categories 9-10. See Annex 11 for a description of CYP calculation and Annex 12 for CYP numbers by outlet type and method category.</p> <p>† The total number of FP products audited (oral contraceptive, injection and insertion products) in rural and urban areas were 886 and 3,449 respectively. A total of 2 injection products and 4 tablet products were excluded from market share analysis due to inconsistent or missing generic names, 56 emergency contraceptive products (6 rural &amp; 50 urban), 129 oral contraceptives (12 rural &amp; 117 urban), 205 male condoms (27 rural &amp; 178 urban), 17 female condoms (1 rural &amp; 16 urban) and 10 Cyclebeads (5 rural &amp; 5 urban), were excluded from market share analysis for missing volume information. 2 male sterilizations and 4 female sterilizations were excluded for missing volume information as well. A total of 179 products were excluded due to outlier volumes and prices (7 rural &amp; 172 urban).</p>										
Source: FPwatch Outlet Survey, Nigeria, 2015										